IRIS

IRIS Home | Advanced Search

Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the RfD, RfC, oral slope factor, or inhalation unit risk. Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see Quick Check: Assessments in Development.

  CHEMICAL NAME CASRN EXPOSURE ROUTE ASSESSMENT TYPE CRIT EFFECT TUMOR TYPE WOE CHARACTERIZATION TOXICITY VALUE TYPE TOXICITY VALUE
1 Acenaphthene 83-32-9 Oral Noncancer Hepatotoxicity n/a RfD 6 x 10 -2 mg/kg-day
2 Acenaphthylene 208-96-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
3 Acephate 30560-19-1 Oral Noncancer Inhibition of brain ChE n/a RfD 4 x 10 -3 mg/kg-day
4 Acetaldehyde 75-07-0 Inhalation Cancer Nasal squamous cell carcinoma or adenocarcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 2.2 x 10 -6 per µg/m3
5 Acetaldehyde 75-07-0 Inhalation Noncancer Degeneration of olfactory epithelium n/a RfC 9 x 10 -3 mg/m3
6 Acetochlor 34256-82-1 Oral Noncancer Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males n/a RfD 2 x 10 -2 mg/kg-day
7 Acetone 67-64-1 Oral Noncancer Nephropathy n/a RfD 9 x 10 -1 mg/kg-day
8 Acetonitrile 75-05-8 Inhalation Noncancer Mortality n/a RfC 6 x 10 -2 mg/m3
9 Acetophenone 98-86-2 Oral Noncancer General Toxicity n/a RfD 1 x 10 -1 mg/kg-day
10 Acetyl chloride 75-36-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
11 Acifluorfen, sodium 62476-59-9 Oral Noncancer Mortality and kidney lesions n/a RfD 1.3 x 10 -2 mg/kg-day
12 Acrolein 107-02-8 Inhalation Noncancer Nasal lesions n/a RfC 2 x 10 -5 mg/m3
13 Acrolein 107-02-8 Oral Noncancer Decreased survival n/a RfD 5 x 10 -4 mg/kg-day
14 Acrylamide 79-06-1 Oral Cancer thyroid tumors and tunica vaginalis mesotheliomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 8.3 x 10 -1 per mg/kg-day
15 Acrylamide 79-06-1 Inhalation Cancer thyroid tumors and tunica vaginalis mesotheliomas Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.7 x 10 -4 per µg/m3
16 Acrylamide 79-06-1 Inhalation Noncancer Degenerative nerve changes n/a RfC 6 x 10 -3 mg/m3
17 Acrylamide 79-06-1 Oral Noncancer Degenerative nerve changes n/a RfD 2 x 10 -3 mg/kg-day
18 Acrylic acid 79-10-7 Oral Noncancer Reduced pup weight n/a RfD 5 x 10 -1 mg/kg-day
19 Acrylic acid 79-10-7 Inhalation Noncancer Degeneration of the nasal olfactory epithelium n/a RfC 1 x 10 -3 mg/m3
20 Acrylonitrile 107-13-1 Inhalation Noncancer Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells n/a RfC 2 x 10 -3 mg/m3
21 Acrylonitrile 107-13-1 Oral Cancer Brain and spinal cord astrocytomas, Zymbal gland carcinomas and stomach papillomas/ carcinomas B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
Oral Slope Factor 5.4 x 10 -1 per mg/kg-day
22 Acrylonitrile 107-13-1 Inhalation Cancer Respiratory cancer B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
Inhalation Unit Risk 6.8 x 10 -5 per µg/m3
23 Adiponitrile 111-69-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
24 Alachlor 15972-60-8 Oral Noncancer Hemosiderosis, hemolytic anemia n/a RfD 1 x 10 -2 mg/kg-day
25 Alar 1596-84-5 Oral Noncancer No adverse effects n/a RfD 1.5 x 10 -1 mg/kg-day
26 Aldicarb 116-06-3 Oral Noncancer Sweating as clinical sign of AChe inhibition n/a RfD 1 x 10 -3 mg/kg-day
27 Aldicarb sulfone 1646-88-4 Oral Noncancer Brain ChE inhibition in females n/a RfD 1 x 10 -3 mg/kg-day
28 Aldrin 309-00-2 Inhalation Cancer Liver carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.9 x 10 -3 per µg/m3
29 Aldrin 309-00-2 Oral Noncancer Liver toxicity n/a RfD 3 x 10 -5 mg/kg-day
30 Aldrin 309-00-2 Oral Cancer Liver carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.7 x 10 1 per mg/kg-day
31 Ally 74223-64-6 Oral Noncancer Decreased body weight n/a RfD 2.5 x 10 -1 mg/kg-day
32 Allyl alcohol 107-18-6 Oral Noncancer Impaired renal function and increased liver and kidney weights n/a RfD 5 x 10 -3 mg/kg-day
33 Allyl chloride 107-05-1 Inhalation Noncancer Functional and histological peripheral neurotoxicity n/a RfC 1 x 10 -3 mg/m3
34 Aluminum phosphide 20859-73-8 Oral Noncancer Body weight and clinical parameters n/a RfD 4 x 10 -4 mg/kg-day
35 Amdro 67485-29-4 Oral Noncancer Increased organ weights n/a RfD 3 x 10 -4 mg/kg-day
36 Ametryn 834-12-8 Oral Noncancer Liver toxicity n/a RfD 9 x 10 -3 mg/kg-day
37 4-Aminopyridine 504-24-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
38 Amitraz 33089-61-1 Oral Noncancer Increased mean blood sugar concentration; slight hypothermia n/a RfD 2.5 x 10 -3 mg/kg-day
39 Ammonia 7664-41-7 Inhalation Noncancer Decreased lung function and respiratory symptoms n/a RfC 5 x 10 -1 mg/m3
40 Ammonium acetate 631-61-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
41 Ammonium methacrylate 16325-47-6 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
42 Ammonium sulfamate 7773-06-0 Oral Noncancer Decrease in body weight n/a RfD 2 x 10 -1 mg/kg-day
43 Aniline 62-53-3 Inhalation Noncancer Methemoglobin increase, spleen toxicity n/a RfC 1 x 10 -3 mg/m3
44 Aniline 62-53-3 Oral Cancer Spleen, combined fibrosarcoma, stromal sarcoma, capsular sarcoma and hemangiosarcoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 5.7 x 10 -3 per mg/kg-day
45 Anthracene 120-12-7 Oral Noncancer No observed effects n/a RfD 3 x 10 -1 mg/kg-day
46 Antimony 7440-36-0 Oral Noncancer Longevity, blood glucose, and cholesterol n/a RfD 4 x 10 -4 mg/kg-day
47 Antimony trioxide 1309-64-4 Inhalation Noncancer Pulmonary toxicity, chronic interstitial inflammation n/a RfC 2 x 10 -4 mg/m3
48 Apollo 74115-24-5 Oral Noncancer Liver effects; organ weight changes n/a RfD 1.3 x 10 -2 mg/kg-day
49 Aramite 140-57-8 Inhalation Cancer Neoplastic liver nodules and carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 7.1 x 10 -6 per µg/m3
50 Aramite 140-57-8 Oral Cancer Neoplastic liver nodules and carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.5 x 10 -2 per mg/kg-day
51 Aroclor 1016 12674-11-2 Oral Noncancer Reduced birth weights n/a RfD 7 x 10 -5 mg/kg-day
52 Aroclor 1254 11097-69-1 Oral Noncancer Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes n/a RfD 2 x 10 -5 mg/kg-day
53 Arsenic, Inorganic 7440-38-2 Inhalation Cancer Lung cancer (Brown and Chu, 1983a,b,c; Lee-Feldstein, 1983; Higgins, 1982; Enterline and Marsh, 1982) Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 4.3 x 10 -3 per µg/m3
54 Arsenic, Inorganic 7440-38-2 Oral Noncancer Ischemic heart disease and type 2 diabetes (see Note) n/a RfD 6 x 10 -5 mg/kg-day
55 Arsenic, Inorganic 7440-38-2 Oral Cancer Bladder Cancer and Lung Cancer Carcinogenic to humans (2005 guidelines)
Oral Slope Factor 3.2 x 10 1 per mg/kg-day
56 Arsine 7784-42-1 Inhalation Noncancer Increased hemolysis, abnormal RBC morphology, and increased spleen weight n/a RfC 5 x 10 -5 mg/m3
57 Asbestos 1332-21-4 Inhalation Cancer Lung cancer and mesothelioma A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 2.3 x 10 -1 per f/mL
58 Assure 76578-14-8 Oral Noncancer Liver cell enlargement n/a RfD 9 x 10 -3 mg/kg-day
59 Asulam 3337-71-1 Oral Noncancer Lower ovarian weight, lower liver/body weight n/a RfD 5 x 10 -2 mg/kg-day
60 Atrazine 1912-24-9 Oral Noncancer Decreased body weight gain n/a RfD 3.5 x 10 -2 mg/kg-day
61 Avermectin B1 65195-55-3 Oral Noncancer Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth n/a RfD 4 x 10 -4 mg/kg-day
62 Azobenzene 103-33-3 Oral Cancer Abdominal cavity sarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.1 x 10 -1 per mg/kg-day
63 Azobenzene 103-33-3 Inhalation Cancer Abdominal cavity sarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.1 x 10 -5 per µg/m3
64 Barium and Compounds 7440-39-3 Oral Noncancer Nephropathy n/a RfD 2 x 10 -1 mg/kg-day
65 Baygon 114-26-1 Oral Noncancer Mild cholinergic symptoms and RBD ChE inhibition n/a RfD 4 x 10 -3 mg/kg-day
66 Bayleton 43121-43-3 Oral Noncancer Decreased body weight gain, erythrocyte count and hemoglobin level n/a RfD 3 x 10 -2 mg/kg-day
67 Baythroid 68359-37-5 Oral Noncancer Decreased body weights in males, inflammatory foci in kidneys of females n/a RfD 2.5 x 10 -2 mg/kg-day
68 Benefin 1861-40-1 Oral Noncancer Depressed erythrocyte counts n/a RfD 3 x 10 -1 mg/kg-day
69 Benomyl 17804-35-2 Oral Noncancer Decreased pup weanling weights n/a RfD 5 x 10 -2 mg/kg-day
70 Bentazon (Basagran) 25057-89-0 Oral Noncancer Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs n/a RfD 3 x 10 -2 mg/kg-day
71 Benz[a]anthracene 56-55-3 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
72 Benzaldehyde 100-52-7 Oral Noncancer Forestomach lesions, kidney toxicity n/a RfD 1 x 10 -1 mg/kg-day
73 Benzene 71-43-2 Oral Noncancer Decreased lymphocyte count n/a RfD 4 x 10 -3 mg/kg-day
74 Benzene 71-43-2 Inhalation Cancer Leukemia A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 7.8 x 10 -6 per µg/m3
75 Benzene 71-43-2 Inhalation Cancer Leukemia A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 2.2 x 10 -6 per µg/m3
76 Benzene 71-43-2 Oral Cancer Leukemia A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 5.5 x 10 -2 per mg/kg-day
77 Benzene 71-43-2 Oral Cancer Leukemia A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 1.5 x 10 -2 per mg/kg-day
78 Benzene 71-43-2 Inhalation Noncancer Decreased lymphocyte count n/a RfC 3 x 10 -2 mg/m3
79 Benzidine 92-87-5 Oral Noncancer Brain cell vacuolization; liver cell alterations in females n/a RfD 3 x 10 -3 mg/kg-day
80 Benzidine 92-87-5 Oral Cancer Bladder tumors A (Human carcinogen) (1986 guidelines)
Oral Slope Factor 2.3 x 10 2 per mg/kg-day
81 Benzidine 92-87-5 Inhalation Cancer Bladder tumors A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 6.7 x 10 -2 per µg/m3
82 Benzo[a]pyrene (BaP) 50-32-8 Oral Noncancer Neurobehavioral changes n/a RfD 3 x 10 -4 mg/kg-day
83 Benzo[a]pyrene (BaP) 50-32-8 Oral Cancer forestomach, esophagus, tongue, and larynx tumors Carcinogenic to humans (2005 guidelines)
Oral Slope Factor 2 per mg/kg-day
84 Benzo[a]pyrene (BaP) 50-32-8 Inhalation Cancer Squamous cell neoplasia in the larynx, pharynx, trachea, nasal cavity, esophagus, and forestomach. Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1 x 10 -3 per µg/m3
85 Benzo[a]pyrene (BaP) 50-32-8 Inhalation Noncancer Reduced ovulation rate and ovary weight n/a RfC 3 x 10 -6 mg/m3
86 Benzo[a]pyrene (BaP) 50-32-8 Inhalation Noncancer Decreased embryo/fetal survival n/a RfC 2 x 10 -6 mg/m3
87 Benzo[a]pyrene (BaP) 50-32-8 Oral Noncancer Decreased ovarian follicles and ovary weight n/a RfD 4 x 10 -4 mg/kg-day
88 Benzo[a]pyrene (BaP) 50-32-8 Oral Noncancer Decreased thymus weight and serum IgM n/a RfD 2 x 10 -3 mg/kg-day
89 Benzo[b]fluoranthene 205-99-2 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
90 Benzo[g,h,i]perylene 191-24-2 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
91 Benzo[k]fluoranthene 207-08-9 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
92 Benzoic acid 65-85-0 Oral Noncancer No adverse effects observed n/a RfD 4 mg/kg-day
93 Benzotrichloride 98-07-7 Oral Cancer Lung, adenocarcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.3 x 10 1 per mg/kg-day
94 Benzyl chloride 100-44-7 Oral Cancer Thyroid, C-cell adenoma/ carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.7 x 10 -1 per mg/kg-day
95 Beryllium and compounds 7440-41-7 Oral Noncancer Small intestinal lesions n/a RfD 2 x 10 -3 mg/kg-day
96 Beryllium and compounds 7440-41-7 Inhalation Cancer Lung cancer B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
Carcinogenic potential cannot be determined (1996 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 2.4 x 10 -3 per µg/m3
97 Beryllium and compounds 7440-41-7 Inhalation Noncancer Beryllium sensitization and progression to CBD n/a RfC 2 x 10 -5 mg/m3
98 Bidrin 141-66-2 Oral Noncancer Decreased pup survival n/a RfD 1 x 10 -4 mg/kg-day
99 Biphenthrin 82657-04-3 Oral Noncancer Tremors n/a RfD 1.5 x 10 -2 mg/kg-day
100 Biphenyl 92-52-4 Oral Cancer Liver adenomas or carcinomas Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 8 x 10 -3 per mg/kg-day
101 Biphenyl 92-52-4 Oral Noncancer Renal papillary mineralization in male F344 rats n/a RfD 5 x 10 -1 mg/kg-day
102 Bis(2-chloro-1-methylethyl) ether 108-60-1 Oral Noncancer Decrease in hemoglobin and possible erythrocyte destruction n/a RfD 4 x 10 -2 mg/kg-day
103 Bis(2-chloroethoxy)methane 111-91-1 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
104 Bis(chloroethyl)ether (BCEE) 111-44-4 Oral Cancer Hepatomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.1 per mg/kg-day
105 Bis(chloroethyl)ether (BCEE) 111-44-4 Inhalation Cancer Hepatomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.3 x 10 -4 per µg/m3
106 Bis(chloromethyl)ether (BCME) 542-88-1 Oral Cancer Respiratory tract tumors A (Human carcinogen) (1986 guidelines)
Oral Slope Factor 2.2 x 10 2 per mg/kg-day
107 Bis(chloromethyl)ether (BCME) 542-88-1 Inhalation Cancer Respiratory tract tumors A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 6.2 x 10 -2 per µg/m3
108 Bisphenol A 80-05-7 Oral Noncancer Reduced mean body weight n/a RfD 5 x 10 -2 mg/kg-day
109 Boron and Compounds 7440-42-8 Oral Noncancer Decreased fetal weight (developmental) n/a RfD 2 x 10 -1 mg/kg-day
110 Bromate 15541-45-4 Oral Noncancer Renal effects: urothelial hyperplasia n/a RfD 4 x 10 -3 mg/kg-day
111 Bromate 15541-45-4 Oral Cancer Testicular mesothelioma, renal tubular adenoma and carcinoma, and thyroid follicular cell adenoma and carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Carcinogenic potential cannot be determined (1996 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 7 x 10 -1 per mg/kg-day
112 Brominated dibenzofurans None None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
113 Bromobenzene 108-86-1 Oral Noncancer Hepatocellular cytomegaly in male B6C3F1 mice n/a RfD 8 x 10 -3 mg/kg-day
114 Bromobenzene 108-86-1 Oral Noncancer Hepatocellular cytomegaly in male B6C3F1 mice n/a RfD 2 x 10 -2 mg/kg-day
115 Bromobenzene 108-86-1 Inhalation Noncancer Hepatocellular cytomegaly in female B6C3F1 mice n/a RfC 6 x 10 -2 mg/m3
116 Bromobenzene 108-86-1 Inhalation Noncancer Hepatocellular cytomegaly in female B6C3F1 mice n/a RfC 2 x 10 -1 mg/m3
117 Bromochloromethane 74-97-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
118 Bromodichloromethane 75-27-4 Oral Noncancer Renal cytomegaly n/a RfD 2 x 10 -2 mg/kg-day
119 Bromodichloromethane 75-27-4 Oral Cancer Kidney (tubular cell adenoma and tubular cell adenocarcinoma) B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 6.2 x 10 -2 per mg/kg-day
120 p-Bromodiphenyl ether 101-55-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
121 Bromoform 75-25-2 Oral Noncancer Hepatic lesions n/a RfD 2 x 10 -2 mg/kg-day
122 Bromoform 75-25-2 Oral Cancer Neoplastic lesions in the large intestine B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 7.9 x 10 -3 per mg/kg-day
123 Bromoform 75-25-2 Inhalation Cancer Neoplastic lesions in the large intestine B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.1 x 10 -6 per µg/m3
124 Bromomethane 74-83-9 Inhalation Noncancer Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity n/a RfC 5 x 10 -3 mg/m3
125 Bromomethane 74-83-9 Oral Noncancer Epithelial hyperplasia of the forestomach n/a RfD 1.4 x 10 -3 mg/kg-day
126 Bromotrichloromethane 75-62-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
127 Bromoxynil 1689-84-5 Oral Noncancer No adverse effects n/a RfD 2 x 10 -2 mg/kg-day
128 Bromoxynil octanoate 1689-99-2 Oral Noncancer No effects n/a RfD 2 x 10 -2 mg/kg-day
129 1,3-Butadiene 106-99-0 Inhalation Cancer Leukemia Carcinogenic to humans (1999 guidelines)
Inhalation Unit Risk 3 x 10 -5 per µg/m3
130 1,3-Butadiene 106-99-0 Inhalation Noncancer Ovarian atrophy n/a RfC 2 x 10 -3 mg/m3
131 Butyl benzyl phthalate (BBP) 85-68-7 Oral Noncancer Significantly increased liver-to-body weight and liver-to-brain weight ratios n/a RfD 2 x 10 -1 mg/kg-day
132 Butylate 2008-41-5 Oral Noncancer Increased relative liver weight in male dogs n/a RfD 5 x 10 -2 mg/kg-day
133 t-Butylchloride 507-20-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
134 Butylphthalyl butylglycolate (BPBG) 85-70-1 Oral Noncancer No adverse effect n/a RfD 1 mg/kg-day
135 Cacodylic acid 75-60-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
136 Cadmium 7440-43-9 Inhalation Cancer Lung, trachea, bronchus cancer deaths B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
Inhalation Unit Risk 1.8 x 10 -3 per µg/m3
137 Cadmium 7440-43-9 Oral Noncancer Significant proteinuria n/a RfD 1 x 10 -3 mg/kg-day
138 Cadmium 7440-43-9 Oral Noncancer Significant proteinuria n/a RfD 5 x 10 -4 mg/kg-day
139 Calcium cyanide 592-01-8 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 1 x 10 -3 mg/kg-day
140 Caprolactam 105-60-2 Oral Noncancer Reduced offspring body weight n/a RfD 5 x 10 -1 mg/kg-day
141 Captafol 2425-06-1 Oral Noncancer Kidney and bladder toxicity n/a RfD 2 x 10 -3 mg/kg-day
142 Captan 133-06-2 Oral Noncancer Decreased mean body weights n/a RfD 1.3 x 10 -1 mg/kg-day
143 Carbaryl 63-25-2 Oral Noncancer Kidney and liver toxicity n/a RfD 1 x 10 -1 mg/kg-day
144 Carbofuran 1563-66-2 Oral Noncancer RBC and plasma cholinesterase inhibition, and testicular and uterine effects n/a RfD 5 x 10 -3 mg/kg-day
145 Carbon disulfide 75-15-0 Inhalation Noncancer Peripheral nervous system dysfunction n/a RfC 7 x 10 -1 mg/m3
146 Carbon disulfide 75-15-0 Oral Noncancer Fetal toxicity/ malformations n/a RfD 1 x 10 -1 mg/kg-day
147 Carbon tetrachloride 56-23-5 Oral Noncancer Elevated serum SDH activity n/a RfD 4 x 10 -3 mg/kg-day
148 Carbon tetrachloride 56-23-5 Oral Cancer Hepatocellular adenoma or carcinoma Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 7 x 10 -2 per mg/kg-day
149 Carbon tetrachloride 56-23-5 Inhalation Noncancer Fatty changes in the liver n/a RfC 1 x 10 -1 mg/m3
150 Carbon tetrachloride 56-23-5 Inhalation Cancer Pheochromocytoma Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 6 x 10 -6 per µg/m3
151 Carbosulfan 55285-14-8 Oral Noncancer Decreased body weight n/a RfD 1 x 10 -2 mg/kg-day
152 Carboxin 5234-68-4 Oral Noncancer Reduced weight gain, organ weight changes, increased mortality n/a RfD 1 x 10 -1 mg/kg-day
153 Cerium Oxide and Cerium Compounds 1306-38-3 Inhalation Noncancer Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats n/a RfC 9 x 10 -4 mg/m3
154 Chloral hydrate 302-17-0 Oral Noncancer CNS depression and GI irritation in humans n/a RfD 1 x 10 -1 mg/kg-day
155 Chloramben 133-90-4 Oral Noncancer Hepatocyte degeneration n/a RfD 1.5 x 10 -2 mg/kg-day
156 Chlordane (Technical) 12789-03-6 Inhalation Noncancer Hepatic effects n/a RfC 7 x 10 -4 mg/m3
157 Chlordane (Technical) 12789-03-6 Oral Noncancer Hepatic necrosis n/a RfD 5 x 10 -4 mg/kg-day
158 Chlordane (Technical) 12789-03-6 Inhalation Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 1 x 10 -4 per µg/m3
159 Chlordane (Technical) 12789-03-6 Oral Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 3.5 x 10 -1 per mg/kg-day
160 Chlordecone (Kepone) 143-50-0 Oral Noncancer Renal lesions (glomerulosclerosis) in female Wistar rats n/a RfD 3 x 10 -4 mg/kg-day
161 Chlordecone (Kepone) 143-50-0 Oral Cancer liver hepatocellular carcinoma Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 1 x 10 1 per mg/kg-day
162 Chlorimuron-ethyl 90982-32-4 Oral Noncancer Increase in WBC, decreased in RBC in females, increase in alkaline phosphatase in males n/a RfD 2 x 10 -2 mg/kg-day
163 Chlorine 7782-50-5 Oral Noncancer No observed adverse effects n/a RfD 1 x 10 -1 mg/kg-day
164 Chlorine cyanide 506-77-4 Oral Noncancer Weight loss, thyroid effects, and myelin degeneration n/a RfD 5 x 10 -2 mg/kg-day
165 Chlorine dioxide 10049-04-4 Oral Noncancer Neurodevelopmental effects n/a RfD 3 x 10 -2 mg/kg-day
166 Chlorine dioxide 10049-04-4 Inhalation Noncancer Vascular congestion and peribronchial edema n/a RfC 2 x 10 -4 mg/m3
167 Chlorite (sodium salt) 7758-19-2 Oral Noncancer Neurodevelopmental effects n/a RfD 3 x 10 -2 mg/kg-day
168 1-Chloro-1,1-difluoroethane 75-68-3 Inhalation Noncancer No adverse effects n/a RfC 5 x 10 1 mg/m3
169 2-Chloroacetophenone 532-27-4 Inhalation Noncancer Squamous hyperplasia of the nasal respiratory epithelium n/a RfC 3 x 10 -5 mg/m3
170 p-Chloroaniline 106-47-8 Oral Noncancer Nonneoplastic lesions of splenic capsule n/a RfD 4 x 10 -3 mg/kg-day
171 Chlorobenzene 108-90-7 Oral Noncancer Histopathologic changes in liver n/a RfD 2 x 10 -2 mg/kg-day
172 Chlorobenzilate 510-15-6 Oral Noncancer Decreased stool quantity, food consumption and body weight gains hyperirritability (maternal effects) n/a RfD 2 x 10 -2 mg/kg-day
173 1-Chlorobutane 109-69-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
174 2-Chlorobutane 78-86-4 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
175 Chlorocyclopentadiene 41851-50-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
176 Chlorodifluoromethane 75-45-6 Inhalation Noncancer Increased kidney, adrenal and pituitary weights n/a RfC 5 x 10 1 mg/m3
177 Chloroform 67-66-3 Inhalation Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Likely to be carcinogenic to humans (1999 guidelines)
Not likely to be carcinogenic to humans (1999 guidelines)
Inhalation Unit Risk 2.3 x 10 -5 per µg/m3
178 Chloroform 67-66-3 Oral Noncancer Moderate/marked fatty cyst formation in the liver and elevated SGPT n/a RfD 1 x 10 -2 mg/kg-day
179 Chloromethyl methyl ether (CMME) 107-30-2 None Cancer None A (Human carcinogen) (1986 guidelines)
NA 0 NA
180 beta-Chloronaphthalene 91-58-7 Oral Noncancer Dyspnea, abnormal appearance, liver enlargement n/a RfD 8 x 10 -2 mg/kg-day
181 2-Chlorophenol 95-57-8 Oral Noncancer Reproductive effects n/a RfD 5 x 10 -3 mg/kg-day
182 p-Chlorophenyl methyl sulfide 123-09-1 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
183 p-Chlorophenyl methyl sulfone 98-57-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
184 p-Chlorophenyl methyl sulfoxide 934-73-6 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
185 Chloroprene 126-99-8 Inhalation Noncancer Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively n/a RfC 2 x 10 -2 mg/m3
186 Chloroprene 126-99-8 Inhalation Cancer alveolar/ bronchiolar adenoma or carcinoma hemangioma/ hemangiosarcoma (all organs) mammary gland adenocarcinoma, carcinoma, or adenoacanthoma forestomach squamous cell papilloma or carcinoma hepatocellular adenoma or carcinoma Harderian gland adenoma or carcinoma skin sarcoma and Zymbal's gland carcinoma Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 3 x 10 -4 per µg/m3
187 Chlorothalonil 1897-45-6 Oral Noncancer Renal tubular epithelial vacuolation n/a RfD 1.5 x 10 -2 mg/kg-day
188 o-Chlorotoluene 95-49-8 Oral Noncancer Decrease in body weight gain n/a RfD 2 x 10 -2 mg/kg-day
189 Chlorpropham 101-21-3 Oral Noncancer Kidney, spleen, liver, and bone marrow toxicity n/a RfD 2 x 10 -1 mg/kg-day
190 Chlorsulfuron 64902-72-3 Oral Noncancer Decreased body weight n/a RfD 5 x 10 -2 mg/kg-day
191 Chromium(III), insoluble salts 16065-83-1 Oral Noncancer No effects observed n/a RfD 1.5 mg/kg-day
192 Chromium(VI) 18540-29-9 Oral Noncancer GI tract effects in mice and rats n/a RfD 9 x 10 -4 mg/kg-day
193 Chromium(VI) 18540-29-9 Inhalation Noncancer Ulcerated nasal septum in humans n/a RfC 3 x 10 -5 mg/m3
194 Chromium(VI) 18540-29-9 Inhalation Cancer Lung cancer Carcinogenic to humans (2005 guidelines)
Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.8 x 10 -2 per µg/m3
195 Chromium(VI) 18540-29-9 Oral Cancer Squamous cell carcinoma or squamous cell papilloma. Carcinogenic to humans (2005 guidelines)
Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 2.7 x 10 -1 per mg/kg-day
196 Chrysene 218-01-9 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
197 Coke oven emissions None Inhalation Cancer Respiratory cancer A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 6.2 x 10 -4 per µg/m3
198 Copper 7440-50-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
199 Copper cyanide 544-92-3 Oral Noncancer Decreased body and organ weights, histopathologic alterations in liver and kidney n/a RfD 5 x 10 -3 mg/kg-day
200 Creosote 8001-58-9 None Cancer None B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
NA 0 NA
201 Crotonaldehyde 123-73-9 None Cancer None C (Possible human carcinogen) (1986 guidelines)
NA 0 NA
202 Cumene 98-82-8 Oral Noncancer Increased average kidney weight in female rats n/a RfD 1 x 10 -1 mg/kg-day
203 Cumene 98-82-8 Inhalation Noncancer Increased kidney weights in female rats and adrenal weights in male and female rats n/a RfC 4 x 10 -1 mg/m3
204 Cyanide, free 57-12-5 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section 1.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 6.3 x 10 -4 mg/kg-day
205 Cyanogen 460-19-5 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanogen is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 1 x 10 -3 mg/kg-day
206 Cyanogen bromide 506-68-3 Oral Noncancer Weight loss, thyroid effects and myelin degeneration n/a RfD 9 x 10 -2 mg/kg-day
207 Cyclohexane 110-82-7 Inhalation Noncancer Reduced pup weights in the F1 and F2 generations n/a RfC 6 mg/m3
208 Cyclohexanone 108-94-1 Oral Noncancer Body weight depression n/a RfD 5 mg/kg-day
209 Cyclohexylamine 108-91-8 Oral Noncancer Testicular damage n/a RfD 2 x 10 -1 mg/kg-day
210 Cyhalothrin/Karate 68085-85-8 Oral Noncancer Reduced body weight gain preceding pregnancy reduced body weight gain in offspring during weaning period n/a RfD 5 x 10 -3 mg/kg-day
211 Cypermethrin 52315-07-8 Oral Noncancer G.I. tract disturbances n/a RfD 1 x 10 -2 mg/kg-day
212 Cyromazine 66215-27-8 Oral Noncancer Hematologic effects n/a RfD 7.5 x 10 -3 mg/kg-day
213 Dacthal 1861-32-1 Oral Noncancer Effects on the lungs, liver, kidney, thyroid and thyroid hormones in males and females and eyes of females n/a RfD 1 x 10 -2 mg/kg-day
214 Dalapon, sodium salt 75-99-0 Oral Noncancer Increased kidney body weight ratio n/a RfD 3 x 10 -2 mg/kg-day
215 Danitol 39515-41-8 Oral Noncancer Tremors n/a RfD 2.5 x 10 -2 mg/kg-day
216 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Oral Noncancer Neurobehavioral effects n/a RfD 7 x 10 -3 mg/kg-day
217 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Oral Cancer Liver neoplastic nodules or carcinoma (combined) Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 7 x 10 -4 per mg/kg-day
218 Demeton 8065-48-3 Oral Noncancer ChE inhibition, optic nerve degeneration n/a RfD 4 x 10 -5 mg/kg-day
219 Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 Oral Cancer Hepatocellular carcinoma and adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.4 x 10 -2 per mg/kg-day
220 Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 Oral Noncancer Increased relative liver weight n/a RfD 2 x 10 -2 mg/kg-day
221 Di(2-ethylhexyl)adipate 103-23-1 Oral Noncancer Changes in body weight and liver weight increased liver weight of male and female parents reduced ossification and slightly dilated ureters in fetuses reduced offspring weight gain, total litter weight, and litter size n/a RfD 6 x 10 -1 mg/kg-day
222 Di(2-ethylhexyl)adipate 103-23-1 Oral Cancer Combined hepatocellular adenomas and carcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 1.2 x 10 -3 per mg/kg-day
223 Dibenz[a,h]anthracene 53-70-3 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
224 Dibenzofuran 132-64-9 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
225 1,2-Dibromo-3-chloropropane (DBCP) 96-12-8 Inhalation Noncancer Testicular effects n/a RfC 2 x 10 -4 mg/m3
226 1,4-Dibromobenzene 106-37-6 Oral Noncancer Liver/body weight ratio and hepatic microsomal enzyme induction n/a RfD 1 x 10 -2 mg/kg-day
227 Dibromochloromethane 124-48-1 Oral Cancer Hepatocellular adenoma or carcinoma C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 8.4 x 10 -2 per mg/kg-day
228 Dibromochloromethane 124-48-1 Oral Noncancer Hepatic lesions n/a RfD 2 x 10 -2 mg/kg-day
229 Dibromodichloromethane 594-18-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
230 p,p'-Dibromodiphenyl ether 2050-47-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
231 1,2-Dibromoethane 106-93-4 Oral Cancer Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas Likely to be carcinogenic to humans (1999 guidelines)
Oral Slope Factor 1 mg/kg-day
232 1,2-Dibromoethane 106-93-4 Oral Cancer Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas Likely to be carcinogenic to humans (1999 guidelines)
Oral Slope Factor 2 per mg/kg-day
233 1,2-Dibromoethane 106-93-4 Inhalation Cancer Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas Likely to be carcinogenic to humans (1999 guidelines)
Inhalation Unit Risk 6 x 10 -4 per µg/m3
234 1,2-Dibromoethane 106-93-4 Inhalation Cancer Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas Likely to be carcinogenic to humans (1999 guidelines)
Inhalation Unit Risk 3 x 10 -4 per µg/m3
235 1,2-Dibromoethane 106-93-4 Oral Noncancer Testicular atrophy, liver peliosis, and adrenal cortical degeneration n/a RfD 9 x 10 -3 mg/kg-day
236 1,2-Dibromoethane 106-93-4 Inhalation Noncancer Nasal inflammation n/a RfC 9 x 10 -3 mg/m3
237 Dibutyl phthalate (DBP) 84-74-2 Oral Noncancer Increased mortality n/a RfD 1 x 10 -1 mg/kg-day
238 Dicamba 1918-00-9 Oral Noncancer Maternal (reduced weight gain) and fetal toxicity n/a RfD 3 x 10 -2 mg/kg-day
239 Dichloroacetic acid 79-43-6 Oral Noncancer Lesions observed in the testes, cerebrum, cerebellum, and liver. n/a RfD 4 x 10 -3 mg/kg-day
240 Dichloroacetic acid 79-43-6 Oral Cancer Hepatoadenoma and Hepatocarcinoma Likely to be carcinogenic to humans (1999 guidelines)
Oral Slope Factor 5 x 10 -2 per mg/kg-day
241 1,2-Dichlorobenzene 95-50-1 Oral Noncancer No adverse effects observed n/a RfD 9 x 10 -2 mg/kg-day
242 1,3-Dichlorobenzene 541-73-1 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
243 1,4-Dichlorobenzene 106-46-7 Inhalation Noncancer Increased liver weights in P1 males n/a RfC 8 x 10 -1 mg/m3
244 3,3'-Dichlorobenzidine 91-94-1 Oral Cancer Mammary adenocarcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 4.5 x 10 -1 per mg/kg-day
245 Dichlorodifluoromethane 75-71-8 Oral Noncancer Reduced body weight n/a RfD 2 x 10 -1 mg/kg-day
246 p,p'-Dichlorodiphenyl dichloroethane (DDD) 72-54-8 Oral Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.4 x 10 -1 per mg/kg-day
247 p,p'-Dichlorodiphenyldichloroethylene (DDE) 72-55-9 Oral Cancer Hepatocellular carcinomas, hepatomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 3.4 x 10 -1 per mg/kg-day
248 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Inhalation Cancer Liver tumors, benign and malignant B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 9.7 x 10 -5 per µg/m3
249 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Oral Cancer Liver tumors, benign and malignant B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 3.4 x 10 -1 per mg/kg-day
250 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Oral Noncancer Liver lesions n/a RfD 5 x 10 -4 mg/kg-day
251 1,1-Dichloroethane 75-34-3 None Cancer None C (Possible human carcinogen) (1986 guidelines)
NA 0 NA
252 1,2-Dichloroethane 107-06-2 Inhalation Cancer Hemangiosarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 2.6 x 10 -5 per µg/m3
253 1,2-Dichloroethane 107-06-2 Oral Cancer Hemangiosarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 9.1 x 10 -2 per mg/kg-day
254 cis-1,2-Dichloroethylene 156-59-2 Oral Noncancer Increased relative kidney weight in male rats n/a RfD 2 x 10 -3 mg/kg-day
255 trans-1,2-Dichloroethylene 156-60-5 Oral Noncancer Decrease in number of antibody forming cells (AFCs) against sheep red blood cells (sRBCs) in male mice n/a RfD 2 x 10 -2 mg/kg-day
256 1,1-Dichloroethylene (1,1-DCE) 75-35-4 Inhalation Noncancer Liver toxicity (fatty change) n/a RfC 2 x 10 -1 mg/m3
257 1,1-Dichloroethylene (1,1-DCE) 75-35-4 Oral Noncancer Liver toxicity (fatty change) n/a RfD 5 x 10 -2 mg/kg-day
258 Dichloromethane 75-09-2 Oral Cancer Hepatocellular carcinomas or adenomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 3.3 x 10 -3 per mg/kg-day
259 Dichloromethane 75-09-2 Inhalation Noncancer Hepatic effects (hepatic vacuolation) n/a RfC 6 x 10 -1 mg/m3
260 Dichloromethane 75-09-2 Oral Noncancer Hepatic effects (hepatic vacuolation, liver foci) n/a RfD 6 x 10 -3 mg/kg-day
261 Dichloromethane 75-09-2 Inhalation Cancer Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.7 x 10 -8 per µg/m3
262 2,4-Dichlorophenol 120-83-2 Oral Noncancer Decreased delayed hypersensitivity response n/a RfD 3 x 10 -3 mg/kg-day
263 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) 94-82-6 Oral Noncancer Internal hemorrhage, mortality n/a RfD 8 x 10 -3 mg/kg-day
264 2,4-Dichlorophenoxyacetic acid (2,4-D) 94-75-7 Oral Noncancer Hematologic, hepatic and renal toxicity n/a RfD 1 x 10 -2 mg/kg-day
265 1,2-Dichloropropane 78-87-5 Inhalation Noncancer Hyperplasia of the nasal mucosa n/a RfC 4 x 10 -3 mg/m3
266 2,3-Dichloropropanol 616-23-9 Oral Noncancer Myocardial degeneration, hepatotoxicity and nephrotoxicity n/a RfD 3 x 10 -3 mg/kg-day
267 1,3-Dichloropropene 542-75-6 Inhalation Cancer Bronchioalveolar adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 4 x 10 -6 per µg/m3
268 1,3-Dichloropropene 542-75-6 Inhalation Noncancer Hypertrophy/ hyperplasia of the nasal respiratory epithelium n/a RfC 2 x 10 -2 mg/m3
269 1,3-Dichloropropene 542-75-6 Oral Cancer Hepatocellular adenoma/carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 5 x 10 -2 per mg/kg-day
270 1,3-Dichloropropene 542-75-6 Oral Noncancer Chronic irritation n/a RfD 3 x 10 -2 mg/kg-day
271 1,3-Dichloropropene 542-75-6 Oral Cancer Urinary bladder carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 1 x 10 -1 per mg/kg-day
272 1,3-Dichloropropene 542-75-6 Oral Cancer Hepatocellular adenoma/carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 5 x 10 -2 per mg/kg-day
273 Dichlorvos 62-73-7 Oral Noncancer Plasma and RBC ChE inhibition in males and females brain ChE inhibition in males n/a RfD 5 x 10 -4 mg/kg-day
274 Dichlorvos 62-73-7 Inhalation Noncancer Decreased brain cholinesterase activity n/a RfC 5 x 10 -4 mg/m3
275 Dichlorvos 62-73-7 Oral Cancer Forestomach tumors, pancreatic acinar adenoma, leukemia B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.9 x 10 -1 per mg/kg-day
276 Dieldrin 60-57-1 Inhalation Cancer Liver carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.6 x 10 -3 per µg/m3
277 Dieldrin 60-57-1 Oral Cancer Liver carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.6 x 10 1 per mg/kg-day
278 Dieldrin 60-57-1 Oral Noncancer Liver lesions n/a RfD 5 x 10 -5 mg/kg-day
279 Diesel engine exhaust None Inhalation Noncancer Pulmonary inflammation and histopathology n/a RfC 5 x 10 -3 mg/m3
280 Diethyl phthalate (DEP) 84-66-2 Oral Noncancer Decreased growth rate, food consumption and altered organ weights n/a RfD 8 x 10 -1 mg/kg-day
281 Diethyl-p-nitrophenylphosphate 311-45-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
282 Diethylene glycol dinitrate (DEGDN) 693-21-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
283 Difenzoquat 43222-48-6 Oral Noncancer Decreased body weight n/a RfD 8 x 10 -2 mg/kg-day
284 Diflubenzuron 35367-38-5 Oral Noncancer Methemoglobin and sulfhemoglobin formation n/a RfD 2 x 10 -2 mg/kg-day
285 1,1-Difluoroethane 75-37-6 Inhalation Noncancer No adverse effects observed n/a RfC 4 x 10 1 mg/m3
286 Diisopropyl methylphosphonate (DIMP) 1445-75-6 Oral Noncancer No effects related to treatment n/a RfD 8 x 10 -2 mg/kg-day
287 Dimethipin 55290-64-7 Oral Noncancer Increased absolute and relative liver weight n/a RfD 2 x 10 -2 mg/kg-day
288 Dimethoate 60-51-5 Oral Noncancer Brain ChE inhibition n/a RfD 2 x 10 -4 mg/kg-day
289 Dimethyl phthalate 131-11-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
290 Dimethyl sulfate 77-78-1 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
291 Dimethyl terephthalate (DMT) 120-61-6 Oral Noncancer Chronic kidney inflammation n/a RfD 1 x 10 -1 mg/kg-day
292 N-N-Dimethylaniline 121-69-7 Oral Noncancer Splenomegaly, increased splenic hemosiderosis and hematopoiesis n/a RfD 2 x 10 -3 mg/kg-day
293 N,N-Dimethylformamide 68-12-2 Inhalation Noncancer Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities n/a RfC 3 x 10 -2 mg/m3
294 2,4-Dimethylphenol 105-67-9 Oral Noncancer Clinical signs (lethargy, prostration, and ataxia) and hematological changes n/a RfD 2 x 10 -2 mg/kg-day
295 2,6-Dimethylphenol 576-26-1 Oral Noncancer Body weight changes and histopathological changes of internal organs (liver, spleen and kidneys) n/a RfD 6 x 10 -4 mg/kg-day
296 3,4-Dimethylphenol 95-65-8 Oral Noncancer Changes in blood pressure and body weight histopathological changes in liver, kidney and spleen n/a RfD 1 x 10 -3 mg/kg-day
297 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 Oral Noncancer Cataract formation n/a RfD 2 x 10 -3 mg/kg-day
298 m-Dinitrobenzene 99-65-0 Oral Noncancer Increased splenic weight n/a RfD 1 x 10 -4 mg/kg-day
299 o-Dinitrobenzene 528-29-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
300 2,4-Dinitrophenol 51-28-5 Oral Noncancer Cataract formation n/a RfD 2 x 10 -3 mg/kg-day
301 2,4-Dinitrotoluene 121-14-2 Oral Noncancer Neurotoxicity, Heinz bodies and biliary tract hyperplasia n/a RfD 2 x 10 -3 mg/kg-day
302 2,4-/2,6-Dinitrotoluene mixture Various Oral Cancer Liver: hepatocellular carcinomas, neoplastic nodules; mammary gland: adenomas, fibroadenomas, fibromas, adenocarcinomas/ carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 6.8 x 10 -1 per mg/kg-day
303 Dinoseb 88-85-7 Oral Noncancer Decreased fetal weight n/a RfD 1 x 10 -3 mg/kg-day
304 1,4-Dioxane 123-91-1 Oral Noncancer Liver and kidney toxicity n/a RfD 3 x 10 -2 mg/kg-day
305 1,4-Dioxane 123-91-1 Inhalation Cancer Multiple (nasal, liver, kidney, peritoneal, mammary gland, and Zymbal gland) Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 5 x 10 -6 per µg/m3
306 1,4-Dioxane 123-91-1 Oral Cancer Hepatocellular adenoma and carcinoma Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 1 x 10 -1 per mg/kg-day
307 1,4-Dioxane 123-91-1 Inhalation Noncancer Atrophy and respiratory metaplasia of the olfactory epithelium n/a RfC 3 x 10 -2 mg/m3
308 Diphenamid 957-51-7 Oral Noncancer Liver toxicity n/a RfD 3 x 10 -2 mg/kg-day
309 Diphenylamine 122-39-4 Oral Noncancer Decreased body weight gain, and increased liver and kidney weights n/a RfD 2.5 x 10 -2 mg/kg-day
310 1,2-Diphenylhydrazine 122-66-7 Oral Cancer Hepatocellular carcinomas and neoplastic liver nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 8 x 10 -1 per mg/kg-day
311 1,2-Diphenylhydrazine 122-66-7 Inhalation Cancer Hepatocellular carcinomas and neoplastic liver nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 2.2 x 10 -4 per µg/m3
312 Diquat 2764-72-9 Oral Noncancer Minimal lens opacity and cataracts n/a RfD 2.2 x 10 -3 mg/kg-day
313 Disulfoton 298-04-4 Oral Noncancer ChE inhibition, optic nerve degeneration n/a RfD 4 x 10 -5 mg/kg-day
314 1,4-Dithiane 505-29-3 Oral Noncancer Nasal olfactory lesions n/a RfD 1 x 10 -2 mg/kg-day
315 Diuron 330-54-1 Oral Noncancer Abnormal pigments in blood n/a RfD 2 x 10 -3 mg/kg-day
316 Dodine 2439-10-3 Oral Noncancer Thyroid toxicity n/a RfD 4 x 10 -3 mg/kg-day
317 Endosulfan 115-29-7 Oral Noncancer Reduced body weight gain in males and females increased incidence of marked progressive glomerulonephrosis and blood vessel aneurysms in males n/a RfD 6 x 10 -3 mg/kg-day
318 Endothall 145-73-3 Oral Noncancer Increased absolute and relative weights of stomach and small intestine n/a RfD 2 x 10 -2 mg/kg-day
319 Endrin 72-20-8 Oral Noncancer Mild histological lesions in liver, occasional convulsions n/a RfD 3 x 10 -4 mg/kg-day
320 Epichlorohydrin 106-89-8 Oral Cancer Papillomas and carcinomas of the forestomach B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 9.9 x 10 -3 per mg/kg-day
321 Epichlorohydrin 106-89-8 Inhalation Cancer Nasal cavity tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.2 x 10 -6 per µg/m3
322 Epichlorohydrin 106-89-8 Inhalation Noncancer Changes in the nasal turbinates n/a RfC 1 x 10 -3 mg/m3
323 1,2-Epoxybutane (EBU) 106-88-7 Inhalation Noncancer Degenerative lesions of the nasal cavity n/a RfC 2 x 10 -2 mg/m3
324 Ethephon 16672-87-0 Oral Noncancer Plasma ChE inhibition n/a RfD 5 x 10 -3 mg/kg-day
325 Ethion 563-12-2 Oral Noncancer Plasma cholinesterase inhibition n/a RfD 5 x 10 -4 mg/kg-day
326 2-Ethoxyethanol 110-80-5 Inhalation Noncancer Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin n/a RfC 2 x 10 -1 mg/m3
327 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Inhalation Noncancer Increased absolute kidney weight in female rats n/a RfC 4 x 10 1 mg/m3
328 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Inhalation Cancer Hepatocellular adenomas and carcinomas Suggestive evidence of carcinogenic potential (2005 guidelines)
Inhalation Unit Risk 8 x 10 -5 per mg/m3
329 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Oral Noncancer Increased absolute kidney weight in female rats n/a RfD 1 mg/kg-day
330 Ethyl acetate 141-78-6 Oral Noncancer Mortality and body weight loss n/a RfD 9 x 10 -1 mg/kg-day
331 Ethyl chloride 75-00-3 Inhalation Noncancer Delayed fetal ossification n/a RfC 1 x 10 1 mg/m3
332 S-Ethyl dipropylthiocarbamate (EPTC) 759-94-4 Oral Noncancer Degenerative cardiomyopathy n/a RfD 2.5 x 10 -2 mg/kg-day
333 Ethyl ether 60-29-7 Oral Noncancer Depressed body weights n/a RfD 2 x 10 -1 mg/kg-day
334 Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 Oral Noncancer Neurotoxicity n/a RfD 1 x 10 -5 mg/kg-day
335 Ethylbenzene 100-41-4 Oral Noncancer Liver and kidney toxicity n/a RfD 1 x 10 -1 mg/kg-day
336 Ethylbenzene 100-41-4 Inhalation Noncancer Developmental toxicity n/a RfC 1 mg/m3
337 Ethylene diamine 107-15-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
338 Ethylene glycol 107-21-1 Oral Noncancer Kidney toxicity n/a RfD 2 mg/kg-day
339 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 Oral Noncancer Hemosiderin deposition in the liver n/a RfD 1 x 10 -1 mg/kg-day
340 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 Inhalation Noncancer Hemosiderin deposition in the liver n/a RfC 1.6 mg/m3
341 Ethylene oxide 75-21-8 Inhalation Cancer Lymphoid cancer, (female) breast cancer Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 5 x 10 -3 per µg/m3
342 Ethylene thiourea (ETU) 96-45-7 Oral Noncancer Increased incidence of thyroid hyperplasia n/a RfD 8 x 10 -5 mg/kg-day
343 Ethylphthalyl ethylglycolate (EPEG) 84-72-0 Oral Noncancer Kidney damage and reduced lifespan n/a RfD 3 mg/kg-day
344 Express 101200-48-0 Oral Noncancer Elevated serum bilirubin and AST levels, increased urinary volume n/a RfD 8 x 10 -3 mg/kg-day
345 Fenamiphos 22224-92-6 Oral Noncancer ChE inhibition n/a RfD 2.5 x 10 -4 mg/kg-day
346 Fluometuron 2164-17-2 Oral Noncancer No adverse effects n/a RfD 1.3 x 10 -2 mg/kg-day
347 Fluoranthene 206-44-0 Oral Noncancer Nephropathy, increased liver weights, hematological alterations, and clinical effects n/a RfD 4 x 10 -2 mg/kg-day
348 Fluorene 86-73-7 Oral Noncancer Decreased RBC, packed cell volume and hemoglobin n/a RfD 4 x 10 -2 mg/kg-day
349 Fluorine (soluble fluoride) 7782-41-4 Oral Noncancer Objectionable dental fluorosis, a cosmetic effect n/a RfD 6 x 10 -2 mg/kg-day
350 Fluridone 59756-60-4 Oral Noncancer Glomerulonephritis, atrophic testes, eye keratitis decreased body weight and organ weights n/a RfD 8 x 10 -2 mg/kg-day
351 Flurprimidol 56425-91-3 Oral Noncancer Increased incidence of hepatocellular changes including fatty change and vacuolation (M) increased susceptibility to stress factors (F) n/a RfD 2 x 10 -2 mg/kg-day
352 Flutolanil 66332-96-5 Oral Noncancer Decreased body weight and body weight gains in both doses increased liver weights at high dose n/a RfD 6 x 10 -2 mg/kg-day
353 Fluvalinate 69409-94-5 Oral Noncancer Decreases in body weight gain increase in plantar ulcer (females) n/a RfD 1 x 10 -2 mg/kg-day
354 Folpet 133-07-3 Oral Noncancer Decreased body weight gain, altered serum chemistry parameters (decreased serum cholesterol, total protein, and serum albumin and globulin levels) n/a RfD 1 x 10 -1 mg/kg-day
355 Fonofos 944-22-9 Oral Noncancer Cholinesterase inhibition, cholinergic symptoms, and increased liver weight n/a RfD 2 x 10 -3 mg/kg-day
356 Formaldehyde 50-00-0 Inhalation Cancer Nasopharyngeal cancer, sinonasal cancer, myeloid leukemia Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.1 x 10 -5 per µg/m3
357 Formaldehyde 50-00-0 Inhalation Noncancer Decreased pulmonary function, prevalence of current asthma or degree of asthma control, and allergic conditions in children (See Note) n/a RfC 7 x 10 -3 mg/m3
358 Formaldehyde 50-00-0 Oral Noncancer Reduced weight gain, histopathology in rats n/a RfD 2 x 10 -1 mg/kg-day
359 Fosetyl-al 39148-24-8 Oral Noncancer Slight testicular degeneration n/a RfD 3 mg/kg-day
360 Furan 110-00-9 Oral Noncancer Hepatic lesions n/a RfD 1 x 10 -3 mg/kg-day
361 Furfural 98-01-1 Oral Noncancer Mild hepatocellular vacuolization n/a RfD 3 x 10 -3 mg/kg-day
362 Furmecyclox 60568-05-0 Oral Cancer Combined liver nodules and carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 3 x 10 -2 per mg/kg-day
363 Glufosinate-ammonium 77182-82-2 Oral Noncancer Increased absolute and relative kidney weights in males n/a RfD 4 x 10 -4 mg/kg-day
364 Glycidaldehyde 765-34-4 Oral Noncancer Weight gain retardation, enlarged adrenals, hydropic renal pelvis and hematopoietic effects n/a RfD 4 x 10 -4 mg/kg-day
365 Glyphosate 1071-83-6 Oral Noncancer Increased incidence of renal tubular dilation in F3b offspring n/a RfD 1 x 10 -1 mg/kg-day
366 Haloxyfop-methyl 69806-40-2 Oral Noncancer Reduced relative kidney weights in F0, F1, and F2b adults; reduced fertility in the F1/F2b generation n/a RfD 5 x 10 -5 mg/kg-day
367 Harmony 79277-27-3 Oral Noncancer Reduced body weight gains in males, reduced serum sodium in males and females n/a RfD 1.3 x 10 -2 mg/kg-day
368 Heptachlor 76-44-8 Inhalation Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.3 x 10 -3 per µg/m3
369 Heptachlor 76-44-8 Oral Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 4.5 per mg/kg-day
370 Heptachlor 76-44-8 Oral Noncancer Liver weight increases in males n/a RfD 5 x 10 -4 mg/kg-day
371 Heptachlor epoxide 1024-57-3 Oral Noncancer Increased liver-to-body weight ratio in both males and females n/a RfD 1.3 x 10 -5 mg/kg-day
372 Heptachlor epoxide 1024-57-3 Inhalation Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 2.6 x 10 -3 per µg/m3
373 Heptachlor epoxide 1024-57-3 Oral Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 9.1 per mg/kg-day
374 n-Heptane 142-82-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
375 Hexabromobenzene 87-82-1 Oral Noncancer Induced serum carboxylesterase activity, increased relative liver weight, increased liver porphyrins n/a RfD 2 x 10 -3 mg/kg-day
376 Hexabromodiphenyl ether 36483-60-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
377 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 68631-49-2 Oral Noncancer Neurobehavioral effects n/a RfD 2 x 10 -4 mg/kg-day
378 Hexachlorobenzene 118-74-1 Oral Noncancer Liver effects n/a RfD 8 x 10 -4 mg/kg-day
379 Hexachlorobenzene 118-74-1 Inhalation Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.6 x 10 -4 per µg/m3
380 Hexachlorobenzene 118-74-1 Oral Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.6 per mg/kg-day
381 Hexachlorobutadiene 87-68-3 Inhalation Cancer Renal tubular adenomas and adenocarcinomas C (Possible human carcinogen) (1986 guidelines)
Inhalation Unit Risk 2.2 x 10 -5 per µg/m3
382 Hexachlorobutadiene 87-68-3 Oral Cancer Renal tubular adenomas and adenocarcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 7.8 x 10 -2 per mg/kg-day
383 alpha-Hexachlorocyclohexane (alpha-HCH) 319-84-6 Inhalation Cancer Hepatic nodules and hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.8 x 10 -3 per µg/m3
384 alpha-Hexachlorocyclohexane (alpha-HCH) 319-84-6 Oral Cancer Hepatic nodules and hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 6.3 per mg/kg-day
385 beta-Hexachlorocyclohexane (beta-HCH) 319-85-7 Oral Cancer Hepatic nodules and hepatocellular carcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 1.8 per mg/kg-day
386 beta-Hexachlorocyclohexane (beta-HCH) 319-85-7 Inhalation Cancer Hepatic nodules and hepatocellular carcinomas C (Possible human carcinogen) (1986 guidelines)
Inhalation Unit Risk 5.3 x 10 -4 per µg/m3
387 delta-Hexachlorocyclohexane (delta-HCH) 319-86-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
388 epsilon-Hexachlorocyclohexane (epsilon-HC) 6108-10-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
389 gamma-Hexachlorocyclohexane (gamma-HCH) 58-89-9 Oral Noncancer Liver and kidney toxicity n/a RfD 3 x 10 -4 mg/kg-day
390 technical Hexachlorocyclohexane (t-HCH) 608-73-1 Inhalation Cancer Liver nodules and hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 5.1 x 10 -4 per µg/m3
391 technical Hexachlorocyclohexane (t-HCH) 608-73-1 Oral Cancer Liver nodules and hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.8 per mg/kg-day
392 Hexachlorocyclopentadiene (HCCPD) 77-47-4 Oral Noncancer Chronic irritation n/a RfD 6 x 10 -3 mg/kg-day
393 Hexachlorocyclopentadiene (HCCPD) 77-47-4 Inhalation Noncancer Suppurative inflammation of the nose n/a RfC 2 x 10 -4 mg/m3
394 Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 57653-85-7 Oral Cancer Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 6.2 x 10 3 per mg/kg-day
395 Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 57653-85-7 Inhalation Cancer Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.3 per µg/m3
396 Hexachloroethane 67-72-1 Inhalation Noncancer Neurotoxicity (tremors and ruffled pelt) n/a RfC 3 x 10 -2 mg/m3
397 Hexachloroethane 67-72-1 Oral Noncancer Atrophy and degeneration of renal tubules n/a RfD 7 x 10 -4 mg/kg-day
398 Hexachloroethane 67-72-1 Oral Cancer Renal adenomas and carcinomas (combined) Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 4 x 10 -2 per mg/kg-day
399 Hexachlorophene 70-30-4 Oral Noncancer Swollen salivary glands, status spongiosis in brain and optic nerve n/a RfD 3 x 10 -4 mg/kg-day
400 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Noncancer Kidney medullary papillary necrosis in F344 rats n/a RfD 1 x 10 -2 mg/kg-day
401 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Noncancer Suppurative prostatitis in F344 rats n/a RfD 8 x 10 -4 mg/kg-day
402 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Noncancer Convulsions in F344 rats n/a RfD 4 x 10 -3 mg/kg-day
403 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Cancer Liver (hepatocellular adenomas or carcinomas) and lung (alveolar/bronchiolar adenomas or carcinomas) Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 8 x 10 -2 per mg/kg-day
404 1,6-Hexamethylene diisocyanate 822-06-0 Inhalation Noncancer Degeneration of olfactory epithelium n/a RfC 1 x 10 -5 mg/m3
405 n-Hexane 110-54-3 Inhalation Noncancer Peripheral neuropathy (decreased MCV at 12 weeks) n/a RfC 7 x 10 -1 mg/m3
406 2-Hexanone 591-78-6 Oral Noncancer Axonal swelling of the peripheral nerve n/a RfD 5 x 10 -3 mg/kg-day
407 2-Hexanone 591-78-6 Inhalation Noncancer Motor conduction velocity of the sciatic-tibial nerve n/a RfC 3 x 10 -2 mg/m3
408 Hexazinone 51235-04-2 Oral Noncancer Decreased body weight n/a RfD 3.3 x 10 -2 mg/kg-day
409 Hydrazine/Hydrazine sulfate 302-01-2 Oral Cancer Hepatoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 3 per mg/kg-day
410 Hydrazine/Hydrazine sulfate 302-01-2 Inhalation Cancer Nasal cavity adenoma or adenocarcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.9 x 10 -3 per µg/m3
411 Hydrogen Cyanide and Cyanide Salts Various Inhalation Noncancer Thyroid enlargement and altered iodide uptake n/a RfC 8 x 10 -4 mg/m3
412 Hydrogen Cyanide and Cyanide Salts Various Oral Noncancer Decreased cauda epididymis weight in male F344/N rats n/a RfD 6 x 10 -4 mg/kg-day
413 Hydrogen chloride 7647-01-0 Inhalation Noncancer Hyperplasia of nasal mucosa larynx and trachea n/a RfC 2 x 10 -2 mg/m3
414 Hydrogen sulfide 7783-06-4 Inhalation Noncancer Nasal lesions of the olfactory mucosa n/a RfC 2 x 10 -3 mg/m3
415 Imazalil 35554-44-0 Oral Noncancer Decreased body weight gain n/a RfD 1.3 x 10 -2 mg/kg-day
416 Imazaquin 81335-37-7 Oral Noncancer Decreased body weight gain, skeletal myopathy, slight anemia, bone marrow hyperplasia, elevated serum SGOT, SGPT, CPK n/a RfD 2.5 x 10 -1 mg/kg-day
417 Indeno[1,2,3-cd]pyrene 193-39-5 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
418 Iprodione 36734-19-7 Oral Noncancer Increased RBC Heinz bodies; decreased prostate weight n/a RfD 4 x 10 -2 mg/kg-day
419 Isobutyl alcohol 78-83-1 Oral Noncancer Hypoactivity and ataxia n/a RfD 3 x 10 -1 mg/kg-day
420 Isophorone 78-59-1 Oral Noncancer Kidney pathology n/a RfD 2 x 10 -1 mg/kg-day
421 Isophorone 78-59-1 Oral Cancer Preputial gland carcinoma C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 9.5 x 10 -4 per mg/kg-day
422 Isopropalin 33820-53-0 Oral Noncancer Reduced hemoglobin concentration, lowered hematocrits, and altered organ weights n/a RfD 1.5 x 10 -2 mg/kg-day
423 Isopropyl methyl phosphonic acid (IMPA) 1832-54-8 Oral Noncancer No adverse effects observed n/a RfD 1 x 10 -1 mg/kg-day
424 Isoxaben 82558-50-7 Oral Noncancer Increased BUN; decreased serum AP and AST; decreased food consumption efficiency; increased heart/body weight n/a RfD 5 x 10 -2 mg/kg-day
425 Lactofen 77501-63-4 Oral Noncancer Increased absolute and relative liver weight; hepatocytomegaly in males n/a RfD 2 x 10 -3 mg/kg-day
426 Lead and compounds (inorganic) 7439-92-1 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
427 Libby Amphibole Asbestos 1318-09-8 Inhalation Noncancer Localized pleural thickening n/a RfC 9 x 10 -5 fiber/cc
428 Libby Amphibole Asbestos 1318-09-8 Inhalation Cancer Cancer mortality from lung cancer and mesothelioma Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.7 x 10 -1 per fiber/cc
429 Linuron 330-55-2 Oral Noncancer Abnormal blood pigment n/a RfD 2 x 10 -3 mg/kg-day
430 Londax 83055-99-6 Oral Noncancer Liver effects n/a RfD 2 x 10 -1 mg/kg-day
431 Malathion 121-75-5 Oral Noncancer RBC ChE depression n/a RfD 2 x 10 -2 mg/kg-day
432 Maleic anhydride 108-31-6 Oral Noncancer Renal lesions n/a RfD 1 x 10 -1 mg/kg-day
433 Maleic hydrazide 123-33-1 Oral Noncancer Renal dysfunction n/a RfD 5 x 10 -1 mg/kg-day
434 Maneb 12427-38-2 Oral Noncancer Increased thyroid weight n/a RfD 5 x 10 -3 mg/kg-day
435 Manganese 7439-96-5 Inhalation Noncancer Impairment of neurobehavioral function n/a RfC 5 x 10 -5 mg/m3
436 Manganese 7439-96-5 Oral Noncancer CNS effects n/a RfD 1.4 x 10 -1 mg/kg-day
437 Mepiquat chloride 24307-26-4 Oral Noncancer Sedation and tonoclonic spasms decreased food intake and body weights hematologic effects n/a RfD 3 x 10 -2 mg/kg-day
438 Mercuric chloride (HgCl2) 7487-94-7 Oral Noncancer Autoimmune effects (autoimmune glomerulonephritis) n/a RfD 3 x 10 -4 mg/kg-day
439 Mercury, elemental 7439-97-6 Inhalation Noncancer Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction n/a RfC 3 x 10 -4 mg/m3
440 Merphos 150-50-5 Oral Noncancer Ataxia, delayed neurotoxicity and weight loss n/a RfD 3 x 10 -5 mg/kg-day
441 Merphos oxide 78-48-8 Oral Noncancer Ataxia, delayed neurotoxicity and weight loss n/a RfD 3 x 10 -5 mg/kg-day
442 Metalaxyl 57837-19-1 Oral Noncancer Increased serum alkaline phosphatase levels and increased liver-to-brain weight ratio n/a RfD 6 x 10 -2 mg/kg-day
443 Methacrylonitrile 126-98-7 Oral Noncancer Increased SGOT and SGPT levels n/a RfD 1 x 10 -4 mg/kg-day
444 Methamidophos 10265-92-6 Oral Noncancer ChE inhibition n/a RfD 5 x 10 -5 mg/kg-day
445 Methanol 67-56-1 Oral Noncancer Extra cervical ribs n/a RfD 2 mg/kg-day
446 Methanol 67-56-1 Inhalation Noncancer Reduced brain weight in rat pups at 6 weeks of age n/a RfC 2 x 10 1 mg/m3
447 Methidathion 950-37-8 Oral Noncancer Liver toxicity n/a RfD 1 x 10 -3 mg/kg-day
448 Methomyl 16752-77-5 Oral Noncancer Kidney and spleen pathology n/a RfD 2.5 x 10 -2 mg/kg-day
449 Methoxychlor 72-43-5 Oral Noncancer Excessive loss of litters n/a RfD 5 x 10 -3 mg/kg-day
450 2-Methoxyethanol 109-86-4 Inhalation Noncancer Testicular effects n/a RfC 2 x 10 -2 mg/m3
451 Methyl acrylate 96-33-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
452 Methyl chloride 74-87-3 Inhalation Noncancer Cerebellar lesions n/a RfC 9 x 10 -2 mg/m3
453 Methyl ethyl ketone (MEK) 78-93-3 Inhalation Noncancer Developmental toxicity (skeletal variations) n/a RfC 5 mg/m3
454 Methyl ethyl ketone (MEK) 78-93-3 Oral Noncancer Decreased pup body weight n/a RfD 6 x 10 -1 mg/kg-day
455 Methyl isobutyl ketone (MIBK) 108-10-1 Inhalation Noncancer Reduced fetal body weight, skeletal variations, and increased fetal death in mice, and skeletal variations in rats. n/a RfC 3 mg/m3
456 Methyl methacrylate 80-62-6 Inhalation Noncancer Degeneration/ atrophy of olfactory epithelium (male rats) n/a RfC 7 x 10 -1 mg/m3
457 Methyl methacrylate 80-62-6 Oral Noncancer None n/a RfD 1.4 mg/kg-day
458 Methyl parathion 298-00-0 Oral Noncancer RBC, ChE inhibition; reduced hemoglobin, hematocrit and RBCs n/a RfD 2.5 x 10 -4 mg/kg-day
459 Methyl tert-butyl ether (MTBE) 1634-04-4 Inhalation Noncancer Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females) n/a RfC 3 mg/m3
460 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 Oral Noncancer Male reproductive toxicity and other effects (including decreased body weight gain), increased liver and kidney weights n/a RfD 1 x 10 -2 mg/kg-day
461 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 Oral Noncancer Increased absolute and relative kidney weights n/a RfD 1 x 10 -3 mg/kg-day
462 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 Oral Noncancer Kidney and liver toxicity n/a RfD 5 x 10 -4 mg/kg-day
463 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 Inhalation Noncancer Hyperplasia of olfactory epithelium n/a RfC 6 x 10 -4 mg/m3
464 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 Oral Cancer Thyroid, follicular cell carcinoma/ adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 4.6 x 10 -2 per mg/kg-day
465 Methylmercury (MeHg) 22967-92-6 Oral Noncancer Developmental neuropsychological impairment n/a RfD 1 x 10 -4 mg/kg-day
466 Methylmercury (MeHg) 22967-92-6 Oral Noncancer Developmental neuropsychological impairment n/a RfD 1 x 10 -4 mg/kg-day
467 2-Methylnaphthalene 91-57-6 Oral Noncancer Pulmonary alveolar proteinosis n/a RfD 4 x 10 -3 mg/kg-day
468 2-Methylphenol 95-48-7 Oral Noncancer Decreased body weights and neurotoxicity n/a RfD 5 x 10 -2 mg/kg-day
469 3-Methylphenol 108-39-4 Oral Noncancer Decreased body weights and neurotoxicity n/a RfD 5 x 10 -2 mg/kg-day
470 4-Methylphenol 106-44-5 None Cancer None C (Possible human carcinogen) (1986 guidelines)
NA 0 NA
471 Metolachlor 51218-45-2 Oral Noncancer Decreased body weight gain, decreased pup weight and parental food consumption n/a RfD 1.5 x 10 -1 mg/kg-day
472 Metribuzin 21087-64-9 Oral Noncancer Liver and kidney effects, decreased body weight, mortality n/a RfD 2.5 x 10 -2 mg/kg-day
473 Mirex 2385-85-5 Oral Noncancer Liver cytomegaly, fatty metamorphosis, angiectasis; thyroid cystic follicles n/a RfD 2 x 10 -4 mg/kg-day
474 Molinate 2212-67-1 Oral Noncancer Reproductive toxicity n/a RfD 2 x 10 -3 mg/kg-day
475 Molybdenum 7439-98-7 Oral Noncancer Increased uric acid levels n/a RfD 5 x 10 -3 mg/kg-day
476 Monochloramine 10599-90-3 Oral Noncancer No observed effects n/a RfD 1 x 10 -1 mg/kg-day
477 Naled 300-76-5 Oral Noncancer Brain ChE inhibition n/a RfD 2 x 10 -3 mg/kg-day
478 Naphthalene 91-20-3 Inhalation Noncancer Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively n/a RfC 3 x 10 -3 mg/m3
479 Naphthalene 91-20-3 Oral Noncancer Decreased mean terminal body weight in males n/a RfD 2 x 10 -2 mg/kg-day
480 Napropamide 15299-99-7 Oral Noncancer Decreased body weight gain in parental animals and pups n/a RfD 1 x 10 -1 mg/kg-day
481 Nickel carbonyl 13463-39-3 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
482 Nickel refinery dust None Inhalation Cancer Lung cancer A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 2.4 x 10 -4 per µg/m3
483 Nickel subsulfide 12035-72-2 Inhalation Cancer Lung cancer A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 4.8 x 10 -4 per µg/m3
484 Nickel, soluble salts Various Oral Noncancer Decreased body and organ weights n/a RfD 2 x 10 -2 mg/kg-day
485 Nitrate 14797-55-8 Oral Noncancer Early clinical signs of methemoglobinemia in excess of 10% (0-3 months old infants formula) n/a RfD 1.6 mg/kg-day
486 Nitrite 14797-65-0 Oral Noncancer Methemoglobinemia n/a RfD 1 x 10 -1 mg/kg-day
487 Nitrobenzene 98-95-3 Oral Noncancer Increased methemoglobin levels n/a RfD 2 x 10 -3 mg/kg-day
488 Nitrobenzene 98-95-3 Inhalation Noncancer Bronchiolization of the alveoli and olfactory degeneration n/a RfC 9 x 10 -3 mg/m3
489 Nitrobenzene 98-95-3 Inhalation Cancer Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 4 x 10 -5 per µg/m3
490 Nitroguanidine 556-88-7 Oral Noncancer Reduced weight gain in female rats, maternal/ fetal toxicity in rats, and equivocal evidence of developmental toxicity in rabbits n/a RfD 1 x 10 -1 mg/kg-day
491 2-Nitropropane 79-46-9 Inhalation Noncancer Liver focal vacuolization and nodules n/a RfC 2 x 10 -2 mg/m3
492 N-Nitroso-N-methylethylamine 10595-95-6 Oral Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.2 x 10 1 per mg/kg-day
493 N-Nitroso-di-n-butylamine 924-16-3 Inhalation Cancer Bladder and esophagus tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.6 x 10 -3 per µg/m3
494 N-Nitroso-di-n-butylamine 924-16-3 Oral Cancer Bladder and esophagus tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 5.4 per mg/kg-day
495 N-Nitrosodi-N-propylamine 621-64-7 Oral Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 7 per mg/kg-day
496 N-Nitrosodiethanolamine 1116-54-7 Oral Cancer Hepatocellular carcinoma, cholangiocellular carcinoma and adenoma and neoplastic nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.8 per mg/kg-day
497 N-Nitrosodiethylamine 55-18-5 Inhalation Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.3 x 10 -2 per µg/m3
498 N-Nitrosodiethylamine 55-18-5 Oral Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.5 x 10 2 per mg/kg-day
499 N-Nitrosodimethylamine 62-75-9 Inhalation Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.4 x 10 -2 per µg/m3
500 N-Nitrosodimethylamine 62-75-9 Oral Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 5.1 x 10 1 per mg/kg-day
501 N-Nitrosodiphenylamine 86-30-6 Oral Cancer Transitional cell carcinoma of the bladder B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 4.9 x 10 -3 per mg/kg-day
502 N-Nitrosopyrrolidine 930-55-2 Inhalation Cancer Hepatocellular carcinoma and adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 6.1 x 10 -4 per µg/m3
503 N-Nitrosopyrrolidine 930-55-2 Oral Cancer Hepatocellular carcinoma and adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.1 per mg/kg-day
504 Nonabromodiphenyl ether 63936-56-1 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
505 Norflurazon 27314-13-2 Oral Noncancer Liver and thyroid effects n/a RfD 4 x 10 -2 mg/kg-day
506 NuStar 85509-19-9 Oral Noncancer Liver cell enlargement n/a RfD 7 x 10 -4 mg/kg-day
507 Octabromodiphenyl ether 32536-52-0 Oral Noncancer Induction of hepatic enzymes; liver histopathology n/a RfD 3 x 10 -3 mg/kg-day
508 Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) 2691-41-0 Oral Noncancer Hepatic lesions n/a RfD 5 x 10 -2 mg/kg-day
509 Oryzalin 19044-88-3 Oral Noncancer Increases in serum cholesterol, alkaline phosphatase, and relative liver and kidney weights, and decreases in alanine transaminase and adrenal weights n/a RfD 5 x 10 -2 mg/kg-day
510 Oxadiazon 19666-30-9 Oral Noncancer Increased levels of serum proteins and increased liver weights n/a RfD 5 x 10 -3 mg/kg-day
511 Oxamyl 23135-22-0 Oral Noncancer Decreased body weight gain and food consumption n/a RfD 2.5 x 10 -2 mg/kg-day
512 Oxyfluorfen 42874-03-3 Oral Noncancer Increased absolute liver weight and nonneoplastic lesions n/a RfD 3 x 10 -3 mg/kg-day
513 Paclobutrazol 76738-62-0 Oral Noncancer Elevated liver weights, serum cholesterol, hepatic aminopyrine N-demethylase activity, and alanine transaminase levels n/a RfD 1.3 x 10 -2 mg/kg-day
514 Paraquat 1910-42-5 Oral Noncancer Chronic pneumonitis n/a RfD 4.5 x 10 -3 mg/kg-day
515 Parathion 56-38-2 None Cancer None C (Possible human carcinogen) (1986 guidelines)
NA 0 NA
516 Pendimethalin 40487-42-1 Oral Noncancer Increase in serum alkaline phosphatase and liver weight, and hepatic lesions n/a RfD 4 x 10 -2 mg/kg-day
517 Pentabromodiphenyl ether 32534-81-9 Oral Noncancer Induction of hepatic enzymes n/a RfD 2 x 10 -3 mg/kg-day
518 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) 60348-60-9 Oral Noncancer Neurobehavioral effects n/a RfD 1 x 10 -4 mg/kg-day
519 Pentachlorobenzene 608-93-5 Oral Noncancer Liver and kidney toxicity n/a RfD 8 x 10 -4 mg/kg-day
520 Pentachlorocyclopentadiene 25329-35-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
521 Pentachloronitrobenzene (PCNB) 82-68-8 Oral Noncancer Liver toxicity n/a RfD 3 x 10 -3 mg/kg-day
522 Pentachlorophenol 87-86-5 Oral Cancer Hepatocellular adenomas or carcinomas and adrenal benign or malignant pheochromocytomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 4 x 10 -1 per mg/kg-day
523 Pentachlorophenol 87-86-5 Oral Noncancer Hepatotoxicity n/a RfD 5 x 10 -3 mg/kg-day
524 Perchlorate (ClO4) and Perchlorate Salts 7790-98-9 Oral Noncancer Radioactive iodide uptake inhibition (RAIU) in the thyroid n/a RfD 7 x 10 -4 mg/kg-day
525 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Decreased total T4 n/a RfD 1 x 10 -2 mg/kg-day
526 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Developmental delays n/a RfD 6 x 10 -3 mg/kg-day
527 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Developmental delays n/a RfD 6 x 10 -3 mg/kg-day
528 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Increased hepatocellular hypertrophy n/a RfD 1 x 10 -3 mg/kg-day
529 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Increased hepatocellular hypertrophy n/a RfD 1 x 10 -2 mg/kg-day
530 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Increased hepatocellular hypertrophy (Liver), Decreased total T4 (Thyroid) n/a RfD 1 x 10 -3 mg/kg-day
531 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Developmental delays n/a RfD 6 x 10 -3 mg/kg-day
532 Perfluorodecanoic Acid (PFDA) 335-76-2 Oral Noncancer Decreased serum antibody concentrations for tetanus and diphtheria in children; Decreased birth weight in male and female children n/a RfD 2 x 10 -9 mg/kg-day
533 Perfluorodecanoic Acid (PFDA) 335-76-2 Oral Noncancer Decreased serum antibody concentrations for tetanus and diphtheria in children; Decreased birth weight in male and female children n/a RfD 2 x 10 -9 mg/kg-day
534 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats n/a RfD 5 x 10 -4 mg/kg-day
535 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Increased hepatocellular hypertrophy in adult male Crl:CD Sprague‑Dawley rats n/a RfD 4 x 10 -4 mg/kg-day
536 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Increased hepatocellular hypertrophy in adult rats n/a RfD 1 x 10 -3 mg/kg-day
537 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats n/a RfD 5 x 10 -4 mg/kg-day
538 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats n/a RfD 5 x 10 -3 mg/kg-day
539 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats n/a RfD 8 x 10 -4 mg/kg-day
540 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased total T4 in adult male Harlan Sprague-Dawley rats n/a RfD 1 x 10 -3 mg/kg-day
541 Permethrin 52645-53-1 Oral Noncancer Increased liver weights n/a RfD 5 x 10 -2 mg/kg-day
542 Phenanthrene 85-01-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
543 Phenmedipham 13684-63-4 Oral Noncancer No adverse effects n/a RfD 2.5 x 10 -1 mg/kg-day
544 Phenol 108-95-2 Oral Noncancer Decreased maternal weight gain n/a RfD 3 x 10 -1 mg/kg-day
545 m-Phenylenediamine 108-45-2 Oral Noncancer Increased relative and absolute liver weights and degenerative liver lesions n/a RfD 6 x 10 -3 mg/kg-day
546 Phenylmercuric acetate 62-38-4 Oral Noncancer Renal damage n/a RfD 8 x 10 -5 mg/kg-day
547 Phosgene 75-44-5 Inhalation Noncancer Collagen staining indicative of fibrosis n/a RfC 3 x 10 -4 mg/m3
548 Phosmet 732-11-6 Oral Noncancer Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition n/a RfD 2 x 10 -2 mg/kg-day
549 Phosphine 7803-51-2 Inhalation Noncancer Decreased body weight n/a RfC 3 x 10 -4 mg/m3
550 Phosphine 7803-51-2 Oral Noncancer Body weight and clinical parameters n/a RfD 3 x 10 -4 mg/kg-day
551 Phosphoric acid 7664-38-2 Inhalation Noncancer Bronchiolar fibrosis n/a RfC 1 x 10 -2 mg/m3
552 Phthalic anhydride 85-44-9 Oral Noncancer Lung and kidney histopathology n/a RfD 2 mg/kg-day
553 Picloram 1918-02-1 Oral Noncancer Increased liver weights n/a RfD 7 x 10 -2 mg/kg-day
554 Pirimiphos-methyl 29232-93-7 Oral Noncancer Transient plasma ChE depression n/a RfD 1 x 10 -2 mg/kg-day
555 Polychlorinated Biphenyls (PCBs) 1336-36-3 Inhalation Cancer Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1 x 10 -4 per µg/m3
556 Polychlorinated Biphenyls (PCBs) 1336-36-3 Oral Cancer Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2 per mg/kg-day
557 Potassium cyanide 151-50-8 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 2 x 10 -3 mg/kg-day
558 Potassium silver cyanide 506-61-6 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 5 x 10 -3 mg/kg-day
559 Prochloraz 67747-09-5 Oral Cancer Liver adenoma/ carcinoma combined C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 1.5 x 10 -1 per mg/kg-day
560 Prochloraz 67747-09-5 Oral Noncancer Increase in SAP and liver weights, liver histopathology n/a RfD 9 x 10 -3 mg/kg-day
561 Prometon 1610-18-0 Oral Noncancer No treatment related effects observed n/a RfD 1.5 x 10 -2 mg/kg-day
562 Prometryn 7287-19-6 Oral Noncancer Liver and kidney degeneration and bone marrow atrophy n/a RfD 4 x 10 -3 mg/kg-day
563 Pronamide 23950-58-5 Oral Noncancer No effects n/a RfD 7.5 x 10 -2 mg/kg-day
564 Propachlor 1918-16-7 Oral Noncancer Decreased weight gain, food consumption increased relative liver weights n/a RfD 1.3 x 10 -2 mg/kg-day
565 Propanil 709-98-8 Oral Noncancer Increased relative spleen weight in females n/a RfD 5 x 10 -3 mg/kg-day
566 Propargite 2312-35-8 Oral Noncancer Reduced body weight gain (maternal), increased resorption, reduced body weight (fetal), delayed ossification n/a RfD 2 x 10 -2 mg/kg-day
567 Propargyl alcohol 107-19-7 Oral Noncancer Renal and hepatotoxicity n/a RfD 2 x 10 -3 mg/kg-day
568 Propazine 139-40-2 Oral Noncancer Decrease in body weight n/a RfD 2 x 10 -2 mg/kg-day
569 Propham 122-42-9 Oral Noncancer Increase in male spleen weight and ChE depression in females n/a RfD 2 x 10 -2 mg/kg-day
570 Propiconazole 60207-90-1 Oral Noncancer Gastric mucosal irritation n/a RfD 1.3 x 10 -2 mg/kg-day
571 Propionaldehyde 123-38-6 Inhalation Noncancer Atrophy of olfactory epithelium n/a RfC 8 x 10 -3 mg/m3
572 Propylene glycol monomethyl ether (PGME) 107-98-2 Inhalation Noncancer Mild reversible sedation n/a RfC 2 mg/m3
573 Propylene oxide 75-56-9 Oral Cancer Forestomach, squamous cell carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.4 x 10 -1 per mg/kg-day
574 Propylene oxide 75-56-9 Inhalation Cancer Nasal cavity hemangioma or hemangiosarcoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.7 x 10 -6 per µg/m3
575 Propylene oxide 75-56-9 Inhalation Noncancer Nest-like infolds of the nasal respiratory epithelium n/a RfC 3 x 10 -2 mg/m3
576 Pursuit 81335-77-5 Oral Noncancer Decreased packed cell volume, hemoglobin, erythrocytes in females n/a RfD 2.5 x 10 -1 mg/kg-day
577 Pydrin 51630-58-1 Oral Noncancer Neurological dysfunction n/a RfD 2.5 x 10 -2 mg/kg-day
578 Pyrene 129-00-0 Oral Noncancer Kidney effects (renal tubular pathology, decreased kidney weights) n/a RfD 3 x 10 -2 mg/kg-day
579 Pyridine 110-86-1 Oral Noncancer Increased liver weight n/a RfD 1 x 10 -3 mg/kg-day
580 Quinalphos 13593-03-8 Oral Noncancer No adverse effects reported n/a RfD 5 x 10 -4 mg/kg-day
581 Quinoline 91-22-5 Oral Cancer Hepatic hemangioendotheliomas or hemangiosarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 3 per mg/kg-day
582 Refractory ceramic fibers None None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
583 Resmethrin 10453-86-8 Oral Noncancer Reproductive toxicity n/a RfD 3 x 10 -2 mg/kg-day
584 Rotenone 83-79-4 Oral Noncancer Reduced pup weight n/a RfD 4 x 10 -3 mg/kg-day
585 Savey 78587-05-0 Oral Noncancer Hypertrophy of adrenal cortex (both sexes) hematologic effects (males) n/a RfD 2.5 x 10 -2 mg/kg-day
586 Selenious acid 7783-00-8 Oral Noncancer Clinical selenosis n/a RfD 5 x 10 -3 mg/kg-day
587 Selenium and Compounds 7782-49-2 Oral Noncancer Clinical selenosis n/a RfD 5 x 10 -3 mg/kg-day
588 Selenium sulfide 7446-34-6 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
589 Sethoxydim 74051-80-2 Oral Noncancer Mild anemia in males n/a RfD 9 x 10 -2 mg/kg-day
590 Silver 7440-22-4 Oral Noncancer Argyria n/a RfD 5 x 10 -3 mg/kg-day
591 Silver cyanide 506-64-9 Oral Noncancer Weight loss, thyroid effects, and myelin degeneration n/a RfD 1 x 10 -1 mg/kg-day
592 Simazine 122-34-9 Oral Noncancer Reduction in weight gains hematological changes in females n/a RfD 5 x 10 -3 mg/kg-day
593 Sodium azide 26628-22-8 Oral Noncancer Clinical sign (e.g., hunched postures) and reduced body weight n/a RfD 4 x 10 -3 mg/kg-day
594 Sodium cyanide 143-33-9 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 1 x 10 -3 mg/kg-day
595 Sodium diethyldithiocarbamate 148-18-5 Oral Noncancer Reduced body weight n/a RfD 3 x 10 -2 mg/kg-day
596 Sodium fluoroacetate 62-74-8 Oral Noncancer Increased heart weight in females and males; decreased testis weight and altered spermatogenesis in males. n/a RfD 2 x 10 -5 mg/kg-day
597 Strontium 7440-24-6 Oral Noncancer Rachitic bone n/a RfD 6 x 10 -1 mg/kg-day
598 Strychnine 57-24-9 Oral Noncancer Toxicity/histopathology n/a RfD 3 x 10 -4 mg/kg-day
599 Styrene 100-42-5 Inhalation Noncancer CNS effects n/a RfC 1 mg/m3
600 Styrene 100-42-5 Oral Noncancer Red blood cell and liver effects n/a RfD 2 x 10 -1 mg/kg-day
601 Systhane 88671-89-0 Oral Noncancer Testicular atrophy n/a RfD 2.5 x 10 -2 mg/kg-day
602 Tebuthiuron 34014-18-1 Oral Noncancer Depressed body weight gain in F1 females n/a RfD 7 x 10 -2 mg/kg-day
603 Terbacil 5902-51-2 Oral Noncancer Increase in thyroid/body weight ratio; slight increase in liver weights; elevated alkaline phosphatase n/a RfD 1.3 x 10 -2 mg/kg-day
604 Terbutryn 886-50-0 Oral Noncancer Hematologic effects in females n/a RfD 1 x 10 -3 mg/kg-day
605 Tetrabromodiphenyl ether 40088-47-9 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
606 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 5436-43-1 Oral Noncancer Neurobehavioral effects n/a RfD 1 x 10 -4 mg/kg-day
607 1,2,4,5-Tetrachlorobenzene 95-94-3 Oral Noncancer Kidney lesions n/a RfD 3 x 10 -4 mg/kg-day
608 Tetrachlorocyclopentadiene 695-77-2 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
609 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6 Oral Noncancer Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates n/a RfD 7 x 10 -10 mg/kg-day
610 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6 Oral Noncancer Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates n/a RfD 7 x 10 -10 mg/kg-day
611 1,1,1,2-Tetrachloroethane 630-20-6 Inhalation Cancer Hepatocellular adenoma or carcinoma C (Possible human carcinogen) (1986 guidelines)
Inhalation Unit Risk 7.4 x 10 -6 per µg/m3
612 1,1,1,2-Tetrachloroethane 630-20-6 Oral Noncancer Mineralization of the kidneys in males, hepatic clear cell change in females n/a RfD 3 x 10 -2 mg/kg-day
613 1,1,1,2-Tetrachloroethane 630-20-6 Oral Cancer Hepatocellular adenoma or carcinoma C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 2.6 x 10 -2 per mg/kg-day
614 1,1,2,2-Tetrachloroethane 79-34-5 Oral Noncancer Increased relative liver weight in rats n/a RfD 2 x 10 -2 mg/kg-day
615 1,1,2,2-Tetrachloroethane 79-34-5 Oral Noncancer Increased relative liver weight in rats n/a RfD 5 x 10 -2 mg/kg-day
616 1,1,2,2-Tetrachloroethane 79-34-5 Oral Cancer hepatocellular carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 2 x 10 -1 per mg/kg-day
617 Tetrachloroethylene (Perchloroethylene) 127-18-4 Oral Noncancer (See Note) n/a RfD 6 x 10 -3 mg/kg-day
618 Tetrachloroethylene (Perchloroethylene) 127-18-4 Oral Cancer Hepatocellular adenomas or carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 2.1 x 10 -3 per mg/kg-day
619 Tetrachloroethylene (Perchloroethylene) 127-18-4 Inhalation Noncancer (See Note) n/a RfC 4 x 10 -2 mg/m3
620 Tetrachloroethylene (Perchloroethylene) 127-18-4 Inhalation Cancer Hepatocellular adenomas or carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 2.6 x 10 -7 per µg/m3
621 2,3,4,6-Tetrachlorophenol 58-90-2 Oral Noncancer Increased liver weights and centrilobular hypertrophy n/a RfD 3 x 10 -2 mg/kg-day
622 Tetrachlorovinphos 961-11-5 Oral Noncancer Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition n/a RfD 3 x 10 -2 mg/kg-day
623 Tetraethyl lead 78-00-2 Oral Noncancer Histopathology of liver and thymus n/a RfD 1 x 10 -7 mg/kg-day
624 Tetraethyldithiopyrophosphate 3689-24-5 Oral Noncancer Depressed RBC and plasma cholinesterase activity n/a RfD 5 x 10 -4 mg/kg-day
625 1,1,1,2-Tetrafluoroethane 811-97-2 Inhalation Noncancer Leydig cell hyperplasia n/a RfC 8 x 10 1 mg/m3
626 Tetrahydrofuran 109-99-9 Inhalation Noncancer Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) n/a RfC 2 mg/m3
627 Tetrahydrofuran 109-99-9 Oral Noncancer Decreased pup body weight gain n/a RfD 9 x 10 -1 mg/kg-day
628 Thallium (I), soluble salts Various None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
629 Thallium acetate 563-68-8 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
630 Thallium carbonate 6533-73-9 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
631 Thallium chloride 7791-12-0 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
632 Thallium nitrate 10102-45-1 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
633 Thallium oxide 1314-32-5 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
634 Thallium selenite 12039-52-0 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
635 Thallium(I) sulfate 7446-18-6 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
636 Thiobencarb 28249-77-6 Oral Noncancer Decrease in body weight, increase in BUN n/a RfD 1 x 10 -2 mg/kg-day
637 Thiophanate-methyl 23564-05-8 Oral Noncancer Decreased body weight, decreased spermatogenesis, and histological evidence of hyperthyroidism n/a RfD 8 x 10 -2 mg/kg-day
638 Thiram 137-26-8 Oral Noncancer Neurotoxicity n/a RfD 5 x 10 -3 mg/kg-day
639 Toluene 108-88-3 Inhalation Noncancer Neurological effects in occupationally-exposed workers n/a RfC 5 mg/m3
640 Toluene 108-88-3 Oral Noncancer Increased kidney weight n/a RfD 8 x 10 -2 mg/kg-day
641 2,4-/2,6-Toluene diisocyanate mixture (TDI) 26471-62-5 Inhalation Noncancer Chronic lung-function decline n/a RfC 7 x 10 -5 mg/m3
642 Toxaphene 8001-35-2 Inhalation Cancer Hepatocellular carcinomas and neoplastic nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.2 x 10 -4 per µg/m3
643 Toxaphene 8001-35-2 Oral Cancer Hepatocellular carcinomas and neoplastic nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.1 per mg/kg-day
644 Tralomethrin 66841-25-6 Oral Noncancer Decreased body weight gain in males increased food and water consumption in males and females n/a RfD 7.5 x 10 -3 mg/kg-day
645 Triallate 2303-17-5 Oral Noncancer Increased hemosiderin deposition, serum alkaline phosphatase, and liver weight in females n/a RfD 1.3 x 10 -2 mg/kg-day
646 Triasulfuron 82097-50-5 Oral Noncancer Centrilobular hepatocytomegaly in males n/a RfD 1 x 10 -2 mg/kg-day
647 1,2,4-Tribromobenzene 615-54-3 Oral Noncancer Increased liver-to-body weight ratio and hepatic microsomal enzyme induction n/a RfD 5 x 10 -3 mg/kg-day
648 Tribromochloromethane 594-15-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
649 Tribromodiphenyl ether 49690-94-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
650 Tributyltin oxide (TBTO) 56-35-9 Oral Noncancer Immunosuppression n/a RfD 3 x 10 -4 mg/kg-day
651 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) 76-13-1 Oral Noncancer Psychomotor impairment n/a RfD 3 x 10 1 mg/kg-day
652 Trichloroacetic acid 76-03-9 Oral Noncancer Hepatocellular necrosis n/a RfD 2 x 10 -2 mg/kg-day
653 Trichloroacetic acid 76-03-9 Oral Cancer Hepatocellular adenomas or carcinomas Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 7 x 10 -2 per mg/kg-day
654 1,2,4-Trichlorobenzene 120-82-1 Oral Noncancer Increased adrenal weights; vacuolization of zona fasciculata in the cortex n/a RfD 1 x 10 -2 mg/kg-day
655 Trichlorocyclopentadiene 77323-84-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
656 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 7 mg/m3
657 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Liver histopathologic changes n/a RfC 5 mg/m3
658 1,1,1-Trichloroethane 71-55-6 Oral Noncancer Reduced body weight n/a RfD 7 mg/kg-day
659 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 9 mg/m3
660 1,1,1-Trichloroethane 71-55-6 Oral Noncancer Reduced body weight n/a RfD 2 mg/kg-day
661 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 7 mg/m3
662 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 6 mg/m3
663 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 5 mg/m3
664 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Liver histopathologic changes n/a RfC 5 mg/m3
665 1,1,2-Trichloroethane 79-00-5 Oral Noncancer Clinical serum chemistry (effects on erythrocytes and depressed humoral immune status) n/a RfD 4 x 10 -3 mg/kg-day
666 1,1,2-Trichloroethane 79-00-5 Inhalation Cancer Hepatocellular carcinoma C (Possible human carcinogen) (1986 guidelines)
Inhalation Unit Risk 1.6 x 10 -5 per µg/m3
667 1,1,2-Trichloroethane 79-00-5 Oral Cancer Hepatocellular carcinoma C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 5.7 x 10 -2 per mg/kg-day
668 Trichloroethylene 79-01-6 Oral Cancer Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors Carcinogenic to humans (2005 guidelines)
Oral Slope Factor 5.2 x 10 -2 per mg/kg-day
669 Trichloroethylene 79-01-6 Inhalation Cancer Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 4.8 x 10 -6 per µg/m3
670 Trichloroethylene 79-01-6 Oral Noncancer (See Note) n/a RfD 5 x 10 -4 mg/kg-day
671 Trichloroethylene 79-01-6 Inhalation Noncancer (See Note) n/a RfC 2 x 10 -3 mg/m3
672 Trichlorofluoromethane 75-69-4 Oral Noncancer Survival and histopathology (pleuritis and pericarditis) n/a RfD 3 x 10 -1 mg/kg-day
673 2,4,5-Trichlorophenol 95-95-4 Oral Noncancer Liver and kidney pathology n/a RfD 1 x 10 -1 mg/kg-day
674 2,4,6-Trichlorophenol 88-06-2 Oral Cancer Leukemia B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.1 x 10 -2 per mg/kg-day
675 2,4,6-Trichlorophenol 88-06-2 Inhalation Cancer Leukemia B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.1 x 10 -6 per µg/m3
676 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) 93-72-1 Oral Noncancer Histopathological changes in liver n/a RfD 8 x 10 -3 mg/kg-day
677 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) 93-76-5 Oral Noncancer Increased urinary coproporphyrins n/a RfD 1 x 10 -2 mg/kg-day
678 1,1,2-Trichloropropane 598-77-6 Oral Noncancer Mild lesions in liver, kidney and thyroid n/a RfD 5 x 10 -3 mg/kg-day
679 1,2,3-Trichloropropane 96-18-4 Oral Noncancer Increased absolute liver weight in male rats n/a RfD 4 x 10 -3 mg/kg-day
680 1,2,3-Trichloropropane 96-18-4 Oral Cancer alimentary system squamous cell neoplasms, liver hepatocellular adenomas or carcinomas, Harderian gland adenomas, uterine/cervix adenomas or carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 3 x 10 1 per mg/kg-day
681 1,2,3-Trichloropropane 96-18-4 Inhalation Noncancer peribronchial lymphoid hyperplasia in male rats n/a RfC 3 x 10 -4 mg/m3
682 Tridiphane 58138-08-2 Oral Noncancer Decreased fertility index and depressed body weight of dams n/a RfD 3 x 10 -3 mg/kg-day
683 Triethylamine 121-44-8 Inhalation Noncancer Inflammation of the nasal passage n/a RfC 7 x 10 -3 mg/m3
684 Trifluralin 1582-09-8 Oral Cancer Combined renal pelvis carcinomas, urinary bladder papillomas and/or thyroid adenomas and carcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 7.7 x 10 -3 per mg/kg-day
685 Trifluralin 1582-09-8 Oral Noncancer Increased liver weights; increase in methemoglobin n/a RfD 7.5 x 10 -3 mg/kg-day
686 1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 6 x 10 -2 mg/m3
687 1,2,3-Trimethylbenzene 526-73-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 4 x 10 -2 mg/kg-day
688 1,2,3-Trimethylbenzene 526-73-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 1 x 10 -2 mg/kg-day
689 1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Inflammatory lung lesions n/a RfC 2 x 10 -1 mg/m3
690 1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 2 x 10 -1 mg/m3
691 1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Decreased segmented neutrophils n/a RfC 6 x 10 -2 mg/m3
692 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Inflammatory lung lesions n/a RfC 2 x 10 -1 mg/m3
693 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased fetal weight n/a RfC 4 mg/m3
694 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased maternal weight n/a RfC 3 mg/m3
695 1,2,4-Trimethylbenzene 95-63-6 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 1 x 10 -2 mg/kg-day
696 1,2,4-Trimethylbenzene 95-63-6 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 4 x 10 -2 mg/kg-day
697 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 6 x 10 -2 mg/m3
698 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 2 x 10 -1 mg/m3
699 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased clotting time n/a RfC 8 x 10 -2 mg/m3
700 1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 6 x 10 -2 mg/m3
701 1,3,5-Trimethylbenzene 108-67-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 1 x 10 -2 mg/kg-day
702 1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased fetal weight n/a RfC 4 mg/m3
703 1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased maternal weight n/a RfC 4 x 10 -1 mg/m3
704 1,3,5-Trimethylbenzene 108-67-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 4 x 10 -2 mg/kg-day
705 1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 2 x 10 -1 mg/m3
706 2,2,4-Trimethylpentane 540-84-1 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
707 1,3,5-Trinitrobenzene 99-35-4 Oral Noncancer Methemoglobinemia and spleen-erythroid cell hyperplasia n/a RfD 3 x 10 -2 mg/kg-day
708 2,4,6-Trinitrotoluene (TNT) 118-96-7 Oral Noncancer Liver effects n/a RfD 5 x 10 -4 mg/kg-day
709 2,4,6-Trinitrotoluene (TNT) 118-96-7 Oral Cancer Urinary bladder, transitional cell papilloma and transitional squamous cell carcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 3 x 10 -2 per mg/kg-day
710 Uranium, soluble salts Various Oral Noncancer Initial body weight loss moderate nephrotoxicity n/a RfD 3 x 10 -3 mg/kg-day
711 Urea 57-13-6 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
712 Vanadium pentoxide 1314-62-1 Oral Noncancer Decreased hair cystine n/a RfD 9 x 10 -3 mg/kg-day
713 Vernam 1929-77-7 Oral Noncancer Decreased body weight n/a RfD 1 x 10 -3 mg/kg-day
714 Vinclozolin 50471-44-8 Oral Noncancer Organ weight changes (adrenal and kidney) n/a RfD 2.5 x 10 -2 mg/kg-day
715 Vinyl acetate 108-05-4 Inhalation Noncancer Nasal epithelial lesions n/a RfC 2 x 10 -1 mg/m3
716 Vinyl bromide 593-60-2 Inhalation Noncancer Hypertrophy, basophilic and eosinophilic foci, in the liver n/a RfC 3 x 10 -3 mg/m3
717 Vinyl chloride 75-01-4 Inhalation Cancer Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 8.8 x 10 -6 per µg/m3
718 Vinyl chloride 75-01-4 Oral Cancer Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 7.2 x 10 -1 per mg/kg-day
719 Vinyl chloride 75-01-4 Oral Cancer Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 7.5 x 10 -1 per mg/kg-day
720 Vinyl chloride 75-01-4 Oral Cancer Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 1.4 per mg/kg-day
721 Vinyl chloride 75-01-4 Inhalation Cancer Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 4.4 x 10 -6 per µg/m3
722 Vinyl chloride 75-01-4 Inhalation Cancer Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 8.8 x 10 -6 per µg/m3
723 Vinyl chloride 75-01-4 Oral Cancer Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 1.5 per mg/kg-day
724 Vinyl chloride 75-01-4 Oral Noncancer Liver cell polymorphism n/a RfD 3 x 10 -3 mg/kg-day
725 Vinyl chloride 75-01-4 Inhalation Noncancer Liver cell polymorphism n/a RfC 1 x 10 -1 mg/m3
726 Vinyl chloride 75-01-4 Inhalation Cancer Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 4.4 x 10 -6 per µg/m3
727 Warfarin 81-81-2 Oral Noncancer Increased prothrombin time n/a RfD 3 x 10 -4 mg/kg-day
728 White phosphorus 7723-14-0 Oral Noncancer Parturition mortality; forelimb hair loss n/a RfD 2 x 10 -5 mg/kg-day
729 Xylenes 1330-20-7 Oral Noncancer Decreased body weight, increased mortality n/a RfD 2 x 10 -1 mg/kg-day
730 Xylenes 1330-20-7 Inhalation Noncancer Impaired motor coordination (decreased rotarod performance) n/a RfC 1 x 10 -1 mg/m3
731 Zinc and Compounds 7440-66-6 Oral Noncancer Decreases in erythrocyte Cu, Zn-superoxide dismutase (ESOD) activity in healthy adult male and female volunteers n/a RfD 3 x 10 -1 mg/kg-day
732 Zinc cyanide 557-21-1 Oral Noncancer Weight loss, thyroid effects, and myelin degeneration n/a RfD 5 x 10 -2 mg/kg-day
733 Zinc phosphide 1314-84-7 Oral Noncancer Reduction of food intake and body weight n/a RfD 3 x 10 -4 mg/kg-day
734 Zineb 12122-67-7 Oral Noncancer Thyroid hyperplasia n/a RfD 5 x 10 -2 mg/kg-day
735 n-Butanol 71-36-3 Oral Noncancer Hypoactivity and ataxia n/a RfD 1 x 10 -1 mg/kg-day
736 tert-Butyl Alcohol (tBA) 75-65-0 Inhalation Noncancer Increased severity of nephropathy n/a RfC 5 mg/m3
737 tert-Butyl Alcohol (tBA) 75-65-0 Oral Cancer Renal adenomas and carcinomas, thyroid adenomas Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 5 x 10 -4 per mg/kg-day
738 tert-Butyl Alcohol (tBA) 75-65-0 Oral Noncancer Increased severity of nephropathy n/a RfD 4 x 10 -1 mg/kg-day

  CHEMICAL NAME CASRN PRINCIPAL CRITICAL EFFECT SYSTEM PRINCIPAL CRITICAL DESCRIPTION PRINCIPAL STUDY STUDY CITATION EXPERIMENTAL DOSE TYPE POD VALUE RFD VALUE UNCERTAINTY FACTOR MODIFYING FACTOR STUDY CONFIDENCE DATA CONFIDENCE OVERALL CONFIDENCE DOSE TYPE DURATION
1 Acenaphthene 83-32-9 Hepatic Hepatotoxicity Mouse oral subchronic study U.S. EPA, 1989 No Observable Adverse Effect Level 175.0 mg/kg-day 0.06 mg/kg-day 3000 1 Low Low Low Threshold Chronic
2 Acephate 30560-19-1 Nervous Inhibition of brain ChE 90-day rat feeding study (LEL for male subjects) Chevron Chemical Co., 1987a Lowest Effect Level 0.12 mg/kg-day 0.004 mg/kg-day 30 1 Medium High High Threshold Chronic
3 Acetochlor 34256-82-1 Hematologic, Hepatic, Nervous, Reproductive, Urinary Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males 1-year dog feeding study ICI, Inc., 1988a No Observable Adverse Effect Level 2.0 mg/kg-day 0.02 mg/kg-day 100 1 High High High Threshold Chronic
4 Acetone 67-64-1 Urinary Nephropathy Subchronic drinking water study in rats Dietz, et., al, 1991 NTP, 1991 No Observable Adverse Effect Level 900.0 mg/kg-day 0.9 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
5 Acetophenone 98-86-2 Other General Toxicity Rat oral subchronic study Hagen et al., 1967 No Observable Adverse Effect Level 423.0 mg/kg-day 0.1 mg/kg-day 3000 1 Low Low Low Threshold Chronic
6 Acifluorfen, sodium 62476-59-9 Developmental, Other, Urinary Mortality and kidney lesions 2-generation reproduction rat study Rhone-Poulenc, Inc., 1986 No Observed Effect Level 1.25 mg/kg-day 0.013 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
7 Acrolein 107-02-8 Other Decreased survival Chronic gavage rat study Parent et. al., 1992a No Observable Adverse Effect Level 0.05 mg/kg-day 0.0005 mg/kg-day 100 1 Medium High Medium/High Threshold Chronic
8 Acrylamide 79-06-1 Nervous Degenerative nerve changes Chronic rat study Johnson et al. 1986 Human Equivalent Dose 0.053 mg/kg-day 0.002 mg/kg-day 30 1 Medium/High Medium/High Medium/High Threshold Chronic
9 Acrylic acid 79-10-7 Developmental Reduced pup weight Rat reproductive study BASF, 1993 No Observable Adverse Effect Level 53.0 mg/kg-day 0.5 mg/kg-day 100 1 High High High Threshold Chronic
10 Alachlor 15972-60-8 Hematologic, Other Hemosiderosis, hemolytic anemia 1-year dog feeding study Monsanto Co., 1984a No Observable Adverse Effect Level 1.0 mg/kg-day 0.01 mg/kg-day 100 1 High High High Threshold Chronic
11 Alar 1596-84-5 Other No adverse effects 3-generation reproduction rat study, 3-generation reproduction rat study Uniroyal Chemical, 1966 No Observed Effect Level 15.0 mg/kg-day 0.15 mg/kg-day 100 1 Low Medium Low Threshold Chronic
12 Aldicarb 116-06-3 Nervous Sweating as clinical sign of AChe inhibition Acute human oral exposure study Rhone-Poulenc, 1992 No Observable Adverse Effect Level 0.01 mg/kg-day 0.001 mg/kg-day 10 1 Medium Medium Medium Threshold Chronic
13 Aldicarb sulfone 1646-88-4 Nervous Brain ChE inhibition in females 1-year dog feeding study Union Carbide Agricultural Products Co., 1987 No Observable Adverse Effect Level 0.11 mg/kg-day 0.001 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
14 Aldrin 309-00-2 Hepatic Liver toxicity Rat chronic feeding study Fitzhugh et al., 1964 Lowest Observable Adverse Effect Level 0.025 mg/kg-day 3e-05 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
15 Ally 74223-64-6 Other Decreased body weight 2-year rat feeding/oncogenicity study duPont, 1985a No Observed Effect Level 25.0 mg/kg-day 0.25 mg/kg-day 100 1 High High High Threshold Chronic
16 Allyl alcohol 107-18-6 Hepatic, Urinary Impaired renal function and increased liver and kidney weights Subchronic oral rat study (drinking water) Carpanini et al., 1978 No Observed Effect Level 4.8 mg/kg-day 0.005 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
17 Aluminum phosphide 20859-73-8 Other Body weight and clinical parameters Rat chronic oral study Hackenburg, 1972 No Observable Adverse Effect Level 0.043 mg/kg-day 0.0004 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
18 Amdro 67485-29-4 Hepatic, Other Increased organ weights 26-week dog feeding study American Cyanamid, 1980 No Observed Effect Level 0.33 mg/kg-day 0.0003 mg/kg-day 1000 1 Medium High High Threshold Chronic
19 Ametryn 834-12-8 Hepatic Liver toxicity Rat subchronic oral gavage bioassay Ciba-Geigy, 1961a No Observed Effect Level 8.6 mg/kg-day 0.009 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
20 Amitraz 33089-61-1 Hematologic Increased mean blood sugar concentration; slight hypothermia 2-year dog oral feeding study Upjohn Co., 1972a No Observed Effect Level 0.25 mg/kg-day 0.0025 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
21 Ammonium sulfamate 7773-06-0 Other Decrease in body weight 90-day rat feeding study Gupta et al., 1979 No Observed Effect Level 214.3 mg/kg-day 0.2 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
22 Anthracene 120-12-7 Other No observed effects Subchronic toxicity study in mice U.S. EPA, 1989 No Observed Effect Level 1000.0 mg/kg-day 0.3 mg/kg-day 3000 1 Low Low Low Threshold Chronic
23 Antimony 7440-36-0 Hematologic, Other Longevity, blood glucose, and cholesterol Rat chronic oral bioassay Schroeder et al., 1970 Lowest Observable Adverse Effect Level 0.35 mg/kg-day 0.0004 mg/kg-day 1000 1 Low Low Low Threshold Chronic
24 Apollo 74115-24-5 Endocrine, Hepatic Liver effects; organ weight changes 1-year feeding dog study BFC Chemicals, Inc., 1984 No Observed Effect Level 1.25 mg/kg-day 0.013 mg/kg-day 100 1 High High High Threshold Chronic
25 Aroclor 1016 12674-11-2 Developmental Reduced birth weights Monkey reproductive bioassay Barsotti and van Miller, 1984; Levin et al., 1988; Schantz et al., 1989, 1991 No Observable Adverse Effect Level 0.007 mg/kg-day 7e-05 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
26 Aroclor 1254 11097-69-1 Dermal, Immune, Ocular Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes Monkey clinical and immunologic studies Arnold et al., 1994a,b; Tryphonas et al., 1989, 1991a,b Lowest Observable Adverse Effect Level 0.005 mg/kg-day 2e-05 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
27 Arsenic, Inorganic 7440-38-2 Cardiovascular, Endocrine Ischemic heart disease and type 2 diabetes (see Note) Human chronic oral exposure Tseng, 1977; Tseng et al., 1968 See Note None None 6e-05 mg/kg-day 3 1 Medium Medium Medium/High Threshold Chronic
28 Assure 76578-14-8 Hepatic Liver cell enlargement 2-year rat feeding study (NOEL for male subjects) duPont, 1985 No Observed Effect Level 0.9 mg/kg-day 0.009 mg/kg-day 100 1 High High High Threshold Chronic
29 Asulam 3337-71-1 Hepatic, Reproductive Lower ovarian weight, lower liver/body weight 2-generation reproduction rat study Rhone-Poulenc, 1981a Lowest Effect Level 50.0 mg/kg-day 0.05 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
30 Atrazine 1912-24-9 Other Decreased body weight gain 2-year rat feeding study Ciba-Geigy Corp., 1986 No Observable Adverse Effect Level 3.5 mg/kg-day 0.035 mg/kg-day 100 1 High High High Threshold Chronic
31 Avermectin B1 65195-55-3 Developmental Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth 2-generation rat reproduction study Merck and Co., 1984 No Observed Effect Level 0.12 mg/kg-day 0.0004 mg/kg-day 300 1 Medium High High Threshold Chronic
32 Barium and Compounds 7440-39-3 Urinary Nephropathy 2-year drinking water study in mice NTP (1994) Benchmark Dose based on the LED10 (Lowest Effective Dose) 63.0 mg/kg-day 0.2 mg/kg-day 300 1 High Medium Medium Threshold Chronic
33 Baygon 114-26-1 Nervous Mild cholinergic symptoms and RBD ChE inhibition Single-dose human study Vandekar et al., 1971 Lowest Effect Level 0.36 mg/kg-day 0.004 mg/kg-day 100 1 Low Medium Medium Threshold Chronic
34 Bayleton 43121-43-3 Hematologic, Other Decreased body weight gain, erythrocyte count and hemoglobin level 2-year rat dietary study Mobay Chemical, 1978 No Observed Effect Level 2.5 mg/kg-day 0.03 mg/kg-day 100 1 High High High Threshold Chronic
35 Baythroid 68359-37-5 Other, Urinary Decreased body weights in males, inflammatory foci in kidneys of females 2-year rat study, dietary Mobay Chemical, 1983a No Observed Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 High High High Threshold Chronic
36 Benefin 1861-40-1 Hematologic Depressed erythrocyte counts Dog chronic oral bioassay Eli Lilly and Co., 1972 No Observable Adverse Effect Level 25.0 mg/kg-day 0.3 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
37 Benomyl 17804-35-2 Developmental Decreased pup weanling weights 3-generation reproduction rat study du Pont, 1968a No Observed Effect Level 5.0 mg/kg-day 0.05 mg/kg-day 100 1 Medium High High Threshold Chronic
38 Bentazon (Basagran) 25057-89-0 Hematologic Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs 1 year dog feeding study Allen et al., 1989 No Observable Adverse Effect Level 3.2 mg/kg-day 0.03 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
39 Benzaldehyde 100-52-7 Gastrointestinal, Urinary Forestomach lesions, kidney toxicity Rat oral toxicity study (subchronic) Kluwe et al., 1983 No Observed Effect Level 143.0 mg/kg-day 0.1 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
40 Benzene 71-43-2 Immune Decreased lymphocyte count Human occupational inhalation study Rothman et. al., 1996 Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.2 mg/kg-day 0.004 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
41 Benzidine 92-87-5 Hepatic, Nervous Brain cell vacuolization; liver cell alterations in females Mouse chronic oral bioassay Littlefield et al., 1983 Lowest Observable Adverse Effect Level 2.7 mg/kg-day 0.003 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
42 Benzo[a]pyrene (BaP) 50-32-8 Reproductive Decreased ovarian follicles and ovary weight Gavage subchronic (60 d) reproductive toxicity study in rats Xu et al. (2010) Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.37 mg/kg-day 0.0004 mg/kg-day 1000 1 None None Medium None Chronic
43 Benzo[a]pyrene (BaP) 50-32-8 Immune Decreased thymus weight and serum IgM Gavage subchronic (35 d) study in rats De Jong et al. (1999) Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.9 mg/kg-day 0.002 mg/kg-day 1000 1 None None Low Benchmark Chronic
44 Benzo[a]pyrene (BaP) 50-32-8 Developmental Neurobehavioral changes Gavage neurodevelopmental study in rats (postnatal days [PNDs] 5−11) Chen et al. (2012) Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.092 mg/kg-day 0.0003 mg/kg-day 300 1 Medium Medium Medium Benchmark Chronic
45 Benzoic acid 65-85-0 Other No adverse effects observed Human daily per capita intakes FDA, 1973; Selected Committee on Review of the GRAS List No Observable Adverse Effect Level 4.4 mg/kg-day 4.0 mg/kg-day 1 1 Medium Medium Medium Threshold Chronic
46 Beryllium and compounds 7440-41-7 Gastrointestinal Small intestinal lesions Dog dietary study Morgareidge et al., 1976 Benchmark Dose 0.46 mg/kg-day 0.002 mg/kg-day 300 1 Medium Low/Medium Low/Medium Threshold Chronic
47 Bidrin 141-66-2 Reproductive Decreased pup survival 3-generation rat reproduction study Shell Chemical, 1965a No Observed Effect Level 0.1 mg/kg-day 0.0001 mg/kg-day 1000 1 Low Low Low Threshold Chronic
48 Biphenthrin 82657-04-3 Nervous Tremors 1-year dog feeding study FMC Corporation, 1985 No Observed Effect Level 1.5 mg/kg-day 0.015 mg/kg-day 100 1 Medium High High Threshold Chronic
49 Biphenyl 92-52-4 Urinary Renal papillary mineralization in male F344 rats 2-year dietary study Umeda et al. (2002) Benchmark Dose based on the LED10 (Lowest Effective Dose) 13.9 mg/kg-day 0.5 mg/kg-day 30 10 High Medium/High Medium/High None Chronic
50 Bis(2-chloro-1-methylethyl) ether 108-60-1 Hematologic Decrease in hemoglobin and possible erythrocyte destruction 104-week mouse study oral exposure (diet) Mitsumori et al., 1979 No Observable Adverse Effect Level 35.8 mg/kg-day 0.04 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
51 Bisphenol A 80-05-7 Other Reduced mean body weight Rat chronic oral bioassay NTP, 1982 Lowest Observable Adverse Effect Level 50.0 mg/kg-day 0.05 mg/kg-day 1000 1 Medium High High Threshold Chronic
52 Boron and Compounds 7440-42-8 Developmental Decreased fetal weight (developmental) Rat dietary gestational exposure to boric acid Price et al., 1996a; Heindel et al., 1992 Benchmark Dose based on the LED10 (Lowest Effective Dose) 10.3 mg/kg-day 0.2 mg/kg-day 66 1 High High High Benchmark Chronic
53 Bromate 15541-45-4 Urinary Renal effects: urothelial hyperplasia Rat feeding study DeAngelo et al., 1998 No Observable Adverse Effect Level 1.1 mg/kg-day 0.004 mg/kg-day 300 1 High Medium Medium Threshold Chronic
54 Bromobenzene 108-86-1 Hepatic Hepatocellular cytomegaly in male B6C3F1 mice 90-day oral gavage administration NTP (1985b) Benchmark Dose based on the LED10 (Lowest Effective Dose) 24.1 mg/kg-day 0.008 mg/kg-day 3000 1 Medium Low/Medium Low/Medium None Chronic
55 Bromobenzene 108-86-1 Hepatic Hepatocellular cytomegaly in male B6C3F1 mice 90-day oral gavage administration NTP (1985b) Benchmark Dose based on the LED10 (Lowest Effective Dose) 24.1 mg/kg-day 0.02 mg/kg-day 1000 1 Medium Medium Medium None Subchronic
56 Bromodichloromethane 75-27-4 Urinary Renal cytomegaly Chronic mouse gavage bioassay NTP, 1986 Lowest Observable Adverse Effect Level 17.9 mg/kg-day 0.02 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
57 Bromoform 75-25-2 Hepatic Hepatic lesions Rat, subchronic oral gavage bioassay NTP, 1989 No Observed Effect Level 17.9 mg/kg-day 0.02 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
58 Bromomethane 74-83-9 Gastrointestinal Epithelial hyperplasia of the forestomach Rat subchronic gavage study Danse et al., 1984 No Observable Adverse Effect Level 1.4 mg/kg-day 0.0014 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
59 Bromoxynil 1689-84-5 Other No adverse effects 2-year rat feeding/ oncogenic study Union Carbide, 1982 No Observed Effect Level 5.0 mg/kg-day 0.02 mg/kg-day 300 1 Low Medium Medium Threshold Chronic
60 Bromoxynil octanoate 1689-99-2 Other No effects 2-year rat feeding study Union Carbide, 1982 No Observed Effect Level 7.3 mg/kg-day 0.02 mg/kg-day 300 1 Low Medium Medium Threshold Chronic
61 Butyl benzyl phthalate (BBP) 85-68-7 Hepatic Significantly increased liver-to-body weight and liver-to-brain weight ratios 6-month rat study oral exposure (diet) NTP, 1985 No Observable Adverse Effect Level 159.0 mg/kg-day 0.2 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
62 Butylate 2008-41-5 Hepatic Increased relative liver weight in male dogs 12-month dog feeding study Stauffer Chemical Co., 1987a No Observable Adverse Effect Level 5.0 mg/kg-day 0.05 mg/kg-day 100 1 High High High Threshold Chronic
63 Butylphthalyl butylglycolate (BPBG) 85-70-1 Other No adverse effect Rat, chronic oral bioassay B.F. Goodrich Co., 1950 No Observed Effect Level 1000.0 mg/kg-day 1.0 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
64 Cadmium 7440-43-9 Urinary Significant proteinuria Human studies involving chronic exposures U.S. EPA, 1985 No Observable Adverse Effect Level 0.005 mg/kg-day 0.0005 mg/kg-day 10 1 Not Available High High Threshold Chronic
65 Cadmium 7440-43-9 Urinary Significant proteinuria Human studies involving chronic exposures U.S. EPA, 1985 No Observable Adverse Effect Level 0.01 mg/kg-day 0.001 mg/kg-day 10 1 None None High None Chronic
66 Calcium cyanide 592-01-8 Reproductive Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. None None None None None 0.001 mg/kg-day None None None None None None Chronic
67 Caprolactam 105-60-2 Developmental Reduced offspring body weight Rat oral three generation reproduction study Serotta et al., 1984 No Observable Adverse Effect Level 50.0 mg/kg-day 0.5 mg/kg-day 100 1 High High High Threshold Chronic
68 Captafol 2425-06-1 Urinary Kidney and bladder toxicity One-year dog feeding study Ortho-Chevron, 1985a Lowest Effect Level 2.0 mg/kg-day 0.002 mg/kg-day 1000 1 High High High Threshold Chronic
69 Captan 133-06-2 Other Decreased mean body weights One-generation and three-generation rat reproduction studies Stauffer Chemical Co., 1982a Chevron Chemical Co., 1982 No Observed Effect Level 12.5 mg/kg-day 0.13 mg/kg-day 100 1 Medium High High Threshold Chronic
70 Carbaryl 63-25-2 Hepatic, Urinary Kidney and liver toxicity Rat chronic feeding study Carpenter et al., 1961 No Observable Adverse Effect Level 9.6 mg/kg-day 0.1 mg/kg-day 100 1 High Medium Medium Threshold Chronic
71 Carbofuran 1563-66-2 Nervous, Reproductive RBC and plasma cholinesterase inhibition, and testicular and uterine effects One-year dog feeding study FMC Corp., 1983 No Observed Effect Level 0.5 mg/kg-day 0.005 mg/kg-day 100 1 High High High Threshold Chronic
72 Carbon disulfide 75-15-0 Developmental Fetal toxicity/ malformations Rabbit inhalation teratogenic study Hardin et al., 1981 No Observed Effect Level 11.0 mg/kg-day 0.1 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
73 Carbon tetrachloride 56-23-5 Hepatic Elevated serum SDH activity Subchronic oral rat study Bruckner et al., 1986 Benchmark Dose based on the LED10 (Lowest Effective Dose) 3.9 mg/kg-day 0.004 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
74 Carbosulfan 55285-14-8 Other Decreased body weight 2-year rat feeding study FMC, 1982a No Observed Effect Level 1.0 mg/kg-day 0.01 mg/kg-day 100 1 High High High Threshold Chronic
75 Carboxin 5234-68-4 Other Reduced weight gain, organ weight changes, increased mortality 2-year rat feeding study Uniroyal Chemical, 1969a No Observed Effect Level 10.0 mg/kg-day 0.1 mg/kg-day 100 1 Medium High High Threshold Chronic
76 Chloral hydrate 302-17-0 Gastrointestinal, Nervous CNS depression and GI irritation in humans Subchronic human pharmacological information Goodman and Gilman, 1985 Lowest Observable Adverse Effect Level 10.7 mg/kg-day 0.1 mg/kg-day 100 1 Medium High High Threshold Chronic
77 Chloramben 133-90-4 Hepatic Hepatocyte degeneration 18-month feeding study in CD-1 mice Union Carbide, 1978 Lowest Effect Level 15.0 mg/kg-day 0.015 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
78 Chlordane (Technical) 12789-03-6 Hepatic Hepatic necrosis Mouse 104-week oral study Khasawinah and Grutsch, 1989a No Observable Adverse Effect Level 0.15 mg/kg-day 0.0005 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
79 Chlordecone (Kepone) 143-50-0 Urinary Renal lesions (glomerulosclerosis) in female Wistar rats 2-year feeding study Larson et al., 1979 Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.08 mg/kg-day 0.0003 mg/kg-day 300 1 Medium Medium Medium Benchmark Chronic
80 Chlorimuron-ethyl 90982-32-4 Hematologic Increase in WBC, decreased in RBC in females, increase in alkaline phosphatase in males 1-year dog study oral exposure (diet) duPont, 1985 No Observed Effect Level 6.25 mg/kg-day 0.02 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
81 Chlorine 7782-50-5 None No observed adverse effects Rat chronic drinking water study NTP, 1992 No Observable Adverse Effect Level 14.4 mg/kg-day 0.1 mg/kg-day 100 1 High Medium Medium Threshold Chronic
82 Chlorine cyanide 506-77-4 Endocrine, Nervous, Other Weight loss, thyroid effects, and myelin degeneration Rat chronic oral study Howard and Hanzal, 1955 No Observable Adverse Effect Level 25.3 mg/kg-day 0.05 mg/kg-day 100 5 Medium Medium Medium Threshold Chronic
83 Chlorine dioxide 10049-04-4 Developmental, Nervous Neurodevelopmental effects Two-generation rat drinking water study CMA, 1996 No Observable Adverse Effect Level 3.0 mg/kg-day 0.03 mg/kg-day 100 1 Medium High Medium/High Threshold Chronic
84 Chlorite (sodium salt) 7758-19-2 Developmental, Nervous Neurodevelopmental effects Two-generation rat drinking water study CMA, 1996 No Observable Adverse Effect Level 3.0 mg/kg-day 0.03 mg/kg-day 100 1 Medium High Medium/High Threshold Chronic
85 p-Chloroaniline 106-47-8 Immune Nonneoplastic lesions of splenic capsule Rat, chronic oral bioassay NCI, 1979 Lowest Observable Adverse Effect Level 12.5 mg/kg-day 0.004 mg/kg-day 3000 1 Low Low Low Threshold Chronic
86 Chlorobenzene 108-90-7 Hepatic Histopathologic changes in liver 13-week dog study, oral exposure (capsule) Monsanto Co., 1967a; Knapp et al., 1971 No Observable Adverse Effect Level 19.0 mg/kg-day 0.02 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
87 Chlorobenzilate 510-15-6 Nervous, Other Decreased stool quantity, food consumption and body weight gains hyperirritability (maternal effects) Rabbit teratology study Ciba-Geigy Corp., 1984a No Observed Effect Level 5.0 mg/kg-day 0.02 mg/kg-day 300 1 Low Medium Medium Threshold Chronic
88 Chloroform 67-66-3 Hepatic Moderate/marked fatty cyst formation in the liver and elevated SGPT Dog, chronic oral bioassay Heywood et al., 1979 Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.0 mg/kg-day 0.01 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
89 beta-Chloronaphthalene 91-58-7 Hepatic, Other, Respiratory Dyspnea, abnormal appearance, liver enlargement Mouse subchronic oral gavage study U.S. EPA, 1989 No Observable Adverse Effect Level 250.0 mg/kg-day 0.08 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
90 2-Chlorophenol 95-57-8 Reproductive Reproductive effects Rat subchronic drinking water study Exon and Koller, 1982 No Observable Adverse Effect Level 5.0 mg/kg-day 0.005 mg/kg-day 1000 1 Low Low Low Threshold Chronic
91 Chlorothalonil 1897-45-6 Urinary Renal tubular epithelial vacuolation 2-year dog feeding study Diamond Shamrock Chemical, 1970a No Observed Effect Level 1.5 mg/kg-day 0.015 mg/kg-day 100 1 High Medium Medium Threshold Chronic
92 o-Chlorotoluene 95-49-8 Other Decrease in body weight gain 15-week rat study oral exposure (gavage) Gibson et al., 1974a No Observable Adverse Effect Level 20.0 mg/kg-day 0.02 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
93 Chlorpropham 101-21-3 Hematologic, Hepatic, Immune, Urinary Kidney, spleen, liver, and bone marrow toxicity 2-generation rat reproduction study PPG Industries, 1983a No Observed Effect Level 50.0 mg/kg-day 0.2 mg/kg-day 300 1 High Medium Medium Threshold Chronic
94 Chlorsulfuron 64902-72-3 Other Decreased body weight 2-year rat study oral exposure (diet) du Pont, 1980a No Observed Effect Level 5.0 mg/kg-day 0.05 mg/kg-day 100 1 High High High None Chronic
95 Chromium(III), insoluble salts 16065-83-1 Other No effects observed Rat chronic feeding study Ivankovic and Preussman, 1975 No Observable Adverse Effect Level 1468.0 mg/kg-day 1.5 mg/kg-day 100 10 Low Low Low Threshold Chronic
96 Chromium(VI) 18540-29-9 Gastrointestinal GI tract effects in mice and rats None None Human Equivalent Dose 0.0911 mg/kg-day 0.0009 mg/kg-day 100 None None None Medium/High None Chronic
97 Copper cyanide 544-92-3 Hepatic, Other, Urinary Decreased body and organ weights, histopathologic alterations in liver and kidney Rat oral subchronic study U.S. EPA, 1986 No Observable Adverse Effect Level 5.0 mg/kg-day 0.005 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
98 Cumene 98-82-8 Urinary Increased average kidney weight in female rats Rat oral gavage study Wolf et al., 1956 No Observable Adverse Effect Level 110.0 mg/kg-day 0.1 mg/kg-day 1000 1 Low Medium Low Threshold Chronic
99 Cyanide, free 57-12-5 Reproductive Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section 1.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. Decreased cauda epididymis weight in rats in the subchronic oral study conducted by NTP (1993). A total UF of 3,000 was applied to the POD: 10 for the extrapolation from animals to humans (UFA), 10 for the extrapolation from a subchronic to chronic exposure duration (UFS) 10 for human intraspecies variability (UFH) and 3 to account for database deficiencies (UFD). None None None None 0.00063 mg/kg-day 3000 None None None Low/Medium None Chronic
100 Cyanogen 460-19-5 Other Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanogen is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. None None None None None 0.001 mg/kg-day None None None None None None Chronic
101 Cyanogen bromide 506-68-3 Endocrine, Nervous, Other Weight loss, thyroid effects and myelin degeneration Rat chronic oral study Howard and Hanzal, 1955 No Observable Adverse Effect Level 44.0 mg/kg-day 0.09 mg/kg-day 100 5 Medium Medium Low Threshold Chronic
102 Cyclohexanone 108-94-1 Other Body weight depression Chronic rat oral study Lijinsky and Kovatch, 1986 No Observable Adverse Effect Level 462.0 mg/kg-day 5.0 mg/kg-day 100 1 High Medium Medium Threshold Chronic
103 Cyclohexylamine 108-91-8 Reproductive Testicular damage Rat chronic oral study Gaunt et al., 1976 No Observable Adverse Effect Level 18.0 mg/kg-day 0.2 mg/kg-day 100 1 High High High Threshold Chronic
104 Cyhalothrin/Karate 68085-85-8 Developmental, Other Reduced body weight gain preceding pregnancy reduced body weight gain in offspring during weaning period 3-generation reproduction study in rats Coopers Animal Health and Imperial Chemical Industries, 1984 No Observed Effect Level 0.5 mg/kg-day 0.005 mg/kg-day 100 1 High High High Threshold Chronic
105 Cypermethrin 52315-07-8 Gastrointestinal G.I. tract disturbances 1-year dog feeding study ICI Americas, Inc., 1982a No Observed Effect Level 1.0 mg/kg-day 0.01 mg/kg-day 100 1 High High High Threshold Chronic
106 Cyromazine 66215-27-8 Hematologic Hematologic effects 6-month dog study oral exposure (diet) Ciba-Geigy, 1980 No Observed Effect Level 0.75 mg/kg-day 0.0075 mg/kg-day 100 1 High High High Threshold Chronic
107 Dacthal 1861-32-1 Endocrine, Hepatic, Ocular, Respiratory, Urinary Effects on the lungs, liver, kidney, thyroid and thyroid hormones in males and females and eyes of females 2-year rat feeding study ISK Biotech Corp., 1993 No Observable Adverse Effect Level 1.0 mg/kg-day 0.01 mg/kg-day 100 1 High High High Threshold Chronic
108 Dalapon, sodium salt 75-99-0 Urinary Increased kidney body weight ratio 2-year rat study oral exposure (diet) Paynter et al., 1960 No Observed Effect Level 8.45 mg/kg-day 0.03 mg/kg-day 300 1 Low Low Low Threshold Chronic
109 Danitol 39515-41-8 Nervous Tremors 1-year dog feeding study Sumitomo Chemical Co., Ltd., 1984 No Observable Adverse Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 Medium High High Threshold Chronic
110 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Nervous Neurobehavioral effects Single dose gavage study in mice Viberg et al., 2003 No Observable Adverse Effect Level 2.22 mg/kg 0.007 mg/kg-day 300 1 Low Medium Low Threshold Chronic
111 Demeton 8065-48-3 Nervous ChE inhibition, optic nerve degeneration 2-year feeding in rats (disulfoton) Mobay Chemical, 1985 Lowest Effect Level 0.04 mg/kg-day 4e-05 mg/kg-day 1000 1 High Low Low Threshold Chronic
112 Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 Hepatic Increased relative liver weight Guinea pig subchronic-to-chronic oral bioassay Carpenter et al., 1953 Lowest Observable Adverse Effect Level 19.0 mg/kg-day 0.02 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
113 Di(2-ethylhexyl)adipate 103-23-1 Developmental, Hepatic, Musculoskeletal, Other, Urinary Changes in body weight and liver weight increased liver weight of male and female parents reduced ossification and slightly dilated ureters in fetuses reduced offspring weight gain, total litter weight, and litter size Rat teratogenicity feeding study one-generation rat reproductive study ICI, 1988a,b No Observable Adverse Effect Level 170.0 mg/kg-day 0.6 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
114 1,4-Dibromobenzene 106-37-6 Hepatic Liver/body weight ratio and hepatic microsomal enzyme induction Rat subchronic oral study Carlson and Tardiff, 1977 No Observable Adverse Effect Level 10.0 mg/kg-day 0.01 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
115 Dibromochloromethane 124-48-1 Hepatic Hepatic lesions Rat, subchronic gavage bioassay NTP, 1985 No Observed Effect Level 21.4 mg/kg-day 0.02 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
116 1,2-Dibromoethane 106-93-4 Endocrine, Hepatic, Reproductive Testicular atrophy, liver peliosis, and adrenal cortical degeneration Rat chronic oral gavage study NCI, 1978 Lowest Observable Adverse Effect Level 27.0 mg/kg-day 0.009 mg/kg-day 3000 1 Low/Medium Low/Medium Low/Medium Benchmark Chronic
117 Dibutyl phthalate (DBP) 84-74-2 Other Increased mortality Rat subchronic to chronic, oral bioassay Smith, 1953 No Observable Adverse Effect Level 125.0 mg/kg-day 0.1 mg/kg-day 1000 1 Low Low Low Threshold Chronic
118 Dicamba 1918-00-9 Developmental, Other Maternal (reduced weight gain) and fetal toxicity Rabbit developmental study Velsicol Chemical, 1978 No Observed Effect Level 3.0 mg/kg-day 0.03 mg/kg-day 100 1 Medium High High Threshold Chronic
119 Dichloroacetic acid 79-43-6 Hepatic, Nervous, Reproductive Lesions observed in the testes, cerebrum, cerebellum, and liver. Dog, Subchronic Oral Cicmanec et. al., 1991 Lowest Observable Adverse Effect Level 12.5 mg/kg-day 0.004 mg/kg-day 3000 1 High Medium Medium Threshold None
120 1,2-Dichlorobenzene 95-50-1 Other No adverse effects observed 2-year rat study, oral exposure (gavage) NTP, 1985 No Observable Adverse Effect Level 85.7 mg/kg-day 0.09 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
121 Dichlorodifluoromethane 75-71-8 Other Reduced body weight Rat chronic oral study Sherman, 1974 No Observable Adverse Effect Level 15.0 mg/kg-day 0.2 mg/kg-day 100 1 High Medium Medium Threshold Chronic
122 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Hepatic Liver lesions 27-week rat feeding study Laug et al., 1950 No Observed Effect Level 0.05 mg/kg-day 0.0005 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
123 trans-1,2-Dichloroethylene 156-60-5 Immune Decrease in number of antibody forming cells (AFCs) against sheep red blood cells (sRBCs) in male mice Subchronic oral mouse study Shopp et al. (1985) Benchmark Dose based on the LED10 (Lowest Effective Dose) 65.0 mg/kg-day 0.02 mg/kg-day 3000 1 Medium Low/Medium Low Threshold Chronic
124 cis-1,2-Dichloroethylene 156-59-2 Urinary Increased relative kidney weight in male rats Subchronic oral rat study McCauley et al. (1995, 1990) Benchmark Dose based on the LED10 (Lowest Effective Dose) 5.1 mg/kg-day 0.002 mg/kg-day 3000 1 Medium Low/Medium Low Threshold Chronic
125 1,1-Dichloroethylene (1,1-DCE) 75-35-4 Hepatic Liver toxicity (fatty change) Rat chronic drinking water study Quast et al., 1983 Benchmark Dose based on the LED10 (Lowest Effective Dose) 4.6 mg/kg-day 0.05 mg/kg-day 100 1 High Medium Medium Threshold Chronic
126 Dichloromethane 75-09-2 Hepatic Hepatic effects (hepatic vacuolation, liver foci) 2-Year rat drinking water bioassay Serota et al., 1986a Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.19 mg/kg-day 0.006 mg/kg-day 30 1 High Medium/High High None Chronic
127 2,4-Dichlorophenol 120-83-2 Immune Decreased delayed hypersensitivity response Rat, subchronic to chronic Exon and Koller, 1985 No Observed Effect Level 0.3 mg/kg-day 0.003 mg/kg-day 100 1 Low Low Low Threshold Chronic
128 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) 94-82-6 Other Internal hemorrhage, mortality Dog subchronic oral bioassay Rhodia, Inc., 1969a No Observable Adverse Effect Level 8.0 mg/kg-day 0.008 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
129 2,4-Dichlorophenoxyacetic acid (2,4-D) 94-75-7 Hematologic, Hepatic, Urinary Hematologic, hepatic and renal toxicity 90-day rat oral bioassay and 1-year interim report from a 2-year rat oral bioassay Dow Chemical Co., 1983 No Observable Adverse Effect Level 1.0 mg/kg-day 0.01 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
130 2,3-Dichloropropanol 616-23-9 Cardiovascular, Hepatic, Urinary Myocardial degeneration, hepatotoxicity and nephrotoxicity Rat oral subchronic study U.S. EPA, 1989 No Observable Adverse Effect Level 10.0 mg/kg-day 0.003 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
131 1,3-Dichloropropene 542-75-6 Gastrointestinal Chronic irritation Rat chronic feeding study Stott et al., 1995 Benchmark Dose based on the LED10 (Lowest Effective Dose) 3.4 mg/kg-day 0.03 mg/kg-day 100 1 High High High Threshold Chronic
132 Dichlorvos 62-73-7 Nervous Plasma and RBC ChE inhibition in males and females brain ChE inhibition in males 1-year dog feeding study AMVAC Chemical Corp., 1990 No Observable Adverse Effect Level 0.05 mg/kg-day 0.0005 mg/kg-day 100 1 High Medium Medium Threshold Chronic
133 Dieldrin 60-57-1 Hepatic Liver lesions 2-year rat feeding study Walker et al., 1969 No Observable Adverse Effect Level 0.005 mg/kg-day 5e-05 mg/kg-day 100 1 Low Medium Medium Threshold Chronic
134 Diethyl phthalate (DEP) 84-66-2 Other Decreased growth rate, food consumption and altered organ weights Rat, subchronic oral feeding study Brown et al., 1978 No Observable Adverse Effect Level 750.0 mg/kg-day 0.8 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
135 Difenzoquat 43222-48-6 Other Decreased body weight 2-year rat feeding study American Cyanamid Co., 1975 No Observed Effect Level 25.0 mg/kg-day 0.08 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
136 Diflubenzuron 35367-38-5 Hematologic Methemoglobin and sulfhemoglobin formation One-year dog feeding study Duphar, 1985 No Observed Effect Level 2.0 mg/kg-day 0.02 mg/kg-day 100 1 High High High Threshold Chronic
137 Diisopropyl methylphosphonate (DIMP) 1445-75-6 Other No effects related to treatment 90-day dog feeding study U.S. DOD, 1980 No Observed Effect Level 75.0 mg/kg-day 0.08 mg/kg-day 1000 1 Low Low Low Threshold Chronic
138 Dimethipin 55290-64-7 Hepatic Increased absolute and relative liver weight 2-year rat feeding study Uniroyal Chemical Co., 1981a No Observed Effect Level 2.0 mg/kg-day 0.02 mg/kg-day 100 1 Medium High High Threshold Chronic
139 Dimethoate 60-51-5 Nervous Brain ChE inhibition 2-year rat feeding study American Cyanamid Co., 1986a No Observed Effect Level 0.05 mg/kg-day 0.0002 mg/kg-day 300 1 High Medium Medium Threshold Chronic
140 Dimethyl terephthalate (DMT) 120-61-6 Urinary Chronic kidney inflammation Rat chronic dietary study NCI, 1979 Lowest Observable Adverse Effect Level 125.0 mg/kg-day 0.1 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
141 N-N-Dimethylaniline 121-69-7 Hematologic, Immune, Other Splenomegaly, increased splenic hemosiderosis and hematopoiesis Mouse subchronic gavage bioassay Abdo et al., 1984 Lowest Observable Adverse Effect Level 22.32 mg/kg-day 0.002 mg/kg-day 10000 1 Low Low Low Threshold Chronic
142 3,4-Dimethylphenol 95-65-8 Cardiovascular, Hepatic, Immune, Other, Urinary Changes in blood pressure and body weight histopathological changes in liver, kidney and spleen Rat oral 1-year study Veldre and Janes, 1979 No Observed Effect Level 1.4 mg/kg-day 0.001 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
143 2,4-Dimethylphenol 105-67-9 Hematologic, Nervous Clinical signs (lethargy, prostration, and ataxia) and hematological changes Mouse subchronic oral gavage U.S. EPA, 1989 No Observable Adverse Effect Level 50.0 mg/kg-day 0.02 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
144 2,6-Dimethylphenol 576-26-1 Hepatic, Immune, Other, Urinary Body weight changes and histopathological changes of internal organs (liver, spleen and kidneys) Rat subchronic toxicity study Veldre and Janes, 1979 No Observed Effect Level 0.6 mg/kg-day 0.0006 mg/kg-day 1000 1 Low Low Low Threshold Chronic
145 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 Ocular Cataract formation Adult human subchronic oral study Horner, 1942 Lowest Observable Adverse Effect Level 2.0 mg/kg-day 0.002 mg/kg-day 1000 1 Low Low Low Threshold Chronic
146 m-Dinitrobenzene 99-65-0 Immune Increased splenic weight Rat subchronic oral study Cody et al., 1981 No Observable Adverse Effect Level 0.4 mg/kg-day 0.0001 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
147 2,4-Dinitrophenol 51-28-5 Ocular Cataract formation Human chronic and subchronic exposures Horner, 1942 Lowest Observable Adverse Effect Level 2.0 mg/kg-day 0.002 mg/kg-day 1000 1 Low Low Low Threshold Chronic
148 2,4-Dinitrotoluene 121-14-2 Hematologic, Hepatic, Nervous Neurotoxicity, Heinz bodies and biliary tract hyperplasia Dog feeding study, 2-year Ellis et al., 1985 No Observable Adverse Effect Level 0.2 mg/kg-day 0.002 mg/kg-day 100 1 High High High Threshold Chronic
149 Dinoseb 88-85-7 Developmental Decreased fetal weight 3-generation rat reproduction study Dow Chemical Co., 1981a Lowest Effect Level 1.0 mg/kg-day 0.001 mg/kg-day 1000 1 Low Low Low Threshold Chronic
150 1,4-Dioxane 123-91-1 Hepatic, Urinary Liver and kidney toxicity Chronic oral male rat study Kociba et al. 1974 No Observable Adverse Effect Level 9.6 mg/kg-day 0.03 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
151 Diphenamid 957-51-7 Hepatic Liver toxicity 2-year dog feeding study Upjohn Co., 1966a No Observed Effect Level 3.0 mg/kg-day 0.03 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
152 Diphenylamine 122-39-4 Hepatic, Other, Urinary Decreased body weight gain, and increased liver and kidney weights 2-year dog feeding study Thomas et al., 1967 No Observed Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
153 Diquat 2764-72-9 Ocular Minimal lens opacity and cataracts Chronic rat study, dietary Chevron Chemical, 1985 No Observed Effect Level 0.22 mg/kg-day 0.0022 mg/kg-day 100 1 High Medium Medium Threshold Chronic
154 Disulfoton 298-04-4 Nervous ChE inhibition, optic nerve degeneration 2-year rat study oral exposure (diet) Mobay Chemical, 1985 Lowest Effect Level 0.04 mg/kg-day 4e-05 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
155 1,4-Dithiane 505-29-3 Nervous, Respiratory Nasal olfactory lesions 90-day gavage rat study Schieferstein et al., 1988 Lowest Observable Adverse Effect Level 105.0 mg/kg-day 0.01 mg/kg-day 10000 1 Low Low Low Threshold Chronic
156 Diuron 330-54-1 Hematologic Abnormal pigments in blood 2-year dog feeding study du Pont, 1964a No Observed Effect Level 0.625 mg/kg-day 0.002 mg/kg-day 300 1 Low Low Low Threshold Chronic
157 Dodine 2439-10-3 Endocrine Thyroid toxicity 1-year dog feeding study American Cyanamid, 1958 No Observed Effect Level 1.25 mg/kg-day 0.004 mg/kg-day 300 1 Low Low Low Threshold Chronic
158 Endosulfan 115-29-7 Cardiovascular, Other, Urinary Reduced body weight gain in males and females increased incidence of marked progressive glomerulonephrosis and blood vessel aneurysms in males 2-year rat feeding study (NOAEL for males) Hoechst Celanese Corp., 1989a No Observable Adverse Effect Level 0.6 mg/kg-day 0.006 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
159 Endothall 145-73-3 Gastrointestinal Increased absolute and relative weights of stomach and small intestine Two-year feeding study in dogs Pennwalt Agchem., 1965 No Observed Effect Level 2.0 mg/kg-day 0.02 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
160 Endrin 72-20-8 Hepatic, Nervous Mild histological lesions in liver, occasional convulsions Dog chronic oral bioassay Velsicol Chemical Corporation, 1969 No Observed Effect Level 0.025 mg/kg-day 0.0003 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
161 Ethephon 16672-87-0 Nervous Plasma ChE inhibition 16-day human study Union Carbide, 1977a Lowest Effect Level 0.5 mg/kg-day 0.005 mg/kg-day 100 1 Low Medium Low Threshold Chronic
162 Ethion 563-12-2 Nervous Plasma cholinesterase inhibition Cholinesterase inhibition study in humans FMC Corp., 1970 No Observed Effect Level 0.05 mg/kg-day 0.0005 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
163 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Urinary Increased absolute kidney weight in female rats 2-year drinking water study in male and female F344 rats Suzuki et al., 2012; JPEC, 2010a Benchmark Dose based on the LED10 (Lowest Effective Dose) 28.8 mg/kg-day 1.0 mg/kg-day 30 1 High High High Benchmark Chronic
164 Ethyl acetate 141-78-6 Other Mortality and body weight loss Rat oral subchronic study U.S. EPA, 1986 No Observed Effect Level 900.0 mg/kg-day 0.9 mg/kg-day 1000 1 High Low Low Threshold Chronic
165 S-Ethyl dipropylthiocarbamate (EPTC) 759-94-4 Cardiovascular Degenerative cardiomyopathy 2-generation reproduction rat study PPG Industries, 1986a No Observed Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
166 Ethyl ether 60-29-7 Other Depressed body weights Rat oral subchronic study U.S. EPA, 1986 No Observable Adverse Effect Level 500.0 mg/kg-day 0.2 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
167 Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 Nervous Neurotoxicity 90-day hen delayed neurotoxicity bioassay Morabani, Nissan, duPont and Velsicol, 1982 No Observed Effect Level 0.01 mg/kg-day 1e-05 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
168 Ethylbenzene 100-41-4 Hepatic, Urinary Liver and kidney toxicity Rat subchronic to chronic oral bioassay Wolf et al., 1956 No Observed Effect Level 97.1 mg/kg-day 0.1 mg/kg-day 1000 1 Low Low Low Threshold Chronic
169 Ethylene glycol 107-21-1 Urinary Kidney toxicity Chronic rat oral feeding study DePass et al., 1986a No Observable Adverse Effect Level 200.0 mg/kg-day 2.0 mg/kg-day 100 1 High High High Threshold Chronic
170 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 Hematologic Hemosiderin deposition in the liver Chronic (rat and mouse) inhalation study NTP (2000) Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.4 mg/kg-day 0.1 mg/kg-day 10 1 High Medium/High Medium/High Threshold Chronic
171 Ethylene thiourea (ETU) 96-45-7 Endocrine Increased incidence of thyroid hyperplasia Rat 24-month feeding study Graham et al., 1975 Lowest Observable Adverse Effect Level 0.25 mg/kg-day 8e-05 mg/kg-day 3000 1 Medium Medium Medium Threshold Chronic
172 Ethylphthalyl ethylglycolate (EPEG) 84-72-0 Urinary Kidney damage and reduced lifespan Rat, chronic oral bioassay Hodge et al., 1953 No Observed Effect Level 250.0 mg/kg-day 3.0 mg/kg-day 100 1 Medium Low Low Threshold Chronic
173 Express 101200-48-0 Other, Urinary Elevated serum bilirubin and AST levels, increased urinary volume 1-year dog feeding study du Pont, 1986a No Observed Effect Level 0.79 mg/kg-day 0.008 mg/kg-day 100 1 High High High Threshold Chronic
174 Fenamiphos 22224-92-6 Nervous ChE inhibition 2-year dog feeding study Chemagro Corp., 1972a No Observed Effect Level 0.025 mg/kg-day 0.00025 mg/kg-day 100 1 High High High Threshold Chronic
175 Fluometuron 2164-17-2 Other No adverse effects 103-week rat feeding study NCI, 1980 No Observable Adverse Effect Level 12.5 mg/kg-day 0.013 mg/kg-day 1000 1 Low Low Low Threshold Chronic
176 Fluoranthene 206-44-0 Hepatic, Urinary Nephropathy, increased liver weights, hematological alterations, and clinical effects Mouse subchronic study U.S. EPA, 1988 No Observable Adverse Effect Level 125.0 mg/kg-day 0.04 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
177 Fluorene 86-73-7 Hematologic Decreased RBC, packed cell volume and hemoglobin Mouse subchronic study U.S. EPA, 1989 No Observable Adverse Effect Level 125.0 mg/kg-day 0.04 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
178 Fluorine (soluble fluoride) 7782-41-4 Gastrointestinal Objectionable dental fluorosis, a cosmetic effect Epidemiologic study in children Hodge, 1950, cited in Underwood, 1977 No Observable Adverse Effect Level 0.06 mg/kg-day 0.06 mg/kg-day 1 1 High High High Threshold Chronic
179 Fluridone 59756-60-4 Ocular, Other, Reproductive, Urinary Glomerulonephritis, atrophic testes, eye keratitis decreased body weight and organ weights 2-year rat feeding study Elanco Products, 1980a No Observed Effect Level 8.0 mg/kg-day 0.08 mg/kg-day 100 1 Medium High High Threshold Chronic
180 Flurprimidol 56425-91-3 Hepatic, Other Increased incidence of hepatocellular changes including fatty change and vacuolation (M) increased susceptibility to stress factors (F) 2-generation rat reproduction study Eli Lilly and Co., 1986a No Observed Effect Level 1.8 mg/kg-day 0.02 mg/kg-day 100 1 Medium High High Threshold Chronic
181 Flutolanil 66332-96-5 Hepatic, Other, Reproductive Decreased body weight and body weight gains in both doses increased liver weights at high dose 3-generation reproduction and teratology study in rats NOR-AM Chemical Co., 1982a Lowest Effect Level 63.7 mg/kg-day 0.06 mg/kg-day 1000 1 Low Medium Medium Threshold Chronic
182 Fluvalinate 69409-94-5 Dermal, Other Decreases in body weight gain increase in plantar ulcer (females) 2-year feeding/ oncogenicity study in rats Zoecon, 1984 No Observed Effect Level 1.0 mg/kg-day 0.01 mg/kg-day 100 1 High High High Threshold Chronic
183 Folpet 133-07-3 Hepatic, Other Decreased body weight gain, altered serum chemistry parameters (decreased serum cholesterol, total protein, and serum albumin and globulin levels) Chronic oral toxicity study in dogs Chevron Chemical, 1986 No Observed Effect Level 10.0 mg/kg-day 0.1 mg/kg-day 100 1 High High High Threshold Chronic
184 Fonofos 944-22-9 Hepatic, Nervous Cholinesterase inhibition, cholinergic symptoms, and increased liver weight 2-year dog feeding study Stauffer Chemical Co., 1969 No Observed Effect Level 0.2 mg/kg-day 0.002 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
185 Formaldehyde 50-00-0 Gastrointestinal, Other, Urinary Reduced weight gain, histopathology in rats Rat 2-year bioassay Til et al., 1989 No Observable Adverse Effect Level 15.0 mg/kg-day 0.2 mg/kg-day 100 1 High Medium Medium Threshold Chronic
186 Fosetyl-al 39148-24-8 Reproductive Slight testicular degeneration 2-year dog feeding study Rhone-Poulenc, 1981a No Observed Effect Level 250.0 mg/kg-day 3.0 mg/kg-day 100 1 Medium High High Threshold Chronic
187 Furan 110-00-9 Hepatic Hepatic lesions Mouse subchronic oral study NTP, 1982 No Observable Adverse Effect Level 1.4 mg/kg-day 0.001 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
188 Furfural 98-01-1 Hepatic Mild hepatocellular vacuolization Rat oral subchronic study NTP, 1981a Lowest Observable Adverse Effect Level 7.9 mg/kg-day 0.003 mg/kg-day 3000 1 Low Low Low Threshold Chronic
189 Glufosinate-ammonium 77182-82-2 Urinary Increased absolute and relative kidney weights in males 13-week rat feeding study Hoescht AG, 1982a No Observed Effect Level 0.4 mg/kg-day 0.0004 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
190 Glycidaldehyde 765-34-4 Endocrine, Hematologic, Other, Urinary Weight gain retardation, enlarged adrenals, hydropic renal pelvis and hematopoietic effects Rat subchronic inhalation study Hine et al., 1961 No Observable Adverse Effect Level 1.09 mg/kg-day 0.0004 mg/kg-day 3000 1 Low Low Low Threshold Chronic
191 Glyphosate 1071-83-6 Developmental, Urinary Increased incidence of renal tubular dilation in F3b offspring 3-generation rat reproduction study Monsanto Co., 1981a No Observed Effect Level 10.0 mg/kg-day 0.1 mg/kg-day 100 1 High High High Threshold Chronic
192 Haloxyfop-methyl 69806-40-2 Reproductive, Urinary Reduced relative kidney weights in F0, F1, and F2b adults; reduced fertility in the F1/F2b generation 3-generation rat reproduction study Dow Chemical U.S.A., 1985a No Observed Effect Level 0.005 mg/kg-day 5e-05 mg/kg-day 100 1 High High High Threshold Chronic
193 Harmony 79277-27-3 Other Reduced body weight gains in males, reduced serum sodium in males and females 2-year rat feeding study du Pont, 1986a No Observed Effect Level 1.25 mg/kg-day 0.013 mg/kg-day 100 1 Medium High High Threshold Chronic
194 Heptachlor 76-44-8 Hepatic Liver weight increases in males 2-year rat feeding study Velsicol Chemical, 1955a No Observed Effect Level 0.15 mg/kg-day 0.0005 mg/kg-day 300 1 Low Low Low Threshold Chronic
195 Heptachlor epoxide 1024-57-3 Hepatic Increased liver-to-body weight ratio in both males and females 60-week dog feeding study Dow Chemical Co., 1958 Lowest Effect Level 0.0125 mg/kg-day 1.3e-05 mg/kg-day 1000 1 Low Medium Low Threshold Chronic
196 Hexabromobenzene 87-82-1 Hepatic Induced serum carboxylesterase activity, increased relative liver weight, increased liver porphyrins Rat dietary subchronic study Mendoza et al., 1977 No Observable Adverse Effect Level 2.0 mg/kg-day 0.002 mg/kg-day 1000 1 Low Low Low Threshold Chronic
197 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 68631-49-2 Nervous Neurobehavioral effects Single dose gavage study in mice Viberg et al. 2003 No Observable Adverse Effect Level 0.45 mg/kg 0.0002 mg/kg-day 3000 1 Low Low Low Benchmark Chronic
198 Hexachlorobenzene 118-74-1 Hepatic Liver effects Rat chronic feeding study Arnold et al., 1985 No Observable Adverse Effect Level 0.08 mg/kg-day 0.0008 mg/kg-day 100 1 Medium High Medium Threshold Chronic
199 gamma-Hexachlorocyclohexane (gamma-HCH) 58-89-9 Hepatic, Urinary Liver and kidney toxicity Rat, subchronic oral bioassay (NOAEL for females) Zoecon Corp., 1983 No Observable Adverse Effect Level 0.33 mg/kg-day 0.0003 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
200 Hexachlorocyclopentadiene (HCCPD) 77-47-4 Gastrointestinal Chronic irritation Rat subchronic gavage bioassay Abdo et al., 1984 Benchmark Dose based on the LED10 (Lowest Effective Dose) 6.0 mg/kg-day 0.006 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
201 Hexachloroethane 67-72-1 Urinary Atrophy and degeneration of renal tubules 16-week subchronic dietary exposure study, male F344 rats Gorzinski et al., 1985 Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.728 mg/kg-day 0.0007 mg/kg-day 1000 1 High Low/Medium Low/Medium Threshold Chronic
202 Hexachlorophene 70-30-4 Gastrointestinal, Nervous Swollen salivary glands, status spongiosis in brain and optic nerve 13-week dog feeding study Nationwide Chemical Corp., 1974 Lowest Effect Level 0.75 mg/kg-day 0.0003 mg/kg-day 3000 1 Medium Medium Medium Threshold Chronic
203 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Urinary Kidney medullary papillary necrosis in F344 rats 2-year rat feeding study Levine et al., 1983 No Observable Adverse Effect Level 3.9 mg/kg-day 0.01 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
204 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Nervous Convulsions in F344 rats 90-day oral gavage study in F344 rats Crouse et al., 2006 Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.3 mg/kg-day 0.004 mg/kg-day 300 1 Medium None Medium Benchmark Chronic
205 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Reproductive Suppurative prostatitis in F344 rats 2-year rat feeding study Levine et al., 1983 Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.23 mg/kg-day 0.0008 mg/kg-day 300 1 Low Low Low Benchmark Chronic
206 2-Hexanone 591-78-6 Nervous Axonal swelling of the peripheral nerve 13-Month drinking water study in rats O'Donoghue et al., 1978 Benchmark Dose based on the LED10 (Lowest Effective Dose) 5.0 mg/kg-day 0.005 mg/kg-day 1000 1 Medium Low/Medium Medium Benchmark Chronic
207 Hexazinone 51235-04-2 Other Decreased body weight 2-year rat feeding study du Pont, 1977 No Observed Effect Level 10.0 mg/kg-day 0.033 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
208 Hydrogen Cyanide and Cyanide Salts Various Reproductive Decreased cauda epididymis weight in male F344/N rats 13-Week drinking water study NTP, 1993 Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.9 mg/kg-day 0.0006 mg/kg-day 3000 1 Medium Low/Medium Low/Medium Benchmark Chronic
209 Imazalil 35554-44-0 Other Decreased body weight gain 2-year dog feeding study Penwalt Corp., 1977 No Observed Effect Level 1.25 mg/kg-day 0.013 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
210 Imazaquin 81335-37-7 Hematologic, Hepatic, Immune, Other Decreased body weight gain, skeletal myopathy, slight anemia, bone marrow hyperplasia, elevated serum SGOT, SGPT, CPK One-year dog feeding study American Cyanamid, 1984a No Observed Effect Level 25.0 mg/kg-day 0.25 mg/kg-day 100 1 High High High Threshold Chronic
211 Iprodione 36734-19-7 Hematologic, Reproductive Increased RBC Heinz bodies; decreased prostate weight 1-year dog feeding study Rhone-Poulenc, 1984 No Observed Effect Level 4.2 mg/kg-day 0.04 mg/kg-day 100 1 Medium High High Threshold Chronic
212 Isobutyl alcohol 78-83-1 Nervous Hypoactivity and ataxia Rat oral subchronic study U.S. EPA, 1986 No Observed Effect Level 316.0 mg/kg-day 0.3 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
213 Isophorone 78-59-1 Urinary Kidney pathology 90-day dog feeding study Nor-Am Agricultural Products, Inc., 1972a No Observed Effect Level 150.0 mg/kg-day 0.2 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
214 Isopropalin 33820-53-0 Hematologic, Other Reduced hemoglobin concentration, lowered hematocrits, and altered organ weights 90-day rat feeding study Elanco Products, 1969a No Observed Effect Level 15.0 mg/kg-day 0.015 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
215 Isopropyl methyl phosphonic acid (IMPA) 1832-54-8 Other No adverse effects observed Rat drinking water study 90-day Mecler, 1981 No Observable Adverse Effect Level 279.0 mg/kg-day 0.1 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
216 Isoxaben 82558-50-7 Cardiovascular, Hepatic, Urinary Increased BUN; decreased serum AP and AST; decreased food consumption efficiency; increased heart/body weight 2-year rat feeding study (NOEL for males) Elanco Products, 1985a No Observed Effect Level 5.0 mg/kg-day 0.05 mg/kg-day 100 1 High High High Threshold Chronic
217 Lactofen 77501-63-4 Hepatic Increased absolute and relative liver weight; hepatocytomegaly in males 78-week oncogenic study in mice PPG Industries, 1985a Lowest Effect Level 1.5 mg/kg-day 0.002 mg/kg-day 1000 1 High High High Threshold Chronic
218 Linuron 330-55-2 Hematologic Abnormal blood pigment 2-year dog feeding study du Pont, 1962 Lowest Effect Level 0.625 mg/kg-day 0.002 mg/kg-day 300 1 Medium High High Threshold Chronic
219 Londax 83055-99-6 Hepatic Liver effects 1-year dog feeding study (NOEL for females) du Pont, 1986a No Observed Effect Level 19.9 mg/kg-day 0.2 mg/kg-day 100 1 High High High Threshold Chronic
220 Malathion 121-75-5 Nervous RBC ChE depression Subchronic human feeding study Moeller and Rider, 1962 No Observed Effect Level 0.23 mg/kg-day 0.02 mg/kg-day 10 1 Medium Medium Medium Threshold Chronic
221 Maleic anhydride 108-31-6 Urinary Renal lesions Rat oral chronic study U.S. EPA, 1983 No Observable Adverse Effect Level 10.0 mg/kg-day 0.1 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
222 Maleic hydrazide 123-33-1 Urinary Renal dysfunction 2-year rat feeding study Uniroyal Chemical Co., 1981 Lowest Effect Level 500.0 mg/kg-day 0.5 mg/kg-day 1000 1 Low Medium Medium Threshold Chronic
223 Maneb 12427-38-2 Endocrine Increased thyroid weight 6-month monkey feeding study Rohm and Haas Co., 1977; Maneb Task Force, 1986 No Observed Effect Level 5.0 mg/kg-day 0.005 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
224 Manganese 7439-96-5 Nervous CNS effects Human chronic ingestion data NRC, 1989; Freeland- Graves et al., 1987; WHO, 1973 No Observable Adverse Effect Level 0.14 mg/kg-day 0.14 mg/kg-day 1 1 Medium Medium Medium Threshold Chronic
225 Mepiquat chloride 24307-26-4 Hematologic, Nervous, Other Sedation and tonoclonic spasms decreased food intake and body weights hematologic effects 90-day dog feeding study BASF Wyandotte Chemical, 1977a No Observed Effect Level 25.0 mg/kg-day 0.03 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
226 Mercuric chloride (HgCl2) 7487-94-7 Immune, Urinary Autoimmune effects (autoimmune glomerulonephritis) Rat subchronic feeding and subcutaneous studies U.S. EPA, 1987 Lowest Observable Adverse Effect Level 0.317 mg/kg-day 0.0003 mg/kg-day 1000 1 Not Available High High Threshold Chronic
227 Merphos 150-50-5 Nervous, Other Ataxia, delayed neurotoxicity and weight loss 90-day hen delayed neurotoxicity study Abou-Donia et al., 1980 No Observed Effect Level 0.1 mg/kg-day 3e-05 mg/kg-day 3000 1 Low Low Low Threshold Chronic
228 Merphos oxide 78-48-8 Nervous, Other Ataxia, delayed neurotoxicity and weight loss 90-day hen delayed neurotoxicity study Abou-Donia et al., 1979 No Observed Effect Level 0.1 mg/kg-day 3e-05 mg/kg-day 3000 1 Low Low Low Threshold Chronic
229 Metalaxyl 57837-19-1 Hepatic Increased serum alkaline phosphatase levels and increased liver-to-brain weight ratio 6-month dog feeding study Ciba-Geigy, 1981a No Observed Effect Level 6.25 mg/kg-day 0.06 mg/kg-day 100 1 Medium High High Threshold Chronic
230 Methacrylonitrile 126-98-7 Hepatic Increased SGOT and SGPT levels Dog subchronic study Pozzani et al., 1968 No Observable Adverse Effect Level 0.34 mg/kg-day 0.0001 mg/kg-day 3000 1 Low Low Low Threshold Chronic
231 Methamidophos 10265-92-6 Nervous ChE inhibition One-year dog feeding study Mobay Chemical, 1984a Lowest Effect Level 0.05 mg/kg-day 5e-05 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
232 Methanol 67-56-1 Developmental Extra cervical ribs CD-1 mice, Inhalation developmental toxicity study exposure during gestation days GD7-GD17 Rogers et al. (1993b) Benchmark Dose based on the LED10 (Lowest Effective Dose) 43.1 mg/L 2.0 mg/kg-day 100 1 High Medium Medium/High None Chronic
233 Methidathion 950-37-8 Hepatic Liver toxicity 2-year dog feeding study Ciba-Geigy, 1967 No Observed Effect Level 0.1 mg/kg-day 0.001 mg/kg-day 100 1 Medium High High Threshold Chronic
234 Methomyl 16752-77-5 Immune, Urinary Kidney and spleen pathology 2-year feeding study dogs du Pont, 1968a No Observed Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 Medium High High Threshold Chronic
235 Methoxychlor 72-43-5 Developmental Excessive loss of litters Rabbit teratology study Kincaid Enterprises, 1986 No Observed Effect Level 5.01 mg/kg-day 0.005 mg/kg-day 1000 1 Low Low Low Threshold Chronic
236 Methyl ethyl ketone (MEK) 78-93-3 Developmental Decreased pup body weight Multigeneration reproductive developmental rat drinking water study Cox et al., 1975 Lowest Effect Dose 639.0 mg/kg-day 0.6 mg/kg-day 1000 1 Low/Medium Low Low Threshold Chronic
237 Methyl methacrylate 80-62-6 Other None Rat drinking water study Borzelleca et al., 1964 No Observable Adverse Effect Level 136.0 mg/kg-day 1.4 mg/kg-day 100 1 Low/Medium Low/Medium Low/Medium Threshold Chronic
238 Methyl parathion 298-00-0 Hematologic, Nervous RBC, ChE inhibition; reduced hemoglobin, hematocrit and RBCs 2-year rat feeding study Monsanto Co., 1984 No Observed Effect Level 0.025 mg/kg-day 0.00025 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
239 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 Hepatic, Other, Reproductive, Urinary Male reproductive toxicity and other effects (including decreased body weight gain), increased liver and kidney weights 13-week dog feeding study Rhodia, Inc., 1970a No Observed Effect Level 12.0 mg/kg-day 0.01 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
240 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 Urinary Increased absolute and relative kidney weights 90-day rat feeding study BASF Aktiegesellschaft, 1985 No Observed Effect Level 3.0 mg/kg-day 0.001 mg/kg-day 3000 1 Medium Medium Medium Threshold Chronic
241 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 Hepatic, Urinary Kidney and liver toxicity 1-year dog feeding study Industry Task Force on MCPA, 1986a No Observed Effect Level 0.15 mg/kg-day 0.0005 mg/kg-day 300 1 High Medium Medium Threshold Chronic
242 Methylmercury (MeHg) 22967-92-6 Developmental, Nervous Developmental neuropsychological impairment Human epidemiological studies Grandjean et al., 1997 Budtz-Jorgensen et al., 1999a Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.00086 mg/kg-day 0.0001 mg/kg-day 10 1 High High High None Chronic
243 Methylmercury (MeHg) 22967-92-6 Developmental, Nervous Developmental neuropsychological impairment Human epidemiological studies Grandjean et al., 1997 Budtz-Jorgensen et al., 1999a Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.0015 mg/kg-day 0.0001 mg/kg-day 10 1 High High High None Chronic
244 2-Methylnaphthalene 91-57-6 Respiratory Pulmonary alveolar proteinosis B6C3F1 male and female mice 81-week dietary study Murata et al. (1997) Benchmark Dose 4.7 mg/kg-day 0.004 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
245 2-Methylphenol 95-48-7 Nervous, Other Decreased body weights and neurotoxicity 90-day oral subchronic neurotoxicity study in rats U.S. EPA, 1986, 1987 No Observable Adverse Effect Level 50.0 mg/kg-day 0.05 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
246 3-Methylphenol 108-39-4 Nervous Decreased body weights and neurotoxicity 90-day oral subchronic neurotoxicity study in rats U.S. EPA, 1986, 1987 No Observable Adverse Effect Level 50.0 mg/kg-day 0.05 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
247 Metolachlor 51218-45-2 Other, Reproductive Decreased body weight gain, decreased pup weight and parental food consumption 2-year rat feeding study Ciba-Geigy, 1983 No Observed Effect Level 15.0 mg/kg-day 0.15 mg/kg-day 100 1 Medium High High Threshold Chronic
248 Metribuzin 21087-64-9 Hepatic, Other, Urinary Liver and kidney effects, decreased body weight, mortality 2-year feeding study in dogs Mobay Chemical, 1974a No Observed Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 High Medium Medium Threshold Chronic
249 Mirex 2385-85-5 Endocrine, Hepatic Liver cytomegaly, fatty metamorphosis, angiectasis; thyroid cystic follicles Rat chronic dietary feeding study NTP, 1990 No Observable Adverse Effect Level 0.07 mg/kg-day 0.0002 mg/kg-day 300 1 High High High Threshold Chronic
250 Molinate 2212-67-1 Reproductive Reproductive toxicity Rat fertility study (gavage) Stauffer Chemical Co., 1981 No Observed Effect Level 0.2 mg/kg-day 0.002 mg/kg-day 100 1 Medium Low Low Threshold Chronic
251 Molybdenum 7439-98-7 Urinary Increased uric acid levels Human 6-year to lifetime dietary exposure study Koval'skiy et al., 1961 Lowest Observable Adverse Effect Level 0.14 mg/kg-day 0.005 mg/kg-day 30 1 Medium Medium Medium Threshold Chronic
252 Monochloramine 10599-90-3 Other No observed effects Rat chronic oral study NTP, 1992 No Observable Adverse Effect Level 9.5 mg/kg-day 0.1 mg/kg-day 100 1 High Medium Medium Threshold Chronic
253 Naled 300-76-5 Nervous Brain ChE inhibition 2-year rat study, dietary Chevron Chemical Co., 1984a No Observed Effect Level 0.2 mg/kg-day 0.002 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
254 Naphthalene 91-20-3 Other Decreased mean terminal body weight in males Subchronic oral rat study BCL, 1980a No Observable Adverse Effect Level 71.0 mg/kg-day 0.02 mg/kg-day 3000 1 High Low Low Threshold Chronic
255 Napropamide 15299-99-7 Reproductive Decreased body weight gain in parental animals and pups 3-generation rat reproduction study Stauffer Chemical Co., 1978a No Observed Effect Level 30.0 mg/kg-day 0.1 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
256 Nickel, soluble salts Various Other Decreased body and organ weights Rat chronic oral study Ambrose et al., 1976 No Observable Adverse Effect Level 5.0 mg/kg-day 0.02 mg/kg-day 300 1 Low Medium Medium Threshold Chronic
257 Nitrate 14797-55-8 Hematologic Early clinical signs of methemoglobinemia in excess of 10% (0-3 months old infants formula) Human epidemiological surveys Bosch et al., 1950; Walton, 1951 No Observable Adverse Effect Level 1.6 mg/kg-day 1.6 mg/kg-day 1 1 High High High Threshold Chronic
258 Nitrite 14797-65-0 Hematologic Methemoglobinemia Infant chronic exposure to drinking water Walton, 1951 No Observed Effect Level 1.0 mg/kg-day 0.1 mg/kg-day 1 10 High High High Threshold Chronic
259 Nitrobenzene 98-95-3 Hematologic Increased methemoglobin levels Subchronic rat study NTP, 1983 Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.8 mg/kg-day 0.002 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
260 Nitroguanidine 556-88-7 Developmental, Other Reduced weight gain in female rats, maternal/ fetal toxicity in rats, and equivocal evidence of developmental toxicity in rabbits 90-day rat study oral exposure (diet) Morgan et al., 1988 Coppes et al., 1988a, b No Observable Adverse Effect Level 316.0 mg/kg-day 0.1 mg/kg-day 3000 1 Medium Medium Medium Threshold Chronic
261 Norflurazon 27314-13-2 Endocrine, Hepatic Liver and thyroid effects 6-month dog feeding study Sandoz-Wander, 1973 No Observed Effect Level 3.75 mg/kg-day 0.04 mg/kg-day 100 1 High High High Threshold Chronic
262 NuStar 85509-19-9 Hepatic Liver cell enlargement 1-year dog feeding study du Pont, 1985 No Observed Effect Level 0.2 mg/kg-day 0.0007 mg/kg-day 300 1 High Medium Medium Threshold Chronic
263 Octabromodiphenyl ether 32536-52-0 Hepatic Induction of hepatic enzymes; liver histopathology Subchronic, rat, oral (gavage) Carlson, 1980 No Observable Adverse Effect Level 2.51 mg/kg-day 0.003 mg/kg-day 1000 1 Low Low Low Threshold Chronic
264 Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) 2691-41-0 Hepatic Hepatic lesions 13-week rat feeding study U.S. DOD, 1985a No Observable Adverse Effect Level 50.0 mg/kg-day 0.05 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
265 Oryzalin 19044-88-3 Endocrine, Hepatic, Urinary Increases in serum cholesterol, alkaline phosphatase, and relative liver and kidney weights, and decreases in alanine transaminase and adrenal weights 1-year dog feeding study Eli Lilly Co., 1986 No Observed Effect Level 5.0 mg/kg-day 0.05 mg/kg-day 100 1 Medium High High Threshold Chronic
266 Oxadiazon 19666-30-9 Hematologic, Hepatic Increased levels of serum proteins and increased liver weights 2-year rat feeding study Rhone-Poulenc, 1981 No Observed Effect Level 0.5 mg/kg-day 0.005 mg/kg-day 100 1 High Medium Medium Threshold Chronic
267 Oxamyl 23135-22-0 Other Decreased body weight gain and food consumption 2-year rat feeding/ oncogenic study du Pont, 1972a No Observed Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 Low Medium Medium Threshold Chronic
268 Oxyfluorfen 42874-03-3 Hepatic Increased absolute liver weight and nonneoplastic lesions 20-month mouse feeding study Rohm & Haas, 1977a No Observed Effect Level 0.3 mg/kg-day 0.003 mg/kg-day 100 1 High High High Threshold Chronic
269 Paclobutrazol 76738-62-0 Hepatic Elevated liver weights, serum cholesterol, hepatic aminopyrine N-demethylase activity, and alanine transaminase levels 90-day rat feeding study ICI Americas, Inc., 1983a No Observed Effect Level 12.5 mg/kg-day 0.013 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
270 Paraquat 1910-42-5 Respiratory Chronic pneumonitis 1-year dog feeding study Chevron Chemical Company, 1983a No Observed Effect Level 0.45 mg/kg-day 0.0045 mg/kg-day 100 1 High High High Threshold Chronic
271 Pendimethalin 40487-42-1 Hepatic Increase in serum alkaline phosphatase and liver weight, and hepatic lesions 2-year dog feeding study American Cyanamid, 1979 No Observed Effect Level 12.5 mg/kg-day 0.04 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
272 Pentabromodiphenyl ether 32534-81-9 Hepatic Induction of hepatic enzymes Subchronic, rat, oral (gavage) Carlson, 1980 No Observable Adverse Effect Level 1.77 mg/kg-day 0.002 mg/kg-day 1000 1 Low Low Low Threshold Chronic
273 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) 60348-60-9 Nervous Neurobehavioral effects Single dose gavage study in mice Viberg et al. (2004a) Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.29 mg/kg 0.0001 mg/kg-day 3000 1 Low Low Low Benchmark Chronic
274 Pentachlorobenzene 608-93-5 Hepatic, Urinary Liver and kidney toxicity Subchronic rat oral bioassay (including weanlings) Linder et al., 1980 Lowest Observable Adverse Effect Level 8.3 mg/kg-day 0.0008 mg/kg-day 10000 1 Medium Low Low Threshold Chronic
275 Pentachloronitrobenzene (PCNB) 82-68-8 Hepatic Liver toxicity 2-year dog feeding study Olin Mathieson Corp., 1968a No Observed Effect Level 0.75 mg/kg-day 0.003 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
276 Pentachlorophenol 87-86-5 Hepatic Hepatotoxicity 1-Year beagle dog study Mecler, 1996 Lowest Observable Adverse Effect Level 1.5 mg/kg-day 0.005 mg/kg-day 300 1 Medium High Medium Threshold Chronic
277 Perchlorate (ClO4) and Perchlorate Salts 7790-98-9 Endocrine Radioactive iodide uptake inhibition (RAIU) in the thyroid Adult human volunteers Greer et al. (2002) No Observed Effect Level 0.007 mg/kg-day 0.0007 mg/kg-day 10 1 Medium/High Medium High Threshold Chronic
278 Perfluorobutanoic Acid (PFBA) 375-22-4 Endocrine Decreased total T4 90-day oral gavage study in male Sprague-Dawley rats BUTENHOFF, 2012 No Observable Adverse Effect Level 1.27 mg/kg-day 0.01 mg/kg-day 100 1 High Medium Low/Medium Threshold Subchronic
279 Perfluorobutanoic Acid (PFBA) 375-22-4 Developmental Developmental delays Gestational oral gavage study in female CD-1 mice DAS, 2008 Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.62 mg/kg-day 0.006 mg/kg-day 100 1 High Medium Low/Medium Benchmark Chronic
280 Perfluorobutanoic Acid (PFBA) 375-22-4 Developmental Developmental delays Gestational oral gavage study in female CD-1 mice DAS, 2008 Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.62 mg/kg-day 0.006 mg/kg-day 100 1 High Medium Low/Medium Benchmark Subchronic
281 Perfluorobutanoic Acid (PFBA) 375-22-4 Endocrine, Hepatic Increased hepatocellular hypertrophy (Liver), Decreased total T4 (Thyroid) 90-day oral gavage study in male Sprague-Dawley rats BUTENHOFF, 2012 No Observable Adverse Effect Level 1.27 mg/kg-day 0.001 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
282 Perfluorobutanoic Acid (PFBA) 375-22-4 Developmental Developmental delays Gestational oral gavage study in female CD-1 mice DAS, 2008 Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.62 mg/kg-day 0.006 mg/kg-day 100 1 High Medium Low/Medium Benchmark Subchronic
283 Perfluorobutanoic Acid (PFBA) 375-22-4 Hepatic Increased hepatocellular hypertrophy 90-day oral gavage study in male Sprague-Dawley rats BUTENHOFF, 2012 No Observable Adverse Effect Level 1.27 mg/kg-day 0.001 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
284 Perfluorobutanoic Acid (PFBA) 375-22-4 Hepatic Increased hepatocellular hypertrophy 90-day oral gavage study in male Sprague-Dawley rats BUTENHOFF, 2012 No Observable Adverse Effect Level 1.27 mg/kg-day 0.01 mg/kg-day 100 1 High Medium Medium Threshold Subchronic
285 Perfluorodecanoic Acid (PFDA) 335-76-2 Developmental, Immune Decreased serum antibody concentrations for tetanus and diphtheria in children; Decreased birth weight in male and female children Birth cohort study of children in the Faroe Island Wikstrom, 2020 None None None 2e-09 mg/kg-day 30 1 Medium Low/Medium Medium Threshold Chronic
286 Perfluorodecanoic Acid (PFDA) 335-76-2 Developmental, Immune Decreased serum antibody concentrations for tetanus and diphtheria in children; Decreased birth weight in male and female children Birth cohort study of children in the Faroe Islands Wikstrom, 2020 None None None 2e-09 mg/kg-day 30 1 Medium Low/Medium Medium Threshold Subchronic
287 Perfluorohexanesulfonic Acid (PFHxS) 355-46-4 Endocrine Decreased serum total T4 levels in F1 Wistar rats (Ramhoj et al., 2018) None None No Observable Adverse Effect Level 2.45e-05 mg/kg-day 2e-07 mg/kg-day 100 None None None Medium None Subchronic
288 Perfluorohexanesulfonic Acid (PFHxS) 355-46-4 Developmental, Immune Decreased serum anti-tetanus antibody concentration in children at age 7 yrs (Grandjean et al., 2012; Budtz-Jorgensen and Grandjean, 2018) None None Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.16e-08 mg/kg-day 4e-10 mg/kg-day 30 None None None Medium None Subchronic
289 Perfluorohexanesulfonic Acid (PFHxS) 355-46-4 Endocrine Decreasedserum total T4 levels in F1 Wistar rats (Ramhoj et al., 2018) None Ramhoj et al., 2018 No Observable Adverse Effect Level 2.45e-05 mg/kg-day 2e-07 mg/kg-day 100 None None None Medium None Chronic
290 Perfluorohexanesulfonic Acid (PFHxS) 355-46-4 Developmental, Immune Decreased serum anti-tetanus antibody concentration in children at age 7 yrs (Grandjean et al., 2012; Budtz-Jorgensen and Grandjean, 2018) None Grandjean et al., 2012; Budtz-Jorgensen and Grandjean, 2018 Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.16e-08 mg/kg-day 4e-10 mg/kg-day 30 None None None Medium None Chronic
291 Perfluorohexanoic Acid (PFHxA) 307-24-4 Developmental Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats One-generation reproductive gavage study in Sprague-Dawley rats Loveless, 2009 Benchmark Dose 0.048 mg/kg-day 0.0005 mg/kg-day 100 1 High Medium Medium Benchmark Chronic
292 Perfluorohexanoic Acid (PFHxA) 307-24-4 Hepatic Increased hepatocellular hypertrophy in adult rats Increased hepatocellular hypertrophy in adult male Crl:CD Sprague‑Dawley rats Loveless, 2009 Benchmark Dose 0.11 mg/kg-day 0.001 mg/kg-day 100 1 High Medium Medium Benchmark Subchronic
293 Perfluorohexanoic Acid (PFHxA) 307-24-4 Hematologic Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats 90 day gavage study in male and female Sprague-Dawley rats Chengelis, 2009 Benchmark Dose 0.078 mg/kg-day 0.0008 mg/kg-day 100 1 High Low/Medium Low/Medium Benchmark Subchronic
294 Perfluorohexanoic Acid (PFHxA) 307-24-4 Developmental Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats One-generation reproductive gavage study in Sprague-Dawley rats Loveless, 2009 Benchmark Dose 0.048 mg/kg-day 0.0005 mg/kg-day 100 1 High Medium Medium Benchmark Subchronic
295 Perfluorohexanoic Acid (PFHxA) 307-24-4 Hematologic Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats 2 year cancer gavage bioassay in male and female Sprague-Dawley rats Klaunig, 2015 Benchmark Dose 0.52 mg/kg-day 0.005 mg/kg-day 100 1 High Medium Medium Benchmark Chronic
296 Perfluorohexanoic Acid (PFHxA) 307-24-4 Endocrine Decreased total T4 in adult male Harlan Sprague-Dawley rats 28 day gavage study in male and female Harlan Sprague-Dawley rats NTP, 2018 Benchmark Dose 0.029 mg/kg-day 0.001 mg/kg-day 300 1 High Medium Medium Benchmark Subchronic
297 Perfluorohexanoic Acid (PFHxA) 307-24-4 Hepatic Increased hepatocellular hypertrophy in adult male Crl:CD Sprague‑Dawley rats 90-day oral gavage study in male and female Sprague-Dawley rats Loveless, 2009 Benchmark Dose 0.11 mg/kg-day 0.0004 mg/kg-day 300 1 High Medium Medium Benchmark Chronic
298 Permethrin 52645-53-1 Hepatic Increased liver weights 2-year rat feeding study FMC Corp., 1977 No Observed Effect Level 5.0 mg/kg-day 0.05 mg/kg-day 100 1 High High High Threshold Chronic
299 Phenmedipham 13684-63-4 Other No adverse effects 2-year rat feeding/ carcinogenicity study Nor-Am Agricultural Products, Inc., 1980a No Observable Adverse Effect Level 25.0 mg/kg-day 0.25 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
300 Phenol 108-95-2 Other Decreased maternal weight gain Rat developmental study Argus Research Laboratories, 1997 Benchmark Dose based on the LED10 (Lowest Effective Dose) 93.0 mg/kg-day 0.3 mg/kg-day 300 1 Medium Medium/High Medium/High Threshold Chronic
301 m-Phenylenediamine 108-45-2 Hepatic Increased relative and absolute liver weights and degenerative liver lesions Rat oral subchronic study Hofer et al., 1982 No Observed Effect Level 6.0 mg/kg-day 0.006 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
302 Phenylmercuric acetate 62-38-4 Urinary Renal damage Rat oral chronic study Fitzhugh et al., 1950 No Observable Adverse Effect Level 0.0084 mg/kg-day 8e-05 mg/kg-day 100 1 Medium Low Low Threshold Chronic
303 Phosmet 732-11-6 Hepatic, Nervous, Other Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition 2-year rat feeding study Stauffer Chemical, 1967 No Observed Effect Level 2.0 mg/kg-day 0.02 mg/kg-day 100 1 High High High Threshold Chronic
304 Phosphine 7803-51-2 Other Body weight and clinical parameters Rat chronic oral study Hackenburg, 1972 No Observed Effect Level 0.026 mg/kg-day 0.0003 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
305 Phthalic anhydride 85-44-9 Respiratory, Urinary Lung and kidney histopathology Chronic mouse oral study NCI, 1979 Lowest Observable Adverse Effect Level 1562.0 mg/kg-day 2.0 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
306 Picloram 1918-02-1 Hepatic Increased liver weights 6-month dog feeding study Dow Chemical, 1982a No Observed Effect Level 7.0 mg/kg-day 0.07 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
307 Pirimiphos-methyl 29232-93-7 Nervous Transient plasma ChE depression 56-day human feeding study ICI Americas, 1976a No Observed Effect Level 0.25 mg/kg-day 0.01 mg/kg-day 25 1 High High High Threshold Chronic
308 Potassium cyanide 151-50-8 Reproductive Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. None None None None None 0.002 mg/kg-day None None None None None None Chronic
309 Potassium silver cyanide 506-61-6 Reproductive Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. None None None None None 0.005 mg/kg-day None None None None None None Chronic
310 Prochloraz 67747-09-5 Hepatic Increase in SAP and liver weights, liver histopathology 2-year dog feeding study FBC Limited, 1981 No Observed Effect Level 0.9 mg/kg-day 0.009 mg/kg-day 100 1 Medium High High Threshold Chronic
311 Prometon 1610-18-0 Other No treatment related effects observed Subchronic rat feeding study Ciba-Geigy, 1982a No Observable Adverse Effect Level 15.0 mg/kg-day 0.015 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
312 Prometryn 7287-19-6 Hematologic, Hepatic, Immune, Urinary Liver and kidney degeneration and bone marrow atrophy 106-week dog feeding study Ciba-Geigy, 1965a No Observed Effect Level 3.75 mg/kg-day 0.004 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
313 Pronamide 23950-58-5 Other No effects 2-year dog feeding study Rohm & Haas, Co., 1970a No Observed Effect Level 7.5 mg/kg-day 0.075 mg/kg-day 100 1 High Medium Medium Threshold Chronic
314 Propachlor 1918-16-7 Hepatic, Other Decreased weight gain, food consumption increased relative liver weights 90-day feeding study in rats Monsanto Co., 1964a No Observed Effect Level 13.3 mg/kg-day 0.013 mg/kg-day 1000 1 Low Low Low Threshold Chronic
315 Propanil 709-98-8 Immune Increased relative spleen weight in females 2-year rat feeding study Rohm and Haas Co., 1964a No Observed Effect Level 5.0 mg/kg-day 0.005 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
316 Propargite 2312-35-8 Developmental, Musculoskeletal, Other Reduced body weight gain (maternal), increased resorption, reduced body weight (fetal), delayed ossification Rabbit developmental toxicity study (NOEL maternal and fetotoxic) Uniroyal Chemical, 1982 No Observed Effect Level 2.0 mg/kg-day 0.02 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
317 Propargyl alcohol 107-19-7 Hepatic, Urinary Renal and hepatotoxicity Rat oral subchronic study U.S. EPA, 1987 No Observable Adverse Effect Level 5.0 mg/kg-day 0.002 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
318 Propazine 139-40-2 Other Decrease in body weight 2-year rat feeding study Ciba-Geigy, 1980a No Observed Effect Level 5.0 mg/kg-day 0.02 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
319 Propham 122-42-9 Immune, Nervous Increase in male spleen weight and ChE depression in females 90-day rat feeding study PPG Industries, 1979 No Observed Effect Level 50.0 mg/kg-day 0.02 mg/kg-day 3000 1 Low Low Low Threshold Chronic
320 Propiconazole 60207-90-1 Gastrointestinal Gastric mucosal irritation 1-year dog feeding study Ciba Geigy, 1985a No Observed Effect Level 1.25 mg/kg-day 0.013 mg/kg-day 100 1 Medium High High Threshold Chronic
321 Pursuit 81335-77-5 Hematologic Decreased packed cell volume, hemoglobin, erythrocytes in females 1-year dog study oral exposure (diet) American Cyanamid Co., 1987a No Observed Effect Level 25.0 mg/kg-day 0.25 mg/kg-day 100 1 High High High Threshold Chronic
322 Pydrin 51630-58-1 Nervous Neurological dysfunction 13-week rat feeding study Shell Development Co., 1984 No Observed Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 High High High Threshold Chronic
323 Pyrene 129-00-0 Urinary Kidney effects (renal tubular pathology, decreased kidney weights) Mouse subchronic oral bioassay U.S. EPA, 1989 No Observable Adverse Effect Level 75.0 mg/kg-day 0.03 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
324 Pyridine 110-86-1 Hepatic Increased liver weight 90-day rat oral gavage study U.S. EPA, 1986 No Observable Adverse Effect Level 1.0 mg/kg-day 0.001 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
325 Quinalphos 13593-03-8 Other No adverse effects reported Two-year dog feeding study Sandoz, Ltd., 1980a No Observed Effect Level 0.05 mg/kg-day 0.0005 mg/kg-day 100 1 High Medium Medium Threshold Chronic
326 Resmethrin 10453-86-8 Reproductive Reproductive toxicity 3-generation rat reproduction study Penwick Corp., 1979a Lowest Effect Level 25.0 mg/kg-day 0.03 mg/kg-day 1000 1 High High High Threshold Chronic
327 Rotenone 83-79-4 Developmental Reduced pup weight 2-generation rat reproduction study U.S. Fish and Wildlife Service, 1983 No Observed Effect Level 0.38 mg/kg-day 0.004 mg/kg-day 100 1 Medium Medium Medium None Chronic
328 Savey 78587-05-0 Endocrine, Hematologic Hypertrophy of adrenal cortex (both sexes) hematologic effects (males) 1-year dog feeding study du Pont, 1984a No Observed Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 Medium High High Threshold Chronic
329 Selenious acid 7783-00-8 Dermal, Hematologic, Nervous Clinical selenosis Human epidemiological study Yang et al., 1989b No Observable Adverse Effect Level 0.015 mg/kg-day 0.005 mg/kg-day 3 1 Medium High High Threshold Chronic
330 Selenium and Compounds 7782-49-2 Dermal, Hematologic, Nervous Clinical selenosis Human epidemiological study Yang et al., 1989b No Observable Adverse Effect Level 0.015 mg/kg-day 0.005 mg/kg-day 3 1 Medium High High Threshold Chronic
331 Sethoxydim 74051-80-2 Hematologic Mild anemia in males 1-year dog study oral exposure (diet) (NOEL for males) BASF Corporation, 1984 No Observed Effect Level 8.86 mg/kg-day 0.09 mg/kg-day 100 1 High High High Threshold Chronic
332 Silver 7440-22-4 Dermal Argyria 2- to 9-year human i.v. study Gaul and Staud, 1935 Lowest Observable Adverse Effect Level 0.014 mg/kg-day 0.005 mg/kg-day 3 1 Medium Low Low Threshold Chronic
333 Silver cyanide 506-64-9 Endocrine, Nervous, Other Weight loss, thyroid effects, and myelin degeneration Rat chronic oral study Howard and Hanzal, 1955 No Observable Adverse Effect Level 55.7 mg/kg-day 0.1 mg/kg-day 100 5 Medium Low Low Threshold Chronic
334 Simazine 122-34-9 Hematologic, Other Reduction in weight gains hematological changes in females 2-year rat feeding study Ciba-Geigy Corp., 1988a No Observable Adverse Effect Level 0.52 mg/kg-day 0.005 mg/kg-day 100 1 Medium High High Threshold Chronic
335 Sodium azide 26628-22-8 Other Clinical sign (e.g., hunched postures) and reduced body weight Rat oral subchronic study NCI, 1981 No Observable Adverse Effect Level 3.57 mg/kg-day 0.004 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
336 Sodium cyanide 143-33-9 Reproductive Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. None None None None None 0.001 mg/kg-day None None None None None None Chronic
337 Sodium diethyldithiocarbamate 148-18-5 Other Reduced body weight Rat subchronic oral study Sunderman et al., 1967 No Observed Effect Level 30.0 mg/kg-day 0.03 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
338 Sodium fluoroacetate 62-74-8 Cardiovascular, Reproductive Increased heart weight in females and males; decreased testis weight and altered spermatogenesis in males. 13-week rat oral study (gavage) U.S. EPA, 1988 No Observable Adverse Effect Level 0.05 mg/kg-day 2e-05 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
339 Strontium 7440-24-6 Musculoskeletal Rachitic bone 20-day, 9-week, and 3-year oral studies in young and adult rats Storey, 1961; Marie et al., 1985; Skoryna, 1981 No Observable Adverse Effect Level 190.0 mg/kg-day 0.6 mg/kg-day 300 1 Medium Medium Medium Threshold Chronic
340 Strychnine 57-24-9 Other Toxicity/histopathology Rat oral short-term to subchronic study Seidl and Zbinden, 1982 Lowest Observable Adverse Effect Level 2.5 mg/kg-day 0.0003 mg/kg-day 10000 1 Low Low Low Threshold Chronic
341 Styrene 100-42-5 Hematologic, Hepatic Red blood cell and liver effects Dog subchronic oral study Quast et al., 1979 No Observable Adverse Effect Level 200.0 mg/kg-day 0.2 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
342 Systhane 88671-89-0 Reproductive Testicular atrophy 2-year chronic rat feeding study Rohm and Haas, 1986a No Observed Effect Level 2.49 mg/kg-day 0.025 mg/kg-day 100 1 High High High Threshold Chronic
343 Tebuthiuron 34014-18-1 Other Depressed body weight gain in F1 females 2-generation rat reproduction study Elanco Products, 1981 No Observed Effect Level 7.0 mg/kg-day 0.07 mg/kg-day 100 1 High High High Threshold Chronic
344 Terbacil 5902-51-2 Endocrine, Hepatic Increase in thyroid/body weight ratio; slight increase in liver weights; elevated alkaline phosphatase 2-year dog feeding study duPont, 1967a No Observed Effect Level 1.25 mg/kg-day 0.013 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
345 Terbutryn 886-50-0 Hematologic Hematologic effects in females 2-year rat feeding study Ciba-Geigy, 1980a No Observed Effect Level 0.1 mg/kg-day 0.001 mg/kg-day 100 1 High High High Threshold Chronic
346 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 5436-43-1 Nervous Neurobehavioral effects Single dose gavage study in mice Eriksson et al., 2001 Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.35 mg/kg 0.0001 mg/kg-day 3000 1 Low Low Low Benchmark Chronic
347 1,2,4,5-Tetrachlorobenzene 95-94-3 Urinary Kidney lesions Rat oral subchronic study Chu et al., 1984 No Observable Adverse Effect Level 0.34 mg/kg-day 0.0003 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
348 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6 Reproductive Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates Epidemiologic cohort study Mocarelli et al., (2008) / Baccarelli et al., (2008) Lowest Observable Adverse Effect Level 2e-08 mg/kg-day 7e-10 mg/kg-day 30 None High High High None None
349 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6 Developmental, Endocrine, Reproductive Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates Epidemiologic cohort study Mocarelli et al., 2008 / Baccarelli et al., 2008 Lowest Observable Adverse Effect Level 2e-08 mg/kg-day 7e-10 mg/kg-day 30 1 High High High None Chronic
350 1,1,2,2-Tetrachloroethane 79-34-5 Hepatic Increased relative liver weight in rats Subchronic dietary study NTP (2004) Benchmark Dose based on the LED10 (Lowest Effective Dose) 15.0 mg/kg-day 0.05 mg/kg-day 300 1 High Medium Medium None Chronic
351 1,1,2,2-Tetrachloroethane 79-34-5 Hepatic Increased relative liver weight in rats Subchronic dietary study NTP (2004) Benchmark Dose based on the LED10 (Lowest Effective Dose) 15.0 mg/kg-day 0.02 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
352 1,1,1,2-Tetrachloroethane 630-20-6 Hepatic, Urinary Mineralization of the kidneys in males, hepatic clear cell change in females Rat, chronic oral gavage study NTP, 1983 Lowest Observable Adverse Effect Level 89.3 mg/kg-day 0.03 mg/kg-day 3000 1 Low Low Low Threshold Chronic
353 Tetrachloroethylene (Perchloroethylene) 127-18-4 Nervous, Ocular (See Note) None None None None None 0.006 mg/kg-day None None Medium Medium Medium None Chronic
354 2,3,4,6-Tetrachlorophenol 58-90-2 Hepatic Increased liver weights and centrilobular hypertrophy Rat oral subchronic study U.S. EPA, 1986 No Observable Adverse Effect Level 25.0 mg/kg-day 0.03 mg/kg-day 1000 1 High Medium Medium Threshold Chronic
355 Tetrachlorovinphos 961-11-5 Hepatic, Nervous, Other, Urinary Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition Two-year dog feeding study Shell Chemical Co., 1968 No Observed Effect Level 3.13 mg/kg-day 0.03 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
356 Tetraethyl lead 78-00-2 Hepatic, Immune Histopathology of liver and thymus Rat subchronic study Schepers, 1964 Lowest Observable Adverse Effect Level 0.0012 mg/kg-day 1e-07 mg/kg-day 10000 1 Medium Medium Medium Threshold Chronic
357 Tetraethyldithiopyrophosphate 3689-24-5 Nervous Depressed RBC and plasma cholinesterase activity Rat subchronic oral study Kimmerle and Klimmer, 1974 No Observed Effect Level 0.5 mg/kg-day 0.0005 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
358 Tetrahydrofuran 109-99-9 Developmental Decreased pup body weight gain Rat two-generation reproduction study Hellwig et al. (2002)/BASF (1996) Benchmark Dose based on the LED10 (Lowest Effective Dose) 928.0 mg/kg-day 0.9 mg/kg-day 1000 1 Medium Low Low/Medium None Chronic
359 Thiobencarb 28249-77-6 Other, Urinary Decrease in body weight, increase in BUN 2-year rat feeding study Chevron Chemical, 1984a No Observed Effect Level 1.0 mg/kg-day 0.01 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
360 Thiophanate-methyl 23564-05-8 Endocrine, Other, Reproductive Decreased body weight, decreased spermatogenesis, and histological evidence of hyperthyroidism 2-year rat feeding study Pennwalt Corp., 1972a No Observed Effect Level 8.0 mg/kg-day 0.08 mg/kg-day 100 1 High High High Threshold Chronic
361 Thiram 137-26-8 Nervous Neurotoxicity 2-year rat feeding study duPont, 1954 No Observed Effect Level 5.0 mg/kg-day 0.005 mg/kg-day 1000 1 Low Low Low Threshold Chronic
362 Toluene 108-88-3 Urinary Increased kidney weight 13-week gavage study in rats NTP, 1990 Benchmark Dose based on the LED10 (Lowest Effective Dose) 238.0 mg/kg-day 0.08 mg/kg-day 3000 1 Medium Medium Medium Threshold Chronic
363 Tralomethrin 66841-25-6 Other Decreased body weight gain in males increased food and water consumption in males and females 2-year rat feeding study Roussel UCLAF, 1984 No Observed Effect Level 0.75 mg/kg-day 0.0075 mg/kg-day 100 1 High High High Threshold Chronic
364 Triallate 2303-17-5 Hepatic, Other Increased hemosiderin deposition, serum alkaline phosphatase, and liver weight in females 2-year dog feeding study Monsanto, 1979 No Observable Adverse Effect Level 1.275 mg/kg-day 0.013 mg/kg-day 100 1 Medium High High Threshold Chronic
365 Triasulfuron 82097-50-5 Hepatic Centrilobular hepatocytomegaly in males 2-year mouse feeding/carcinogenicity study Ciba-Geigy Corporation, 1988 No Observed Effect Level 1.2 mg/kg-day 0.01 mg/kg-day 100 1 Medium High High Threshold Chronic
366 1,2,4-Tribromobenzene 615-54-3 Hepatic Increased liver-to-body weight ratio and hepatic microsomal enzyme induction Rat oral subchronic study Carlson and Tardiff, 1977 No Observable Adverse Effect Level 5.0 mg/kg-day 0.005 mg/kg-day 1000 1 Low Low Low Threshold Chronic
367 Tributyltin oxide (TBTO) 56-35-9 Immune Immunosuppression 18-month immunotoxicity study in rats Vos et al., 1990 Benchmark Dose 0.03 mg/kg-day 0.0003 mg/kg-day 100 1 High High High Threshold Chronic
368 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) 76-13-1 Nervous Psychomotor impairment Epidemiologic study: human occupational exposure Imbus and Adkins, 1972 No Observable Adverse Effect Level 273.0 mg/kg-day 30.0 mg/kg-day 10 1 Low Low Low Threshold Chronic
369 Trichloroacetic acid 76-03-9 Hepatic Hepatocellular necrosis 60-week drinking water exposure study, male B6C3F1 mice DeAngelo et al., 2008 Benchmark Dose based on the LED10 (Lowest Effective Dose) 18.0 mg/kg-day 0.02 mg/kg-day 1000 1 Medium Medium Medium None Chronic
370 1,2,4-Trichlorobenzene 120-82-1 Endocrine Increased adrenal weights; vacuolization of zona fasciculata in the cortex Rat reproductive study Robinson et al., 1981 No Observable Adverse Effect Level 14.8 mg/kg-day 0.01 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
371 1,1,1-Trichloroethane 71-55-6 Other Reduced body weight 90-Day mouse dietary study NTP (2000) Benchmark Dose based on the LED10 (Lowest Effective Dose) 2155.0 mg/kg-day 7.0 mg/kg-day 300 1 Medium Low/Medium Low/Medium None Subchronic
372 1,1,1-Trichloroethane 71-55-6 Other Reduced body weight 90-Day mouse dietary study NTP (2000) Benchmark Dose based on the LED10 (Lowest Effective Dose) 2155.0 mg/kg-day 2.0 mg/kg-day 1000 1 High Low/Medium Low/Medium Benchmark Chronic
373 1,1,2-Trichloroethane 79-00-5 Hematologic, Immune Clinical serum chemistry (effects on erythrocytes and depressed humoral immune status) Mouse subchronic drinking water study White et al., 1985 Sanders et al., 1985 No Observable Adverse Effect Level 3.9 mg/kg-day 0.004 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
374 Trichloroethylene 79-01-6 Developmental, Immune (See Note) None None None None None 0.0005 mg/kg-day None 1 High High High None Chronic
375 Trichlorofluoromethane 75-69-4 Cardiovascular, Other, Respiratory Survival and histopathology (pleuritis and pericarditis) Cancer bioassay studies in rats and mice NCI, 1978 Lowest Observable Adverse Effect Level 349.0 mg/kg-day 0.3 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
376 2,4,5-Trichlorophenol 95-95-4 Hepatic, Urinary Liver and kidney pathology Rat oral subchronic study McCollister et al., 1961 No Observed Effect Level 100.0 mg/kg-day 0.1 mg/kg-day 1000 1 Medium Low Low Threshold Chronic
377 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) 93-72-1 Hepatic Histopathological changes in liver Dog chronic oral bioassay Mullison, 1966; Gehring and Betso, 1978 No Observed Effect Level 0.75 mg/kg-day 0.008 mg/kg-day 100 1 Medium Medium Medium Threshold Chronic
378 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) 93-76-5 Urinary Increased urinary coproporphyrins 2-year rat feeding study Kociba et al., 1979 No Observable Adverse Effect Level 3.0 mg/kg-day 0.01 mg/kg-day 300 1 High Medium Medium Threshold Chronic
379 1,1,2-Trichloropropane 598-77-6 Endocrine, Hepatic, Urinary Mild lesions in liver, kidney and thyroid Rat oral subchronic study Villeneuve et al., 1985 No Observed Effect Level 15.0 mg/kg-day 0.005 mg/kg-day 3000 1 Medium Low Low Threshold Chronic
380 1,2,3-Trichloropropane 96-18-4 Hepatic Increased absolute liver weight in male rats 2-year bioassay NTP, 1993 Benchmark Dose based on the LED10 (Lowest Effective Dose) 1.1 mg/kg-day 0.004 mg/kg-day 300 1 High Medium/High Medium/High Benchmark Chronic
381 Tridiphane 58138-08-2 Other, Reproductive Decreased fertility index and depressed body weight of dams Rat, 2-generation reproduction study Dow Chemical, 1984 No Observed Effect Level 0.33 mg/kg-day 0.003 mg/kg-day 100 1 Medium High High Threshold Chronic
382 Trifluralin 1582-09-8 Hematologic, Hepatic Increased liver weights; increase in methemoglobin 12-month dog feeding study Hoechst Aktiengesellschaft, 1984a No Observed Effect Level 0.75 mg/kg-day 0.0075 mg/kg-day 100 1 High High High Threshold Chronic
383 1,2,4-Trimethylbenzene 95-63-6 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Dose based on the LED10 (Lowest Effective Dose) 3.5 mg/kg-day 0.01 mg/kg-day 300 1 Low/Medium Low/Medium Low Benchmark Chronic
384 1,2,3-Trimethylbenzene 526-73-8 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Dose based on the LED10 (Lowest Effective Dose) 3.5 mg/kg-day 0.01 mg/kg-day 300 1 Low/Medium Low/Medium Low Benchmark Chronic
385 1,2,4-Trimethylbenzene 95-63-6 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Dose based on the LED10 (Lowest Effective Dose) 3.5 mg/kg-day 0.04 mg/kg-day 100 1 None None Low Benchmark Subchronic
386 1,3,5-Trimethylbenzene 108-67-8 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Dose based on the LED10 (Lowest Effective Dose) 3.5 mg/kg-day 0.01 mg/kg-day 300 1 Low/Medium Low/Medium Low Benchmark Chronic
387 1,2,3-Trimethylbenzene 526-73-8 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Dose based on the LED10 (Lowest Effective Dose) 3.5 mg/kg-day 0.04 mg/kg-day 100 1 Low Low Low Benchmark Subchronic
388 1,3,5-Trimethylbenzene 108-67-8 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Dose based on the LED10 (Lowest Effective Dose) 3.5 mg/kg-day 0.04 mg/kg-day 100 1 Low Low Low Benchmark Subchronic
389 1,3,5-Trinitrobenzene 99-35-4 Hematologic Methemoglobinemia and spleen-erythroid cell hyperplasia Rat 2-year dietary study Reddy et al., 1996, 1997 No Observable Adverse Effect Level 2.68 mg/kg-day 0.03 mg/kg-day 100 1 High Medium Medium Threshold Chronic
390 2,4,6-Trinitrotoluene (TNT) 118-96-7 Hepatic Liver effects 26-week dog feeding study U.S. DOD, 1983 Lowest Observable Adverse Effect Level 0.5 mg/kg-day 0.0005 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
391 Uranium, soluble salts Various Other, Urinary Initial body weight loss moderate nephrotoxicity 30-day oral rabbit bioassay (diet) Maynard and Hodge, 1949 Lowest Observable Adverse Effect Level 2.8 mg/kg-day 0.003 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
392 Vanadium pentoxide 1314-62-1 Dermal Decreased hair cystine Rat chronic oral study Stokinger et al., 1953 No Observable Adverse Effect Level 0.89 mg/kg-day 0.009 mg/kg-day 100 1 Low Low Low Threshold Chronic
393 Vernam 1929-77-7 Other Decreased body weight 2-generation reproduction rat study Stauffer Chemical Co., 1983 No Observed Effect Level 1.0 mg/kg-day 0.001 mg/kg-day 1000 1 High Low Low Threshold Chronic
394 Vinclozolin 50471-44-8 Endocrine, Urinary Organ weight changes (adrenal and kidney) 6-month dog feeding study BASF Corp., 1982 No Observed Effect Level 2.5 mg/kg-day 0.025 mg/kg-day 100 1 High High High Threshold Chronic
395 Vinyl chloride 75-01-4 Hepatic Liver cell polymorphism Rat chronic feeding study Til et al., 1983, 1991 No Observable Adverse Effect Level 0.09 mg/kg-day 0.003 mg/kg-day 30 1 High Medium/High Medium Threshold Chronic
396 Warfarin 81-81-2 Hematologic Increased prothrombin time Human clinical studies Huff, 1985 Lowest Observable Adverse Effect Level 0.029 mg/kg-day 0.0003 mg/kg-day 100 1 Low Low Low Threshold Chronic
397 White phosphorus 7723-14-0 Dermal, Reproductive Parturition mortality; forelimb hair loss Reproductive rat study Condray, 1985 No Observable Adverse Effect Level 0.015 mg/kg-day 2e-05 mg/kg-day 1000 1 Low Low Low Threshold Chronic
398 Xylenes 1330-20-7 Other Decreased body weight, increased mortality Chronic F344/N rat study, Oral gavage exposure NTP, 1986 No Observable Adverse Effect Level 179.0 mg/kg-day 0.2 mg/kg-day 1000 1 Medium Medium Medium Threshold Chronic
399 Zinc and Compounds 7440-66-6 Hematologic, Immune Decreases in erythrocyte Cu, Zn-superoxide dismutase (ESOD) activity in healthy adult male and female volunteers None Yadrick et al., 1989, Fischer et al., 1984, Davis et al., 2000, Milne et al., 2001 Lowest Observable Adverse Effect Level 0.91 mg/kg-day 0.3 mg/kg-day 3 1 Medium/High High Medium/High Threshold Chronic
400 Zinc cyanide 557-21-1 Endocrine, Nervous, Other Weight loss, thyroid effects, and myelin degeneration Rat chronic oral study Howard and Hanzal, 1955 No Observable Adverse Effect Level 24.3 mg/kg-day 0.05 mg/kg-day 100 5 Medium Medium Medium Threshold Chronic
401 Zinc phosphide 1314-84-7 Other Reduction of food intake and body weight Rat subchronic oral study Bai et al, 1980 Lowest Observable Adverse Effect Level 3.48 mg/kg-day 0.0003 mg/kg-day 10000 1 Medium Low Low Threshold Chronic
402 Zineb 12122-67-7 Endocrine Thyroid hyperplasia Rat, chronic oral bioassay Blackwell-Smith et al., 1953 Lowest Observable Adverse Effect Level 25.0 mg/kg-day 0.05 mg/kg-day 500 1 Medium Medium Medium Threshold Chronic
403 n-Butanol 71-36-3 Nervous Hypoactivity and ataxia Rat oral subchronic study U.S. EPA, 1986 No Observable Adverse Effect Level 125.0 mg/kg-day 0.1 mg/kg-day 1000 1 High Low Low Threshold Chronic
404 tert-Butyl Alcohol (tBA) 75-65-0 Urinary Increased severity of nephropathy 2-year drinking water study in female rats NTP 1995 Benchmark Dose based on the LED10 (Lowest Effective Dose) 43.2 mg/kg-day 0.4 mg/kg-day 100 1 High Medium Medium Benchmark Chronic

  CHEMICAL NAME CASRN PRINCIPAL CRITICAL EFFECT SYSTEM PRINCIPAL CRITICAL DESCRIPTION PRINCIPAL STUDY STUDY CITATION EXPERIMENTAL DOSE TYPE POD VALUE RFC VALUE UNCERTAINTY FACTOR MODIFYING FACTOR STUDY CONFIDENCE DATA CONFIDENCE OVERALL CONFIDENCE DOSE TYPE DURATION
1 Acetaldehyde 75-07-0 Nervous, Respiratory Degeneration of olfactory epithelium Short-term rat inhalation studies Appleman et al., 1986 1982 No Observable Adverse Effect Level 8.7 mg/m3 0.009 mg/m3 1000 1 Medium Low Low Threshold Chronic
2 Acetonitrile 75-05-8 Other Mortality Mouse subchronic/chronic inhalation studies NTP, 1996 No Observable Adverse Effect Level 60.0 mg/m3 0.06 mg/m3 100 10 Medium Medium Medium Threshold Chronic
3 Acrolein 107-02-8 Respiratory Nasal lesions Subchronic rat inhalation study Feron et. al., 1978 Lowest Observable Adverse Effect Level 0.02 mg/m3 2e-05 mg/m3 1000 1 Medium Low/Medium Medium Threshold Chronic
4 Acrylamide 79-06-1 Nervous Degenerative nerve changes Chronic rat study Johnson et al. 1986 Human Equivalent Concentration 0.18 mg/m3 0.006 mg/m3 30 1 Medium/High Low/Medium Medium Threshold Chronic
5 Acrylic acid 79-10-7 Nervous, Respiratory Degeneration of the nasal olfactory epithelium Mouse subchronic inhalation study Miller et al., 1981a Lowest Observable Adverse Effect Level 0.33 mg/m3 0.001 mg/m3 300 1 Medium Medium Medium Threshold Chronic
6 Acrylonitrile 107-13-1 Respiratory Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells Rat 2-year inhalation study Quast et al., 1980 Lowest Observable Adverse Effect Level 1.9 mg/m3 0.002 mg/m3 1000 1 Medium Medium Medium Threshold Chronic
7 Allyl chloride 107-05-1 Nervous Functional and histological peripheral neurotoxicity Rabbit subchronic inhalation study Lu et al., 1982 No Observable Adverse Effect Level 3.6 mg/m3 0.001 mg/m3 3000 1 Low Low Low Threshold Chronic
8 Ammonia 7664-41-7 Respiratory Decreased lung function and respiratory symptoms Occupational epidemiology studies Holness et al. (1989), supported by Rahman et al. (2007), Ballal et al. (1998), and Ali et al. (2001) No Observable Adverse Effect Level 4.9 mg/m3 0.5 mg/m3 10 1 Medium Medium Medium Threshold Chronic
9 Aniline 62-53-3 Hematologic Methemoglobin increase, spleen toxicity 20-26 week inhalation rat, guinea pig and mouse study Oberst et al., 1956 No Observable Adverse Effect Level 3.4 mg/m3 0.001 mg/m3 3000 1 Low Low Low Threshold Chronic
10 Antimony trioxide 1309-64-4 Respiratory Pulmonary toxicity, chronic interstitial inflammation Rat 1-year inhalation toxicity study Newton et al., 1994 Benchmark Concentration 0.074 mg/m3 0.0002 mg/m3 300 1 Medium Medium Medium Threshold Chronic
11 Arsine 7784-42-1 Hematologic, Immune Increased hemolysis, abnormal RBC morphology, and increased spleen weight 13-week rat and mouse and 28-day hamster inhalation study Blair et al., 1990a,b No Observable Adverse Effect Level 0.014 mg/m3 5e-05 mg/m3 300 1 High Medium Medium Threshold Chronic
12 Benzene 71-43-2 Immune Decreased lymphocyte count Human occupational inhalation study Rothman et. al., 1996 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 8.2 mg/m3 0.03 mg/m3 300 1 Medium Medium Medium Threshold Chronic
13 Benzo[a]pyrene (BaP) 50-32-8 Developmental Decreased embryo/fetal survival Developmental toxicity study in rats (GDs 11−20) Archibong et al. (2002) Lowest Observable Adverse Effect Level 0.0046 mg/m3 2e-06 mg/m3 3000 1 Low/Medium Low Low/Medium Threshold Chronic
14 Benzo[a]pyrene (BaP) 50-32-8 Reproductive Reduced ovulation rate and ovary weight Premating study in rats (14 d) Archibong et al. (2012) Lowest Observable Adverse Effect Level 0.0091 mg/m3 3e-06 mg/m3 3000 1 None None Low/Medium Threshold Chronic
15 Beryllium and compounds 7440-41-7 Immune, Respiratory Beryllium sensitization and progression to CBD Occupational study Kreiss et al., 1996 Lowest Observable Adverse Effect Level 0.0002 mg/m3 2e-05 mg/m3 10 1 Medium Medium Medium Threshold Chronic
16 Bromobenzene 108-86-1 Hepatic Hepatocellular cytomegaly in female B6C3F1 mice 13-week inhalation study NTP (1985d) Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 63.0 mg/m3 0.06 mg/m3 1000 1 Medium Low/Medium Low/Medium None Chronic
17 Bromobenzene 108-86-1 Hepatic Hepatocellular cytomegaly in female B6C3F1 mice 13-week inhalation study NTP (1985d) Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 63.0 mg/m3 0.2 mg/m3 300 1 Medium Medium Medium None Subchronic
18 Bromomethane 74-83-9 Nervous, Respiratory Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity Rat 29-month inhalation study Reuzel et al., 1987, 1991 Lowest Observable Adverse Effect Level 0.48 mg/m3 0.005 mg/m3 100 1 Medium High High Threshold Chronic
19 1,3-Butadiene 106-99-0 Reproductive Ovarian atrophy 2-year mouse inhalation study NTP, 1993 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 1.98 mg/m3 0.002 mg/m3 1000 1 High High Medium Threshold Chronic
20 Carbon disulfide 75-15-0 Nervous Peripheral nervous system dysfunction Occupational study Johnson et al., 1983 Benchmark Concentration 19.7 mg/m3 0.7 mg/m3 30 1 Medium Medium Medium Threshold Chronic
21 Carbon tetrachloride 56-23-5 Hepatic Fatty changes in the liver Chronic inhalation toxicity study in rats Nagano et al., 2007b, JBRC, 1998 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 14.3 mg/m3 0.1 mg/m3 100 1 High Medium Medium Threshold Chronic
22 Cerium Oxide and Cerium Compounds 1306-38-3 Respiratory Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats Subchronic inhalation study BRL, 1994 (unpublished study) Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 0.86 mg/m3 0.0009 mg/m3 1000 1 Medium Low Low Benchmark Chronic
23 Chlordane (Technical) 12789-03-6 Hepatic Hepatic effects Rat subchronic inhalation study Khasawinah et al., 1989a No Observable Adverse Effect Level 0.65 mg/m3 0.0007 mg/m3 1000 1 Medium Low Low Threshold Chronic
24 Chlorine dioxide 10049-04-4 Cardiovascular, Respiratory Vascular congestion and peribronchial edema 60-day rat inhalation study Paulet and Desbrousses, 1972 Lowest Observable Adverse Effect Level 0.64 mg/m3 0.0002 mg/m3 3000 1 Low Low Low Threshold Chronic
25 1-Chloro-1,1-difluoroethane 75-68-3 Other No adverse effects 2-year rat inhalation study Seckar et al., 1986 No Observable Adverse Effect Level 14710.0 mg/m3 50.0 mg/m3 300 1 Medium Medium Medium Threshold Chronic
26 2-Chloroacetophenone 532-27-4 Respiratory Squamous hyperplasia of the nasal respiratory epithelium Chronic rat inhalation study NTP, 1990 Lowest Observable Adverse Effect Level 0.03 mg/m3 3e-05 mg/m3 1000 1 Medium Low Low Threshold Chronic
27 Chlorodifluoromethane 75-45-6 Endocrine, Urinary Increased kidney, adrenal and pituitary weights Chronic rat inhalation study Tinston et al., 1981a No Observable Adverse Effect Level 5260.0 mg/m3 50.0 mg/m3 100 1 High Medium Medium Threshold Chronic
28 Chloroprene 126-99-8 Immune, Nervous, Respiratory Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively 2-year chronic inhalation study NTP, 1998 Benchmark Dose based on the LED10 (Lowest Effective Dose) 2.0 mg/m3 0.02 mg/m3 100 1 High Medium/High Medium/High Threshold Chronic
29 Chromium(VI) 18540-29-9 Respiratory Ulcerated nasal septum in humans None None Lowest Observable Adverse Effect Level 0.0034 mg/m3 3e-05 mg/m3 100 None None None Medium None Chronic
30 Cumene 98-82-8 Endocrine, Urinary Increased kidney weights in female rats and adrenal weights in male and female rats Rat 13-week inhalation study Cushman et al., 1995 No Observable Adverse Effect Level 435.0 mg/m3 0.4 mg/m3 1000 1 High Medium Medium Threshold Chronic
31 Cyclohexane 110-82-7 Developmental Reduced pup weights in the F1 and F2 generations Rat, 2-generation reproductive/developmental toxicity study DuPont HLR, 1997a Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 1822.0 mg/m3 6.0 mg/m3 300 1 High Low/Medium Low/Medium Threshold None
32 1,2-Dibromo-3-chloropropane (DBCP) 96-12-8 Reproductive Testicular effects 13-week subchronic rabbit inhalation study Rao et al., 1982 No Observable Adverse Effect Level 0.17 mg/m3 0.0002 mg/m3 1000 1 Medium Medium Medium Threshold Chronic
33 1,2-Dibromoethane 106-93-4 Respiratory Nasal inflammation Mouse chronic inhalation study NTP, 1982 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 2.8 mg/m3 0.009 mg/m3 300 1 Medium Medium Medium Benchmark Chronic
34 1,4-Dichlorobenzene 106-46-7 Hepatic Increased liver weights in P1 males Rat multigeneration reproductive study Chlorobenzene Producers Assn., 1986 No Observable Adverse Effect Level 75.0 mg/m3 0.8 mg/m3 100 1 Medium Medium Medium Threshold Chronic
35 1,1-Dichloroethylene (1,1-DCE) 75-35-4 Hepatic Liver toxicity (fatty change) Rat chronic inhalation study Quast et al., 1986 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 6.9 mg/m3 0.2 mg/m3 30 1 High Medium Medium Threshold Chronic
36 Dichloromethane 75-09-2 Hepatic Hepatic effects (hepatic vacuolation) 2-Year rat inhalation bioassay Nitschke et al. (1988a) Benchmark Dose based on the LED10 (Lowest Effective Dose) 17.2 mg/m3 0.6 mg/m3 30 1 High Medium/High Medium/High None Chronic
37 1,2-Dichloropropane 78-87-5 Respiratory Hyperplasia of the nasal mucosa Rat 13-week inhalation study Nitschke et al., 1988 Lowest Observable Adverse Effect Level 1.3 mg/m3 0.004 mg/m3 300 1 High Medium Medium Threshold None
38 1,3-Dichloropropene 542-75-6 Respiratory Hypertrophy/ hyperplasia of the nasal respiratory epithelium Chronic inhalation study in B6C3F1 mice Lomax et al., 1989 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 0.72 mg/m3 0.02 mg/m3 30 1 High High High Threshold Chronic
39 Dichlorvos 62-73-7 Nervous Decreased brain cholinesterase activity Carworth Farm E strain rat chronic inhalation study Blair et al., 1976 No Observable Adverse Effect Level 0.05 mg/m3 0.0005 mg/m3 100 1 Medium Medium Medium Threshold Chronic
40 Diesel engine exhaust None Respiratory Pulmonary inflammation and histopathology Rat chronic inhalation study Ishinishi et. al., (1988) No Observable Adverse Effect Level 0.144 mg/m3 0.005 mg/m3 30 1 Medium Medium Medium Threshold Chronic
41 1,1-Difluoroethane 75-37-6 Other No adverse effects observed 2-year inhalation study McAlack and Schneider, 1982 No Observable Adverse Effect Level 12051.0 mg/m3 40.0 mg/m3 300 1 Medium Medium Medium Threshold Chronic
42 N,N-Dimethylformamide 68-12-2 Hepatic Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities Human occupational studies Cirla et al., 1984; Catenacci et al., 1984 Lowest Observable Adverse Effect Level 7.9 mg/m3 0.03 mg/m3 300 1 Medium Medium Medium Threshold Chronic
43 1,4-Dioxane 123-91-1 Nervous, Respiratory Atrophy and respiratory metaplasia of the olfactory epithelium Chronic inhalation male rat study Kasai et al. 2009 Lowest Observable Adverse Effect Level 32.2 mg/m3 0.03 mg/m3 1000 1 Medium Medium Medium None Chronic
44 Epichlorohydrin 106-89-8 Respiratory Changes in the nasal turbinates Rat and mouse 90-day inhalation study Quast et al., 1979a No Observable Adverse Effect Level 0.36 mg/m3 0.001 mg/m3 300 1 Medium Medium Medium Threshold Chronic
45 1,2-Epoxybutane (EBU) 106-88-7 Respiratory Degenerative lesions of the nasal cavity 2-year mouse inhalation study NTP, 1988 Lowest Observable Adverse Effect Level 4.8 mg/m3 0.02 mg/m3 300 1 Medium Medium Medium Threshold Chronic
46 2-Ethoxyethanol 110-80-5 Hematologic, Reproductive Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin New Zealand White Rabbit subchronic toxicity study Barbee et al., 1984 No Observable Adverse Effect Level 68.0 mg/m3 0.2 mg/m3 300 1 Medium Medium Medium Threshold Chronic
47 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Urinary Increased absolute kidney weight in female rats 2-year inhalation study in male and female F344 rats Saito et al., 2013; JPEC, 2010b No Observable Adverse Effect Level 1110.0 mg/m3 40.0 mg/m3 30 1 Medium High Medium Threshold Chronic
48 Ethyl chloride 75-00-3 Developmental, Musculoskeletal Delayed fetal ossification Mouse developmental inhalation study Scortichini et al., 1986 No Observable Adverse Effect Level 4000.0 mg/m3 10.0 mg/m3 300 1 Medium Medium Medium Threshold Chronic
49 Ethylbenzene 100-41-4 Developmental Developmental toxicity Rat and rabbit developmental inhalation studies Andrew et al., 1981; Hardin et al., 1981 No Observable Adverse Effect Level 434.0 mg/m3 1.0 mg/m3 300 1 Low Low Low Threshold Chronic
50 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 Hematologic Hemosiderin deposition in the liver Chronic (rat and mouse) inhalation study NTP (2000) Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 16.0 mg/m3 1.6 mg/m3 10 1 High Medium/High Medium/High Threshold Chronic
51 Formaldehyde 50-00-0 Respiratory Decreased pulmonary function, prevalence of current asthma or degree of asthma control, and allergic conditions in children (See Note) None None None None None 0.007 mg/m3 None None None None High None Chronic
52 Hexachlorocyclopentadiene (HCCPD) 77-47-4 Respiratory Suppurative inflammation of the nose Chronic inhalation study in B6C3F1 mice NTP, 1994 No Observable Adverse Effect Level 0.024 mg/m3 0.0002 mg/m3 100 1 High Medium Medium Threshold Chronic
53 Hexachloroethane 67-72-1 Nervous Neurotoxicity (tremors and ruffled pelt) 6-week subchronic inhalation study, male and female Sprague-Dawley rats Weeks et al., 1979 No Observable Adverse Effect Level 83.0 mg/m3 0.03 mg/m3 3000 1 Low Low Low Threshold Chronic
54 1,6-Hexamethylene diisocyanate 822-06-0 Nervous, Respiratory Degeneration of olfactory epithelium Rat chronic inhalation study Mobay, Inc., 1989 No Observable Adverse Effect Level 0.001 mg/m3 1e-05 mg/m3 100 1 High Medium Medium Threshold Chronic
55 n-Hexane 110-54-3 Nervous Peripheral neuropathy (decreased MCV at 12 weeks) Rat subchronic inhalation study Huang et al., 1989 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 215.0 mg/m3 0.7 mg/m3 300 1 Medium Medium Medium Threshold Chronic
56 2-Hexanone 591-78-6 Nervous Motor conduction velocity of the sciatic-tibial nerve Subchronic inhalation study in monkeys Johnson et al., 1977 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 90.0 mg/m3 0.03 mg/m3 3000 1 Medium Low Low Benchmark Chronic
57 Hydrogen Cyanide and Cyanide Salts Various Endocrine Thyroid enlargement and altered iodide uptake Epidemiology study El Ghawabi et al., 1975 Lowest Observable Adverse Effect Level 2.5 mg/m3 0.0008 mg/m3 3000 1 Medium Low/Medium Low/Medium Threshold Chronic
58 Hydrogen chloride 7647-01-0 Respiratory Hyperplasia of nasal mucosa larynx and trachea Rat chronic inhalation study Sellakumar et al., 1994; Albert et al., 1982 Lowest Observable Adverse Effect Level 6.1 mg/m3 0.02 mg/m3 300 1 Low Low Low Threshold Chronic
59 Hydrogen sulfide 7783-06-4 Nervous, Respiratory Nasal lesions of the olfactory mucosa Rat Subchronic Inhalation Study Brenneman et. al., 2000 No Observable Adverse Effect Level 0.64 mg/m3 0.002 mg/m3 300 1 Medium Medium/High Medium/High Threshold Chronic
60 Libby Amphibole Asbestos 1318-09-8 Respiratory Localized pleural thickening Occupational epidemiology study Rohs et al. (2008) Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 0.026 fiber/cc 9e-05 fiber/cc 300 1 Medium Medium Medium None Chronic
61 Manganese 7439-96-5 Nervous Impairment of neurobehavioral function Occupational exposure to manganese dioxide Roels et al., 1992 Lowest Observable Adverse Effect Level 0.05 mg/m3 5e-05 mg/m3 1000 1 Medium Medium Medium Threshold Chronic
62 Mercury, elemental 7439-97-6 Nervous Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction Human occupational inhalation studies Fawer et al., 1983; Piikivi and Tolonen, 1989; Piikivi and Hanninen, 1989; Piikivi, 1989; Ngim et al., 1992; Liang et al., 1993 Lowest Observable Adverse Effect Level 0.009 mg/m3 0.0003 mg/m3 30 1 Medium Medium Medium Threshold Chronic
63 Methanol 67-56-1 Developmental, Nervous Reduced brain weight in rat pups at 6 weeks of age Male Sprague-Dawley rats, Developmental inhalation exposure through gestation and 3, 6 or 8 weeks postnatal NEDO (1987) Benchmark Dose based on the LED10 (Lowest Effective Dose) 858.0 mg-hr/L 20.0 mg/m3 100 1 High Medium Medium/High None Chronic
64 2-Methoxyethanol 109-86-4 Reproductive Testicular effects Subchronic inhalation studies in male New Zealand White Rabbits and Sprague-Dawley rats Miller et al., 1983 No Observable Adverse Effect Level 17.0 mg/m3 0.02 mg/m3 1000 1 Medium Medium Medium Threshold Chronic
65 Methyl chloride 74-87-3 Nervous Cerebellar lesions Mouse 11-day continuous inhalation study Landry et al., 1983, 1985 No Observable Adverse Effect Level 94.6 mg/m3 0.09 mg/m3 1000 1 High Medium Medium Threshold Chronic
66 Methyl ethyl ketone (MEK) 78-93-3 Developmental, Musculoskeletal Developmental toxicity (skeletal variations) Mouse developmental study Schwetz et al., 1991 Lowest Effect Concentration 1517.0 mg/m3 5.0 mg/m3 300 1 High Medium Medium Threshold Chronic
67 Methyl isobutyl ketone (MIBK) 108-10-1 Developmental, Musculoskeletal Reduced fetal body weight, skeletal variations, and increased fetal death in mice, and skeletal variations in rats. Rat and mouse developmental inhalation study Tyl et. al., 1987 No Observable Adverse Effect Level 1026.0 mg/m3 3.0 mg/m3 300 1 Medium Low/Medium Low/Medium Threshold Chronic
68 Methyl methacrylate 80-62-6 Nervous, Respiratory Degeneration/ atrophy of olfactory epithelium (male rats) Rat chronic inhalation study Hazelton Laboratories 1979a Lomax, 1992 Lomax et al., 1997 Benchmark Concentration 7.2 mg/m3 0.7 mg/m3 10 1 High Medium/High Medium/High Threshold Chronic
69 Methyl tert-butyl ether (MTBE) 1634-04-4 Hepatic, Ocular, Other, Urinary Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females) Chronic rat 24-month inhalation study Chun et al., 1992 No Observable Adverse Effect Level 259.0 mg/m3 3.0 mg/m3 100 1 Medium Medium Medium Threshold Chronic
70 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 Nervous, Respiratory Hyperplasia of olfactory epithelium Rat inhalation studies Reuzel et al., 1990, 1994b Benchmark Concentration 0.06 mg/m3 0.0006 mg/m3 100 1 High Medium Medium Threshold Chronic
71 Naphthalene 91-20-3 Nervous, Respiratory Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively Chronic mouse inhalation study NTP, 1992a Lowest Observable Adverse Effect Level 9.3 mg/m3 0.003 mg/m3 3000 1 Medium Low/Medium Medium Threshold Chronic
72 Nitrobenzene 98-95-3 Nervous, Respiratory Bronchiolization of the alveoli and olfactory degeneration Chronic mouse study CIIT, 1993 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 0.26 mg/m3 0.009 mg/m3 30 1 High High Medium None Chronic
73 2-Nitropropane 79-46-9 Hepatic Liver focal vacuolization and nodules Rat chronic inhalation study Griffin et al., 1980, 1981; Angus Chemical Co., 1985a, b Lowest Observable Adverse Effect Level 16.0 mg/m3 0.02 mg/m3 1000 1 Low Low Low Threshold Chronic
74 Phosgene 75-44-5 Respiratory Collagen staining indicative of fibrosis Subchronic inhalation study in rats Kodavanti et al., 1997 Benchmark Dose based on the LED10 (Lowest Effective Dose) 0.03 mg/m3 0.0003 mg/m3 100 1 Medium Medium Medium Benchmark Chronic
75 Phosphine 7803-51-2 Other Decreased body weight Mouse subchronic inhalation study Barbosa et al., 1994 No Observable Adverse Effect Level 0.25 mg/m3 0.0003 mg/m3 1000 1 Medium Low Low Threshold Chronic
76 Phosphoric acid 7664-38-2 Respiratory Bronchiolar fibrosis 13-week rat inhalation study Aranyi et al., 1988a Benchmark Concentration 3.4 mg/m3 0.01 mg/m3 300 1 Medium Medium Medium Threshold Chronic
77 Propionaldehyde 123-38-6 Nervous, Respiratory Atrophy of olfactory epithelium Subchronic inhalation study in rats Union Carbide, 1993 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 8.0 mg/m3 0.008 mg/m3 1000 1 Low/Medium Low Low/Medium Benchmark Chronic
78 Propylene glycol monomethyl ether (PGME) 107-98-2 Nervous Mild reversible sedation Rat/rabbit subchronic inhalation study Landry et al., 1983 No Observable Adverse Effect Level 658.0 mg/m3 2.0 mg/m3 300 1 Medium Medium Medium Threshold Chronic
79 Propylene oxide 75-56-9 Respiratory Nest-like infolds of the nasal respiratory epithelium 2-year rat chronic inhalation study Kuper et al., 1988 Lowest Observable Adverse Effect Level 2.9 mg/m3 0.03 mg/m3 100 1 Medium Medium Medium Threshold Chronic
80 Styrene 100-42-5 Nervous CNS effects Occupational study Mutti et al., 1984 No Observable Adverse Effect Level 34.0 mg/m3 1.0 mg/m3 30 1 Medium Medium Medium Threshold Chronic
81 Tetrachloroethylene (Perchloroethylene) 127-18-4 Nervous, Ocular (See Note) None None None None None 0.04 mg/m3 None None Medium Medium Medium None Chronic
82 1,1,1,2-Tetrafluoroethane 811-97-2 Reproductive Leydig cell hyperplasia Rat chronic inhalation study Collins et al., 1995 Benchmark Concentration 8200.0 mg/m3 80.0 mg/m3 100 1 High Medium Medium Threshold Chronic
83 Tetrahydrofuran 109-99-9 Hepatic, Nervous Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) Subchronic mouse study NTP (1998) Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 246.0 mg/m3 2.0 mg/m3 100 1 High Medium/High Medium/High None Chronic
84 Toluene 108-88-3 Nervous Neurological effects in occupationally-exposed workers Multiple human studies Abbate et al., 1993, Boey et al., 1997, Cavalleri et al., 2000, Eller et al., 1999, Foo et al., 1990, Murata et al., 1993, Nakatsuka et al., 1992, Neubert et al., 2001, Vrca et al., 1995, Zavalic et al., 1998a No Observable Adverse Effect Level 46.0 mg/m3 5.0 mg/m3 10 1 High High High Threshold Chronic
85 2,4-/2,6-Toluene diisocyanate mixture (TDI) 26471-62-5 Respiratory Chronic lung-function decline Prospective occupational study Diem et al., 1982 No Observable Adverse Effect Level 0.002 mg/m3 7e-05 mg/m3 30 1 Medium Medium Medium Threshold Chronic
86 1,1,1-Trichloroethane 71-55-6 Nervous Performance on neurobehavioral tests Human subjects exposed for 3.5 hr Mackay et al. (1987) Lowest Observable Adverse Effect Level 950.0 mg/m3 7.0 mg/m3 100 1 Medium Medium Medium None None
87 1,1,1-Trichloroethane 71-55-6 Hepatic Liver histopathologic changes 2-Year inhalation rat study, 14-Week inhalation mouse study Quast et al. (1988, 1984), McNutt et al. (1975) No Observable Adverse Effect Level 1553.0 mg/m3 5.0 mg/m3 100 1 Low Medium Medium None Subchronic
88 1,1,1-Trichloroethane 71-55-6 Hepatic Liver histopathologic changes 2-Year inhalation rat study, 14-Week inhalation mouse study Quast et al. (1988, 1984), McNutt et al. (1975) No Observable Adverse Effect Level 1553.0 mg/m3 5.0 mg/m3 100 1 Low Medium Medium None Chronic
89 1,1,1-Trichloroethane 71-55-6 Nervous Performance on neurobehavioral tests Human subjects exposed for 3.5 hr Mackay et al. (1987) Lowest Observable Adverse Effect Level 950.0 mg/m3 9.0 mg/m3 100 1 Medium Medium Medium None None
90 1,1,1-Trichloroethane 71-55-6 Nervous Performance on neurobehavioral tests Human subjects exposed for 3.5 hr Mackay et al. (1987) Lowest Observable Adverse Effect Level 950.0 mg/m3 7.0 mg/m3 100 1 Medium Medium Medium None None
91 1,1,1-Trichloroethane 71-55-6 Nervous Performance on neurobehavioral tests Human subjects exposed for 3.5 hr Mackay et al. (1987) Lowest Observable Adverse Effect Level 950.0 mg/m3 6.0 mg/m3 100 1 Medium Medium Medium None None
92 1,1,1-Trichloroethane 71-55-6 Nervous Performance on neurobehavioral tests Human subjects exposed for 3.5 hr Mackay et al. (1987) Lowest Observable Adverse Effect Level 526.0 mg/m3 5.0 mg/m3 100 1 Medium Medium Medium None None
93 Trichloroethylene 79-01-6 Developmental, Immune (See Note) None None None None None 0.002 mg/m3 None None High High High None Chronic
94 1,2,3-Trichloropropane 96-18-4 Respiratory peribronchial lymphoid hyperplasia in male rats 13-week inhalation Study Johannsen et al., 1988 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 0.9 mg/m3 0.0003 mg/m3 3000 1 Low/Medium Low Low Benchmark Chronic
95 Triethylamine 121-44-8 Respiratory Inflammation of the nasal passage 28-week rat inhalation study Lynch et al., 1990 No Observable Adverse Effect Level 19.5 mg/m3 0.007 mg/m3 3000 1 Medium Low Low Threshold Chronic
96 1,2,4-Trimethylbenzene 95-63-6 Hematologic Decreased clotting time Korsak and Rydzyński 1996 No Observable Adverse Effect Level 24.3 mg/m3 0.08 mg/m3 300 1 None None Low/Medium None Chronic
97 1,2,4-Trimethylbenzene 95-63-6 Respiratory Inflammatory lung lesions Korsak et al. 2000a No Observable Adverse Effect Level 61.65 mg/m3 0.2 mg/m3 300 1 None None Low/Medium None Chronic
98 1,2,4-Trimethylbenzene 95-63-6 Developmental Decreased fetal weight Saillenfait et al. 2005 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 395.16 mg/m3 4.0 mg/m3 100 1 None None Low/Medium Benchmark Chronic
99 1,2,4-Trimethylbenzene 95-63-6 Other Decreased maternal weight Saillenfait et al. 2005 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 758.06 mg/m3 3.0 mg/m3 300 1 None None Low/Medium None Chronic
100 1,2,4-Trimethylbenzene 95-63-6 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 18.15 mg/m3 0.06 mg/m3 300 1 Low/Medium Low/Medium Low/Medium Benchmark Chronic
101 1,2,3-Trimethylbenzene 526-73-8 Respiratory Inflammatory lung lesions Korsak et al. 2000b No Observable Adverse Effect Level 66.56 mg/m3 0.2 mg/m3 300 1 None None Low/Medium None Chronic
102 1,2,4-Trimethylbenzene 95-63-6 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 18.15 mg/m3 0.2 mg/m3 100 1 None None Low/Medium Benchmark Subchronic
103 1,2,3-Trimethylbenzene 526-73-8 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 18.15 mg/m3 0.2 mg/m3 100 1 None None Low/Medium Benchmark Subchronic
104 1,2,3-Trimethylbenzene 526-73-8 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 18.15 mg/m3 0.06 mg/m3 300 1 Low/Medium Low/Medium Low/Medium Benchmark Chronic
105 1,3,5-Trimethylbenzene 108-67-8 Developmental Decreased fetal weight Saillenfait et al. 2005 No Observable Adverse Effect Level 367.75 mg/m3 4.0 mg/m3 100 1 Low/Medium Low/Medium Low/Medium None Chronic
106 1,3,5-Trimethylbenzene 108-67-8 Other Decreased maternal weight Saillenfait et al. 2005 No Observable Adverse Effect Level 124.25 mg/m3 0.4 mg/m3 300 1 None None Low/Medium None Chronic
107 1,3,5-Trimethylbenzene 108-67-8 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Dose based on the LED10 (Lowest Effective Dose) 18.15 mg/m3 0.2 mg/m3 100 1 Low/Medium Low/Medium Low/Medium Threshold Subchronic
108 1,3,5-Trimethylbenzene 108-67-8 Nervous Decreased pain sensitivity in male Wistar rats Korsak and Rydzyński 1996 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 18.15 mg/m3 0.06 mg/m3 300 1 Low/Medium Low/Medium Low/Medium Threshold Chronic
109 1,2,3-Trimethylbenzene 526-73-8 Hematologic Decreased segmented neutrophils Korsak et al. 2000b Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 16.65 mg/m3 0.06 mg/m3 300 1 None None Low/Medium Benchmark Chronic
110 Vinyl acetate 108-05-4 Nervous, Respiratory Nasal epithelial lesions Chronic inhalation study in rats and mice Owen, 1988 Beems, 1988 Dreef-van der Meulen, 1988 No Observable Adverse Effect Level 5.0 mg/m3 0.2 mg/m3 30 1 High High High Threshold Chronic
111 Vinyl bromide 593-60-2 Hepatic Hypertrophy, basophilic and eosinophilic foci, in the liver Chronic rat inhalation study Benya et al., 1982; Busey, 1979 Lowest Observable Adverse Effect Level 7.7 mg/m3 0.003 mg/m3 3000 1 Medium Low Low Threshold Chronic
112 Vinyl chloride 75-01-4 Hepatic Liver cell polymorphism Rat chronic feeding study Til et al., 1983, 1991 No Observable Adverse Effect Level 2.5 mg/m3 0.1 mg/m3 30 1 High Medium/High Medium Threshold Chronic
113 Xylenes 1330-20-7 Nervous Impaired motor coordination (decreased rotarod performance) Subchronic inhalation study in male rats Korsak et. al., 1994 No Observable Adverse Effect Level 39.0 mg/m3 0.1 mg/m3 300 1 Medium Medium Medium Threshold Chronic
114 tert-Butyl Alcohol (tBA) 75-65-0 Urinary Increased severity of nephropathy Route-to-route extrapolation from 2-year drinking water study NTP 1995 Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) 491.0 mg/m3 5.0 mg/m3 100 1 High Medium Medium None Chronic

  CHEMICAL NAME CASRN ROUTE WOE DESCRIPTION WOE TITLE WOE NARRITIVE
1 Acenaphthylene 208-96-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate data from animal bioassays.
2 Acephate 30560-19-1 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) The classification is based on increased incidence of hepatocellular carcinomas and adenomas in female mice.
3 Acetaldehyde 75-07-0 None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on increased incidence of nasal tumors in male and female rats and laryngeal tumors in male and female hamsters after inhalation exposure.
4 Acetone 67-64-1 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) In accordance with the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) data are inadequate for an assessment of the human carcinogenic potential of acetone.
5 Acetonitrile 75-05-8 Undefined Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), the carcinogenic potential of ACN following inhalation, oral, or dermal exposure is best characterized as "cannot be determined because the existing evidence is composed of conflicting data (e.g., some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm any concern)."
6 Acetonitrile 75-05-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), the carcinogenic potential of ACN following inhalation, oral, or dermal exposure is best characterized as "cannot be determined because the existing evidence is composed of conflicting data (e.g., some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm any concern)."
7 Acetophenone 98-86-2 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and no animal data.
8 Acetyl chloride 75-36-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data or animal data.
9 Acrolein 107-02-8 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), the potential carcinogenicity of acrolein cannot be determined because the existing data are inadequate for an assessment of human carcinogenic potential for either the oral or inhalation route of exposure. There are no adequate human studies of the carcinogenic potential of acrolein. Collectively, experimental studies provide inadequate evidence that acrolein causes cancer in laboratory animals.
10 Acrylamide 79-06-1 Combined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) In accordance with the Guidelines for Carcinogen Risk Assessment U.S. EPA, 2005, acrylamide (AA) is characterized as "likely to be carcinogenic to humans."
11 Acrylonitrile 107-13-1 Undefined B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) The observation of a statistically significant increase in incidence of lung cancer in exposed workers and observation of tumors, generally astrocytomas in the brain, in studies in two rat strains exposed by various routes (drinking water, gavage, and inhalation) forms the basis for this classification.
12 Adiponitrile 111-69-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human and no animal cancer data were available. Adiponitrile was negative for mutagenicity in Salmonella with and without activation.
13 Aldicarb 116-06-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Aldicarb was not found to induce statistically significant increases in tumor incidence in mice or rats in feeding studies or mice in a skin painting study. In the feeding studies there were, however, significant trends in pituitary tumors in female rats and fibrosarcomas in the male mouse. This evidence, together with the fact that less than maximum tolerated doses were used, indicates that the available assays are inadequate to assess the carcinogenic potential of aldicarb.
14 Aldrin 309-00-2 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Orally administered aldrin produced significant increases in tumor responses in three different strains of mice in both males and females. Tumor induction has been observed for structurally related chemicals, including dieldrin, a metabolite.
15 Allyl chloride 107-05-1 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Classification is based on a low (but biologically important) incidence of forestomach tumors in female mice and positive results in a variety of genetic toxicity tests. Allyl chloride is an alkylating agent and structurally related to probable human carcinogens.
16 4-Aminopyridine 504-24-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
17 Ammonium acetate 631-61-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data
18 Ammonium methacrylate 16325-47-6 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data
19 Aniline 62-53-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Induction of tumors of the spleen and the body cavity in two strains of rat, and some supporting genetic toxicological evidence.
20 Anthracene 120-12-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate data from animal bioassays.
21 Apollo 74115-24-5 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on an increase in thyroid gland follicular cell tumors in male rats and supportive findings in pituitary/thyroid hormone activity.
22 Aramite 140-57-8 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and sufficient data from animal bioassays including increased incidence of liver tumors and/or neoplastic nodules in three strains of male and female rats and males of one strain of mice, and extrahepatic biliary system tumors in dogs following chronic oral exposure.
23 Arsenic, Inorganic 7440-38-2 Undefined Carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Bladder and lung cancer are acknowledged as known hazard outcomes for inorganic arsenic (ATSDR, 2007; ATSDR, 2016; Health Canada, 2006; IARC, 2004; IARC, 2012; NRC, 2013; NTP, 2016; WHO, 2011; WHO, 2011), and the strength of evidence for these health outcomes was considered robust (as described in Section 3.2 and Appendix A of the IRIS Toxicological Review). Bladder cancer and lung cancer were classified as carcinogenic to humans in the 1995 IRIS Toxicological Review based on epidemiologic evidence (U.S. EPA, 1995), and that classification is retained in the current assessment.
24 Asbestos 1332-21-4 Undefined A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Observation of increased mortality and incidence of lung cancer, mesotheliomas and gastrointestinal cancer in occupationally exposed workers are consistent across investigators and study populations. Animal studies by inhalation in two strains of rats showed similar findings for lung cancer and mesotheliomas. Animal evidence for carcinogenicity via ingestion is limited (male rats fed intermediate-range chrysotile fibers; i.e., >10 um length, developed benign polyps), and epidemiologic data in this regard are inadequate.
25 Assure 76578-14-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate animal data.
26 Azobenzene 103-33-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Azobenzene induced invasive sarcomas in the spleen and other abdominal organs in male and female F344 rats following dietary administration. It is genotoxic and may be converted to benzidine, a known human carcinogen, under the acidic conditions in the stomach.
27 Barium and Compounds 7440-39-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, barium would be classified as Group D, not classifiable as to human carcinogenicity. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), barium is considered not likely to be carcinogenic to humans following oral exposure and its carcinogenic potential cannot be determined following inhalation exposure.
28 Barium and Compounds 7440-39-3 Oral Not likely to be carcinogenic to humans Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, barium would be classified as Group D, not classifiable as to human carcinogenicity. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), barium is considered not likely to be carcinogenic to humans following oral exposure and its carcinogenic potential cannot be determined following inhalation exposure.
29 Barium and Compounds 7440-39-3 Inhalation Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, barium would be classified as Group D, not classifiable as to human carcinogenicity. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), barium is considered not likely to be carcinogenic to humans following oral exposure and its carcinogenic potential cannot be determined following inhalation exposure.
30 Bentazon (Basagran) 25057-89-0 Undefined E (Evidence of non-carcinogenicity for humans) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, Bentazon would be classified as evidence of non-carcinogenicity for humans, or a Group E chemical. Under EPA's proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), Bentazon would be characterized as not likely to be carcinogenic to humans by any route of exposure.
31 Bentazon (Basagran) 25057-89-0 Undefined Not likely to be carcinogenic to humans Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, Bentazon would be classified as evidence of non-carcinogenicity for humans, or a Group E chemical. Under EPA's proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), Bentazon would be characterized as not likely to be carcinogenic to humans by any route of exposure.
32 Benz[a]anthracene 56-55-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and sufficient data from animal bioassays. Benz[a]anthracene produced tumors in mice exposed by gavage; intraperitoneal, subcutaneous or intramuscular injection; and topical application. Benz[a]anthracene produced mutations in bacteria and in mammalian cells, and transformed mammalian cells in culture.
33 Benzene 71-43-2 Undefined Known/likely human carcinogen Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Benzene is classified as a "known" human carcinogen (Category A) under the Risk Assessment Guidelines of 1986. Under the proposed revised Carcinogen Risk Assessment Guidelines (U.S. EPA, 1996), benzene is characterized as a known human carcinogen for all routes of exposure based upon convincing human evidence as well as supporting evidence from animal studies. (U.S. EPA, 1979, 1985, 1998; ATSDR, 1997).
34 Benzene 71-43-2 Undefined A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Benzene is classified as a "known" human carcinogen (Category A) under the Risk Assessment Guidelines of 1986. Under the proposed revised Carcinogen Risk Assessment Guidelines (U.S. EPA, 1996), benzene is characterized as a known human carcinogen for all routes of exposure based upon convincing human evidence as well as supporting evidence from animal studies. (U.S. EPA, 1979, 1985, 1998; ATSDR, 1997).
35 Benzidine 92-87-5 Undefined A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Observation of increased incidence of bladder cancer and bladder cancer-related deaths in exposed workers
36 Benzo[a]pyrene (BaP) 50-32-8 Combined Carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), benzo[a]pyrene is “carcinogenic to humans” based on strong and consistent evidence in animals and humans.
37 Benzo[b]fluoranthene 205-99-2 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and sufficient data from animal bioassays. Benzo[b]fluoranthene produced tumors in mice after lung implantation, intraperitoneal (i.p.) or subcutaneous (s.c.) injection, and skin painting.
38 Benzo[g,h,i]perylene 191-24-2 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate animal data from lung implant, skin-painting and subcutaneous injection bioassays.
39 Benzo[k]fluoranthene 207-08-9 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and sufficient data from animal bioassays. Benzo[k]fluoranthene produced tumors after lung implantation in mice and when administered with a promoting agent in skin-painting studies. Equivocal results have been found in a lung adenoma assay in mice. Benzo[k]fluoranthene is mutagenic in bacteria.
40 Benzoic acid 65-85-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and inadequate data from animal bioassays
41 Benzotrichloride 98-07-7 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human data and sufficient evidence of carcinogenicity in animals; namely, significantly increased incidences of benign and malignant tumors at multiple sites in one strain of female mice treated orally, dermally, and by inhalation. There is also evidence of mutagenicity in a variety of test systems.
42 Benzyl chloride 100-44-7 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human data and sufficient evidence of carcinogenicity in animals; namely significantly increased incidences of benign and malignant tumors at multiple sites in both sexes of mice and a significant increase in thyroid tumors in female rats. There was evidence of mutagenicity in a variety of test systems.
43 Beryllium and compounds 7440-41-7 Undefined B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) B1; probable human carcinogen. Based on the limited evidence of carcinogenicity in humans exposed to airborne beryllium (lung cancer) and sufficient evidence of carcinogenicity in animals (lung cancer in rats and monkeys inhaling beryllium, lung tumors in rats exposed to beryllium via intratracheal instillation, and osteosarcomas in rabbits and possibly mice receiving intravenous or intramedullary injection), beryllium is reclassified from a B2 (inadequate human data) to a B1 probable human carcinogen (limited human data) using criteria of the 1986 Guidelines for Carcinogen Risk Assessment. Using the 1996 proposed Guidelines for Carcinogen Risk Assessment, inhaled beryllium would be characterized as a "likely" carcinogen in humans, and the human carcinogenic potential of ingested beryllium cannot be determined.
44 Beryllium and compounds 7440-41-7 Oral Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) B1; probable human carcinogen. Based on the limited evidence of carcinogenicity in humans exposed to airborne beryllium (lung cancer) and sufficient evidence of carcinogenicity in animals (lung cancer in rats and monkeys inhaling beryllium, lung tumors in rats exposed to beryllium via intratracheal instillation, and osteosarcomas in rabbits and possibly mice receiving intravenous or intramedullary injection), beryllium is reclassified from a B2 (inadequate human data) to a B1 probable human carcinogen (limited human data) using criteria of the 1986 Guidelines for Carcinogen Risk Assessment. Using the 1996 proposed Guidelines for Carcinogen Risk Assessment, inhaled beryllium would be characterized as a "likely" carcinogen in humans, and the human carcinogenic potential of ingested beryllium cannot be determined.
45 Beryllium and compounds 7440-41-7 Inhalation Known/likely human carcinogen Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) B1; probable human carcinogen. Based on the limited evidence of carcinogenicity in humans exposed to airborne beryllium (lung cancer) and sufficient evidence of carcinogenicity in animals (lung cancer in rats and monkeys inhaling beryllium, lung tumors in rats exposed to beryllium via intratracheal instillation, and osteosarcomas in rabbits and possibly mice receiving intravenous or intramedullary injection), beryllium is reclassified from a B2 (inadequate human data) to a B1 probable human carcinogen (limited human data) using criteria of the 1986 Guidelines for Carcinogen Risk Assessment. Using the 1996 proposed Guidelines for Carcinogen Risk Assessment, inhaled beryllium would be characterized as a "likely" carcinogen in humans, and the human carcinogenic potential of ingested beryllium cannot be determined.
46 Biphenyl 92-52-4 None Suggestive evidence of carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for biphenyl provides “suggestive evidence of carcinogenic potential” based on increased incidence of urinary bladder tumors (transitional cell papillomas and carcinomas) in male F344 rats (Umeda et al., 2002) and liver tumors (hepatocellular adenomas and carcinomas) in female BDF1 mice (Umeda et al., 2005) exposed to biphenyl in the diet for 104 weeks, as well as information on mode of carcinogenic action. The carcinogenic potential of biphenyl in humans has not been investigated.
47 Bis(2-chloroethoxy)methane 111-91-1 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data.
48 Bis(chloroethyl)ether (BCEE) 111-44-4 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Positive carcinogenicity results in two strains of mice and evidence of mutagenicity
49 Bis(chloromethyl)ether (BCME) 542-88-1 Undefined A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Statistically significant increases in lung tumors (oat cell carcinomas) observed in six studies of exposed workers and bioassay data from rats and mice.
50 Boron and Compounds 7440-42-8 Oral Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), data are inadequate for an assessment of human carcinogenic potential for boron.
51 Bromate 15541-45-4 Oral Known/likely human carcinogen Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under the current Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986), bromate would be classified as B2, probable human carcinogen. Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), bromate should be evaluated as a likely human carcinogen by the oral route of exposure. Insufficient data are available to evaluate the human carcinogenic potential of bromate by the inhalation route.
52 Bromate 15541-45-4 Inhalation Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under the current Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986), bromate would be classified as B2, probable human carcinogen. Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), bromate should be evaluated as a likely human carcinogen by the oral route of exposure. Insufficient data are available to evaluate the human carcinogenic potential of bromate by the inhalation route.
53 Bromate 15541-45-4 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the current Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986), bromate would be classified as B2, probable human carcinogen. Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), bromate should be evaluated as a likely human carcinogen by the oral route of exposure. Insufficient data are available to evaluate the human carcinogenic potential of bromate by the inhalation route.
54 Brominated dibenzofurans None Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No data in humans or animals
55 Bromobenzene 108-86-1 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of bromobenzene.
56 Bromochloromethane 74-97-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on the lack of data regarding the carcinogenicity of bromochloromethane in humans or animals; however, there are data indicative of genotoxic effects and structural relationships to halogenated methanes classified as B2 probable human carcinogens.
57 Bromodichloromethane 75-27-4 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human data and sufficient evidence of carcinogenicity in two animal species (mice and rats) as shown by increased incidence of kidney tumors and tumors of the large intestine in male and female rats, kidney tumors in male mice, and liver tumors in female mice.
58 p-Bromodiphenyl ether 101-55-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and inadequate animal data.
59 Bromoform 75-25-2 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human data and sufficient evidence of carcinogenicity in animals, namely an increased incidence of tumors after oral administration of bromoform in rats and intraperitoneal administration in mice. Bromoform is genotoxic in several assay systems. Also, bromoform is structurally related to other trihalomethanes (e.g., chloroform, bromodichloromethane, dibromochloromethane) which have been verified as either probable or possible carcinogens.
60 Bromomethane 74-83-9 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Inadequate human and animal data: a single mortality study from which direct exposure associations could not be deduced and studies in several animal species with too few animals, too brief exposure or observation time for adequate power. Bromomethane has shown genotoxicity.
61 Bromotrichloromethane 75-62-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no data regarding the carcinogenicity of bromotrichloromethane in humans or animals.
62 1,3-Butadiene 106-99-0 Undefined Carcinogenic to humans Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under EPA's 1999 Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), 1,3-butadiene is characterized as carcinogenic to humans by inhalation. This characterization is supported by the total weight of evidence provided by the following: (1) sufficient evidence from epidemiologic studies of the majority of U.S. workers occupationally exposed to 1,3-butadiene, either to the monomer or to the polymer by inhalation, showing increased lymphohematopoietic cancers and a dose-response relationship for leukemias in polymer workers (see Section II.A.2), (2) sufficient evidence in laboratory animal studies showing that 1,3-butadiene causes tumors at multiple sites in mice and rats by inhalation (see Section II.A.3), and (3) numerous studies consistently demonstrating that 1,3-butadiene is metabolized into genotoxic metabolites by experimental animals and humans (see Section II.A.4). The specific mechanisms of 1,3-butadiene-induced carcinogenesis are unknown however, the scientific evidence strongly suggests that the carcinogenic effects are mediated by genotoxic metabolites of 1,3-butadiene, i.e., the monoepoxide, the diepoxide, and the epoxydiol.
63 Butyl benzyl phthalate (BBP) 85-68-7 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on statistically significant increase in mononuclear cell leukemia in female rats; the response in male rats was inconclusive and there was no such response in mice.
64 t-Butylchloride 507-20-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human carcinogenicity data and inadequate animal data.
65 Cacodylic acid 75-60-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and inadequate data in animals
66 Cadmium 7440-43-9 Undefined B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Limited evidence from occupational epidemiologic studies of cadmium is consistent across investigators and study populations. There is sufficient evidence of carcinogenicity in rats and mice by inhalation and intramuscular and subcutaneous injection. Seven studies in rats and mice wherein cadmium salts (acetate, sulfate, chloride) were administered orally have shown no evidence of carcinogenic response.
67 Carbon tetrachloride 56-23-5 Undefined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), carbon tetrachloride is "likely to be carcinogenic to humans."
68 Cerium Oxide and Cerium Compounds 1306-38-3 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) In accordance with U.S. EPA (2005a) Guidelines for Carcinogen Risk Assessment, there is "inadequate information to assess the carcinogenic potential" of cerium in humans.
69 Chloral hydrate 302-17-0 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the 1986 cancer guidelines (U.S. EPA, 1986), chloral hydrate is assigned to Group C, possible human carcinogen. Under the 1996 proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), chloral hydrate shows suggestive evidence of human carcinogenicity by the oral route of exposure. There are no carcinogenicity data from humans.
70 Chloral hydrate 302-17-0 Oral Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under the 1986 cancer guidelines (U.S. EPA, 1986), chloral hydrate is assigned to Group C, possible human carcinogen. Under the 1996 proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), chloral hydrate shows suggestive evidence of human carcinogenicity by the oral route of exposure. There are no carcinogenicity data from humans.
71 Chlordane (Technical) 12789-03-6 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the 1996 Proposed Guidelines, chlordane would be characterized as a likely carcinogen by all routes of exposure.
72 Chlordane (Technical) 12789-03-6 Undefined Known/likely human carcinogen Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under the 1996 Proposed Guidelines, chlordane would be characterized as a likely carcinogen by all routes of exposure.
73 Chlordecone (Kepone) 143-50-0 Undefined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the U.S. EPA Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), chlordecone is "likely to be carcinogenic to humans" based on data from an oral cancer bioassay in rats and mice demonstrating an increase in the incidence of hepatocellular carcinomas in both sexes of both species (NCI, 1976a, b).
74 Chlorine dioxide 10049-04-4 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the current guidelines (U.S. EPA, 1986), chlorine dioxide is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorine dioxide cannot be determined because no satisfactory human or animal studies assessing the chronic carcinogenic potential of chlorine dioxide have been located.
75 Chlorine dioxide 10049-04-4 Undefined Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under the current guidelines (U.S. EPA, 1986), chlorine dioxide is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorine dioxide cannot be determined because no satisfactory human or animal studies assessing the chronic carcinogenic potential of chlorine dioxide have been located.
76 Chlorite (sodium salt) 7758-19-2 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the current guidelines (U.S. EPA, 1986), chlorite is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorite cannot be determined because of a lack of human data and limitations in animal studies.
77 Chlorite (sodium salt) 7758-19-2 Undefined Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under the current guidelines (U.S. EPA, 1986), chlorite is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorite cannot be determined because of a lack of human data and limitations in animal studies.
78 Chlorobenzene 108-90-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data, inadequate animal data and predominantly negative genetic toxicity data in bacterial, yeast, and mouse lymphoma cells.
79 2-Chlorobutane 78-86-4 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human carcinogenicity data and inadequate animal data.
80 1-Chlorobutane 109-69-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human carcinogenicity data and inadequate animal data.
81 Chlorocyclopentadiene 41851-50-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Lack of data concerning carcinogenicity in humans or animals.
82 Chloroform 67-66-3 Undefined Likely to be carcinogenic to humans Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996; U.S. EPA, 1999), chloroform is likely to be carcinogenic to humans by all routes of exposure under high-exposure conditions that lead to cytotoxicity and regenerative hyperplasia in susceptible tissues (U.S. EPA, 1998a,b). Chloroform is not likely to be carcinogenic to humans by any route of exposure under exposure conditions that do not cause cytotoxicity and cell regeneration.

This weight-of-evidence conclusion is based on: 1) observations in animals exposed by both oral and inhalation pathways which indicate that sustained or repeated cytotoxicity with secondary regenerative hyperplasia precedes, and is probably required for, hepatic and renal neoplasia; 2) there are no epidemiological data specific to chloroform and, at most, equivocal epidemiological data related to drinking water exposures that cannot necessarily be negative, although there are some scattered positive results that generally have limitations such as excessively high dose or with confounding factors. Thus, the weigh-of-evidence of the genotoxicity data on chloroform supports a conclusion that chloroform is not strongly mutagenic, and the genotoxicity is not likely to be the predominant mode of action underlying the carcinogenic potential of chloroform. Although no cancer data exist for exposures via the dermal pathway, the weight-of-evidence conclusion is considered to be applicable to this pathway as well, because chloroform absorbed through the skin and into the blood is expected to be metabolized and to cause toxicity in much the same way as chloroform absorbed by other exposure routes.
83 Chloroform 67-66-3 Undefined Not likely to be carcinogenic to humans Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996; U.S. EPA, 1999), chloroform is likely to be carcinogenic to humans by all routes of exposure under high-exposure conditions that lead to cytotoxicity and regenerative hyperplasia in susceptible tissues (U.S. EPA, 1998a,b). Chloroform is not likely to be carcinogenic to humans by any route of exposure under exposure conditions that do not cause cytotoxicity and cell regeneration.

This weight-of-evidence conclusion is based on: 1) observations in animals exposed by both oral and inhalation pathways which indicate that sustained or repeated cytotoxicity with secondary regenerative hyperplasia precedes, and is probably required for, hepatic and renal neoplasia; 2) there are no epidemiological data specific to chloroform and, at most, equivocal epidemiological data related to drinking water exposures that cannot necessarily be negative, although there are some scattered positive results that generally have limitations such as excessively high dose or with confounding factors. Thus, the weigh-of-evidence of the genotoxicity data on chloroform supports a conclusion that chloroform is not strongly mutagenic, and the genotoxicity is not likely to be the predominant mode of action underlying the carcinogenic potential of chloroform. Although no cancer data exist for exposures via the dermal pathway, the weight-of-evidence conclusion is considered to be applicable to this pathway as well, because chloroform absorbed through the skin and into the blood is expected to be metabolized and to cause toxicity in much the same way as chloroform absorbed by other exposure routes.
84 Chloroform 67-66-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996; U.S. EPA, 1999), chloroform is likely to be carcinogenic to humans by all routes of exposure under high-exposure conditions that lead to cytotoxicity and regenerative hyperplasia in susceptible tissues (U.S. EPA, 1998a,b). Chloroform is not likely to be carcinogenic to humans by any route of exposure under exposure conditions that do not cause cytotoxicity and cell regeneration.

This weight-of-evidence conclusion is based on: 1) observations in animals exposed by both oral and inhalation pathways which indicate that sustained or repeated cytotoxicity with secondary regenerative hyperplasia precedes, and is probably required for, hepatic and renal neoplasia; 2) there are no epidemiological data specific to chloroform and, at most, equivocal epidemiological data related to drinking water exposures that cannot necessarily be negative, although there are some scattered positive results that generally have limitations such as excessively high dose or with confounding factors. Thus, the weigh-of-evidence of the genotoxicity data on chloroform supports a conclusion that chloroform is not strongly mutagenic, and the genotoxicity is not likely to be the predominant mode of action underlying the carcinogenic potential of chloroform. Although no cancer data exist for exposures via the dermal pathway, the weight-of-evidence conclusion is considered to be applicable to this pathway as well, because chloroform absorbed through the skin and into the blood is expected to be metabolized and to cause toxicity in much the same way as chloroform absorbed by other exposure routes.
85 Chloromethyl methyl ether (CMME) 107-30-2 Undefined A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) The observation of an increased incidence of respiratory cancer in exposed workers and the observation of respiratory tumors in mice, rats, and hamsters exposed by inhalation forms the basis for this classification.
86 p-Chlorophenyl methyl sulfide 123-09-1 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human or animal studies found in the available literature
87 p-Chlorophenyl methyl sulfone 98-57-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human or animal studies found in the available literature
88 p-Chlorophenyl methyl sulfoxide 934-73-6 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human or animal studies found in the available literature
89 Chloroprene 126-99-8 Undefined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is evidence that chloroprene is "likely to be carcinogenic to humans"
90 Chromium(III), insoluble salts 16065-83-1 Undefined Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Applying the criteria for evaluating the overall weight-of-evidence for carcinogenicity to humans outlined in EPA's guidelines for carcinogen risk assessment (U.S. EPA, 1986), trivalent chromium is most appropriately designated a Group D -- Not classified as to its human carcinogenicity. Using the Proposed Guidelines for Carcinogen Risk Assessment (EPA, 1996), there are inadequate data to determine the potential carcinogenicity of trivalent chromium, as discussed below. However, the classification of hexavalent chromium as a known human carcinogen raises a concern for the carcinogenic potential of trivalent chromium.
91 Chromium(III), insoluble salts 16065-83-1 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Applying the criteria for evaluating the overall weight-of-evidence for carcinogenicity to humans outlined in EPA's guidelines for carcinogen risk assessment (U.S. EPA, 1986), trivalent chromium is most appropriately designated a Group D -- Not classified as to its human carcinogenicity. Using the Proposed Guidelines for Carcinogen Risk Assessment (EPA, 1996), there are inadequate data to determine the potential carcinogenicity of trivalent chromium, as discussed below. However, the classification of hexavalent chromium as a known human carcinogen raises a concern for the carcinogenic potential of trivalent chromium.
92 Chromium(VI) 18540-29-9 Inhalation Carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), Cr(VI) is “likely to be carcinogenic” via oral exposure based on sufficiently supported [laboratory] animal studies relevant to humans. This assessment maintains the previous conclusion (U.S. EPA, 1998) that Cr(VI) is “carcinogenic to humans” via inhalation exposure.
93 Chromium(VI) 18540-29-9 Oral Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), Cr(VI) is “likely to be carcinogenic” via oral exposure based on sufficiently supported [laboratory] animal studies relevant to humans. This assessment maintains the previous conclusion (U.S. EPA, 1998) that Cr(VI) is “carcinogenic to humans” via inhalation exposure.
94 Chrysene 218-01-9 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and sufficient data from animal bioassays. Chrysene produced carcinomas and malignant lymphoma in mice after intraperitoneal injection and skin carcinomas in mice following dermal exposure. Chrysene produced chromosomal abnormalities in hamsters and mouse germ cells after gavage exposure, positive responses in bacterial gene mutation assays and transformed mammalian cells exposed in culture.
95 Coke oven emissions None Undefined A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Studies of coke oven workers have shown increased risk of mortality from cancer of the lung, trachea and bronchus; cancer of the kidney; cancer of the prostate; and cancer at all sites combined. In animals, extracts and condensates of coke oven emissions were found to be carcinogenic in both inhalation studies and skin-painting bioassays. The mutagenicity of whole extracts and condensates, as well as their individual components, provides supportive evidence for carcinogenicity.
96 Copper 7440-50-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) There are no human data, inadequate animal data from assays of copper compounds, and equivocal mutagenicity data.
97 Creosote 8001-58-9 Undefined B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Limited evidence of the association between occupational creosote contact and subsequent tumor formation, sufficient evidence of local and distant tumor formation after dermal application to mice, and some evidence of mutagenic activity, as well as the well-documented carcinogenicity of other coal tar products to humans.
98 Crotonaldehyde 123-73-9 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and an increased incidence of hepatocellular carcinomas and hepatic neoplastic nodules (combined) in male F344 rats. The possible carcinogenicity of crotonaldehyde is supported by genotoxic activity and the expected reactivity of croton oil and aldehyde. Crotonaldehyde is also a suspected metabolite of N-nitrosopyrrolidine, a probable human carcinogen.
99 Cumene 98-82-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), it is concluded that the carcinogenic potential of cumene cannot be determined because no adequate data, such as well-conducted long-term animal studies or reliable human epidemiological studies, are available for any assessment.
100 Cumene 98-82-8 Undefined Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under the proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), it is concluded that the carcinogenic potential of cumene cannot be determined because no adequate data, such as well-conducted long-term animal studies or reliable human epidemiological studies, are available for any assessment.
101 Cyanide, free 57-12-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Pertinent data regarding carcinogenicity have not been located in the available literature.
102 Cyclohexane 110-82-7 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Cyclohexane is characterized as "Data are inadequate for an assessment of human carcinogenic potential" (U.S. EPA, 1999).
103 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Undefined Suggestive evidence of carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for decabromodiphenyl ether provides suggestive evidence of carcinogenic potential.
104 Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Orally administered DEHP produced significant dose-related increases in liver tumor responses in rats and mice of both sexes.
105 Di(2-ethylhexyl)adipate 103-23-1 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on an absence of human data and increased incidence of liver tumors in female mice. Except for a positive dominant lethal assay, there was no evidence of genotoxicity; this compound does, however, exhibit structural relationships to other nongenotoxic compounds classified as probable and possible human carcinogens.
106 Dibenz[a,h]anthracene 53-70-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and sufficient data from animal bioassays. Dibenz[a,h]anthracene produced carcinomas in mice following oral or dermal exposure and injection site tumors in several species following subcutaneous or intramuscular administration. Dibenz[a,h]anthracene has induced DNA damage and gene mutations in bacteria as well as gene mutations and transformation in several types of mammalian cell cultures.
107 Dibenzofuran 132-64-9 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and no animal data for dibenzofuran alone.
108 Dibromochloromethane 124-48-1 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human data and limited evidence of carcinogenicity in animals; namely, positive carcinogenic evidence in B6C3Fl mice (males and females), together with positive mutagenicity data, and structural similarity to other trihalomethanes, which are known animal carcinogens.
109 Dibromodichloromethane 594-18-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on the lack of data regarding the carcinogenicity of dibromodichloromethane in humans or animals.
110 p,p'-Dibromodiphenyl ether 2050-47-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
111 1,2-Dibromoethane 106-93-4 Undefined Likely to be carcinogenic to humans Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), 2-dibromoethane is considered "likely to be carcinogenic to humans" based on strong evidence of carcinogenicity in animals and inconclusive evidence of carcinogenicity in an exposed human population.
112 Dibutyl phthalate (DBP) 84-74-2 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Pertinent data regarding carcinogenicity was not located in the available literature.
113 Dichloroacetic acid 79-43-6 Undefined Likely to be carcinogenic to humans Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) EPA believes that DCA is likely to be a carcinogen in humans.
114 1,3-Dichlorobenzene 541-73-1 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data, no animal data and limited genetic data.
115 1,2-Dichlorobenzene 95-50-1 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and evidence of both negative and positive trends for carcinogenic responses in rats and mice.
116 3,3'-Dichlorobenzidine 91-94-1 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on statistically significantly increased tumor incidences in rats, mice and dogs. Additional support is provided by positive evidence of genotoxicity and structural relationship to the known human bladder carcinogen benzidine.
117 p,p'-Dichlorodiphenyl dichloroethane (DDD) 72-54-8 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on an increased incidence of lung tumors in male and female mice, liver tumors in male mice and thyroid tumors in male rats. DDD is structurally similar to, and is a known metabolite of DDT, a probable human carcinogen.
118 p,p'-Dichlorodiphenyldichloroethylene (DDE) 72-55-9 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased incidence of liver tumors including carcinomas in two strains of mice and in hamsters and of thyroid tumors in female rats by diet.
119 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Observation of tumors (generally of the liver) in seven studies in various mouse strains and three studies in rats. DDT is structurally similar to other probable carcinogens, such as DDD and DDE.
120 1,1-Dichloroethane 75-34-3 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and limited evidence of carcinogenicity in two animal species (rats and mice) as shown by an increased incidence of mammary gland adenocarcinomas and hemangiosarcomas in female rats and an increased incidence of hepatocellular carcinomas and benign uterine polyps in mice.
121 1,2-Dichloroethane 107-06-2 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on the induction of several tumor types in rats and mice treated by gavage and lung papillomas in mice after topical application
122 cis-1,2-Dichloroethylene 156-59-2 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of cis-1,2-DCE.
123 trans-1,2-Dichloroethylene 156-60-5 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of trans-1,2-DCE.
124 1,1-Dichloroethylene (1,1-DCE) 75-35-4 Oral Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the 1986 cancer guidelines (U.S. EPA, 1986), 1,1-DCE is assigned to Group C, possible human carcinogen. Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes 1,1-DCE exhibits suggestive evidence of carcinogenicity but not sufficient evidence to assess human carcinogenic potential following inhalation exposure in studies in rodents. Male mice developed kidney tumors at one exposure in a lifetime bioassay, a finding tempered by the absence of similar results in female mice or male or female rats and by the enzymatic differences (i.e., CYP2E1) between male mice and female mice, male and female rats, and human kidney cells. Limited evidence of genotoxicity has been reported in bacterial systems with metabolic activation. The data for 1,1-DCE are inadequate for an assessment of human carcinogenic potential by the oral route, based on the absence of statistically or biologically significant tumors in limited bioassays in rats and mice balanced against the suggestive evidence in male mice in a single bioassay by inhalation and the limited evidence of genotoxicity. The human epidemiological results on the carcinogenicity of 1,1-DCE are too limited to draw useful conclusions. EPA concludes that the results of kidney tumors in one sex and one exposure in a single species of rodents are too limited to support an exposure-response assessment.
125 1,1-Dichloroethylene (1,1-DCE) 75-35-4 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the 1986 cancer guidelines (U.S. EPA, 1986), 1,1-DCE is assigned to Group C, possible human carcinogen. Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes 1,1-DCE exhibits suggestive evidence of carcinogenicity but not sufficient evidence to assess human carcinogenic potential following inhalation exposure in studies in rodents. Male mice developed kidney tumors at one exposure in a lifetime bioassay, a finding tempered by the absence of similar results in female mice or male or female rats and by the enzymatic differences (i.e., CYP2E1) between male mice and female mice, male and female rats, and human kidney cells. Limited evidence of genotoxicity has been reported in bacterial systems with metabolic activation. The data for 1,1-DCE are inadequate for an assessment of human carcinogenic potential by the oral route, based on the absence of statistically or biologically significant tumors in limited bioassays in rats and mice balanced against the suggestive evidence in male mice in a single bioassay by inhalation and the limited evidence of genotoxicity. The human epidemiological results on the carcinogenicity of 1,1-DCE are too limited to draw useful conclusions. EPA concludes that the results of kidney tumors in one sex and one exposure in a single species of rodents are too limited to support an exposure-response assessment.
126 1,1-Dichloroethylene (1,1-DCE) 75-35-4 Inhalation Suggestive evidence of carcinogenicity, but not sufficient to assess human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the 1986 cancer guidelines (U.S. EPA, 1986), 1,1-DCE is assigned to Group C, possible human carcinogen. Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes 1,1-DCE exhibits suggestive evidence of carcinogenicity but not sufficient evidence to assess human carcinogenic potential following inhalation exposure in studies in rodents. Male mice developed kidney tumors at one exposure in a lifetime bioassay, a finding tempered by the absence of similar results in female mice or male or female rats and by the enzymatic differences (i.e., CYP2E1) between male mice and female mice, male and female rats, and human kidney cells. Limited evidence of genotoxicity has been reported in bacterial systems with metabolic activation. The data for 1,1-DCE are inadequate for an assessment of human carcinogenic potential by the oral route, based on the absence of statistically or biologically significant tumors in limited bioassays in rats and mice balanced against the suggestive evidence in male mice in a single bioassay by inhalation and the limited evidence of genotoxicity. The human epidemiological results on the carcinogenicity of 1,1-DCE are too limited to draw useful conclusions. EPA concludes that the results of kidney tumors in one sex and one exposure in a single species of rodents are too limited to support an exposure-response assessment.
127 Dichloromethane 75-09-2 Combined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Following U.S. EPA (2005) Guidelines for Carcinogen Risk Assessment, dichloromethane is "likely to be carcinogenic in humans," based predominantly on evidence of carcinogenicity at two sites in 2-year bioassays in male and female B6C3F1 mice (liver and lung tumors) with inhalation exposure (NTP, 1986) and at one site in male B6C3F1 mice (liver tumors) with drinking water exposure (Serota et al., 1986b; Hazleton Laboratories, 1983).
128 1,3-Dichloropropene 542-75-6 Undefined Known/likely human carcinogen Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Although the available human data are inadequate, 1,3-dichloropropene is characterized as "likely" to be a human carcinogen in accordance with the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996).
129 1,3-Dichloropropene 542-75-6 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Although the available human data are inadequate, 1,3-dichloropropene is characterized as "likely" to be a human carcinogen in accordance with the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996).
130 Dichlorvos 62-73-7 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Significant increases in forestomach tumors in female and male B6C3F1 mice and leukemias and pancreatic acinar adenomas in Fischer 344 rats. Supporting evidence included observation of tumors at other sites in the rat and observation of mutagenicity for both dichlorvos and a major metabolite dichloroacetaldehyde. A structurally related material, dichloropropene, also induces forestomach tumors in rodents.
131 Dieldrin 60-57-1 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Dieldrin is carcinogenic in seven strains of mice when administered orally. Dieldrin is structurally related to compounds (aldrin, chlordane, heptachlor, heptachlor epoxide, and chlorendic acid) which produce tumors in rodents.
132 Diesel engine exhaust None Undefined Likely to be carcinogenic to humans Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Using U.S. EPA's revised draft 1999 Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), diesel exhaust (DE) is likely to be carcinogenic to humans by inhalation from environmental exposures.
133 Diethyl phthalate (DEP) 84-66-2 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Pertinent data regarding carcinogenicity were not located in the available literature.
134 Diethyl-p-nitrophenylphosphate 311-45-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
135 Diethylene glycol dinitrate (DEGDN) 693-21-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human or animal carcinogenic studies found in the available literature.
136 Diisopropyl methylphosphonate (DIMP) 1445-75-6 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No data from cancer bioassays or epidemiological studies are available.
137 Dimethipin 55290-64-7 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Classification is based on an elevated combined incidence of pulmonary adenomas/carcinomas in male, but not in female, CD-1 mice. A rat study is undergoing further evaluation.
138 Dimethyl phthalate 131-11-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Pertinent data regarding carcinogenicity was not located in the available literature.
139 Dimethyl sulfate 77-78-1 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Classification is based on induction of local carcinomas following inhalation and subcutaneous exposures in rats, tumor induction in rats following prenatal exposure, and evidence suggestive of carcinogenicity in hamsters and mice by inhalation. Dimethyl sulfate alkylates cellular macromolecules and is genotoxic.
140 m-Dinitrobenzene 99-65-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no data in humans and animals.
141 o-Dinitrobenzene 528-29-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no data in humans and animals.
142 2,4-/2,6-Dinitrotoluene mixture Various Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on multiple benign and malignant tumor types at multiple sites in both sexes of rats (2 strains) and malignant renal tumors in male mice. The classification is supported by evidence of mutagenicity.
143 Dinoseb 88-85-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Dinoseb was not observed to be carcinogenic in two inadequate studies in rats and in mice. In a third study, an increase in benign liver tumors in female mice was not considered to be treatment-related. The increase was much lower in the high dose than the mid dose, there were no decreases in time to tumor, nor any evidence of any of the potentially predisposing lesions in the liver such as hypertrophy, hyperplasia or degeneration which are often associated with known hepatocellular carcinogens.
144 1,4-Dioxane 123-91-1 Undefined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) In accordance with the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), 1,4-dioxane is characterized as "likely to be carcinogenic to humans."
145 1,2-Diphenylhydrazine 122-66-7 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Positive results of studies in both rats and mice form the basis for this classification. Two apparently negative studies lack information on compound purity, experimental design, and statistical treatment.
146 1,4-Dithiane 505-29-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no data in humans and animals.
147 Endrin 72-20-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Oral administration of endrin did not produce carcinogenic effects in either sex of two strains of rats and three strains of mice. An NCI bioassay was suggestive of responses in male and female rats although NCI reported a no evidence conclusion. The inadequacies of several of the bioassays call into question the strength of the reported negative findings. These inadequacies and the suggestive responses in the NCI bioassay do not support a Group E classification; rather a Group D classification best reflects the equivocal data.
148 Epichlorohydrin 106-89-8 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Human data are inadequate. Multiple studies in rats and mice administered epichlorohydrin by various routes were positive. As epichlorohydrin is a strong alkylating agent, tumors are produced at the site of application.
149 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Inhalation Suggestive evidence of carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), ethyl tertiary butyl ether has “suggestive evidence of carcinogenic potential" for the inhalation route and “inadequate information to assess carcinogenic potential” for the oral route.
150 Ethylbenzene 100-41-4 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Nonclassifiable due to lack of animal bioassays and human studies.
151 Ethylene diamine 107-15-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate animal data.
152 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 Undefined Not likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), EGBE is deemed "not likely to be carcinogenic to humans" at environmental concentrations at or below the RfD and RfC, based on laboratory animal evidence, mode-of-action information, and limited human study information.
153 Ethylene oxide 75-21-8 Inhalation Carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), ethylene oxide is "carcinogenic to humans" by the inhalation route of exposure, based on (1) strong, but less than conclusive on its own, epidemiological evidence of lymphohematopoietic cancers and breast cancer in EtO exposed workers, (2) extensive evidence of carcinogenicity in laboratory animals, including lymphohematopoietic cancers in rats and mice and mammary carcinomas in mice following inhalation exposure, (3) clear evidence that EtO is genotoxic and sufficient weight of evidence to support a mutagenic mode of action for EtO carcinogenicity, and (4) strong evidence that the key precursor events are anticipated to occur in humans and progress to tumors, including evidence of chromosome damage in humans exposed to EtO.
154 Fluoranthene 206-44-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate data from animal bioassays.
155 Fluorene 86-73-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate data from animal bioassays.
156 Folpet 133-07-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Folpet has induced carcinoma and adenoma of the duodenum (an unusual site) in both sexes of both CD-1 and B6C3F1 mice. Folpet is also mutagenic in several in vitro assays and is a structural analogue of captan, which has been shown to induce carcinoma in the duodenum of two mouse strains.
157 Fomesafen 72178-02-0 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Fomesafen produced liver adenomas and carcinomas in both sexes of Charles River CD-1 mice.
158 Formaldehyde 50-00-0 Inhalation Carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), formaldehyde is “carcinogenic to humans by the inhalation route of exposure”. This conclusion is independently supported by three sets of evidence, namely evidence integration (aka “weight of evidence”) judgments that the evidence demonstrates that formaldehyde inhalation causes nasopharyngeal cancer, sinonasal cancer, and myeloid leukemia, in exposed humans (see the IRIS Toxicological Review for details on the human, animal, and/or mechanistic evidence that supports each of these three judgments).
159 Fosetyl-al 39148-24-8 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased incidence of urinary bladder tumors (adenomas/carcinomas combined) in male rats. No increase in tumor incidence occurred in female rats or in mice of either sex.
160 Furmecyclox 60568-05-0 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Dose-related increased incidence of neoplastic nodules, carcinomas and combined neoplasic nodules/carcinomas in the liver of female rats and increased incidence of liver nodules and carcinomas and urothelial tumors of the bladder in male rats.
161 Glycidaldehyde 765-34-4 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and an increased incidence of malignant tumors in rats and mice following subcutaneous injection of glycidaldehyde and of skin carcinomas following dermal application to mice. Glycidaldehyde shows mutagenic activity in many assay systems and is known to be highly reactive because of the epoxide and the aldehyde groups. A number of structurally related epoxide compounds are also carcinogenic in experimental animals, including the analogues glycidol and propylene oxide.
162 Glyphosate 1071-83-6 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Inadequate evidence for oncogenicity in animals. Glyphosate was originally classified as C, possible human carcinogen, on the basis of increased incidence of renal tumors in mice. Following independent review of the slides the classification was changed to D on the basis of a lack of statistical significance and uncertainty as to a treatment-related effect.
163 Heptachlor 76-44-8 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Inadequate human data, but sufficient evidence exist from studies in which benign and malignant liver tumors were induced in three strains of mice of both sexes. Several structurally related compounds are liver carcinogens.
164 Heptachlor epoxide 1024-57-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Sufficient evidence exists from rodent studies in which liver carcinomas were induced in two strains of mice of both sexes and in CFN female rats. Several structurally related compounds are liver carcinogens.
165 n-Heptane 142-82-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
166 Hexabromodiphenyl ether 36483-60-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
167 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 68631-49-2 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of 2,2',4,4',5,5'-hexabromodiphenyl ether.
168 Hexachlorobenzene 118-74-1 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Hexachlorobenzene, when administered orally, has been shown to induce tumors in the liver, thyroid and kidney in three rodent species.
169 Hexachlorobutadiene 87-68-3 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Observation of renal neoplasms in male and female rats in one study.
170 alpha-Hexachlorocyclohexane (alpha-HCH) 319-84-6 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Dietary alpha-HCH has been shown to cause increased incidence of liver tumors in five mouse strains and in Wistar rats.
171 beta-Hexachlorocyclohexane (beta-HCH) 319-85-7 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increases in benign liver tumors in CF1 mice fed beta-HCH
172 delta-Hexachlorocyclohexane (delta-HCH) 319-86-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate data from animal bioassays.
173 epsilon-Hexachlorocyclohexane (epsilon-HC) 6108-10-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate data from animal bioassays.
174 technical Hexachlorocyclohexane (t-HCH) 608-73-1 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Assays in four strains of mice have yielded positive carcinogenicity results for t-HCH administered in the diet.
175 Hexachlorocyclopentadiene (HCCPD) 77-47-4 Undefined Not likely to be carcinogenic to humans Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) According to the existing Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986a), evaluation of the weight-of-evidence for carcinogenicity to humans indicates that HCCPD is most appropriately categorized as Group E, Evidence of Noncarcinogenicity to Humans, via inhalation exposure. In accordance with U.S. EPA's Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), HCCPD is not likely to be a human carcinogen by the inhalation route based on current data indicating no evidence of cancer in well-conducted bioassays in two species of rodents; the absence of increased deaths from cancer in the limited human occupational studies available; and lack of mutagenicity in a variety of test systems.
176 Hexachlorocyclopentadiene (HCCPD) 77-47-4 Undefined E (Evidence of non-carcinogenicity for humans) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) According to the existing Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986a), evaluation of the weight-of-evidence for carcinogenicity to humans indicates that HCCPD is most appropriately categorized as Group E, Evidence of Noncarcinogenicity to Humans, via inhalation exposure. In accordance with U.S. EPA's Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), HCCPD is not likely to be a human carcinogen by the inhalation route based on current data indicating no evidence of cancer in well-conducted bioassays in two species of rodents; the absence of increased deaths from cancer in the limited human occupational studies available; and lack of mutagenicity in a variety of test systems.
177 Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 57653-85-7 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Hepatic tumors in mice and rats by gavage
178 Hexachloroethane 67-72-1 Undefined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the U.S. EPA Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005b), HCE is "likely to be carcinogenic to humans" based on evidence of multiple tumor types in both sexes of rats and mice (NTP, 1989 NCI, 1978).
179 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 None Suggestive evidence of carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is suggestive evidence of carcinogenic potential for RDX based on evidence of benign and malignant tumors in the liver and lungs of B6C3F1 mice or F344 rats.
180 n-Hexane 110-54-3 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the emGuidelines for Carcinogen Risk Assessment/em (U.S. EPA, 2005b), there is eminadequate information to assess the carcinogenic potential of n-hexane./em
181 2-Hexanone 591-78-6 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for 2-hexanone is "inadequate to assess human carcinogenic potential."
182 Hydrazine/Hydrazine sulfate 302-01-2 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Tumors have been induced in mice, rats and hamsters following oral, inhalation or intraperitoneal administration of hydrazine and sulfate. Hydrazine is mutagenic in numerous assays.
183 Hydrogen Cyanide and Cyanide Salts Various Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the U.S. EPA (2005a) Guidelines for Carcinogen Risk Assessment, there is "inadequate information to assess the carcinogenic potential" of cyanide.
184 Hydrogen sulfide 7783-06-4 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), data are inadequate for an assessment of the carcinogenic potential of hydrogen sulfide.
185 Indeno[1,2,3-cd]pyrene 193-39-5 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and sufficient data from animal bioassays. Indeno[1,2,3-cd]pyrene produced tumors in mice following lung implants, subcutaneous injection and dermal exposure. Indeno[1,2,3-cd]pyrene tested positive in bacterial gene mutation assays.
186 Isophorone 78-59-1 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no data in humans; limited evidence of carcinogenicity of one tumor type in one sex of one animal species as shown by an increase of preputial gland carcinomas in male rats. The apparent renal tubular cell tumor in the male rat is associated with alpha-2u-globulin, considered to be of questionable relevance to humans.
187 Isopropyl methyl phosphonic acid (IMPA) 1832-54-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no data in humans and animals.
188 Isoxaben 82558-50-7 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on a statistically significant increased incidence of benign liver tumors in one species.
189 Lead and compounds (inorganic) 7439-92-1 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Sufficient animal evidence. Ten rat bioassays and one mouse assay have shown statistically significant increases in renal tumors with dietary and subcutaneous exposure to several soluble lead salts. Animal assays provide reproducible results in several laboratories, in multiple rat strains with some evidence of multiple tumor sites. Short term studies show that lead affects gene expression. Human evidence is inadequate.
190 Libby Amphibole Asbestos 1318-09-8 Inhalation Carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the EPA Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), Libby Amphibole asbestos (LAA) is "carcinogenic to humans" following inhalation exposure based on epidemiologic evidence that shows a convincing association between exposure to LAA fibers and increased lung cancer and mesothelioma mortality.
191 Linuron 330-55-2 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Limited evidence indicated linuron produced increases in both testicular hyperplasia and adenomas in male rats in three separate studies. Hepatocellular adenomas were observed in female mice in a single study at the highest dose group tested; the tumors were benign and showed no progression toward malignancy.
192 Manganese 7439-96-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Existing studies are inadequate to assess the carcinogenicity of manganese.
193 Mercuric chloride (HgCl2) 7487-94-7 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on the absence of data in humans and limited evidence of carcinogenicity in rats and mice. Focal papillary hyperplasia and squamous cell papillomas in the forestomach as well as thyroid follicular cell adenomas and carcinomas were observed in male rats gavaged with mercuric chloride for 2 years. The relevance of the forestomach papillomas to assessment of cancer in humans is questionable because no evidence indicated that the papillomas progressed to malignancy. The relevance of the increase in thyroid tumors has also been questioned because these tumors are generally considered to be secondary to hyperplasia; this effect was not observed in the high-dose males. It should also be noted that the authors considered the doses used in the study to exceed the MTD for male rats. In the same study, evidence for increases in squamous cell papillomas in the forestomach of female rats was equivocal. In a second study, equivocal evidence for renal adenomas and adenocarcinomas was observed in male mice; there was a significant positive trend. This tumor type is rare in mice, and the increase in incidence was statistically significant when compared with historic controls. Two other nonpositive lifetime rodent studies were considered inadequate. Mercuric chloride showed mixed results in a number of genotoxicity assays.
194 Mercury, elemental 7439-97-6 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human and animal data. Epidemiologic studies failed to show a correlation between exposure to elemental mercury vapor and carcinogenicity; the findings in these studies were confounded by possible or known concurrent exposures to other chemicals, including human carcinogens, as well as lifestyle factors (e.g., smoking). Findings from genotoxicity tests are severely limited and provide equivocal evidence that mercury adversely affects the number or structure of chromosomes in human somatic cells.
195 Methidathion 950-37-8 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased incidence of liver adenomas, carcinomas, and combined adenomas and carcinomas in male mice. There was no shortening of time to tumor. Short-term tests and structure/activity study were not supportive of a higher classification.
196 Methoxychlor 72-43-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Human data are unavailable, and animal evidence is inconclusive.
197 Methyl acrylate 96-33-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate evidence of carcinogenicity in animals and no human data.
198 Methyl chloride 74-87-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Applying the criteria for evaluating the overall weight-of-evidence for carcinogenicity to humans outlined in EPA's guidelines for carcinogen risk assessment (U.S. EPA, 1986), methyl chloride is most appropriately designated a Group D - Not classifiable as to its human carcinogenicity. Using the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), the available data suggest that methyl chloride would be classified as an agent whose carcinogenic potential cannot be determined.
199 Methyl chloride 74-87-3 Undefined Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Applying the criteria for evaluating the overall weight-of-evidence for carcinogenicity to humans outlined in EPA's guidelines for carcinogen risk assessment (U.S. EPA, 1986), methyl chloride is most appropriately designated a Group D - Not classifiable as to its human carcinogenicity. Using the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), the available data suggest that methyl chloride would be classified as an agent whose carcinogenic potential cannot be determined.
200 Methyl ethyl ketone (MEK) 78-93-3 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes the data are inadequate for an assessment of human carcinogenic potential of MEK. Studies of humans chronically exposed to MEK are inconclusive, and MEK has not been tested for carcinogenicity in animals by the oral or inhalation routes.
201 Methyl isobutyl ketone (MIBK) 108-10-1 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the draft revised cancer guidelines (U.S. EPA, 1999), the data for MIBK are inadequate for an assessment of human carcinogenic potential. No data were located regarding the existence of an association between cancer and MIBK exposure in humans, but studies of the in vivo and in vitro genotoxicity of MIBK overwhelmingly provided negative responses.
202 Methyl methacrylate 80-62-6 Undefined Not likely to be carcinogenic to humans Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, MMA would be classified as evidence of non-carcinogenicity for humans or a Group E chemical. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), MMA is considered not likely to be carcinogenic to humans by any route of exposure because it has been evaluated in four well-conducted chronic inhalation studies in three appropriate animal species without demonstrating carcinogenic effects.
203 Methyl methacrylate 80-62-6 Undefined E (Evidence of non-carcinogenicity for humans) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, MMA would be classified as evidence of non-carcinogenicity for humans or a Group E chemical. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), MMA is considered not likely to be carcinogenic to humans by any route of exposure because it has been evaluated in four well-conducted chronic inhalation studies in three appropriate animal species without demonstrating carcinogenic effects.
204 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under U.S. EPA's 1996 Proposed Guidelines for Carcinogen Risk Assessment, the carcinogenic potential of MDI/PMDI would be characterized as "cannot be determined," but for which there is suggestive evidence that raises concern for carcinogenic effects.
205 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 Undefined Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Under U.S. EPA's 1996 Proposed Guidelines for Carcinogen Risk Assessment, the carcinogenic potential of MDI/PMDI would be characterized as "cannot be determined," but for which there is suggestive evidence that raises concern for carcinogenic effects.
206 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Sufficient evidence from animal experiments: thyroid tumors in male and female rats, and liver carcinoma/adenoma in the female mice with a significant positive trend in male mice. There is evidence of mutagenic activity. There are no human data.
207 Methylmercury (MeHg) 22967-92-6 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate data in humans and limited evidence of carcinogenicity in animals. Male ICR and B6C3F1 mice exposed to methylmercuric chloride in the diet had an increased incidence of renal adenomas, adenocarcinomas and carcinomas. The tumors were observed at a single site and in a single species and single sex. The renal epithelial cell hyperplasia and tumors were observed only in the presence of profound nephrotoxicity and were suggested to be a consequence of reparative changes in the cells. Several nonpositive cancer bioassays were also reported. Although genotoxicity test data suggest that methylmercury is capable of producing chromosomal and nuclear damage, there are also nonpositive genotoxicity data.
208 2-Methylnaphthalene 91-57-6 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes the data are inadequate for an assessment of human carcinogenic potential of 2-methylnaphthalene. Based on the absence of data concerning the carcinogenic potential of 2-methylnaphthalene in humans and limited equivocal evidence in animals.
209 3-Methylphenol 108-39-4 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on an increased incidence of skin papillomas in mice in an initiation-promotion study. The three cresol isomers produced positive results in genetic toxicity studies both alone and in combination.
210 4-Methylphenol 106-44-5 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on an increased incidence of skin papillomas in mice in an initiation-promotion study. The three cresol isomers produced positive results in genetic toxicity studies both alone and in combination.
211 2-Methylphenol 95-48-7 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on an increased incidence of skin papillomas in mice in an initiation-promotion study. The three cresol isomers produced positive results in genetic toxicity studies both alone and in combination.
212 Metolachlor 51218-45-2 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Classification is based on the appearance of proliferative liver lesions (combined neoplastic nodules and carcinomas) at highest dose tested (3000 ppm) in female rats.
213 Metribuzin 21087-64-9 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and inadequate evidence ffom animal bioassays. Metribuzin did not increase the incidence of tumors in a lifetime dietary study using CD-1 mice when compared with both concurrent and historic controls. In a 2-year feeding study in Wistar rats, no significant differences in neoplastic findings between the test and control groups were found. Short-term studies in bacteria and mammalian systems suggest that metribuzin is not mutagenic.
214 Monochloramine 10599-90-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human data and equivocal evidence of carcinogenicity from animal bioassays. A 2-year bioassay showed a marginal increase in mononuclear cell leukemia in female F344/N rats. No evidence of carcinogenic activity was reported in male rats or in male or female B6C3F1 mice. Genotoxicity studies, both in vitro and in vivo, gave negative results.
215 Naphthalene 91-20-3 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Using criteria of the 1986 Guidelines for Carcinogen Risk Assessment, naphthalene is classified in Group C, a possible human carcinogen. This is based on the inadequate data of carcinogenicity in humans exposed to naphthalene via the oral and inhalation routes, and the limited evidence of carcinogenicity in animals via the inhalation route. Using the 1996 Proposed Guidelines for Carcinogen Risk Assessment, the human carcinogenic potential of naphthalene via the oral or inhalation routes "cannot be determined" at this time based on human and animal data; however, there is suggestive evidence (observations of benign respiratory tumors and one carcinoma in female mice only exposed to naphthalene by inhalation [NTP, 1992a]). Additional support includes increase in respiratory tumors associated with exposure to 1-methylnaphthalene.
216 Naphthalene 91-20-3 Undefined Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Using criteria of the 1986 Guidelines for Carcinogen Risk Assessment, naphthalene is classified in Group C, a possible human carcinogen. This is based on the inadequate data of carcinogenicity in humans exposed to naphthalene via the oral and inhalation routes, and the limited evidence of carcinogenicity in animals via the inhalation route. Using the 1996 Proposed Guidelines for Carcinogen Risk Assessment, the human carcinogenic potential of naphthalene via the oral or inhalation routes "cannot be determined" at this time based on human and animal data; however, there is suggestive evidence (observations of benign respiratory tumors and one carcinoma in female mice only exposed to naphthalene by inhalation [NTP, 1992a]). Additional support includes increase in respiratory tumors associated with exposure to 1-methylnaphthalene.
217 Nickel carbonyl 13463-39-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based upon the observation of pulmonary carcinomas and malignant tumors at various sites in rats administered nickel carbonyl by inhalation and intravenous injection, respectively. Nickel administered as nickel carbonyl binds to DNA.
218 Nickel refinery dust None Undefined A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Human data in which exposure to nickel refinery dust caused lung and nasal tumors in sulfide nickel matte refinery workers in several epidemiologic studies in different countries, and on animal data in which carcinomas were produced in rats by inhalation and injection.
219 Nickel subsulfide 12035-72-2 Undefined A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased risks of lung and nasal cancer in humans exposed to nickel refinery dust, most of which was believed to have been nickel subsulfide; increased tumor incidences in animals by several routes of administration in several animal species and strains; and positive results in genotoxicity assays form the basis for this classification.
220 Nitrobenzene 98-95-3 Combined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), nitrobenzene is classified as "likely to be carcinogenic to humans" by any route of exposure.
221 Nitroguanidine 556-88-7 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Pertinent data regarding carcinogenicity have not been located in the available literature.
222 N-Nitroso-N-methylethylamine 10595-95-6 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased incidence of tumors of the liver and other sites in two rat strains
223 N-Nitroso-di-n-butylamine 924-16-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased incidences of several tumor types in rats, mice, and hamsters exposed by various routes.
224 N-Nitrosodi-N-propylamine 621-64-7 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased tumor incidence at multiple sites in two rodent species and in monkeys administered the compound by various routes
225 N-Nitrosodiethanolamine 1116-54-7 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased incidence of liver tumors and tumors at other sites in three strains of rats and in hamsters
226 N-Nitrosodiethylamine 55-18-5 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Induction of tumors at multiple sites in both rodent and nonrodent species exposed by various routes.
227 N-Nitrosodimethylamine 62-75-9 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Induction of tumors at multiple sites in both rodents and nonrodent mammals exposed by various routes.
228 N-Nitrosodiphenylamine 86-30-6 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased incidence of bladder tumors in male and female rats and reticulum cell sarcomas in mice, and structural relationship to carcinogenic nitrosamines
229 N-Nitrosopyrrolidine 930-55-2 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Tumors at more than one site have been observed in two rodent species administered nitrosopyrrolidine orally.
230 Nonabromodiphenyl ether 63936-56-1 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
231 Octabromodiphenyl ether 32536-52-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
232 Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) 2691-41-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No cancer bioassays or epidemiological studies are available.
233 Oryzalin 19044-88-3 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Oryzalin produced tumors (generally benign) at multiple sites in male and female rats. It is structurally related to 2,4-diaminoanisole sulfate which causes malignant tumors at similar sites.
234 Paraquat 1910-42-5 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Paraquat produced squamous cell carcinoma, an uncommon tumor, in the head region in both sexes of Fischer 344 rats.
235 Parathion 56-38-2 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased adrenal cortical tumors in female and male Osborne-Mendel rats and positive trends for thyroid follicular adenomas and pancreatic islet-cell carcinomas in male rats in one study.
236 Pentabromodiphenyl ether 32534-81-9 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and animal data available.
237 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) 60348-60-9 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of 2,2',4,4',5-pentabromodiphenyl ether (BDE-99).
238 Pentachlorobenzene 608-93-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
239 Pentachlorocyclopentadiene 25329-35-5 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Lack of data concerning carcinogenicity to humans or animals.
240 Pentachlorophenol 87-86-5 Undefined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), PCP is "likely to be carcinogenic to humans."
241 Perchlorate (ClO4) and Perchlorate Salts 7790-98-9 Undefined Not likely to be carcinogenic to humans Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under U.S. EPAs 1999 Draft Revised Guidelines for Carcinogen Risk Assessment, perchlorate is not likely to pose a risk of thyroid cancer in humans, at least at doses below those necessary to alter thyroid hormone homeostasis, based on the hormonally-mediated mode of action in rodent studies and species differences in thyroid function.
242 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) None
243 Perfluorohexanoic Acid (PFHxA) 307-24-4 Combined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) None
244 Phenanthrene 85-01-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate data from a single gavage study in rats and skin painting and injection studies in mice.
245 Phenol 108-95-2 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), the data regarding the carcinogenicity of phenol via the oral, inhalation, and dermal exposure routes are inadequate for an assessment of human carcinogenic potential. Phenol was negative in oral carcinogenicity studies in rats and mice, but questions remain regarding increased leukemia in male rats in the bioassay as well as the positive gene mutation data and the positive results in dermal initiation/promotion studies at doses at or above the maximum tolerated dose (MTD). No inhalation studies of an appropriate duration exist. Therefore, no quantitative assessment of carcinogenic potential via any route is possible.
246 Phenol 108-95-2 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), the data regarding the carcinogenicity of phenol via the oral, inhalation, and dermal exposure routes are inadequate for an assessment of human carcinogenic potential. Phenol was negative in oral carcinogenicity studies in rats and mice, but questions remain regarding increased leukemia in male rats in the bioassay as well as the positive gene mutation data and the positive results in dermal initiation/promotion studies at doses at or above the maximum tolerated dose (MTD). No inhalation studies of an appropriate duration exist. Therefore, no quantitative assessment of carcinogenic potential via any route is possible.
247 Phosgene 75-44-5 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005b), there is inadequate information to assess carcinogenic potential of phosgene. A single epidemiology study was not considered adequate for evaluating carcinogenic potential in humans, and no animal cancer bioassays of phosgene have been conducted.
248 Phosphine 7803-51-2 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate data in animals and no tumor data in humans. While phospine has not been associated with cancer in humans, there is some evidence of chromosomal damage (transient chromatid deletions, gaps and breaks, persistent chromosomal translocations). A relationship between these genetic effects and the development of cancer in humans is sometimes postulated.
249 Polychlorinated Biphenyls (PCBs) 1336-36-3 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) A 1996 study found liver tumors in female rats exposed to Aroclors 1260, 1254, 1242, and 1016, and in male rats exposed to 1260. These mixtures contain overlapping groups of congeners that, together, span the range of congeners most often found in environmental mixtures. Earlier studies found high, statistically significant incidences of liver tumors in rats ingesting Aroclor 1260 or Clophen A 60 (Kimbrough et al., 1975 Norback and Weltman, 1985 Schaeffer et al., 1984). Mechanistic studies are beginning to identify several congeners that have dioxin-like activity and may promote tumors by different modes of action. PCBs are absorbed through ingestion, inhalation, and dermal exposure, after which they are transported similarly through the circulation. This provides a reasonable basis for expecting similar internal effects from different routes of environmental exposure. Information on relative absorption rates suggests that differences in toxicity across exposure routes are small. The human studies are being updated currently available evidence is inadequate, but suggestive.
250 Prochloraz 67747-09-5 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Statistically significantly increased incidence and dose-related trend in liver adenomas and carcinomas (combined) in both sexes of one strain of mouse.
251 Propionaldehyde 123-38-6 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) In accordance with the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" for propionaldehyde.
252 Propylene oxide 75-56-9 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human data and an increased incidence of benign and malignant tumors at the site of exposure in two species of animals, when exposed by subcutaneous injection, by inhalation, and by gavage. There was also evidence of mutagenicity in a variety of test systems. Propylene oxide is structurally similar to other chemicals that demonstrate carcinogenic activity in animals.
253 Pyrene 129-00-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and inadequate data from animal bioassays.
254 Quinoline 91-22-5 Undefined Known/likely human carcinogen Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) Quinoline is considered likely to be carcinogenic in humans in accordance with proposed EPA carcinogen risk assessment guidelines (U.S. EPA, 1996) on the basis of observations of exposure-related increased incidence of an unusual malignant tumor in multiple strains of rats and mice, multiple experiments using oral, i.p. and s.c. dosing at an early age. This determination is supported by studies that demonstrate that quinoline is genotoxic.
255 Quinoline 91-22-5 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Quinoline is considered likely to be carcinogenic in humans in accordance with proposed EPA carcinogen risk assessment guidelines (U.S. EPA, 1996) on the basis of observations of exposure-related increased incidence of an unusual malignant tumor in multiple strains of rats and mice, multiple experiments using oral, i.p. and s.c. dosing at an early age. This determination is supported by studies that demonstrate that quinoline is genotoxic.
256 Refractory ceramic fibers None Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and sufficient evidence from animal studies. Chronic inhalation studies showed that several types of RCFs induced mesotheliomas and lung tumors in rats and hamsters. Administration of RCFs by intraperitoneal/intrapleural injection or intratracheal instillation also caused peritoneal/pleural mesotheliomas or lung tumors in rats and hamsters.
257 Selenious acid 7783-00-8 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human data and inadequate evidence of carcinogenicity in animals. The evidence for various selenium compounds in animal and mutagenicity studies is conflicting and difficult to interpret; however, evidence for selenium sulfide is sufficient for a B2 (probable human carcinogen) classification.
258 Selenium and Compounds 7782-49-2 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate human data and inadequate evidence of carcinogenicity in animals. The evidence for various selenium compounds in animal and mutagenicity studies is conflicting and difficult to interpret; however, evidence for selenium sulfide is sufficient for a B2 (probable human carcinogen) classification.
259 Selenium sulfide 7446-34-6 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on inadequate data from human studies and sufficient evidence in animals. When administered orally, selenium sulfide produced hepatocellular carcinomas in both sexes of F344 rats and female B6C3F1 mice and alveolar/bronchiolar carcinomas or adenomas in female B6C3F1 mice.
260 Silver 7440-22-4 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) In animals, local sarcomas have been induced after implantation of foils and discs of silver. However, the interpretation of these findings has been questioned due to the phenomenon of solid-state carcinogenesis in which even insoluble solids such as plastic have been shown to result in local fibrosarcomas.
261 Tetrabromodiphenyl ether 40088-47-9 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
262 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 5436-43-1 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47).
263 Tetrachlorocyclopentadiene 695-77-2 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Lack of data concerning carcinogenicity in humans or animals.
264 1,1,1,2-Tetrachloroethane 630-20-6 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Increased incidence of combined hepatocellular adenomas and carcinomas in female mice; inadequate evidence from human studies.
265 1,1,2,2-Tetrachloroethane 79-34-5 Undefined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a) 1,1,2,2-tetrachloroethane is "likely to be carcinogenic to humans."
266 Tetrachloroethylene (Perchloroethylene) 127-18-4 Undefined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Following EPA (2005a) Guidelines for Carcinogen Risk Assessment, tetrachloroethylene is "likely to be carcinogenic in humans by all routes of exposure."
267 Tetrahydrofuran 109-99-9 Undefined Suggestive evidence of carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for THF provides "suggestive evidence of carcinogenic potential."
268 Thallium (I), soluble salts Various Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential."
269 Thallium acetate 563-68-8 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential."
270 Thallium carbonate 6533-73-9 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential."
271 Thallium chloride 7791-12-0 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential."
272 Thallium nitrate 10102-45-1 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential."
273 Thallium oxide 1314-32-5 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential."
274 Thallium selenite 12039-52-0 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential."
275 Thallium(I) sulfate 7446-18-6 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential."
276 Toluene 108-88-3 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess the carcinogenic potential of toluene because studies of humans chronically exposed to toluene are inconclusive, toluene was not carcinogenic in adequate inhalation cancer bioassays of rats and mice exposed for life (CIIT, 1980 NTP, 1990 Huff, 2003), and increased incidences of mammary cancer and leukemia were reported in a lifetime rat oral bioassay at a dose level of 500 mg/kg-day but not at 800 mg/kg-day (Maltoni et al., 1997).
277 Toxaphene 8001-35-2 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) The classification is based on increased incidence of hepatocellular tumors in mice and thyroid tumors in rats and is supported by mutagenicity in Salmonella.
278 Tribromochloromethane 594-15-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human or animal cancer data.
279 Tribromodiphenyl ether 49690-94-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) No human data and no animal data available.
280 Tributyltin oxide (TBTO) 56-35-9 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) There are no data in humans concerning development of cancer following exposure to tributyltin oxide (TBTO). Cancer bioassays following oral exposure have been conducted in rats and mice. Because of the questionable data from the bioassay in rats, EPA assigns TBTO to the "cannot be determined" category [U.S. EPA, 1996 (proposed)].
281 Tributyltin oxide (TBTO) 56-35-9 Undefined Carcinogenic potential cannot be determined Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) There are no data in humans concerning development of cancer following exposure to tributyltin oxide (TBTO). Cancer bioassays following oral exposure have been conducted in rats and mice. Because of the questionable data from the bioassay in rats, EPA assigns TBTO to the "cannot be determined" category [U.S. EPA, 1996 (proposed)].
282 Trichloroacetic acid 76-03-9 Undefined Suggestive evidence of carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (Cancer Guidelines) (U.S. EPA, 2005a), there is suggestive evidence of carcinogenic potential for TCA based on significantly increased incidences of liver tumors in male B6C3F1 mice exposed via drinking water for 52–104 weeks (DeAngelo et al., 2008 Bull et al., 2002, 1990 Herren-Freund et al., 1987) and female B6C3F1 mice exposed for 51 or 82 weeks (Pereira, 1996), and lack of treatment-related tumors in a study of male F344/N rats following lifetime exposure in drinking water (DeAngelo et al., 1997).
283 1,2,4-Trichlorobenzene 120-82-1 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) A dermal exposure study in mice was found inadequate for drawing conclusions as to carcinogenicity in humans.
284 Trichlorocyclopentadiene 77323-84-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Lack of data concerning carcinogenicity in humans or animals.
285 1,1,1-Trichloroethane 71-55-6 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for 1,1,1-trichloroethane provides "inadequate information to assess carcinogenic potential."
286 1,1,2-Trichloroethane 79-00-5 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Hepatocellular carcinomas and pheochromocytomas in one strain of mice forms the basis for this classification. Carcinogenicity was not shown in rats. 1,1,2-Trichloroethane is structurally related to 1,2-dichloroethane, a probable human carcinogen.
287 Trichloroethylene 79-01-6 Combined Carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), TCE is characterized as "carcinogenic to humans" by all routes of exposure.
288 2,4,6-Trichlorophenol 88-06-2 Undefined B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human data and sufficient evidence in animals; namely, increased incidence of lymphomas or leukemias in male rats and hepatocellular adenomas or carcinomas in male and female mice.
289 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) 93-72-1 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Human data are not available and the available animal cancer bioassay studies are considered to be inadequate.
290 1,2,3-Trichloropropane 96-18-4 Undefined Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 2005), 1,2,3-trichloropropane is "likely to be carcinogenic to humans", based on a statistically significant and dose-related increase in the formation of multiple tumors in both sexes of two species from an NTP (1993) chronic oral bioassay.
291 Trifluralin 1582-09-8 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Classification is based on the induction of urinary tract tumors (renal pelvis carcinomas and urinary bladder papillomas) and thyroid tumors (adenomas/carcinomas combined) in one animal species (F344 rats) in one study. Trifluralin is structurally similar to ethalfluralin, a carcinogen in the rat.
292 1,3,5-Trimethylbenzene 108-67-8 None Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA 2005), there is “inadequate information to assess carcinogenic potential” of TMBs. This characterization is based on the fact that there is no information regarding the carcinogenicity of TMBs in humans and that the only animal study available on the carcinogenicity of 1,2,4‑TMB observed no statistically significant carcinogenic effects. No studies regarding the carcinogenicity of 1,2,3‑TMB or 1,3,5‑TMB were identified in the available scientific literature.
293 1,2,3-Trimethylbenzene 526-73-8 None Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA 2005), there is “inadequate information to assess carcinogenic potential” of TMBs. This characterization is based on the fact that there is no information regarding the carcinogenicity of TMBs in humans and that the only animal study available on the carcinogenicity of 1,2,4‑TMB observed no statistically significant carcinogenic effects. No studies regarding the carcinogenicity of 1,2,3‑TMB or 1,3,5‑TMB were identified in the available scientific literature.
294 1,2,4-Trimethylbenzene 95-63-6 None Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA 2005), there is “inadequate information to assess carcinogenic potential” of TMBs. This characterization is based on the fact that there is no information regarding the carcinogenicity of TMBs in humans and that the only animal study available on the carcinogenicity of 1,2,4‑TMB observed no statistically significant carcinogenic effects. No studies regarding the carcinogenicity of 1,2,3‑TMB or 1,3,5‑TMB were identified in the available scientific literature.
295 2,2,4-Trimethylpentane 540-84-1 Oral Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) In accordance with the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is inadequate information to assess carcinogenic potential for 2,2,4-trimethylpentane.
296 2,4,6-Trinitrotoluene (TNT) 118-96-7 Undefined C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Evidence of human carcinogenicity is inadequate. Urinary bladder papilloma and carcinoma were observed in female Fischer 344 rats. Mutagenic activity was observed in Salmonella with and without metabolic activation.
297 Urea 57-13-6 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of urea.
298 Vinyl chloride 75-01-4 Undefined Known/likely human carcinogen Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) On the basis of sufficient evidence for carcinogenicity in human epidemiology studies, VC is considered to best fit the weight-of-evidence Category "A," according to current EPA Risk Assessment Guidelines (U.S. EPA, 1986). Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), it is concluded that VC is a known human carcinogen by the inhalation route of exposure, based on human epidemiological data, and by analogy the oral route because of positive animal bioassay data as well as pharmacokinetic data allowing dose extrapolation across routes. VC is also considered highly likely to be carcinogenic by the dermal route because it is well absorbed and acts systemically.
299 Vinyl chloride 75-01-4 Undefined A (Human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) On the basis of sufficient evidence for carcinogenicity in human epidemiology studies, VC is considered to best fit the weight-of-evidence Category "A," according to current EPA Risk Assessment Guidelines (U.S. EPA, 1986). Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), it is concluded that VC is a known human carcinogen by the inhalation route of exposure, based on human epidemiological data, and by analogy the oral route because of positive animal bioassay data as well as pharmacokinetic data allowing dose extrapolation across routes. VC is also considered highly likely to be carcinogenic by the dermal route because it is well absorbed and acts systemically.
300 White phosphorus 7723-14-0 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no data in humans or animals.
301 Xylenes 1330-20-7 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), data are inadequate for an assessment of the carcinogenic potential of xylenes. Adequate human data on the carcinogenicity of xylenes are not available, and the available animal data are inconclusive as to the ability of xylenes to cause a carcinogenic response. Evaluations of the genotoxic effects of xylenes have consistently given negative results.
302 Zinc and Compounds 7440-66-6 Undefined Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess carcinogenic potential of zinc, because studies of humans occupationally-exposed to zinc are inadequate or inconclusive, adequate animal bioassays of the possible carcinogenicity of zinc are not available, and results of genotoxic tests of zinc have been equivocal.
303 Zinc and Compounds 7440-66-6 Undefined Data are inadequate for an assessment of human carcinogenic potential Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess carcinogenic potential of zinc, because studies of humans occupationally-exposed to zinc are inadequate or inconclusive, adequate animal bioassays of the possible carcinogenicity of zinc are not available, and results of genotoxic tests of zinc have been equivocal.
304 Zinc and Compounds 7440-66-6 Undefined Not applicable. This substance was not assessed using the 1986 cancer guidelines (U.S. EPA, 1986). Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess carcinogenic potential of zinc, because studies of humans occupationally-exposed to zinc are inadequate or inconclusive, adequate animal bioassays of the possible carcinogenicity of zinc are not available, and results of genotoxic tests of zinc have been equivocal.
305 Zinc and Compounds 7440-66-6 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess carcinogenic potential of zinc, because studies of humans occupationally-exposed to zinc are inadequate or inconclusive, adequate animal bioassays of the possible carcinogenicity of zinc are not available, and results of genotoxic tests of zinc have been equivocal.
306 n-Butanol 71-36-3 Undefined D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) Based on no human and no animal cancer data.
307 tert-Butyl Alcohol (tBA) 75-65-0 None Suggestive evidence of carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), tert-butyl alcohol has “suggestive evidence of carcinogenic potential” for all routes of exposure based on some evidence in animals.

  CHEMICAL NAME CAS REG DISPLAY CA ROUTE TUMOR SITE PT DESC PRECURSOR TUMOR PT STUDY SUBJECT STUDY ROUTE CODE STUDY ROUTE QUALIFIER STUDY CITATION DESC SLOPEFACTOR VALUE SF MUTAGENIC MODE OF ACTION UNIT RISK VALUE UR MUTAGENIC MODE OF ACTION UR EXTRAP METHOD PT FOOTNOTE E4 VALUE E5 VALUE E6 VALUE
1 Acephate 30560-19-1 Oral Hepatic Liver adenomas and carcinomas Tumor Mouse/ CD-1, female Oral Diet Chevron Chemical, 1982a 8.7 x 10 -3 per mg/kg-day No 2.5 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 4 x 10 2 µg/L 4 x 10 1 µg/L 4 µg/L
2 Acetaldehyde 75-07-0 Inhalation Respiratory Nasal squamous cell carcinoma or adenocarcinoma Tumor Rat/SPF Wistar, male Inhalation None Woutersen and Appleman, 1984 None No 2.2 x 10 -6 per µg/m3 No Linearized multistage-variable exposure input form (extra risk) None 5 x 10 1 µg/m3 5 µg/m3 5 x 10 -1 µg/m3
3 Acrylamide 79-06-1 Inhalation Endocrine, Reproductive thyroid tumors and tunica vaginalis mesotheliomas Tumor Rat/Fischer 344, males Oral drinking water Johnson et al., 1986 None No 1.7 x 10 -4 per µg/m3 No Multistage model with linear extrapolation from the point of departure (BMDL), summed risk, includes application of age-dependent adjustment factors (ADAFs). EPA has concluded that acrylamide is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the inhalation unit risk (IUR) addressing lifetime exposure includes application of ADAFs. The IUR is recommended for lifetime exposures. None None None
4 Acrylamide 79-06-1 Oral Endocrine, Reproductive thyroid tumors and tunica vaginalis mesotheliomas Tumor Rat/Fischer 344, males Oral drinking water Johnson et al., 1986 8.3 x 10 -1 per mg/kg-day No None No Multistage model with linear extrapolation from the point of departure (BMDL), summed risk, includes application of age-dependent adjustment factors (ADAFs). EPA has concluded that acrylamide is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the oral slope factor (OSF) addressing lifetime exposure includes application of ADAFs. The OSF is recommended for lifetime exposures. EPA has also provided an adult-based cancer slope factor of 5 x 10-1 per mg/kg-day. This adult-based cancer slope factor can be used instead of the OSF when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
5 Acrylonitrile 107-13-1 Inhalation Respiratory Respiratory cancer Tumor Humans Inhalation None O'Berg, 1980 None No 6.8 x 10 -5 per µg/m3 No Average relative risk None 1 µg/m3 1 x 10 -1 µg/m3 1 x 10 -2 µg/m3
6 Acrylonitrile 107-13-1 Oral Gastrointestinal, Nervous, Other Brain and spinal cord astrocytomas, Zymbal gland carcinomas and stomach papillomas/ carcinomas Tumor Rats (Spartan Sprague-Dawley, males Fischer 344, males Sprague-Dawley, males) Oral Drinking water Biodynamics, 1980a,b Quast et al., 1980a 5.4 x 10 -1 per mg/kg-day No 1.5 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 6 µg/L 6 x 10 -1 µg/L 6 x 10 -2 µg/L
7 Aldrin 309-00-2 Inhalation Hepatic Liver carcinoma Tumor Mouse/C3H (Davis); mouse/B6C3F1, male (NCI) Oral Diet Davis, 1965, NCI, 1978 None No 4.9 x 10 -3 per µg/m3 No Linearized multistage procedure, extra risk None 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3 2 x 10 -4 µg/m3
8 Aldrin 309-00-2 Oral Hepatic Liver carcinoma Tumor Mouse/C3H (Davis); mouse/B6C3F1, male (NCI) Oral Drin Davis, 1965, NCI, 1978 1.7 x 10 1 per mg/kg-day No 4.9 x 10 -4 per µg/L No Linearized multistage procedure, extra risk None 2 x 10 -1 µg/L 2 x 10 -2 µg/L 2 x 10 -3 µg/L
9 Aniline 62-53-3 Oral Immune Spleen, combined fibrosarcoma, stromal sarcoma, capsular sarcoma and hemangiosarcoma Tumor Rat/CD-F, male Oral Diet CIIT, 1982 5.7 x 10 -3 per mg/kg-day No 1.6 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 6 x 10 2 µg/L 6 x 10 1 µg/L 6 µg/L
10 Aramite 140-57-8 Oral Hepatic Neoplastic liver nodules and carcinomas Tumor Rat/ FDRL, male and female Oral Diet Popper et al., 1960; Oser and Oser, 1962 2.5 x 10 -2 per mg/kg-day No 7.1 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 2 µg/L 1 x 10 1 µg/L 1 µg/L
11 Aramite 140-57-8 Inhalation Hepatic Neoplastic liver nodules and carcinomas Tumor Rat/ FDRL, male and female Oral Diet Popper et al., 1960; Oser and Oser, 1962 None No 7.1 x 10 -6 per µg/m3 No Linearized multistage procedure, extra risk None 1 x 10 1 µg/m3 1 µg/m3 1 x 10 -1 µg/m3
12 Arsenic, Inorganic 7440-38-2 Oral Respiratory, Urinary Bladder Cancer and Lung Cancer Tumor Human Oral None None 3.2 x 10 1 per mg/kg-day No None No Bayesian hierarchical dose-response meta-analysis using the logistic-power model. Cancer slope factor is a combined cancer slope factor representing the risk of developing bladder and/or lung cancer and was derived by combining the individual cancer slope factors of 17.6 per mg/kg-day (1.76 × 10-2 per µg/kg-day) for bladder cancer and 21.3 per mg/kg-day (2.13 × 10-2 per µg/kg-day) for lung cancer. Both individual cancer slope factors were derived from Bayesian dose-response meta-analyses of (1) eleven studies for bladder cancer (Chen et al., 2010; Steinmaus et al., 2013; Wu et al., 2013; Bates et al., 1995; Steinmaus et al., 2003; Bates et al., 2004; Meliker et al., 2010; Baris et al., 2016; Chang et al., 2016; Karagas et al., 2004; Michaud et al., 2004); and (2) six studies for lung cancer (Argos et al., 2014; García-Esquinas et al., 2013; Chen et al., 2010; Dauphiné et al., 2013; Ferreccio et al., 2000; Steinmaus et al., 2013). See Sections 4.3.5, 4.3.6, and 4.7 of the IRIS Toxicological Review for more information. None None None
13 Arsenic, Inorganic 7440-38-2 Inhalation Respiratory Lung cancer (Brown and Chu, 1983a,b,c; Lee-Feldstein, 1983; Higgins, 1982; Enterline and Marsh, 1982) None None None None None None None 4.3 x 10 -3 per µg/m3 None Absolute-risk linear model The 2025 iAs assessment focused on oral exposures and updated the previous RfD and oral slope factor, but did not update the existing inhalation unit risk (IUR). The IUR listed here (1995) remains in effect (https://iris.epa.gov/document/&deid=364455). None None None
14 Asbestos 1332-21-4 Inhalation Respiratory Lung cancer and mesothelioma Tumor Human Inhalation Occupational exposure Selikoff et al., 1979; Peto et al., 1982; Seidman et al., 1979; Peto, 1980; Finkelstein, 1983 None No 2.3 x 10 -1 per f/mL No Additive risk of lung cancer and mesothelioma, using relative risk model for lung cancer and absolute risk model for mesothelioma None 4 x 10 -4 f/mL 4 x 10 -5 f/mL 4 x 10 -6 f/mL
15 Azobenzene 103-33-3 Inhalation Other Abdominal cavity sarcomas Tumor Rats/ F344, female Oral Diet NCI, 1979 None No 3.1 x 10 -5 per µg/m3 No Linearized multistage procedure, extra risk None 3 µg/m3 3 x 10 -1 µg/m3 3 x 10 -2 µg/m3
16 Azobenzene 103-33-3 Oral Other Abdominal cavity sarcomas Tumor Rats/ F344, female Oral Diet NCI, 1979 1.1 x 10 -1 per mg/kg-day No 3.1 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 3 x 10 1 µg/L 3 µg/L 3 x 10 -1 µg/L
17 Benzene 71-43-2 Oral Hematologic Leukemia Tumor Human Inhalation Occupational exposure Rinsky et al., 1981, 1987 Paustenbach et al., 1993 Crump, 1994 U. S. EPA, 1998 U.S. EPA, 1999 1.5 x 10 -2 per mg/kg-day No 4.4 x 10 -7 per µg/L No Linear extrapolation of human occupational data None 1 x 10 2 µg/L 1 x 10 1 µg/L 1 µg/L
18 Benzene 71-43-2 Inhalation Hematologic Leukemia Tumor Human Inhalation None Rinsky et al., 1981, 1987 Paustenbach et al., 1993 Crump and Allen, 1984 Crump, 1992, 1994 U.S. EPA, 1998 None No 7.8 x 10 -6 per µg/m3 No Low-dose linearity utilizing maximum likelihood estimates None 4.5 x 10 1 µg/m3 4.5 µg/m3 4.5 x 10 -1 µg/m3
19 Benzene 71-43-2 Oral Hematologic Leukemia Tumor Human Inhalation Occupational exposure Rinsky et al., 1981, 1987 Paustenbach et al., 1993 Crump, 1994 U. S. EPA, 1998 U.S. EPA, 1999 5.5 x 10 -2 per mg/kg-day No 1.6 x 10 -6 per µg/L No Linear extrapolation of human occupational data None 1 x 10 3 µg/L 1 x 10 2 µg/L 1 x 10 1 µg/L
20 Benzene 71-43-2 Inhalation Hematologic Leukemia Tumor Human Inhalation None Rinsky et al., 1981, 1987 Paustenbach et al., 1993 Crump and Allen, 1984 Crump, 1992, 1994 U.S. EPA, 1998 None No 2.2 x 10 -6 per µg/m3 No Low-dose linearity utilizing maximum likelihood estimates None 1.3 x 10 1 µg/m3 1.3 µg/m3 1.3 x 10 -1 µg/m3
21 Benzidine 92-87-5 Inhalation Urinary Bladder tumors Tumor Human Inhalation Occupational exposure Zavon, 1973 None No 6.7 x 10 -2 per µg/m3 No One-hit with time factor, extra risk None 2 x 10 -3 µg/m3 2 x 10 -4 µg/m3 2 x 10 -5 µg/m3
22 Benzidine 92-87-5 Oral Urinary Bladder tumors Tumor Human Inhalation Occupational exposure Zavon, 1973 2.3 x 10 2 per mg/kg-day No 6.7 x 10 -3 per µg/L No One-hit with time factor, extra risk None 2 x 10 -2 µg/L 2 x 10 -3 µg/L 2 x 10 -4 µg/L
23 Benzo[a]pyrene (BaP) 50-32-8 Inhalation Gastrointestinal, Respiratory Squamous cell neoplasia in the larynx, pharynx, trachea, nasal cavity, esophagus, and forestomach. Tumor male hamsters Inhalation None Thyssen et al., 1981 None Yes 1 x 10 -3 per µg/m3 Yes Time-to-tumor dose-response model with linear extrapolation from the POD ((BMCL10(HED)) associated with 10% extra cancer risk, includes application of age-dependent adjustment factors (ADAFs). EPA has concluded that benzo[a]pyrene is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the inhalation unit risk (IUR) addressing lifetime exposure includes application of ADAFs. The IUR is recommended for lifetime exposures. EPA has also provided an adult-based cancer unit risk of 6 x 10-4 per µg/m3. This adult-based cancer unit risk can be used instead of the IUR when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
24 Benzo[a]pyrene (BaP) 50-32-8 Oral Gastrointestinal forestomach, esophagus, tongue, and larynx tumors Tumor male and female Wistar rats female B6C3F1 mice Oral Gavage Diet Kroese et al. 2001; Beland and Culp, 1998 2 per mg/kg-day Yes None Yes Time-to-tumor dose-response model with linear extrapolation from the POD (BMDL10(HED)) associated with 10% extra cancer risk, includes application of age-dependent adjustment factors (ADAFs). EPA has concluded that benzo[a]pyrene is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the oral slope factor (OSF) addressing lifetime exposure includes application of ADAFs. The OSF is recommended for lifetime exposures. EPA has also provided an adult-based cancer slope factor of 1 per mg/kg-day. This adult-based cancer slope factor can be used instead of the OSF when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
25 Benzotrichloride 98-07-7 Oral Respiratory Lung, adenocarcinoma Tumor Mouse/ ICR, female Oral Gavage, sesame oil Fukuda et al., 1978 1.3 x 10 1 per mg/kg-day No 3.6 x 10 -4 per µg/L No Linearized multistage procedure, extra risk None 3 x 10 -1 µg/L 3 x 10 -2 µg/L 3 x 10 -3 µg/L
26 Benzyl chloride 100-44-7 Oral Endocrine Thyroid, C-cell adenoma/ carcinoma Tumor Rat/Fischer 344, female Oral Gavage, corn oil Lijinsky, 1986 1.7 x 10 -1 per mg/kg-day No 4.9 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 2 x 10 1 µg/L 2 µg/L 2 x 10 -1 µg/L
27 Beryllium and compounds 7440-41-7 Inhalation Respiratory Lung cancer Tumor Human, male Inhalation Occupational exposure Wagoner et al., 1980 None No 2.4 x 10 -3 per µg/m3 No Relative risk None 4 x 10 -2 µg/m3 4 x 10 -3 µg/m3 4 x 10 -4 µg/m3
28 Biphenyl 92-52-4 Oral Hepatic Liver adenomas or carcinomas Tumor female BDF1 mice Oral Diet Umeda et al., 2005 8 x 10 -3 per mg/kg-day None 2.3 x 10 -7 per µg/L None Multistage model with linear extrapolation from the POD (LED10). None 4.3 x 10 2 µg/L 4.3 x 10 1 µg/L 4 µg/L
29 Bis(chloroethyl)ether (BCEE) 111-44-4 Inhalation Hepatic Hepatomas Tumor Mouse/(C57B1/6 x C3H/AnF)F1, male Oral Gavage followed by diet Innes et al., 1969 None No 3.3 x 10 -4 per µg/m3 No Linearized multistage procedure, extra risk None 3 x 10 -1 µg/m3 3 x 10 -2 µg/m3 3 x 10 -3 µg/m3
30 Bis(chloroethyl)ether (BCEE) 111-44-4 Oral Hepatic Hepatomas Tumor Mouse/(C57B1/6 x C3H/AnF)F1, male Oral Gavage followed by diet Innes et al., 1969 1.1 per mg/kg-day No 3.3 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 3 µg/L 3 x 10 -1 µg/L 3 x 10 -2 µg/L
31 Bis(chloromethyl)ether (BCME) 542-88-1 Oral Respiratory Respiratory tract tumors Tumor Rat/Sprague-Dawley, male Inhalation None Kuschner et al., 1975 2.2 x 10 2 per mg/kg-day No 6.2 x 10 -3 per µg/L No Linearized multistage procedure, extra risk None 1.6 x 10 -2 µg/L 1.6 x 10 -3 µg/L 1.6 x 10 -4 µg/L
32 Bis(chloromethyl)ether (BCME) 542-88-1 Inhalation Respiratory Respiratory tract tumors Tumor Rat/Sprague-Dawley, male Inhalation None Kuschner et al., 1975 None No 6.2 x 10 -2 per µg/m3 No Linearized multistage procedure, extra risk None 1.6 x 10 -3 µg/m3 1.6 x 10 -4 µg/m3 1.6 x 10 -5 µg/m3
33 Bromate 15541-45-4 Oral Endocrine, Reproductive, Urinary Testicular mesothelioma, renal tubular adenoma and carcinoma, and thyroid follicular cell adenoma and carcinoma Tumor F344 rats, male Oral Drinking water DeAngelo et al., 1998 7 x 10 -1 per mg/kg-day No 2 x 10 -5 per µg/L No Time-to-tumor, Weibull None 5 µg/L 5 x 10 -1 µg/L 5 x 10 -2 µg/L
34 Bromodichloromethane 75-27-4 Oral Urinary Kidney (tubular cell adenoma and tubular cell adenocarcinoma) Tumor B6C3F1 mice, male Oral Gavage, corn oil NTP, 1987 6.2 x 10 -2 per mg/kg-day No 1.8 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 6 x 10 1 µg/L 6 µg/L 6 x 10 -1 µg/L
35 Bromoform 75-25-2 Inhalation Gastrointestinal Neoplastic lesions in the large intestine Tumor F344/N rat, female Oral Gavage in corn oil NTP, 1988 None No 1.1 x 10 -6 per µg/m3 No Linearized multistage procedure, extra risk None 9 x 10 1 µg/m3 9 µg/m3 9 x 10 -1 µg/m3
36 Bromoform 75-25-2 Oral Gastrointestinal Neoplastic lesions in the large intestine Tumor F344/N rat, female Oral Gavage in corn oil NTP, 1988 7.9 x 10 -3 per mg/kg-day No 2.3 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 4 x 10 2 µg/L 4 x 10 1 µg/L 4 µg/L
37 1,3-Butadiene 106-99-0 Inhalation Hematologic Leukemia Tumor Human Inhalation None Health Canada, 1998; U.S. EPA, 2002 None No 3 x 10 -5 per µg/m3 No Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied. None 3 µg/m3 3 x 10 -1 µg/m3 3 x 10 -2 µg/m3
38 Cadmium 7440-43-9 Inhalation Respiratory Lung, trachea, bronchus cancer deaths Tumor Human/ white male Inhalation Exposure in the workplace Thun et al., 1985 None No 1.8 x 10 -3 per µg/m3 No Two stage; only first affected by exposure; extra risk None 6 x 10 -2 µg/m3 6 x 10 -3 µg/m3 6 x 10 -4 µg/m3
39 Carbon tetrachloride 56-23-5 Inhalation Endocrine Pheochromocytoma Tumor Male BDF1 mouse Inhalation None Nagano et al. 2007b, JBRC 1998 None No 6 x 10 -6 per µg/m3 No Log-probit model with linear extrapolation from the POD (LEC10). None 1.7 x 10 1 µg/m3 1.7 µg/m3 1.7 x 10 -1 µg/m3
40 Carbon tetrachloride 56-23-5 Oral Hepatic Hepatocellular adenoma or carcinoma Tumor Female BDF1 mouse Inhalation route-to-route extrapolation, PBPK modeling Nagano et al., 2007b, JBRC, 1998 7 x 10 -2 per mg/kg-day No 2 x 10 -6 per µg/L No Multistage model with linear extrapolation from the POD (LED10). None 5 x 10 1 µg/L 5 µg/L 5 x 10 -1 µg/L
41 Chlordane (Technical) 12789-03-6 Oral Hepatic Hepatocellular carcinoma Tumor Mouse/ CD-1 (IRDC); mouse/ B6C3F1(NCI); mouse/ ICR (Khasawinah and Grutsch) Oral Diet IRDC, 1973; NCI, 1977; Khasawinah and Grutsch, 1989b 3.5 x 10 -1 per mg/kg-day No 1 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 1 µg/L 1 µg/L 1 x 10 -1 µg/L
42 Chlordane (Technical) 12789-03-6 Inhalation Hepatic Hepatocellular carcinoma Tumor Mouse/ CD-1 (IRDC); mouse/ B6C3F1(NCI); mouse/ ICR (Khasawinah and Grutsch) Oral Diet IRDC, 1973; NCI, 1977; Khasawinah and Grutsch, 1989b None No 1 x 10 -4 per µg/m3 No Linearized multistage procedure, extra risk None 1 µg/m3 1 x 10 -1 µg/m3 1 x 10 -2 µg/m3
43 Chlordecone (Kepone) 143-50-0 Oral Hepatic liver hepatocellular carcinoma Tumor B6C3F1 mice Oral dietary NCI (1976a) 1 x 10 1 per mg/kg-day No 3 x 10 -4 per µg/L No Multistage-Weibull model (implemented in TOX_RISK) with linear extrapolation from the POD (BMDL10). None 3.3 x 10 -1 µg/L 3.3 x 10 -2 µg/L 3.3 x 10 -3 µg/L
44 Chloroform 67-66-3 Inhalation Hepatic Hepatocellular carcinoma Tumor Mouse, B6C3F1, female Oral Gavage NCI, 1976 None No 2.3 x 10 -5 per µg/m3 No Linearized multistage procedure, extra risk None 4 µg/m3 4 x 10 -1 µg/m3 4 x 10 -2 µg/m3
45 Chloroprene 126-99-8 Inhalation Dermal, Gastrointestinal, Hepatic, Ocular, Other, Reproductive, Respiratory alveolar/ bronchiolar adenoma or carcinoma hemangioma/ hemangiosarcoma (all organs) mammary gland adenocarcinoma, carcinoma, or adenoacanthoma forestomach squamous cell papilloma or carcinoma hepatocellular adenoma or carcinoma Harderian gland adenoma or carcinoma skin sarcoma and Zymbal's gland carcinoma Tumor female B6C3F1 mice Inhalation None NTP, 1998 None No 3 x 10 -4 per µg/m3 No Multistage model with linear extrapolation from the point of departure (BMDL), summed risk. ADAF -- EPA has concluded that chloroprene is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the inhalation unit risk is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. None None None
46 Chromium(VI) 18540-29-9 Inhalation Respiratory Lung cancer Tumor None None None None None No 1.8 x 10 -2 per µg/m3 No Linear extrapolation from LEC01 derived from Cox proportional hazard model with 5 year lag using lifetable analysis. EPA has concluded that Cr(VI) is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the inhalation unit risk (IUR) addressing lifetime exposure includes application of age-dependent adjustment factors (ADAFs). The IUR is recommended for lifetime exposures. An adult-based cancer inhalation unit risk of 0.011 per µg/m3 is also provided. This adult-based cancer inhalation unit risk can be used instead of the IUR when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
47 Chromium(VI) 18540-29-9 Oral Gastrointestinal Squamous cell carcinoma or squamous cell papilloma. None None None None NTP, 2008 2.7 x 10 -1 per mg/kg-day None None None HEDs calculated using BW3/4 scaling EPA has concluded that Cr(VI) is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the oral slope factor (OSF) addressing lifetime exposure includes application of age-dependent adjustment factors (ADAFs). The OSF is recommended for lifetime exposures. An adult-based cancer slope factor of 0.16 per mg/kg-day is also provided. This adult-based cancer slope factor can be used instead of the OSF when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
48 Coke oven emissions None Inhalation Respiratory Respiratory cancer Tumor Human, male Inhalation Occupational Mazumdar et al., 1975; Land, 1976 None No 6.2 x 10 -4 per µg/m3 No Linearized multistage procedure None 2 x 10 -1 µg/m3 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3
49 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Oral Hepatic Liver neoplastic nodules or carcinoma (combined) Tumor Male F344/N rats Oral diet NTP (1986) 7 x 10 -4 per mg/kg-day No 2 x 10 -8 per µg/L No Multistage model with linear extrapolation from the point of departure (LED12). None 5 x 10 3 µg/L 5 x 10 2 µg/L 5 x 10 1 µg/L
50 Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 Oral Hepatic Hepatocellular carcinoma and adenoma Tumor Mouse/ B6C3F1, male Oral Diet NTP, 1982 1.4 x 10 -2 per mg/kg-day No 4 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 3 x 10 2 µg/L 3 x 10 1 µg/L 3 µg/L
51 Di(2-ethylhexyl)adipate 103-23-1 Oral Hepatic Combined hepatocellular adenomas and carcinomas Tumor Mouse/ B6C3F1, female Oral Diet NTP, 1982 1.2 x 10 -3 per mg/kg-day No 3.4 x 10 -8 per µg/L No Linearized multistage procedure, extra risk None 3 x 10 3 µg/L 3 x 10 2 µg/L 3 x 10 1 µg/L
52 Dibromochloromethane 124-48-1 Oral Hepatic Hepatocellular adenoma or carcinoma Tumor Mouse/ B6C3F1, female Oral Gavage NTP, 1985 8.4 x 10 -2 per mg/kg-day No 2.4 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 4 x 10 1 µg/L 4 µg/L 4 x 10 -1 µg/L
53 1,2-Dibromoethane 106-93-4 Oral Endocrine, Gastrointestinal, Other Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas Tumor Rat/Osborne-Mendel, male Oral gavage NCI, 1978 1 mg/kg-day None None None Multistage model with Poly-3 adjusted incidence data central tendency estimate None None None None
54 1,2-Dibromoethane 106-93-4 Oral Endocrine, Gastrointestinal, Other Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas Tumor Rat/Osborne-Mendel, male Oral gavage NCI, 1978 2 per mg/kg-day None 6 x 10 -5 per µg/L None Multistage model with Poly-3 adjusted incidence data linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range. None 2 µg/L 2 x 10 -1 µg/L 2 x 10 -2 µg/L
55 1,2-Dibromoethane 106-93-4 Inhalation Other, Reproductive, Respiratory Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas Tumor Rat/ Fischer 344, male Inhalation None NTP, 1982 None No 6 x 10 -4 per µg/m3 No Multistage-Weibull model linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range. None 2 x 10 -1 µg/m3 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3
56 1,2-Dibromoethane 106-93-4 Inhalation Other, Reproductive, Respiratory Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas Tumor Rat/ Fischer 344, male Inhalation None NTP, 1982 None No 3 x 10 -4 per µg/m3 No Multistage model with Poly-3 adjusted incidence data central tendency estimate None None None None
57 Dichloroacetic acid 79-43-6 Oral Hepatic Hepatoadenoma and Hepatocarcinoma Tumor Male B6C3F1 mice Oral drinking water DeAngelo et. al., 1999 5 x 10 -2 per mg/kg-day No 1.4 x 10 -6 per µg/L No Multistage model with Benchmark Dose Modeling None 7 x 10 1 µg/L 7 µg/L 7 x 10 -1 µg/L
58 3,3'-Dichlorobenzidine 91-94-1 Oral Reproductive Mammary adenocarcinoma Tumor Rat/ ChR-CD, female Oral Diet Stula et al., 1975 4.5 x 10 -1 per mg/kg-day No 1.3 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 8 µg/L 8 x 10 -1 µg/L 8 x 10 -2 µg/L
59 p,p'-Dichlorodiphenyl dichloroethane (DDD) 72-54-8 Oral Hepatic Liver tumors Tumor Mouse/ CF-1, males Oral Diet Tomatis et al., 1974 2.4 x 10 -1 per mg/kg-day No 6.9 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 1 µg/L 1 µg/L 1 x 10 -1 µg/L
60 p,p'-Dichlorodiphenyldichloroethylene (DDE) 72-55-9 Oral Hepatic Hepatocellular carcinomas, hepatomas Tumor Mouse/ B6C3F1; mouse/ CF-1; hamsters/ Syrian Golden Oral Diet NCI, 1978; Tomatis et al., 1974; Rossi et al., 1983 3.4 x 10 -1 per mg/kg-day No 9.7 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 1 µg/L 1 µg/L 1 x 10 -1 µg/L
61 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Oral Hepatic Liver tumors, benign and malignant Tumor Mouse/ CF-1; Mouse/ BALB/C; Rat/ MRC Porton; Rat/ Wistar Oral Diet Turusov et al., 1973; Terracini et al., 1973; Thorpe and Walker, 1973; Tomatis and Turusov, 1975; Cabral et al., 1982; Rossi et al., 1977 3.4 x 10 -1 per mg/kg-day No 9.7 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 1 µg/L 1 µg/L 1 x 10 -1 µg/L
62 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Inhalation Hepatic Liver tumors, benign and malignant Tumor Mouse/ CF-1; Mouse/ BALB/C; Rat/ MRC Porton; Rat/ Wistar Oral Diet Turusov et al., 1973; Terracini et al., 1973; Thorpe and Walker, 1973; Tomatis and Turusov, 1975; Cabral et al., 1982; Rossi et al., 1977 None No 9.7 x 10 -5 per µg/m3 No Linear multistage procedure, extra risk None 1 µg/m3 1 x 10 -1 µg/m3 1 x 10 -2 µg/m3
63 1,2-Dichloroethane 107-06-2 Oral Other Hemangiosarcomas Tumor Rat/ Osborne-Mendel, male Oral Gavage NCI, 1978 9.1 x 10 -2 per mg/kg-day No 2.6 x 10 -6 per µg/L No Linearized multistage procedure with time-to-death analysis, extra risk None 4 x 10 1 µg/L 4 µg/L 4 x 10 -1 µg/L
64 1,2-Dichloroethane 107-06-2 Inhalation Other Hemangiosarcomas Tumor Rat/ Osborne-Mendel, male Oral Gavage NCI, 1978 None No 2.6 x 10 -5 per µg/m3 No Linearized multistage procedure, extra risk None 4 µg/m3 4 x 10 -1 µg/m3 4 x 10 -2 µg/m3
65 Dichloromethane 75-09-2 Inhalation Hepatic, Respiratory Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas Tumor Male B6C3F1 mice Inhalation None Mennear et al., 1988; NTP, 1986 None Yes 1.7 x 10 -8 per µg/m3 Yes Multistage model with linear extrapolation from the point of departure (BMDL10), includes application of age-dependent adjustment factors (ADAFs). EPA has concluded that dichloromethane is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the inhalation unit risk (IUR) addressing lifetime exposure includes application of ADAFs. The IUR is recommended for lifetime exposures. EPA has also provided an adult-based cancer unit risk of 1 x 10-8 per µg/m3. This adult-based cancer unit risk can be used instead of the IUR when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
66 Dichloromethane 75-09-2 Oral Hepatic Hepatocellular carcinomas or adenomas Tumor Male B6C3F1 mice Oral drinking water Serota et al., 1986b 3.3 x 10 -3 per mg/kg-day Yes None Yes Multistage model with linear extrapolation from the point of departure (BMDL10), includes application of age-dependent adjustment factors (ADAFs). EPA has concluded that dichloromethane is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the oral slope factor (OSF) addressing lifetime exposure includes application of ADAFs. The OSF is recommended for lifetime exposures. EPA has also provided an adult-based cancer slope factor of 2 x 10-3 per mg/kg-day. This adult-based cancer slope factor can be used instead of the OSF when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
67 1,3-Dichloropropene 542-75-6 Oral Urinary Urinary bladder carcinoma Tumor female mouse Oral gavage NTP, 1985 1 x 10 -1 per mg/kg-day No 3 x 10 -6 per µg/L No Linearized multistage model, extra risk None 4 x 10 1 µg/L 4 µg/L 4 x 10 -1 µg/L
68 1,3-Dichloropropene 542-75-6 Inhalation Respiratory Bronchioalveolar adenoma Tumor Male mouse Inhalation None Lomax et al., 1989 None No 4 x 10 -6 per µg/m3 No Linearized multistage model, extra risk None 2 x 10 1 µg/m3 2 µg/m3 2 x 10 -1 µg/m3
69 1,3-Dichloropropene 542-75-6 Oral Hepatic Hepatocellular adenoma/carcinoma Tumor male rat Oral dietary Stott et al., 1995 5 x 10 -2 per mg/kg-day No 1 x 10 -6 per µg/L No Linearized multistage model, extra risk None 8 x 10 1 µg/L 8 µg/L 8 x 10 -1 µg/L
70 1,3-Dichloropropene 542-75-6 Oral Hepatic Hepatocellular adenoma/carcinoma Tumor male rat Oral gavage NTP, 1985 5 x 10 -2 per mg/kg-day No 2 x 10 -6 per µg/L No Linearized multistage model, extra risk None 7 x 10 1 µg/L 7 µg/L 7 x 10 -1 µg/L
71 Dichlorvos 62-73-7 Oral Endocrine, Gastrointestinal, Hematologic Forestomach tumors, pancreatic acinar adenoma, leukemia Tumor Mouse and rat Oral Gavage NTP, 1986a,b 2.9 x 10 -1 per mg/kg-day No 8.3 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 1 µg/L 1 µg/L 1 x 10 -1 µg/L
72 Dieldrin 60-57-1 Inhalation Hepatic Liver carcinoma Tumor Mouse Oral Diet Davis (1965), reevaluated by Reuber, 1974 (cited in Epstein, 1975a); Walker et al., 1972; Thorpe and Walker, 1973; NCI, 1978a,b; Tennekes et al., 1981; Meierhenry et al., 1983 None No 4.6 x 10 -3 per µg/m3 No Linearized multistage procedure, extra risk None 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3 2 x 10 -4 µg/m3
73 Dieldrin 60-57-1 Oral Hepatic Liver carcinoma Tumor Mouse Oral Diet Davis (1965), reevaluated by Reuber, 1974 (cited in Epstein, 1975a); Walker et al., 1972; Thorpe and Walker, 1973; NCI, 1978a,b; Tennekes et al., 1981; Meierhenry et al., 1983 1.6 x 10 1 per mg/kg-day No 4.6 x 10 -4 per µg/L No Linearized multistage procedure, extra risk None 2 x 10 -1 µg/L 2 x 10 -2 µg/L 2 x 10 -3 µg/L
74 2,4-/2,6-Dinitrotoluene mixture Various Oral Hepatic, Reproductive Liver: hepatocellular carcinomas, neoplastic nodules; mammary gland: adenomas, fibroadenomas, fibromas, adenocarcinomas/ carcinomas Tumor Rat/Sprague-Dawley, female Oral Diet Ellis et al., 1979 6.8 x 10 -1 per mg/kg-day No 1.9 x 10 -5 per µg/L No Linearized multistage procedure None 5 µg/L 5 x 10 -1 µg/L 5 x 10 -2 µg/L
75 1,4-Dioxane 123-91-1 Oral Hepatic Hepatocellular adenoma and carcinoma Tumor Female BDF1 mouse Oral Drinking water Kano et al. 2009 1 x 10 -1 per mg/kg-day No 2.9 x 10 -6 per µg/L No Log-logistic model with linear extrapolation from the POD (BMDL50HED) associated with 50% extra cancer risk. None 3.5 x 10 1 µg/L 3.5 µg/L 3.5 x 10 -1 µg/L
76 1,4-Dioxane 123-91-1 Inhalation Gastrointestinal, Hepatic, Other, Reproductive, Respiratory, Urinary Multiple (nasal, liver, kidney, peritoneal, mammary gland, and Zymbal gland) Precursor Male F344 rats Inhalation None Kasai et al. 2009 None None 5 x 10 -6 per µg/m3 None Multi-tumor dose-response model with linear extrapolation from the POD (BMDL10HED) associated with 10% extra cancer risk. None None None None
77 1,2-Diphenylhydrazine 122-66-7 Oral Hepatic Hepatocellular carcinomas and neoplastic liver nodules Tumor Rat/Fisher 344, male Oral Diet NCI, 1979 8 x 10 -1 per mg/kg-day No 2.2 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 5 µg/L 5 x 10 -1 µg/L 5 x 10 -2 µg/L
78 1,2-Diphenylhydrazine 122-66-7 Inhalation Hepatic Hepatocellular carcinomas and neoplastic liver nodules Tumor Rat/Fisher 344, male Oral Diet NCI, 1979 None No 2.2 x 10 -4 per µg/m3 No Linearized multistage procedure, extra risk None 5 x 10 -1 µg/m3 5 x 10 -2 µg/m3 5 x 10 -3 µg/m3
79 Epichlorohydrin 106-89-8 Inhalation Respiratory Nasal cavity tumors Tumor Rat/Sprague-Dawley, male Inhalation None Laskin et al., 1980 None No 1.2 x 10 -6 per µg/m3 No Linearized multistage procedure, extra risk None 8 x 10 1 µg/m3 8 µg/m3 8 x 10 -1 µg/m3
80 Epichlorohydrin 106-89-8 Oral Gastrointestinal Papillomas and carcinomas of the forestomach Tumor Rat/Wistar, male Oral Drinking water Konishi et al., 1980 9.9 x 10 -3 per mg/kg-day No 2.8 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 3 x 10 2 µg/L 3 x 10 1 µg/L 3 µg/L
81 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Inhalation Hepatic Hepatocellular adenomas and carcinomas None Male and female F344 rats Inhalation 2-year inhalation bioassay Saito et al. 2013; JPEC, 2010b None None 8 x 10 -5 per mg/m3 None Linear extrapolation from the POD ((BMCL10(HED)) associated with 10% extra cancer risk. None None None None
82 Ethylene oxide 75-21-8 Inhalation Immune, Reproductive Lymphoid cancer, (female) breast cancer Tumor Human occupational epidemiology study: NIOSH study of sterilizer workers Inhalation None Steenland et al., 2003, 2004 None Yes 5 x 10 -3 per µg/m3 Yes Linear extrapolation. Two-piece linear spline model with knot at 1,600 ppm × days for lymphoid cancer. Two-piece linear spline model with knot at 5,750 ppm × days for breast cancer incidence in females. POD of 1% extra risk was used for both cancer types, includes application of age-dependent adjustment factors (ADAFs). EPA has concluded that ethylene oxide is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the inhalation unit risk (IUR) addressing lifetime exposure includes application of ADAFs. The IUR is recommended for lifetime exposures. EPA has also provided an adult-based cancer unit risk of 3 x 10-3 per µg/m3. This adult-based cancer unit risk can be used instead of the IUR when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
83 Folpet 133-07-3 Oral Gastrointestinal Digestive tract tumors (adenoma and/ or adenocarcinoma) Tumor Mouse/CD1, males and females Oral Diet Chevron, 1982 3.5 x 10 -3 per mg/kg-day No 1 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 3 µg/L 1 x 10 2 µg/L 1 x 10 1 µg/L
84 Fomesafen 72178-02-0 Oral Hepatic Liver adenomas and carcinomas Tumor Mice/ CD-1; males Oral Diet Huntingdon, 1985 1.9 x 10 -1 per mg/kg-day No 5.4 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 2 x 10 1 µg/L 2 µg/L 2 x 10 -1 µg/L
85 Formaldehyde 50-00-0 Inhalation Hematologic, Respiratory Nasopharyngeal cancer, sinonasal cancer, myeloid leukemia Tumor None Inhalation None None None No 1.1 x 10 -5 per µg/m3 No Based on nasopharyngeal cancer (NPC) incidence (Beane Freeman, 2013), linear low-dose extrapolation from the 95% lower bound on the exposure level associated with the extra risk level serving as the benchmark response and application of age-dependent adjustment factors (ADAFs) due to an operant mutagenic mode-of-action (MOA) for nasal cancers (see Section 3.2.5 of the Toxicological Review). Confidence in the IUR is Medium (see Section 5.2 of the Toxicological Review). The IUR is based on NPC alone, although it was concluded that the evidence demonstrates that formaldehyde inhalation also causes myeloid leukemia and sinonasal cancer (see Section 5.2 of the Toxicological Review for details). Thus, the IUR may underestimate the actual total cancer risk. Less-than-lifetime exposure scenarios with a very large fraction of exposure during adulthood may not warrant ADAF adjustment, and one may choose to use the unadjusted unit risk estimate of 7.4 × 10-6 per µg/m3 or the adult-based estimate of 6.4 × 10-6 per µg/m3 (see Section 5.2.4 of the Toxicological Review). 8 µg/m3 8 x 10 -1 µg/m3 8 x 10 -2 µg/m3
86 Furmecyclox 60568-05-0 Oral Hepatic Combined liver nodules and carcinomas Tumor Rat/Sprague-Dawley OF-A, female Oral Diet BASF Wyandotte, 1984a 3 x 10 -2 per mg/kg-day No 8.6 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 2 µg/L 1 x 10 1 µg/L 1 µg/L
87 Heptachlor 76-44-8 Inhalation Hepatic Hepatocellular carcinomas Tumor Mouse/C3H; mouse/B6C3F1 Oral Diet Davis, 1965; NCI, 1977 None No 1.3 x 10 -3 per µg/m3 No Linearized multistage procedure, extra risk None 8 x 10 -2 µg/m3 8 x 10 -3 µg/m3 8 x 10 -4 µg/m3
88 Heptachlor 76-44-8 Oral Hepatic Hepatocellular carcinomas Tumor Mouse/C3H; mouse/B6C3F1 Oral Diet Davis, 1965; NCI, 1977 4.5 per mg/kg-day No 1.3 x 10 -4 per µg/L No Linearized multistage procedure, extra risk None 8 x 10 -1 µg/L 8 x 10 -2 µg/L 8 x 10 -3 µg/L
89 Heptachlor epoxide 1024-57-3 Oral Hepatic Hepatocellular carcinomas Tumor Mouse/C3H (Davis); mouse/CD1 (Velsicol) Oral Diet Davis, 1965; Velsicol, 1973 9.1 per mg/kg-day No 2.6 x 10 -4 per µg/L No Linearized multistage procedure, extra risk None 4 x 10 -1 µg/L 4 x 10 -2 µg/L 4 x 10 -3 µg/L
90 Heptachlor epoxide 1024-57-3 Inhalation Hepatic Hepatocellular carcinomas Tumor Mouse/C3H (Davis); mouse/CD1 (Velsicol) Oral Diet Davis, 1965; Velsicol, 1973 None No 2.6 x 10 -3 per µg/m3 No Linearized multistage procedure, extra risk None 4 x 10 -2 µg/m3 4 x 10 -3 µg/m3 4 x 10 -4 µg/m3
91 Hexachlorobenzene 118-74-1 Inhalation Hepatic Hepatocellular carcinoma Tumor Rat/Sprague-Dawley, female Oral Diet Erturk et al., 1986 None No 4.6 x 10 -4 per µg/m3 No Linearized multistage, extra risk None 2 x 10 -1 µg/m3 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3
92 Hexachlorobenzene 118-74-1 Oral Hepatic Hepatocellular carcinoma Tumor Rat/Sprague-Dawley, female Oral Diet Erturk et al., 1986 1.6 per mg/kg-day No 4.6 x 10 -5 per µg/L No Linearized multistage, extra risk None 2 µg/L 2 x 10 -1 µg/L 2 x 10 -2 µg/L
93 Hexachlorobutadiene 87-68-3 Inhalation Urinary Renal tubular adenomas and adenocarcinomas Tumor Rat, Sprague-Dawley, male Oral Diet Kociba et al., 1977 None No 2.2 x 10 -5 per µg/m3 No Linearized multistage procedure, extra risk None 5 µg/m3 5 x 10 -1 µg/m3 5 x 10 -2 µg/m3
94 Hexachlorobutadiene 87-68-3 Oral Urinary Renal tubular adenomas and adenocarcinomas Tumor Rat, Sprague-Dawley, male Oral Diet Kociba et al., 1977 7.8 x 10 -2 per mg/kg-day No 2.2 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 5 x 10 1 µg/L 5 µg/L 5 x 10 -1 µg/L
95 alpha-Hexachlorocyclohexane (alpha-HCH) 319-84-6 Inhalation Hepatic Hepatic nodules and hepatocellular carcinomas Tumor Mouse/dd, male Oral Diet Ito et al., 1973a None No 1.8 x 10 -3 per µg/m3 No Linearized multistage procedure, extra risk None 6 x 10 -2 µg/m3 6 x 10 -3 µg/m3 6 x 10 -4 µg/m3
96 alpha-Hexachlorocyclohexane (alpha-HCH) 319-84-6 Oral Hepatic Hepatic nodules and hepatocellular carcinomas Tumor Mouse/dd, male Oral Diet Ito et al., 1973a 6.3 per mg/kg-day No 1.8 x 10 -4 per µg/L No Linearized multistage procedure, extra risk None 6 x 10 -1 µg/L 6 x 10 -2 µg/L 6 x 10 -3 µg/L
97 beta-Hexachlorocyclohexane (beta-HCH) 319-85-7 Oral Hepatic Hepatic nodules and hepatocellular carcinomas Tumor Mouse/CF1, male Oral Diet Thorpe and Walker, 1973 1.8 per mg/kg-day No 5.3 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 2 µg/L 2 x 10 -1 µg/L 2 x 10 -2 µg/L
98 beta-Hexachlorocyclohexane (beta-HCH) 319-85-7 Inhalation Hepatic Hepatic nodules and hepatocellular carcinomas Tumor Mouse/CF1, male Oral Diet Thorpe and Walker, 1973 None No 5.3 x 10 -4 per µg/m3 No Linearized multistage procedure, extra risk None 2 x 10 -1 µg/m3 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3
99 technical Hexachlorocyclohexane (t-HCH) 608-73-1 Inhalation Hepatic Liver nodules and hepatocellular carcinomas Tumor Mouse/Swiss, male Oral Diet Munir et al., 1983 None No 5.1 x 10 -4 per µg/m3 No Linearized multistage procedure None 2 x 10 -1 µg/m3 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3
100 technical Hexachlorocyclohexane (t-HCH) 608-73-1 Oral Hepatic Liver nodules and hepatocellular carcinomas Tumor Mouse/Swiss, male Oral Diet Munir et al., 1983 1.8 per mg/kg-day No 5.1 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 2 µg/L 2 x 10 -1 µg/L 2 x 10 -2 µg/L
101 Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 57653-85-7 Oral Hepatic Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) Tumor Mouse/B6C3F1, male; rat/ Osborne-Mendel, female Oral Gavage NTP, 1980a 6.2 x 10 3 per mg/kg-day No 1.8 x 10 -1 per µg/L No Linearized multistage procedure, extra risk None 6 x 10 -4 µg/L 6 x 10 -5 µg/L 6 x 10 -6 µg/L
102 Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 57653-85-7 Inhalation Hepatic Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) Tumor Mouse/B6C3F1, male; rat/ Osborne-Mendel, female Oral Gavage NTP, 1980a None No 1.3 per µg/m3 No Linearized multistage procedure, extra risk None 8 x 10 -5 µg/m3 8 x 10 -6 µg/m3 8 x 10 -7 µg/m3
103 Hexachloroethane 67-72-1 Oral Urinary Renal adenomas and carcinomas (combined) Tumor Male F344 rats Oral None NTP (1989) 4 x 10 -2 per mg/kg-day No 1 x 10 -6 per µg/L No The multistage model with linear extrapolation from the point of departure (LED10). None 9 x 10 1 µg/L 9 µg/L 9 x 10 -1 µg/L
104 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Hepatic, Respiratory Liver (hepatocellular adenomas or carcinomas) and lung (alveolar/bronchiolar adenomas or carcinomas) Tumor Mouse/B6C3F1, female Oral Diet Lish et al., 1984 8 x 10 -2 per mg/kg-day No None No Linear extrapolation from the POD (BMDL10-HED) associated with a 10% extra cancer risk None None None None
105 Hydrazine/Hydrazine sulfate 302-01-2 Oral Hepatic Hepatoma Tumor Mouse, CBA/Cb/Se; male Oral Gavage (hydrazine sulfate in water) Biancifiori, 1970 3 per mg/kg-day No 8.5 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 1 µg/L 1 x 10 -1 µg/L 1 x 10 -2 µg/L
106 Hydrazine/Hydrazine sulfate 302-01-2 Inhalation Respiratory Nasal cavity adenoma or adenocarcinoma Tumor Rat/F344, male Inhalation None MacEwen et al., 1981 None No 4.9 x 10 -3 per µg/m3 No Linearized multistage procedure, extra risk None 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3 2 x 10 -4 µg/m3
107 Isophorone 78-59-1 Oral Reproductive Preputial gland carcinoma Tumor Rat/ F344/N, male Oral Gavage NTP, 1986 9.5 x 10 -4 per mg/kg-day No 2.7 x 10 -8 per µg/L No Linearized multistage procedure, extra risk None 4 x 10 3 µg/L 4 x 10 2 µg/L 4 x 10 1 µg/L
108 Libby Amphibole Asbestos 1318-09-8 Inhalation Respiratory Cancer mortality from lung cancer and mesothelioma Tumor Humans Inhalation None Sullivan, 2007 None None 1.7 x 10 -1 per fiber/cc None Linear low dose extrapolation below the POD. None 5.9 x 10 -4 fiber/cc 5.9 x 10 -5 fiber/cc 5.9 x 10 -6 fiber/cc
109 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 Oral Endocrine Thyroid, follicular cell carcinoma/ adenoma Tumor Rat/ F344, female Oral Diet NCI, 1979a 4.6 x 10 -2 per mg/kg-day No 1.3 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 8 x 10 1 µg/L 8 µg/L 8 x 10 -1 µg/L
110 Nickel refinery dust None Inhalation Respiratory Lung cancer Tumor Human: refinery and nonrefinery workers Inhalation None Enterline and Marsh, 1982; Chovil et al., 1981; Peto et al., 1984; Magnus et al., 1982 None No 2.4 x 10 -4 per µg/m3 No Additive and multiplicative None 4 x 10 -1 µg/m3 4 x 10 -2 µg/m3 4 x 10 -3 µg/m3
111 Nickel subsulfide 12035-72-2 Inhalation Respiratory Lung cancer Tumor Human: refinery and nonrefinery workers Inhalation None Enterline and Marsh, 1982; Chovil et al., 1981; Peto et al., 1984; Magnus et al., 1982 None No 4.8 x 10 -4 per µg/m3 No Additive and multiplicative None 2 x 10 -1 µg/m3 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3
112 Nitrobenzene 98-95-3 Inhalation Endocrine, Hepatic, Urinary Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas Tumor Rat/F344 (male) Inhalation None CIIT (1993) None No 4 x 10 -5 per µg/m3 No Multistage model with linear extrapolation from the POD (LEC10). None 2.5 µg/m3 2.5 x 10 -1 µg/m3 2.5 x 10 -2 µg/m3
113 N-Nitroso-N-methylethylamine 10595-95-6 Oral Hepatic Hepatocellular carcinomas Tumor Rat/ BD, sex not specified Oral Drinking water Druckrey, 1967; Druckrey et al., 1967 2.2 x 10 1 per mg/kg-day No 6.3 x 10 -4 per µg/L No One-hit None 2 x 10 -1 µg/L 2 x 10 -2 µg/L 2 x 10 -3 µg/L
114 N-Nitroso-di-n-butylamine 924-16-3 Oral Gastrointestinal, Urinary Bladder and esophagus tumors Tumor Mouse/ C57B16, males Oral Drinking water Bertram and Craig, 1970 5.4 per mg/kg-day No 1.6 x 10 -4 per µg/L No Linearized multistage procedure, extra risk None 6 x 10 -1 µg/L 6 x 10 -2 µg/L 6 x 10 -3 µg/L
115 N-Nitroso-di-n-butylamine 924-16-3 Inhalation Gastrointestinal, Urinary Bladder and esophagus tumors Tumor Mouse/ C57B16, males Oral Drinking water Bertram and Craig, 1970 None No 1.6 x 10 -3 per µg/m3 No Linearized multistage procedure, extra risk None 6 x 10 -2 µg/m3 6 x 10 -3 µg/m3 6 x 10 -4 µg/m3
116 N-Nitrosodi-N-propylamine 621-64-7 Oral Hepatic Hepatocellular carcinomas Tumor Rat/ BD, sex not specified Oral Drinking water Druckrey, 1967; Druckrey et al., 1967 7 per mg/kg-day No 2 x 10 -4 per µg/L No One-hit None 5 x 10 -1 µg/L 5 x 10 -2 µg/L 5 x 10 -3 µg/L
117 N-Nitrosodiethanolamine 1116-54-7 Oral Hepatic Hepatocellular carcinoma, cholangiocellular carcinoma and adenoma and neoplastic nodules Tumor Rat/ F344, female Oral Drinking water Lijinsky and Kovatch, 1985 2.8 per mg/kg-day No 8 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 1 µg/L 1 x 10 -1 µg/L 1 x 10 -2 µg/L
118 N-Nitrosodiethylamine 55-18-5 Inhalation Hepatic Liver tumors Tumor Rat/Colworth, female Oral Drinking water Peto et al., 1984 None No 4.3 x 10 -2 per µg/m3 No Weibull, extra risk None 2 x 10 -3 µg/m3 2 x 10 -4 µg/m3 2 x 10 -5 µg/m3
119 N-Nitrosodiethylamine 55-18-5 Oral Hepatic Liver tumors Tumor Rat/Colworth, female Oral Drinking water Peto et al., 1984 1.5 x 10 2 per mg/kg-day No 4.3 x 10 -3 per µg/L No Weibull, extra risk None 2 x 10 -2 µg/L 2 x 10 -3 µg/L 2 x 10 -4 µg/L
120 N-Nitrosodimethylamine 62-75-9 Oral Hepatic Liver tumors Tumor Rat/ Colworth, female Oral Drinking water Peto et al., 1984 5.1 x 10 1 per mg/kg-day No 1.4 x 10 -3 per µg/L No Weibull, extra risk None 7 x 10 -2 µg/L 7 x 10 -3 µg/L 7 x 10 -4 µg/L
121 N-Nitrosodimethylamine 62-75-9 Inhalation Hepatic Liver tumors Tumor Rat/ Colworth, female Oral Drinking water Peto et al., 1984 None No 1.4 x 10 -2 per µg/m3 No Weibull, extra risk None 7 x 10 -3 µg/m3 7 x 10 -4 µg/m3 7 x 10 -5 µg/m3
122 N-Nitrosodiphenylamine 86-30-6 Oral Urinary Transitional cell carcinoma of the bladder Tumor Rat/ F344, female Oral Drinking water NCI, 1979 4.9 x 10 -3 per mg/kg-day No 1.4 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 7 x 10 2 µg/L 7 x 10 1 µg/L 7 µg/L
123 N-Nitrosopyrrolidine 930-55-2 Oral Hepatic Hepatocellular carcinoma and adenoma Tumor Rat/ Sprague-Dawley, male and female Oral Diet Preussmann et al., 1977 2.1 per mg/kg-day No 6.1 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 2 µg/L 2 x 10 -1 µg/L 2 x 10 -2 µg/L
124 N-Nitrosopyrrolidine 930-55-2 Inhalation Hepatic Hepatocellular carcinoma and adenoma Tumor Rat/ Sprague-Dawley, male and female Oral Diet Preussmann et al., 1977 None No 6.1 x 10 -4 per µg/m3 No Linearized multistage procedure, extra risk None 2 x 10 -1 µg/m3 2 x 10 -2 µg/m3 2 x 10 -3 µg/m3
125 Pentachlorophenol 87-86-5 Oral Endocrine, Hepatic Hepatocellular adenomas or carcinomas and adrenal benign or malignant pheochromocytomas Tumor Male B6C3F1 mice Oral Diet NTP, 1989 4 x 10 -1 per mg/kg-day No 1.1 x 10 -5 per µg/L No Multistage model with linear extrapolation from the POD (LED10). None 9 µg/L 9 x 10 -1 µg/L 9 x 10 -2 µg/L
126 Polychlorinated Biphenyls (PCBs) 1336-36-3 Inhalation Hepatic Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas Tumor Female Sprague-Dawley rats Oral Diet Brunner et al., 1996; Norback and Weltman, 1985 None No 1 x 10 -4 per µg/m3 No Linear extrapolation below LED10; route-to-route extrapolation from the oral slope factor For inhalation of an aerosol or dust contaminated with PCBs, see the IRIS Summary for information on the appropriate inhalation unit risk. 1 µg/m3 1 x 10 -1 µg/m3 1 x 10 -2 µg/m3
127 Polychlorinated Biphenyls (PCBs) 1336-36-3 Oral Hepatic Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas Tumor Female Sprague-Dawley rats Oral Diet Brunner et al., 1996 Norback and Weltman, 1985 2 per mg/kg-day None None None Linear extrapolation below LED10s Cancer potency of PCB mixtures is determined by a tiered approach that depends on exposure matrix and route, type of congener present, and lifestage. See IRIS Summary for specific factors used to select appropriate slope factor. High risk and persistence: 2 per mg/kg-day; Low risk and persistence: 0.4 per mg/kg-day; Lowest risk and persistence: 0.07 per mg/kg-day. None None None
128 Prochloraz 67747-09-5 Oral Hepatic Liver adenoma/ carcinoma combined Tumor Mouse/ CD-1, male and female Oral Diet Nor-Am Chemical Co., 1983 1.5 x 10 -1 per mg/kg-day No 4.3 x 10 -6 per µg/L No Male mice: time-to-tumor linearized multistage procedure in dose, Weibull in time. Female mice: linearized multistage procedure None 2 x 10 1 µg/L 2 µg/L 2 x 10 -1 µg/L
129 Propylene oxide 75-56-9 Inhalation Respiratory Nasal cavity hemangioma or hemangiosarcoma Tumor Mouse/ B6C3F1, male Inhalation None NTP, 1985 Renne et al., 1986 None No 3.7 x 10 -6 per µg/m3 No Linearized multistage procedure, extra risk None 3 x 10 1 µg/m3 3 µg/m3 3 x 10 -1 µg/m3
130 Propylene oxide 75-56-9 Oral Gastrointestinal Forestomach, squamous cell carcinoma Tumor Rat/ Sprague-Dawley, female Oral Gavage, salad oil Dunkelberg, 1982 2.4 x 10 -1 per mg/kg-day No 6.8 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 1 µg/L 1 µg/L 1 x 10 -1 µg/L
131 Quinoline 91-22-5 Oral Hepatic Hepatic hemangioendotheliomas or hemangiosarcomas Tumor Male Sprague-Dawley rats Oral Dietary Hirao et al., 1976 3 per mg/kg-day No 9 x 10 -5 per µg/L No Time-to-tumor, multistage-Weibull None 1 µg/L 1 x 10 -1 µg/L 1 x 10 -2 µg/L
132 1,1,2,2-Tetrachloroethane 79-34-5 Oral Hepatic hepatocellular carcinomas Tumor female B6C3F1 mice Oral gavage NCI, 1978 2 x 10 -1 per mg/kg-day No 6 x 10 -6 per µg/L No Multistage model with linear extrapolation from the point of departure (LED10). None 1.7 x 10 1 µg/L 1.7 µg/L 1.7 x 10 -1 µg/L
133 1,1,1,2-Tetrachloroethane 630-20-6 Inhalation Hepatic Hepatocellular adenoma or carcinoma Tumor Mouse/B6C3F1, female Oral Gavage NTP, 1983 None No 7.4 x 10 -6 per µg/m3 No Linearized multistage procedure, extra risk None 1 x 10 1 µg/m3 1 µg/m3 1 x 10 -1 µg/m3
134 1,1,1,2-Tetrachloroethane 630-20-6 Oral Hepatic Hepatocellular adenoma or carcinoma Tumor Mouse/B6C3F1, female Oral Gavage NTP, 1983 2.6 x 10 -2 per mg/kg-day No 7.4 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 2 µg/L 1 x 10 1 µg/L 1 µg/L
135 Tetrachloroethylene (Perchloroethylene) 127-18-4 Inhalation Hepatic Hepatocellular adenomas or carcinomas Tumor Male Crj:BDF1 mice Inhalation None JISA, 1993 0.0 None 2.6 x 10 -7 per µg/m3 None Multistage model with linear extrapolation from the point of departure (BMCL10), followed by extrapolation to humans using the PBPK model of Chiu and Ginsberg (2011). None 4 x 10 2 µg/m3 4 x 10 1 µg/m3 4 µg/m3
136 Tetrachloroethylene (Perchloroethylene) 127-18-4 Oral Hepatic Hepatocellular adenomas or carcinomas Tumor Male Crj:BDF1 mice Inhalation None JISA, 1993 2.1 x 10 -3 per mg/kg-day No 6.1 x 10 -8 per µg/L No Multistage model (with linear extrapolation from the point of departure (BMDL10), followed by route-to-route extrapolation to the oral route and interspecies extrapolation using the PBPK model of Chiu and Ginsberg (2011). None 2 x 10 3 µg/L 2 x 10 2 µg/L 2 x 10 1 µg/L
137 Toxaphene 8001-35-2 Inhalation Hepatic Hepatocellular carcinomas and neoplastic nodules Tumor Mouse/B6C3F1, males Oral Diet Litton Bionetics, 1978 None No 3.2 x 10 -4 per µg/m3 No Linearized multistage procedure, extra risk None 3 x 10 -1 µg/m3 3 x 10 -2 µg/m3 3 x 10 -3 µg/m3
138 Toxaphene 8001-35-2 Oral Hepatic Hepatocellular carcinomas and neoplastic nodules Tumor Mouse/B6C3F1, males Oral Diet Litton Bionetics, 1978 1.1 per mg/kg-day No 3.2 x 10 -5 per µg/L No Linearized multistage procedure, extra risk None 3 µg/L 3 x 10 -1 µg/L 3 x 10 -2 µg/L
139 Trichloroacetic acid 76-03-9 Oral Hepatic Hepatocellular adenomas or carcinomas Tumor Male B6C3F1 mice Oral drinking water DeAngelo et al. (2008) 7 x 10 -2 per mg/kg-day No 2 x 10 -6 per µg/L No Multistage model with linear extrapolation from the POD (LED10). None 5 x 10 1 µg/L 5 µg/L 5 x 10 -1 µg/L
140 1,1,2-Trichloroethane 79-00-5 Oral Hepatic Hepatocellular carcinoma Tumor Mouse/ B6C3F1 Oral Gavage NCI, 1978 5.7 x 10 -2 per mg/kg-day No 1.6 x 10 -6 per µg/L No Linearized multistage procedure, extra risk None 6 x 10 1 µg/L 6 µg/L 6 x 10 -1 µg/L
141 1,1,2-Trichloroethane 79-00-5 Inhalation Hepatic Hepatocellular carcinoma Tumor Mouse/ B6C3F1 Oral Gavage NCI, 1978 None No 1.6 x 10 -5 per µg/m3 No Linearized multistage procedure, extra risk None 6 µg/m3 6 x 10 -1 µg/m3 6 x 10 -2 µg/m3
142 Trichloroethylene 79-01-6 Oral Hematologic, Hepatic, Urinary Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors Tumor Human (epidemiological studies) Inhalation (route-to-route extrapolation to Oral) Charbotel et al., 2006; EPA, 2011; Raaschou-Nielsen et al., 2003 5.2 x 10 -2 per mg/kg-day Yes None Yes PBPK model-based route-to-route extrapolation of the inhalation unit risk estimate for kidney cancer with a factor of 5 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk, includes application of age-dependent adjustment factors (ADAFs). EPA has concluded that trichloroethylene is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the oral slope factor (OSF) addressing lifetime exposure includes application of ADAFs. The OSF is recommended for lifetime exposures. EPA has also provided an adult-based cancer slope factor of 4.6 x 10-2 per mg/kg-day. This adult-based cancer slope factor can be used instead of the OSF when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
143 Trichloroethylene 79-01-6 Inhalation Hematologic, Hepatic, Urinary Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors Tumor Human (epidemiological studies) Inhalation None Charbotel et al. 2006; EPA, 2011; Raaschou-Nielsen et al., 2003 None Yes 4.8 x 10 -6 per µg/m3 Yes Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk, includes application of age-dependent adjustment factors (ADAFs). EPA has concluded that trichloroethylene is carcinogenic by a mutagenic mode of action. Thus, based on the EPA cancer guidelines (2005), the inhalation unit risk (IUR) addressing lifetime exposure includes application of ADAFs. The IUR is recommended for lifetime exposures. EPA has also provided an adult-based cancer unit risk of 4.1 x 10-6 per µg/m3. This adult-based cancer unit risk can be used instead of the IUR when assessing cancer risk associated with exposure scenarios that don’t include early life (< 16 years of age) or when other calculations by the user are necessary (e.g., when applying ADAFs to age-specific exposure estimates). None None None
144 2,4,6-Trichlorophenol 88-06-2 Inhalation Hematologic Leukemia Tumor Rat/F344, male Oral Diet NCI, 1979 None No 3.1 x 10 -6 per µg/m3 No Linearized multistage procedure, extra risk None 3 x 10 1 µg/m3 3 µg/m3 3 x 10 -1 µg/m3
145 2,4,6-Trichlorophenol 88-06-2 Oral Hematologic Leukemia Tumor Rat/F344, male Oral Diet NCI, 1979 1.1 x 10 -2 per mg/kg-day No 3.1 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 3 x 10 2 µg/L 3 x 10 1 µg/L 3 µg/L
146 1,2,3-Trichloropropane 96-18-4 Oral Gastrointestinal, Hepatic, Ocular, Reproductive alimentary system squamous cell neoplasms, liver hepatocellular adenomas or carcinomas, Harderian gland adenomas, uterine/cervix adenomas or carcinomas Tumor B6C3F1 mice (female) Oral Oral gavage NTP, 1993 3 x 10 1 per mg/kg-day No None No Multistage-Weibull model with linear extrapolation from the point of departure (BMDL10). ADAF -- EPA has concluded that 1,2,3-trichloropropane is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the oral slope factor is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. None None None
147 Trifluralin 1582-09-8 Oral Endocrine, Urinary Combined renal pelvis carcinomas, urinary bladder papillomas and/or thyroid adenomas and carcinomas Tumor Rat/F344, male Oral Diet Emmerson et al., 1980 7.7 x 10 -3 per mg/kg-day No 2.2 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 5 x 10 2 µg/L 5 x 10 1 µg/L 5 µg/L
148 2,4,6-Trinitrotoluene (TNT) 118-96-7 Oral Urinary Urinary bladder, transitional cell papilloma and transitional squamous cell carcinomas Tumor Rat/Fischer 344, female Oral Diet U.S. DOD, 1984a 3 x 10 -2 per mg/kg-day No 9 x 10 -7 per µg/L No Linearized multistage procedure, extra risk None 1 x 10 2 µg/L 1 x 10 1 µg/L 1 µg/L
149 Vinyl chloride 75-01-4 Inhalation Hepatic Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules Tumor Female Sprague-Dawley rats Inhalation None Maltoni et al. (1981, 1984) None No 4.4 x 10 -6 per µg/m3 No LMS method None 2.3 x 10 1 µg/m3 2.3 µg/m3 2.3 x 10 -1 µg/m3
150 Vinyl chloride 75-01-4 Inhalation Hepatic Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules Tumor Female Sprague-Dawley rats Inhalation None Maltoni et al. (1981, 1984) None No 8.8 x 10 -6 per µg/m3 No LMS method None None None None
151 Vinyl chloride 75-01-4 Inhalation Hepatic Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules Tumor Female Sprague-Dawley rats Inhalation None Maltoni et al. (1981, 1984) None No 4.4 x 10 -6 per µg/m3 No LED 10/ linear method None None None None
152 Vinyl chloride 75-01-4 Oral Hepatic Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules Tumor Female Wistar rats Oral Diet Feron et al., 1981 1.5 per mg/kg-day No 4.2 x 10 -5 per µg/L No LED 10/ linear method None 2.4 µg/L 2.4 x 10 -1 µg/L 2.4 x 10 -2 µg/L
153 Vinyl chloride 75-01-4 Oral Hepatic Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules Tumor Female Wistar rats Oral Diet Feron et al., 1981 7.2 x 10 -1 per mg/kg-day No 2.1 x 10 -5 per µg/L No LMS method None 4.8 µg/L 4.8 x 10 -1 µg/L 4.8 x 10 -2 µg/L
154 Vinyl chloride 75-01-4 Oral Hepatic Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules Tumor Female Wistar rats Oral Diet Feron et al., 1981 7.5 x 10 -1 per mg/kg-day No 2.1 x 10 -5 per µg/L No LED 10/ linear method None 4.8 µg/L 4.8 x 10 -1 µg/L 4.8 x 10 -2 µg/L
155 Vinyl chloride 75-01-4 Oral Hepatic Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules Tumor Female Wistar rats Oral Diet Feron et al., 1981 1.4 per mg/kg-day No 4.2 x 10 -5 per µg/L No LMS method None 2.4 µg/L 2.4 x 10 -1 µg/L 2.4 x 10 -2 µg/L
156 Vinyl chloride 75-01-4 Inhalation Hepatic Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules Tumor Female Sprague-Dawley rats Inhalation None Maltoni et al. (1981, 1984) None No 8.8 x 10 -6 per µg/m3 No LED 10/ linear method None None None None
157 tert-Butyl Alcohol (tBA) 75-65-0 Oral Endocrine, Urinary Renal adenomas and carcinomas, thyroid adenomas Tumor Renal tumors in male rats F344 and tumors in male mice B63F1 Oral Drinking water (NTP, 1995) 5 x 10 -4 per mg/kg-day No None No None None None None None

  CHEMICAL NAME CASRN REVISION NUMBER REVISION DATE SECTIONS REVISED REVISION DESCRIPTION
1 Acenaphthene 83-32-9 1 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2 Acenaphthene 83-32-9 2 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
3 Acenaphthene 83-32-9 3 20190311 Mar 11,2019 Nanocancer RfD Clean Corrected a typo on the RfD POD value and also removed the adjusted 05 settings on the data entry form by request from S.Rieth.
4 Acenaphthene 83-32-9 4 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
5 Acenaphthylene 208-96-8 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
6 Acephate 30560-19-1 1 20160715 Jul 15,2016 Archiveed Assessment IRIS working with OPP agreed to mark this pesticide chemical archived.
7 Acephate 30560-19-1 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
8 Acetaldehyde 75-07-0 1 None None
9 Acetaldehyde 75-07-0 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
10 Acetochlor 34256-82-1 1 19910801 Aug 1,1991 I.A. Oral RfD now under review
11 Acetochlor 34256-82-1 2 19910801 Aug 1,1991 II. Carcinogenicity assessment now under review
12 Acetochlor 34256-82-1 3 19930901 Sep 1,1993 I.A. Oral RfD on-line
13 Acetochlor 34256-82-1 4 19930901 Sep 1,1993 VI.A. Oral RfD references on-line
14 Acetochlor 34256-82-1 5 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
15 Acetochlor 34256-82-1 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
16 Acetochlor 34256-82-1 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
17 Acetone 67-64-1 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
18 Acetone 67-64-1 2 19890701 Jul 1,1989 VI. Bibliography on-line
19 Acetone 67-64-1 3 19900101 Jan 1,1990 II. Carcinogen assessment now under review
20 Acetone 67-64-1 4 19900701 Jul 1,1990 II. Carcinogen assessment on-line
21 Acetone 67-64-1 5 19900701 Jul 1,1990 IV.F.1. EPA contact changed
22 Acetone 67-64-1 6 19900701 Jul 1,1990 VI.C. Carcinogen references added
23 Acetone 67-64-1 7 19901201 Dec 1,1990 I.A.2. Text edited
24 Acetone 67-64-1 8 19901201 Dec 1,1990 I.A.7. Regulatory actions updated
25 Acetone 67-64-1 9 19901201 Dec 1,1990 II.A.4. Text edited
26 Acetone 67-64-1 10 19920101 Jan 1,1992 IV. Regulatory actions updated
27 Acetone 67-64-1 11 19930801 Aug 1,1993 I.A. Oral RfD noted as pending change
28 Acetone 67-64-1 12 19930801 Aug 1,1993 I.A.6. Work group review date added
29 Acetone 67-64-1 13 19950801 Aug 1,1995 I.A., I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Piot Program replaced the workgroup functions beginning in September, 1995.
30 Acetone 67-64-1 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
31 Acetone 67-64-1 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
32 Acetonitrile 75-05-8 1 19880630 Jun 30,1988 I.A.2. Principal study clarified
33 Acetonitrile 75-05-8 2 19890701 Jul 1,1989 I.B. Inhalation RfD now under review
34 Acetonitrile 75-05-8 3 19890801 Aug 1,1989 I.A. Oral RfD summary noted as pending change
35 Acetonitrile 75-05-8 4 19900201 Feb 1,1990 I.A. Hazelton Labs, 1983 corrected to NTP, 1983
36 Acetonitrile 75-05-8 5 19900201 Feb 1,1990 I.A.2. Text clarified (paragraph 4)
37 Acetonitrile 75-05-8 6 19900201 Feb 1,1990 VI. Bibliography on-line
38 Acetonitrile 75-05-8 7 19900301 Mar 1,1990 VI.A. NTP, 1983 - strain of rats and mice clarified
39 Acetonitrile 75-05-8 8 19920101 Jan 1,1992 I.A.7. Secondary contact changed
40 Acetonitrile 75-05-8 9 19920101 Jan 1,1992 IV. Regulatory actions updated
41 Acetonitrile 75-05-8 10 19960201 Feb 1,1996 I.A.7. Secondary contact deleted
42 Acetonitrile 75-05-8 11 19990303 Mar 3,1999 I., II., VI. RfD withdrawn, discussion added; new RfC and cancer assessment
43 Acetonitrile 75-05-8 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
44 Acetophenone 98-86-2 1 19880822 Aug 22,1988 I.A. oral RfD summary on-line
45 Acetophenone 98-86-2 2 19890101 Jan 1,1989 I.A.7. Contacts phone numbers corrected
46 Acetophenone 98-86-2 3 19890801 Aug 1,1989 VI. Bibliography on-line
47 Acetophenone 98-86-2 4 19901201 Dec 1,1990 II. Carcinogen assessment now under review
48 Acetophenone 98-86-2 5 19910201 Feb 1,1991 II. Carcinogenicity assessment on-line
49 Acetophenone 98-86-2 6 19910201 Feb 1,1991 VI.C. Carcinogen references added
50 Acetophenone 98-86-2 7 19910901 Sep 1,1991 I.B. Inhalation RfC now under review
51 Acetophenone 98-86-2 8 19920101 Jan 1,1992 I.A.7. Secondary contact changed
52 Acetophenone 98-86-2 9 19920101 Jan 1,1992 IV. Regulatory Action section on-line
53 Acetophenone 98-86-2 10 19920801 Aug 1,1992 I.B. Work group review meeting date added
54 Acetophenone 98-86-2 11 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
55 Acetophenone 98-86-2 12 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Office for this information.
56 Acetophenone 98-86-2 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
57 Acetyl chloride 75-36-5 1 19910301 Mar 1,1991 II. Carcinogenicity assessment on-line
58 Acetyl chloride 75-36-5 2 19910301 Mar 1,1991 VI. Bibliography on-line
59 Acetyl chloride 75-36-5 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
60 Acetyl chloride 75-36-5 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
61 Acetyl chloride 75-36-5 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
62 Acifluorfen, sodium 62476-59-9 1 19881201 Dec 1,1988 I.A.2. Text revised
63 Acifluorfen, sodium 62476-59-9 2 19891101 Nov 1,1989 VI. Bibliography on-line
64 Acifluorfen, sodium 62476-59-9 3 19901001 Oct 1,1990 III.A. Health Advisory on-line
65 Acifluorfen, sodium 62476-59-9 4 19901001 Oct 1,1990 VI.D. Health Advisory references added
66 Acifluorfen, sodium 62476-59-9 5 19931101 Nov 1,1993 II. Work group review date added
67 Acifluorfen, sodium 62476-59-9 6 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
68 Acifluorfen, sodium 62476-59-9 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
69 Acrolein 107-02-8 1 19880907 Sep 7,1988 II. Carcinogen summary on-line
70 Acrolein 107-02-8 2 19890401 Apr 1,1989 V. Supplementary data on-line
71 Acrolein 107-02-8 3 19890701 Jul 1,1989 I.B. Inhalation RfD now under review
72 Acrolein 107-02-8 4 19900301 Mar 1,1990 II.A.4. Citations clarified (3rd paragraph)
73 Acrolein 107-02-8 5 19900301 Mar 1,1990 VI. Bibliography on-line
74 Acrolein 107-02-8 6 19900501 May 1,1990 VI.C. Hemminki et al., 1980 citation corrected
75 Acrolein 107-02-8 7 19911001 Oct 1,1991 I.B. Inhalation RfC summary on-line
76 Acrolein 107-02-8 8 19911001 Oct 1,1991 I.B. Inhalation RfC references added
77 Acrolein 107-02-8 9 19920101 Jan 1,1992 IV. Regulatory Action section on-line
78 Acrolein 107-02-8 10 19930701 Jul 1,1993 I.B.1. LOAEL (ADJ) corrected
79 Acrolein 107-02-8 11 19940201 Feb 1,1994 II.D.3. Secondary contact's phone number changed
80 Acrolein 107-02-8 12 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
81 Acrolein 107-02-8 13 20190311 Mar 11,2019 Nanocancer RfD Clean Removed Adjusted and 05 from the RfD table, per request from S. Rieth.
82 Acrolein 107-02-8 14 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
83 Acrylamide 79-06-1 1 19880926 Sep 26,1988 I.A. Oral RfD summary on-line
84 Acrylamide 79-06-1 2 19880926 Sep 26,1988 II. Carcionogen summary on-line
85 Acrylamide 79-06-1 3 19890601 Jun 1,1989 II.D.2. Work group review date added
86 Acrylamide 79-06-1 4 19900901 Sep 1,1990 II. Text edited
87 Acrylamide 79-06-1 5 19900901 Sep 1,1990 III.A. Health Advisory on-line
88 Acrylamide 79-06-1 6 19900901 Sep 1,1990 VI. Bibliography on-line
89 Acrylamide 79-06-1 7 19901001 Oct 1,1990 I.B. Not verified data inadequate
90 Acrylamide 79-06-1 8 19901101 Nov 1,1990 I.B. Inhalation RfC message on-line
91 Acrylamide 79-06-1 9 19901101 Nov 1,1990 VI.B. Inhalation RfC references on-line
92 Acrylamide 79-06-1 10 19910101 Jan 1,1991 II. Text edited
93 Acrylamide 79-06-1 11 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
94 Acrylamide 79-06-1 12 19910301 Mar 1,1991 I.A.5. Database corrected to medium text revised
95 Acrylamide 79-06-1 13 19910801 Aug 1,1991 VI.C. References clarified
96 Acrylamide 79-06-1 14 19920101 Jan 1,1992 IV. Regulatory Action section on-line
97 Acrylamide 79-06-1 15 19930701 Jul 1,1993 II.D.1. Source document and review statement clarified
98 Acrylamide 79-06-1 16 19950801 Aug 1,1995 II.D.2 EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
99 Acrylamide 79-06-1 17 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
100 Acrylamide 79-06-1 18 20010222 Feb 22,2001 I., II. This chemical is being reassessed under the IRIS Program.
101 Acrylamide 79-06-1 19 20100316 Mar 16,2010 I., II., VI. RfD and cancer assessment sections updated, RfC assessment added.
102 Acrylamide 79-06-1 20 20110309 Mar 9,2011 NA Corrections that were made to Table 3-2 of the Toxicological Review of Acrylamide: 1. Some of the superscripts were missing or wrong. 2. The species "hamster" should be "humans". 3. Citaion "j" Fennell et al 2005 should be Fennell et al 2006 4. All citations for Hartmann et al., 2008, 224480 should be Kopp and Dekant, 2009, 224532
103 Acrylamide 79-06-1 21 20180710 Jul 10,2018 Key Values Table A footnote was added for ADAF.
104 Acrylamide 79-06-1 22 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
105 Acrylic acid 79-10-7 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
106 Acrylic acid 79-10-7 2 19870331 Mar 31,1987 I.A.6. Documentation corrected
107 Acrylic acid 79-10-7 3 19880301 Mar 1,1988 I.A.2. Paragraph 3 deleted
108 Acrylic acid 79-10-7 4 19890801 Aug 1,1989 VI. Bibliography on-line
109 Acrylic acid 79-10-7 5 19900901 Sep 1,1990 I.B. Inhalation RfC now under review
110 Acrylic acid 79-10-7 6 19901001 Oct 1,1990 I.B. Inhalation RfC summary on-line
111 Acrylic acid 79-10-7 7 19901001 Oct 1,1990 VI.B. Inhalation RfC references added
112 Acrylic acid 79-10-7 8 19920101 Jan 1,1992 I.A.7. Primary contact changed
113 Acrylic acid 79-10-7 9 19920101 Jan 1,1992 IV. Regulatory actions updated
114 Acrylic acid 79-10-7 10 19940301 Mar 1,1994 I.A. Withdrawn; new oral RfD verified (in preparation)
115 Acrylic acid 79-10-7 11 19940301 Mar 1,1994 I.B. Withdrawn; new inhalation RfC verified (in preparation)
116 Acrylic acid 79-10-7 12 19940301 Mar 1,1994 VI. Bibliography withdrawn
117 Acrylic acid 79-10-7 13 19940401 Apr 1,1994 I.A. Oral RfD summary replaced; new RfD
118 Acrylic acid 79-10-7 14 19940401 Apr 1,1994 I.B. Inhalation RfC summary replaced; new RfC
119 Acrylic acid 79-10-7 15 19940401 Apr 1,1994 VI.A. Oral RfD references replaced
120 Acrylic acid 79-10-7 16 19940401 Apr 1,1994 VI.B. Inhalation RfC references replaced
121 Acrylic acid 79-10-7 17 19940501 May 1,1994 I.A.2. Note moved from Add. Com. Sec. to Prin. Sup. Stud. Sec
122 Acrylic acid 79-10-7 18 19940501 May 1,1994 I.B.1. Note moved from Add. Com. Sec. to Prin. Sup. Stud. Sec
123 Acrylic acid 79-10-7 19 19950501 May 1,1995 I.B.4. Text edited (9th paragraph)
124 Acrylic acid 79-10-7 20 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
125 Acrylic acid 79-10-7 21 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
126 Acrylonitrile 107-13-1 1 19880301 Mar 1,1988 II.B.4. Confidence statement revised
127 Acrylonitrile 107-13-1 2 19890201 Feb 1,1989 II.D.3 Secondary contact's phone number corrected
128 Acrylonitrile 107-13-1 3 19890701 Jul 1,1989 II. Citations for Quast et al. clarified
129 Acrylonitrile 107-13-1 4 19890701 Jul 1,1989 VI. Bibliography on-line
130 Acrylonitrile 107-13-1 5 19900601 Jun 1,1990 IV.A.1. Area code for EPA contact corrected
131 Acrylonitrile 107-13-1 6 19900601 Jun 1,1990 IV.F.1. EPA contact changed
132 Acrylonitrile 107-13-1 7 19910101 Jan 1,1991 I.B. Inhalation RfC now under review
133 Acrylonitrile 107-13-1 8 19910101 Jan 1,1991 II. Text edited
134 Acrylonitrile 107-13-1 9 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
135 Acrylonitrile 107-13-1 10 19911101 Nov 1,1991 I.B. Inhalation RfC summary on-line
136 Acrylonitrile 107-13-1 11 19911101 Nov 1,1991 VI.B. Inhalation RfC references added
137 Acrylonitrile 107-13-1 12 19911201 Dec 1,1991 I.B. Text edited
138 Acrylonitrile 107-13-1 13 19920101 Jan 1,1992 IV. Regulatory actions updated
139 Acrylonitrile 107-13-1 14 19920401 Apr 1,1992 IV.A.1. CAA regulatory action withdrawn
140 Acrylonitrile 107-13-1 15 19920801 Aug 1,1992 I.A. Oral RfD now under review
141 Acrylonitrile 107-13-1 16 19930701 Jul 1,1993 I.A. Work group review date added
142 Acrylonitrile 107-13-1 17 19950801 Aug 1,1995 I.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by the Program replaced the workgroup functions beginning in September, 1995.
143 Acrylonitrile 107-13-1 18 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
144 Acrylonitrile 107-13-1 19 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
145 Adiponitrile 111-69-3 1 19910201 Feb 1,1991 II. Carcinogenicity assessment on-line
146 Adiponitrile 111-69-3 2 19910201 Feb 1,1991 VI. Bibliography on-line
147 Adiponitrile 111-69-3 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
148 Adiponitrile 111-69-3 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
149 Alachlor 15972-60-8 1 19880301 Mar 1,1988 III.A. Health Advisory added
150 Alachlor 15972-60-8 2 19881201 Dec 1,1988 I.A.4. Core graded added to studies 1, 3 and 4
151 Alachlor 15972-60-8 3 19891101 Nov 1,1989 VI. Bibliography on-line
152 Alachlor 15972-60-8 4 19920101 Jan 1,1992 IV. Regulatory actions updated
153 Alachlor 15972-60-8 5 19930901 Sep 1,1993 I.A. Oral RfD revised; same study and number
154 Alachlor 15972-60-8 6 19931101 Nov 1,1993 III.A.2. Ten-day Health Advisory corrected
155 Alachlor 15972-60-8 7 19931101 Nov 1,1993 III.A.9. Documentation revised
156 Alachlor 15972-60-8 8 19931101 Nov 1,1993 IV.B.2. Discussion corrected
157 Alachlor 15972-60-8 9 19931101 Nov 1,1993 VI. Health Advisory references revised
158 Alachlor 15972-60-8 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions,and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
159 Alachlor 15972-60-8 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
160 Alar 1596-84-5 1 19880822 Aug 22,1988 I.A.4. Study 4 text revised
161 Alar 1596-84-5 2 19910201 Feb 1,1991 I.B. Incorrect message removed
162 Alar 1596-84-5 3 19910701 Jul 1,1991 I.A. Principal study clarified
163 Alar 1596-84-5 4 19910701 Jul 1,1991 I.A.4. Citations clarified
164 Alar 1596-84-5 5 19910701 Jul 1,1991 VI. Bibliography on-line
165 Alar 1596-84-5 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
166 Alar 1596-84-5 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
167 Alar 1596-84-5 8 20180927 Sep 27,2018 Noncancer Critical Updated the system from none to other so it would show up in the advanced search.
168 Alar 1596-84-5 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
169 Aldicarb 116-06-3 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
170 Aldicarb 116-06-3 2 19880301 Mar 1,1988 I.A.7. Primary contact changed
171 Aldicarb 116-06-3 3 19880301 Mar 1,1988 III.A. Health Advisory added
172 Aldicarb 116-06-3 4 19880822 Aug 22,1988 II. Carcinogen summary on-line
173 Aldicarb 116-06-3 5 19890501 May 1,1989 I.A.5. Confidence statement revised
174 Aldicarb 116-06-3 6 19890501 May 1,1989 I.A.7. Secondary contact changed
175 Aldicarb 116-06-3 7 19890601 Jun 1,1989 II.D.2. Work group review date added
176 Aldicarb 116-06-3 8 19890801 Aug 1,1989 VI. Bibliography on-line
177 Aldicarb 116-06-3 9 19900701 Jul 1,1990 I.A. Oral RfD summary noted as pending change
178 Aldicarb 116-06-3 10 19900801 Aug 1,1990 I.A. Withdrawn; new Oral RfD verified (in preparation)
179 Aldicarb 116-06-3 11 19900801 Aug 1,1990 III.A.5. DWEL & Lifetime HA withdrawn (RfD withdrawn)
180 Aldicarb 116-06-3 12 19900801 Aug 1,1990 VI.A. Oral RfD references withdrawn
181 Aldicarb 116-06-3 13 19910301 Mar 1,1991 II.D.3 Secondary contact changed
182 Aldicarb 116-06-3 14 19910701 Jul 1,1991 I.A. Oral RfD summary replaced; RfD changed
183 Aldicarb 116-06-3 15 19910701 Jul 1,1991 III.A.5. DWEL and Lifetime HA replaced
184 Aldicarb 116-06-3 16 19910701 Jul 1,1991 VI.A. Oral RfD references replaced
185 Aldicarb 116-06-3 17 19910701 Jul 1,1991 III.A. Section III.A.1-4 replaced
186 Aldicarb 116-06-3 18 19910801 Aug 1,1991 I.A. General edit
187 Aldicarb 116-06-3 19 19920101 Jan 1,1992 IV. Regulatory actions updated
188 Aldicarb 116-06-3 20 19921001 Oct 1,1992 I.A. Oral RfD summary noted as pending change
189 Aldicarb 116-06-3 21 19921001 Oct 1,1992 I.A.6. Work group review date added
190 Aldicarb 116-06-3 22 19921201 Dec 1,1992 I.A.6. Work group review date added
191 Aldicarb 116-06-3 23 19931101 Nov 1,1993 I.A. Oral RfD summary replaced; new RfD
192 Aldicarb 116-06-3 24 19931101 Nov 1,1993 III.A. Health Advisory withdrawn
193 Aldicarb 116-06-3 25 19931101 Nov 1,1993 VI.A. Oral RfD references replaced
194 Aldicarb 116-06-3 26 19931101 Nov 1,1993 VI.D. Health Advisory references withdrawn
195 Aldicarb 116-06-3 27 19940101 Jan 1,1994 III.A. Message revised to include contact's name and number
196 Aldicarb 116-06-3 28 19950801 Aug 1,1995 II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS reveiw. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
197 Aldicarb 116-06-3 29 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or befroe April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
198 Aldicarb 116-06-3 30 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
199 Aldicarb sulfone 1646-88-4 1 19880926 Sep 26,1988 I.A. Oral RfD summary on-line
200 Aldicarb sulfone 1646-88-4 2 19890201 Feb 1,1989 I.A.7. Secondary contact's phone number corrected
201 Aldicarb sulfone 1646-88-4 3 19890801 Aug 1,1989 I.A. Citations clarified
202 Aldicarb sulfone 1646-88-4 4 19890801 Aug 1,1989 VI. Bibliography on-line
203 Aldicarb sulfone 1646-88-4 5 19900701 Jul 1,1990 I.A. Withdrawn; new RfD verified (in preparation)
204 Aldicarb sulfone 1646-88-4 6 19900701 Jul 1,1990 VI. Bibliography withdrawn
205 Aldicarb sulfone 1646-88-4 7 19900901 Sep 1,1990 I.A. Oral RfD summary replaced; RfD changed
206 Aldicarb sulfone 1646-88-4 8 19900901 Sep 1,1990 VI. Bibliography replaced
207 Aldicarb sulfone 1646-88-4 9 19900501 May 1,1990 I.A. Oral RfD withdrawn pending additional review
208 Aldicarb sulfone 1646-88-4 10 19910501 May 1,1991 VI. Bibliography withdrawn
209 Aldicarb sulfone 1646-88-4 11 19920101 Jan 1,1992 IV. Regulatory Action section on-line
210 Aldicarb sulfone 1646-88-4 12 19921001 Oct 1,1992 I.A. Work group review date added
211 Aldicarb sulfone 1646-88-4 13 19930401 Apr 1,1993 I.A. Oral RfD references replaced
212 Aldicarb sulfone 1646-88-4 14 19931101 Nov 1,1993 I.A. Oral RfD summary replaced; new RfD
213 Aldicarb sulfone 1646-88-4 15 19931101 Nov 1,1993 VI.A. Oral RfD references replaced
214 Aldicarb sulfone 1646-88-4 16 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
215 Aldicarb sulfone 1646-88-4 17 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
216 Aldrin 309-00-2 1 19870930 Sep 30,1987 II. Carcinogenicity section added
217 Aldrin 309-00-2 2 19880301 Mar 1,1988 II.B.4 Confidence statement revised
218 Aldrin 309-00-2 3 19881201 Dec 1,1988 II.B.4. Corrected slope factor in text
219 Aldrin 309-00-2 4 19890901 Sep 1,1989 II.A.2. Dirtaglia reference changed to Ditraglia et al.
220 Aldrin 309-00-2 5 19890901 Sep 1,1989 II.A.3. Deichmann reference changed to Deichmann et al.
221 Aldrin 309-00-2 6 19890901 Sep 1,1989 II.B.3. Body weight for mice corrected to kg
222 Aldrin 309-00-2 7 19890901 Sep 1,1989 VI. Bibliography on-line
223 Aldrin 309-00-2 8 19910101 Jan 1,1991 II. Text edited
224 Aldrin 309-00-2 9 19910101 Jan 1,1991 II.C.1 Inhalation slope factor removed (global change)
225 Aldrin 309-00-2 10 19920101 Jan 1,1992 I.A.7. Secondary contact changed
226 Aldrin 309-00-2 11 19920101 Jan 1,1992 IV. Regulatory actions updated
227 Aldrin 309-00-2 12 19930701 Jul 1,1993 II.D.3. Secondary contact's phone number changed
228 Aldrin 309-00-2 13 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementay data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Praogram Offices for this information.
229 Aldrin 309-00-2 14 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
230 Aldrin 309-00-2 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
231 Ally 74223-64-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
232 Allyl alcohol 107-18-6 1 19870930 Sep 30,1987 V. Supplementary Dta section added
233 Allyl alcohol 107-18-6 2 19880301 Mar 1,1988 I.A.1. Dose conversion clarified
234 Allyl alcohol 107-18-6 3 19880301 Mar 1,1988 I.A.2. Text deleted
235 Allyl alcohol 107-18-6 4 19880301 Mar 1,1988 I.A.4. Text clarified
236 Allyl alcohol 107-18-6 5 19880301 Mar 1,1988 I.A.5. Confidence levels revised
237 Allyl alcohol 107-18-6 6 19890801 Aug 1,1989 I.A.4. Citations clarified
238 Allyl alcohol 107-18-6 7 19890801 Aug 1,1989 VI. Bibliography on-line
239 Allyl alcohol 107-18-6 8 19920101 Jan 1,1992 I.A.7. Primary contact changed
240 Allyl alcohol 107-18-6 9 19920101 Jan 1,1992 IV. Regulatory action updated
241 Allyl alcohol 107-18-6 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS useres were directed to the appropriate EPA Program Offices for this information.
242 Allyl alcohol 107-18-6 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
243 Allyl chloride 107-05-1 1 19900901 Sep 1,1990 II. Carcinogen assessment on-line
244 Allyl chloride 107-05-1 2 19900901 Sep 1,1990 VI. Bibliography on-line
245 Allyl chloride 107-05-1 3 19910101 Jan 1,1991 I.B. Inhalation RfC now under review
246 Allyl chloride 107-05-1 4 19910801 Aug 1,1991 VI.C. Eder et al. 1980 reference volume corrected
247 Allyl chloride 107-05-1 5 19911201 Dec 1,1991 I.B. Inhalation RfC on-line
248 Allyl chloride 107-05-1 6 19911201 Dec 1,1991 VI.B. Inhalation RfC references added
249 Allyl chloride 107-05-1 7 19920101 Jan 1,1992 IV. Regulatory Action section on-line
250 Allyl chloride 107-05-1 8 19950501 May 1,1995 I.B. Principal study author name corrected
251 Allyl chloride 107-05-1 9 19950501 May 1,1995 VI.B. Author name corrected
252 Allyl chloride 107-05-1 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
253 Allyl chloride 107-05-1 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
254 Aluminum phosphide 20859-73-8 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
255 Aluminum phosphide 20859-73-8 2 19880301 Mar 1,1988 I.A.6. Documentation revised
256 Aluminum phosphide 20859-73-8 3 19890801 Aug 1,1989 VI. Bibliography on-line
257 Aluminum phosphide 20859-73-8 4 19920101 Jan 1,1992 I.A.7. Primary contact changed
258 Aluminum phosphide 20859-73-8 5 19920101 Jan 1,1992 IV. Regulatory actions updated
259 Aluminum phosphide 20859-73-8 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
260 Aluminum phosphide 20859-73-8 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
261 Amdro 67485-29-4 1 19891101 Nov 1,1989 VI. Bibliography on-line
262 Amdro 67485-29-4 2 19920101 Jan 1,1992 IV. Regulatory Action section on-line
263 Amdro 67485-29-4 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were direcetd to the appropriate EPA Program Office for this information.
264 Amdro 67485-29-4 4 20160715 Jul 15,2016 Archived Assessment IRIS working with OPP agreed to mark this pesticide chemical archived.
265 Amdro 67485-29-4 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
266 Ametryn 834-12-8 1 19880301 Mar 1,1988 I.A.4. Text clarified
267 Ametryn 834-12-8 2 19891101 Nov 1,1989 I.A.4. Species corrected in study 4
268 Ametryn 834-12-8 3 19891101 Nov 1,1989 VI. Bibliography on-line
269 Ametryn 834-12-8 4 19901001 Oct 1,1990 III.A. Health Advisory on-line
270 Ametryn 834-12-8 5 19901001 Oct 1,1990 VI.D. Health Advisory references added
271 Ametryn 834-12-8 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
272 Ametryn 834-12-8 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
273 Ametryn 834-12-8 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
274 4-Aminopyridine 504-24-5 1 19891201 Dec 1,1989 II. Carcinogen summary on-line
275 4-Aminopyridine 504-24-5 2 19891201 Dec 1,1989 VI. Bibliography on-line
276 4-Aminopyridine 504-24-5 3 19911201 Dec 1,1991 II.A.1. Basis statement replaced
277 4-Aminopyridine 504-24-5 4 19911201 Dec 1,1991 II.A.4. Text replaced
278 4-Aminopyridine 504-24-5 5 19911201 Dec 1,1991 II.D.2. Review date of 07/25/1991 added
279 4-Aminopyridine 504-24-5 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
280 4-Aminopyridine 504-24-5 7 19930701 Jul 1,1993 II.D.1. Source document year corrected
281 4-Aminopyridine 504-24-5 8 19950801 Aug 1,1995 II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
282 4-Aminopyridine 504-24-5 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory ACtions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
283 4-Aminopyridine 504-24-5 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
284 Amitraz 33089-61-1 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
285 Amitraz 33089-61-1 2 19881201 Dec 1,1988 I.A.4. Core grades corrected
286 Amitraz 33089-61-1 3 19891001 Oct 1,1989 VI. Bibliography on-line
287 Amitraz 33089-61-1 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
288 Amitraz 33089-61-1 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EP Program Offices for this information.
289 Amitraz 33089-61-1 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
290 Ammonia 7664-41-7 1 19910501 May 1,1991 I.B. Inhalation RfC summary on-line
291 Ammonia 7664-41-7 2 19910501 May 1,1991 VI. Bibliography on-line
292 Ammonia 7664-41-7 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
293 Ammonia 7664-41-7 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this inforamation.
294 Ammonia 7664-41-7 5 20160920 Sep 20,2016 I.B. Update to the noncancer inhalation RfC key values.
295 Ammonia 7664-41-7 6 20180628 Jun 28,2018 IRIS Summary Renamed the IRIS Summary to Executive summary to match the attachment.
296 Ammonia 7664-41-7 7 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
297 Ammonium acetate 631-61-8 1 19910301 Mar 1,1991 II. Carcinogenicity assessment on-line
298 Ammonium acetate 631-61-8 2 19910301 Mar 1,1991 VI. Bibliography on-line
299 Ammonium acetate 631-61-8 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
300 Ammonium acetate 631-61-8 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. Iris users were directed to the appropriate EPA Program Offices for this information.
301 Ammonium acetate 631-61-8 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
302 Ammonium methacrylate 16325-47-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
303 Ammonium sulfamate 7773-06-0 1 19880301 Mar 1,1988 I.A.1. Critical effect identified, LOAEL specified
304 Ammonium sulfamate 7773-06-0 2 19880301 Mar 1,1988 I.A.2. Principal study citation corrected
305 Ammonium sulfamate 7773-06-0 3 19880301 Mar 1,1988 I.A.2. Text revised
306 Ammonium sulfamate 7773-06-0 4 19881201 Dec 1,1988 I.A. Withdrawn; new RfD verified (in preparation)
307 Ammonium sulfamate 7773-06-0 5 19890101 Jan 1,1989 I.A. Oral RfD summary replaced; RfD changed
308 Ammonium sulfamate 7773-06-0 6 19910301 Mar 1,1991 I.A.4. Citations added
309 Ammonium sulfamate 7773-06-0 7 19910301 Mar 1,1991 III.A. Health Advisory on-line
310 Ammonium sulfamate 7773-06-0 8 19910301 Mar 1,1991 VI. Bibliography on-line
311 Ammonium sulfamate 7773-06-0 9 19910601 Jun 1,1991 III.A.4. 70-kg 'child' corrected to 70-kg adult in assumptions
312 Ammonium sulfamate 7773-06-0 10 19920101 Jan 1,1992 IV. Regulatory actions updated
313 Ammonium sulfamate 7773-06-0 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program offices for this information.
314 Ammonium sulfamate 7773-06-0 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
315 Aniline 62-53-3 1 19880907 Sep 7,1988 II. Carcinogen summary on-line
316 Aniline 62-53-3 2 19890401 Apr 1,1989 V. Supplementary data on-line
317 Aniline 62-53-3 3 19890601 Jun 1,1989 II.D.2. Work group review date added
318 Aniline 62-53-3 4 19890801 Aug 1,1989 VI. Bibliography on-line
319 Aniline 62-53-3 5 19901001 Oct 1,1990 I.B. Inhalation RfC now under review
320 Aniline 62-53-3 6 19901101 Nov 1,1990 I.B. Inhalation RfC summary on-line
321 Aniline 62-53-3 7 19901101 Nov 1,1990 VI.B. Inhalation RfC references added
322 Aniline 62-53-3 8 19911101 Nov 1,1991 I.B.6. Source Doc. & Other EPA Documentation corrected
323 Aniline 62-53-3 9 19920101 Jan 1,1992 IV. Regulatory Action section on-line
324 Aniline 62-53-3 10 19931201 Dec 1,1993 I.B.1. Critical effect clarified in study 1
325 Aniline 62-53-3 11 19940201 Feb 1,1994 II.D.3. Secondary contact's phone number changed
326 Aniline 62-53-3 12 19950801 Aug 1,1995 II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
327 Aniline 62-53-3 13 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementarry Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
328 Aniline 62-53-3 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
329 ortho-Anisidine 90-04-0 1 19910901 Sep 1,1991 I.B. Inhalation RfC now under review
330 ortho-Anisidine 90-04-0 2 19911001 Oct 1,1991 I.B. Inhalation RfC message on-line
331 ortho-Anisidine 90-04-0 3 19911001 Oct 1,1991 VI. Bibliography on-line
332 ortho-Anisidine 90-04-0 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were direcetd to the appropriate EPA Program Offices for this information.
333 ortho-Anisidine 90-04-0 5 20181219 Dec 19,2018 Archived Chemical IRIS Program requested that we archive assessments with no values.
334 ortho-Anisidine 90-04-0 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
335 Anthracene 120-12-7 1 19900901 Sep 1,1990 I.A. Oral RfD summary on-line
336 Anthracene 120-12-7 2 19900901 Sep 1,1990 VI. Bibliography on-line
337 Anthracene 120-12-7 3 19910101 Jan 1,1991 II. Carcinogen assessment on-line
338 Anthracene 120-12-7 4 19910101 Jan 1,1991 VI.C. Carcinogen assessment references added
339 Anthracene 120-12-7 5 19910701 Jul 1,1991 I.A.7. Primary and secondary contacts changed
340 Anthracene 120-12-7 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
341 Anthracene 120-12-7 7 19930701 Jul 1,1993 I.A.6. Source Document and Other EPA documentation clarified
342 Anthracene 120-12-7 8 19940901 Sep 1,1994 I.B. Inhalation RfD now under review
343 Anthracene 120-12-7 9 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS reveiw. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
344 Anthracene 120-12-7 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplmentary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
345 Anthracene 120-12-7 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
346 Antimony 7440-36-0 1 19890801 Aug 1,1989 I.A. Gross et al., (1955) citation clarified
347 Antimony 7440-36-0 2 19890801 Aug 1,1989 VI. Bibliography on-line
348 Antimony 7440-36-0 3 19910201 Feb 1,1991 I.A.1. Conversion factor revised
349 Antimony 7440-36-0 4 19910201 Feb 1,1991 I.A.2. Text added
350 Antimony 7440-36-0 5 19910201 Feb 1,1991 I.A.4. Paragraph 2 added
351 Antimony 7440-36-0 6 19910201 Feb 1,1991 VI.A. Dunn, 1928 and Monier-Williams, 1934 added
352 Antimony 7440-36-0 7 19920101 Jan 1,1992 I.A.7. Primary contact changed
353 Antimony 7440-36-0 8 19920101 Jan 1,1992 IV. Regulatory actions updated
354 Antimony 7440-36-0 9 19970401 Apr 1,1997 III>, IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directeed to the appropriate EPA Program Offices for this information.
355 Antimony 7440-36-0 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
356 Antimony trioxide 1309-64-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
357 Apollo 74115-24-5 1 19880301 Mar 1,1988 I.A.3. Text revised
358 Apollo 74115-24-5 2 19880301 Mar 1,1988 I.A.4. Data gaps revised
359 Apollo 74115-24-5 3 19880301 Mar 1,1988 I.A.4. Study description added
360 Apollo 74115-24-5 4 19880301 Mar 1,1988 I.A.4. Data added to 'Other Data Reviewed'
361 Apollo 74115-24-5 5 19880301 Mar 1,1988 I.A.5. Confidence levels revised
362 Apollo 74115-24-5 6 19880301 Mar 1,1988 I.A.6. Dates corrected
363 Apollo 74115-24-5 7 19891101 Nov 1,1989 I.A. Principal study year corrected
364 Apollo 74115-24-5 8 19891101 Nov 1,1989 VI. Bibliography on-line
365 Apollo 74115-24-5 9 19900301 Mar 1,1990 II. Carcinogen assessment now under review
366 Apollo 74115-24-5 10 19910601 Jun 1,1991 II. Carcinogenicity assessment on-line
367 Apollo 74115-24-5 11 19910601 Jun 1,1991 VI.C. Carcinogenicity references added
368 Apollo 74115-24-5 12 19931001 Oct 1,1993 II.D.3. Primary contact changed; secondary's phone no. changed.
369 Apollo 74115-24-5 13 19950801 Aug 1,1995 I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
370 Apollo 74115-24-5 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
371 Apollo 74115-24-5 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
372 Aramite 140-57-8 1 19910601 Jun 1,1991 II. Carcinogenicity assessment on-line
373 Aramite 140-57-8 2 19910601 Jun 1,1991 VI. Bibliography on-line
374 Aramite 140-57-8 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
375 Aramite 140-57-8 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
376 Aramite 140-57-8 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
377 Aroclor 1016 12674-11-2 1 19910801 Aug 1,1991 I.A. Oral RfD now under review
378 Aroclor 1016 12674-11-2 2 19920801 Aug 1,1992 I.A. Work group review dates added
379 Aroclor 1016 12674-11-2 3 19921001 Oct 1,1992 I.A. Work group review date added
380 Aroclor 1016 12674-11-2 4 19921201 Dec 1,1992 I.A. Work group reveiw dates added
381 Aroclor 1016 12674-11-2 5 19930101 Jan 1,1993 I.A. Oral RfD assessment on-line
382 Aroclor 1016 12674-11-2 6 19930101 Jan 1,1993 VI.A. Oral RfD references on-line
383 Aroclor 1016 12674-11-2 7 19930201 Feb 1,1993 VI.A. Oral RfD references corrected
384 Aroclor 1016 12674-11-2 8 19930301 Mar 1,1993 I.A.6. Work group review date added
385 Aroclor 1016 12674-11-2 9 19930901 Sep 1,1993 I.A. Oral RfD noted as going to be externally peer reviewed
386 Aroclor 1016 12674-11-2 10 19931101 Nov 1,1993 I.A. Note revised
387 Aroclor 1016 12674-11-2 11 19940501 May 1,1994 I.A. Peer review note removed; peer review May 24-25
388 Aroclor 1016 12674-11-2 12 19950801 Aug 1,1995 I.A.6., I.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
389 Aroclor 1016 12674-11-2 13 19961101 Nov 1,1996 I.A.7. Primary contact's office changed
390 Aroclor 1016 12674-11-2 14 19970401 Apr 1,1997 III., IV., V. Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
391 Aroclor 1016 12674-11-2 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
392 Aroclor 1248 12672-29-6 1 19920901 Sep 1,1992 I.A. Oral RfD now under review
393 Aroclor 1248 12672-29-6 2 19921201 Dec 1,1992 I.A. Work group review date added
394 Aroclor 1248 12672-29-6 3 19930701 Jul 1,1993 I.A. Work group review date added
395 Aroclor 1248 12672-29-6 4 19930801 Aug 1,1993 I.A. Work group review date added
396 Aroclor 1248 12672-29-6 5 19940401 Apr 1,1994 I.A. Oral RfD message on-line
397 Aroclor 1248 12672-29-6 6 19940401 Apr 1,1994 VI.A. Oral RfD references on-line
398 Aroclor 1248 12672-29-6 7 19961101 Nov 1,1996 I.A. Contact's office changed
399 Aroclor 1248 12672-29-6 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
400 Aroclor 1248 12672-29-6 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
401 Aroclor 1254 11097-69-1 1 19930701 Jul 1,1993 I.A. Oral RfD now under review
402 Aroclor 1254 11097-69-1 2 19930901 Sep 1,1993 A11. Monor edit
403 Aroclor 1254 11097-69-1 3 19940301 Mar 1,1994 I.A. Work group review date added
404 Aroclor 1254 11097-69-1 4 19941001 Oct 1,1994 I.A. Oral RfD summary on-line
405 Aroclor 1254 11097-69-1 5 19941001 Oct 1,1994 VI.A. Oral RfD references on-line
406 Aroclor 1254 11097-69-1 6 19961101 Nov 1,1996 I.A.7. Primary contact's office changed
407 Aroclor 1254 11097-69-1 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
408 Aroclor 1254 11097-69-1 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
409 Arsenic, Inorganic 7440-38-2 1 19880630 Jun 30,1988 II.B. Revised last paragraph
410 Arsenic, Inorganic 7440-38-2 2 19880630 Jun 30,1988 II.C.1. Inhalation slope factor changed
411 Arsenic, Inorganic 7440-38-2 3 19880630 Jun 30,1988 II.C.3. Paragraph 2 added
412 Arsenic, Inorganic 7440-38-2 4 19880907 Sep 7,1988 II.B. Major text changes
413 Arsenic, Inorganic 7440-38-2 5 19881201 Dec 1,1988 II.A.2 Mabuchi et al., citation year corrected
414 Arsenic, Inorganic 7440-38-2 6 19881201 Dec 1,1988 II.A.3. Pershagen et al., citation year corrected
415 Arsenic, Inorganic 7440-38-2 7 19890901 Sep 1,1989 II.C.2. Citations added to Anacondor smelter
416 Arsenic, Inorganic 7440-38-2 8 19890901 Sep 1,1989 VI. Bibliography on-line
417 Arsenic, Inorganic 7440-38-2 9 19900601 Jun 1,1990 II.A.2. 2nd and 3rd paragraph - Text revised
418 Arsenic, Inorganic 7440-38-2 10 19900601 Jun 1,1990 II.A.4. Text corrected
419 Arsenic, Inorganic 7440-38-2 11 19900601 Jun 1,1990 II.C.1. Inhalation slope factor removed (format change)
420 Arsenic, Inorganic 7440-38-2 12 19900601 Jun 1,1990 IV.F.1. EPA contact changed
421 Arsenic, Inorganic 7440-38-2 13 19900601 Jun 1,1990 VI.C. References added
422 Arsenic, Inorganic 7440-38-2 14 19901201 Dec 1,1990 II.B. Changed slope factor to "unit risk", 2nd paragraph, 1st sentence
423 Arsenic, Inorganic 7440-38-2 15 19910201 Feb 1,1991 II.C.3. Text edited
424 Arsenic, Inorganic 7440-38-2 16 19910901 Sep 1,1991 I.A. Oral RfD summary now on-line
425 Arsenic, Inorganic 7440-38-2 17 19910901 Sep 1,1991 I.A. Oral RfD bibliography added
426 Arsenic, Inorganic 7440-38-2 18 19911001 Oct 1,1991 I.A.1. Conversion factor text clarified
427 Arsenic, Inorganic 7440-38-2 19 19911001 Oct 1,1991 IV.B.1. MCLG noted as pending change
428 Arsenic, Inorganic 7440-38-2 20 19920101 Jan 1,1992 IV. Regulatory actions updated
429 Arsenic, Inorganic 7440-38-2 21 19920801 Aug 1,1992 II. Note added to indicate text in oral quant. estimate
430 Arsenic, Inorganic 7440-38-2 22 19921001 Oct 1,1992 VI.C. Missing reference added to bibliography
431 Arsenic, Inorganic 7440-38-2 23 19930201 Feb 1,1993 I.A.4. Citations added to second paragraph
432 Arsenic, Inorganic 7440-38-2 24 19930201 Feb 1,1993 VI.A. References added to bibliography
433 Arsenic, Inorganic 7440-38-2 25 19930301 Mar 1,1993 VI.A. Corrections to references
434 Arsenic, Inorganic 7440-38-2 26 19940301 Mar 1,1994 II.D.2. Work group review date added
435 Arsenic, Inorganic 7440-38-2 27 19940601 Jun 1,1994 II. Carcinogen assessment noted as pending change
436 Arsenic, Inorganic 7440-38-2 28 19950101 Jan 1,1995 II. Pending change note revised
437 Arsenic, Inorganic 7440-38-2 29 19950101 Jan 1,1995 II.B. Dates and document no. added to oral quant. estimate
438 Arsenic, Inorganic 7440-38-2 30 19950601 Jun 1,1995 II. Carcinogenicity assessment replaced
439 Arsenic, Inorganic 7440-38-2 31 19950601 Jun 1,1995 VI.C. Carcinogenicity references replaced
440 Arsenic, Inorganic 7440-38-2 32 19950701 Jul 1,1995 II.D.1 Documentation year corrected; review statement revised
441 Arsenic, Inorganic 7440-38-2 33 19950701 Jul 1,1995 VI.C. U.S. EPA, 1994 corrected to 1993
442 Arsenic, Inorganic 7440-38-2 34 19950801 Aug 1,1995 II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
443 Arsenic, Inorganic 7440-38-2 35 19970401 Apr 1,1997 III.,IV.,V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
444 Arsenic, Inorganic 7440-38-2 36 19980410 Apr 10,1998 II.B.3. Added discussion on expert panel workshop
445 Arsenic, Inorganic 7440-38-2 37 20000211 Feb 11,2000 II.C.2. Corrected alignment of unit risks in table with corresponding studies
446 Arsenic, Inorganic 7440-38-2 38 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
447 Arsine 7784-42-1 1 19930301 Mar 1,1993 I.B. Inhalation RfC now under review
448 Arsine 7784-42-1 2 19940301 Mar 1,1994 I.B. Inhalation RfC on-line
449 Arsine 7784-42-1 3 19940301 Mar 1,1994 VI.B. Inhalation RfC references on-line
450 Arsine 7784-42-1 4 19970401 Apr 1,1997 III.,IV.,V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
451 Arsine 7784-42-1 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
452 Asbestos 1332-21-4 1 19880926 Sep 26,1988 II. Carcinogen summary on-line
453 Asbestos 1332-21-4 2 19890501 May 1,1989 II. Carcinogen summary noted as pending change
454 Asbestos 1332-21-4 3 19891201 Dec 1,1989 VI. Bibliography on-line
455 Asbestos 1332-21-4 4 19910301 Mar 1,1991 II.A.1. Text revised
456 Asbestos 1332-21-4 5 19910701 Jul 1,1991 II.C.3 Last paragraph units changed from ug/cu.m to fibers/ml
457 Asbestos 1332-21-4 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
458 Asbestos 1332-21-4 7 19930701 Jul 1,1993 II.D.1. EPA Documentation clarified
459 Asbestos 1332-21-4 8 19930701 Jul 1,1993 VI.C. References alphabetized correctly
460 Asbestos 1332-21-4 9 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
461 Asbestos 1332-21-4 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
462 Asbestos 1332-21-4 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
463 Assure 76578-14-8 1 19880926 Sep 26,1988 I.A. Oral RfD summary on-line
464 Assure 76578-14-8 2 19891001 Oct 1,1989 VI. Bibliography on-line
465 Assure 76578-14-8 3 19910601 Jun 1,1991 II. Carcinogenicity assessment on-line
466 Assure 76578-14-8 4 19910601 Jun 1,1991 VI.C. Carcinogenicity references added
467 Assure 76578-14-8 5 19910701 Jul 1,1991 II.D.2. Work group review date corrected
468 Assure 76578-14-8 6 19931001 Oct 1,1993 II.D.3. Primary contact changed; secondary's phone no. changed
469 Assure 76578-14-8 7 19950801 Aug 1,1995 II.D.2. EPA's RfD/RfC and CRAVE workgropups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS pilot Program replaced the workgroup functions beginning in September, 1995.
470 Assure 76578-14-8 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
471 Assure 76578-14-8 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
472 Asulam 3337-71-1 1 19891101 Nov 1,1989 VI. Bibliography on-line
473 Asulam 3337-71-1 2 19920101 Jan 1,1992 IV. Regulatory action section on-line
474 Asulam 3337-71-1 3 19950101 Jan 1,1995 I.A. Oral RfD noted as pending change
475 Asulam 3337-71-1 4 19950101 Jan 1,1995 I.A.6. Work group reveiw date added
476 Asulam 3337-71-1 5 19950801 Aug 1,1995 I.A.,I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reveiws that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
477 Asulam 3337-71-1 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
478 Asulam 3337-71-1 7 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
479 Asulam 3337-71-1 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
480 Atrazine 1912-24-9 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
481 Atrazine 1912-24-9 2 19880822 Aug 22,1988 I.A. Withdrawn; new oral RfD in preparation
482 Atrazine 1912-24-9 3 19880907 Sep 7,1988 I.A. Revised oral RfD summary added
483 Atrazine 1912-24-9 4 19891001 Oct 1,1989 VI. Bibliography on-line
484 Atrazine 1912-24-9 5 19900301 Mar 1,1990 I.A. Withdrawn; new oral RfD in preparation
485 Atrazine 1912-24-9 6 19900301 Mar 1,1990 VI.A. Oral RfD references withdrawn
486 Atrazine 1912-24-9 7 19900501 May 1,1990 I.A. Oral RfD summary replaced; RfD unchanged
487 Atrazine 1912-24-9 8 19900501 May 1,1990 VI.A. Oral RfD references replaced
488 Atrazine 1912-24-9 9 19910101 Jan 1,1991 I.A. Text edited
489 Atrazine 1912-24-9 10 19910101 Jan 1,1991 II. Carcinogen assessment now under review
490 Atrazine 1912-24-9 11 19920101 Jan 1,1992 IV. Regulatory Action section on-line
491 Atrazine 1912-24-9 12 19921201 Dec 1,1992 I.A. Oral RfD summary noted as pending change
492 Atrazine 1912-24-9 13 19921201 Dec 1,1992 I.A.6. Work group review date added
493 Atrazine 1912-24-9 14 19930101 Jan 1,1993 I.A. Withdrawn; new oral RfD in preparation
494 Atrazine 1912-24-9 15 19930101 Jan 1,1993 I.A. Work group review date added
495 Atrazine 1912-24-9 16 19930101 Jan 1,1993 VI.A. Oral RfD references withdrawn
496 Atrazine 1912-24-9 17 19931001 Oct 1,1993 I.A. Oral RfD summary replaced; RfD changed
497 Atrazine 1912-24-9 18 19931001 Oct 1,1993 VI.A. Oral RfD references replaced
498 Atrazine 1912-24-9 19 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning ing September, 1995.
499 Atrazine 1912-24-9 20 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
500 Atrazine 1912-24-9 21 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
501 Avermectin B1 65195-55-3 1 19890701 Jul 1,1989 I.A. Oral RfD summary on-line
502 Avermectin B1 65195-55-3 2 19890701 Jul 1,1989 VI. Bibliography on-line
503 Avermectin B1 65195-55-3 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Acions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
504 Avermectin B1 65195-55-3 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
505 Azobenzene 103-33-3 1 19880907 Sep 7,1988 II. Carcinogen summary on-line
506 Azobenzene 103-33-3 2 19890801 Aug 1,1989 VI. Bibliography on-line
507 Azobenzene 103-33-3 3 19910101 Jan 1,1991 II. Text edited
508 Azobenzene 103-33-3 4 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
509 Azobenzene 103-33-3 5 19930701 Jul 1,1993 II.D.3. Secondary contact's phone number changed
510 Azobenzene 103-33-3 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisoreis, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information
511 Azobenzene 103-33-3 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
512 Barium and Compounds 7440-39-3 1 19870930 Sep 30,1987 IV. Regulatory Action section added
513 Barium and Compounds 7440-39-3 2 19880301 Mar 1,1988 I.A.1. Dose conversion clarified
514 Barium and Compounds 7440-39-3 3 19880301 Mar 1,1988 I.A.3. Text changed
515 Barium and Compounds 7440-39-3 4 19880301 Mar 1,1988 I.A.7. Secondary contact changed
516 Barium and Compounds 7440-39-3 5 19880630 Jun 30,1988 I.A.7. Contacts switched
517 Barium and Compounds 7440-39-3 6 19890801 Aug 1,1989 VI. Bibliography on-line
518 Barium and Compounds 7440-39-3 7 19900601 Jun 1,1990 IV.F.1. EPA contact changed
519 Barium and Compounds 7440-39-3 8 19900701 Jul 1,1990 I.A. Withdrawn; new RfD verified (in preparation)
520 Barium and Compounds 7440-39-3 9 19900701 Jul 1,1990 VI. Bibliography withdrawn
521 Barium and Compounds 7440-39-3 10 19900801 Aug 1,1990 I.A. Oral RfD summary replaced; RfD changed
522 Barium and Compounds 7440-39-3 11 19900801 Aug 1,1990 VI. Bibliography replaced
523 Barium and Compounds 7440-39-3 12 19901201 Dec 1,1990 I.B. Inhalation RfC now under review
524 Barium and Compounds 7440-39-3 13 19920101 Jan 1,1992 IV. Regulatory actions updated
525 Barium and Compounds 7440-39-3 14 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
526 Barium and Compounds 7440-39-3 15 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
527 Barium and Compounds 7440-39-3 16 19980330 Mar 30,1998 I.A. Oral RfD Assessment
528 Barium and Compounds 7440-39-3 17 19980330 Mar 30,1998 I.B. Inahalation RfC Assessment
529 Barium and Compounds 7440-39-3 18 19980330 Mar 30,1998 II. Carcinogenicity Assessment
530 Barium and Compounds 7440-39-3 19 19990121 Jan 21,1999 I.A. Minor revisions to RfD Assessment, revised critical effect
531 Barium and Compounds 7440-39-3 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
532 Barium cyanide 542-62-1 1 19880301 Mar 1,1988 I.A.2. Text revised paragraph 3
533 Barium cyanide 542-62-1 2 19890101 Jan 1,1989 I.A.1. LOAEL dose rate units corrected
534 Barium cyanide 542-62-1 3 19910301 Mar 1,1991 VI. Bibliography withdrawn
535 Barium cyanide 542-62-1 4 19891101 Nov 1,1989 VI. Bibliography on-line
536 Barium cyanide 542-62-1 5 19910301 Mar 1,1991 I.A. Oral RfD withdrawn pending additional review
537 Barium cyanide 542-62-1 6 19920101 Jan 1,1992 IV. Regulatory actions updated
538 Barium cyanide 542-62-1 7 19930801 Aug 1,1993 I.A. Oral RfD withdrawn pending addditional review
539 Barium cyanide 542-62-1 8 19930801 Aug 1,1993 I.A. EPA contact changed
540 Barium cyanide 542-62-1 9 19950801 Aug 1,1995 I.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
541 Barium cyanide 542-62-1 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
542 Barium cyanide 542-62-1 11 20181219 Dec 19,2018 Archived Chemical IRIS Program requested that we archive assessments with no values.
543 Barium cyanide 542-62-1 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
544 Baygon 114-26-1 1 19870331 Mar 31,1987 I.A.6. Documentation corrected
545 Baygon 114-26-1 2 19870331 Mar 31,1987 IV.A. Pesticide AI data added
546 Baygon 114-26-1 3 19891101 Nov 1,1989 VI. Bibliography on-line
547 Baygon 114-26-1 4 19901001 Oct 1,1990 III.A. Health Advisory on-line
548 Baygon 114-26-1 5 19901001 Oct 1,1990 VI.D. Health Advisory references added
549 Baygon 114-26-1 6 19920101 Jan 1,1992 IV. Regulatory action updated
550 Baygon 114-26-1 7 19920701 Jul 1,1992 I.A.4. Study 5 citation corrected
551 Baygon 114-26-1 8 19970401 Apr 1,1997 III., IV., V., VI.D. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS useres were directed to the appropriate EPA Program Offices for this information.
552 Baygon 114-26-1 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
553 Bayleton 43121-43-3 1 19880301 Mar 1,1988 I.A.1. Dose conversion clarified
554 Bayleton 43121-43-3 2 19880301 Mar 1,1988 I.A.4. Core grades added
555 Bayleton 43121-43-3 3 19891101 Nov 1,1989 VI. Bibliography on-line
556 Bayleton 43121-43-3 4 19920101 Jan 1,1992 IV. Regulatory action on-line
557 Bayleton 43121-43-3 5 19870401 Apr 1,1987 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS useres were directed to the appropriate EPA Program Offices for this information.
558 Bayleton 43121-43-3 6 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
559 Bayleton 43121-43-3 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
560 Baythroid 68359-37-5 1 19891101 Nov 1,1989 VI. Bibliography on-line
561 Baythroid 68359-37-5 2 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
562 Baythroid 68359-37-5 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
563 Benefin 1861-40-1 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
564 Benefin 1861-40-1 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
565 Benomyl 17804-35-2 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
566 Benomyl 17804-35-2 2 19890301 Mar 1,1989 I.A. Major text revisions
567 Benomyl 17804-35-2 3 19890701 Jul 1,1989 VI. Bibliography on-line
568 Benomyl 17804-35-2 4 19920101 Jan 1,1992 IV. Regulatory action updated
569 Benomyl 17804-35-2 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
570 Benomyl 17804-35-2 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
571 Bentazon (Basagran) 25057-89-0 1 19890401 Apr 1,1989 III. Health Advisory on-line
572 Bentazon (Basagran) 25057-89-0 2 19891101 Nov 1,1989 VI. Bibliography on-line
573 Bentazon (Basagran) 25057-89-0 3 19910501 May 1,1991 I.A. Oral RfD Summary noted as pending change
574 Bentazon (Basagran) 25057-89-0 4 19920101 Jan 1,1992 IV. Regulatory action section on-line
575 Bentazon (Basagran) 25057-89-0 5 19950101 Jan 1,1995 I.A.6. Workgroup review date added
576 Bentazon (Basagran) 25057-89-0 6 19950801 Aug 1,1995 I.A., I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
577 Bentazon (Basagran) 25057-89-0 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
578 Bentazon (Basagran) 25057-89-0 8 19980302 Mar 2,1998 I.A., II., VI. New RfD, cancer assessment
579 Bentazon (Basagran) 25057-89-0 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
580 Benz[a]anthracene 56-55-3 1 19901201 Dec 1,1990 II. Carcinogen assessment on-line
581 Benz[a]anthracene 56-55-3 2 19901201 Dec 1,1990 VI. Bibliography on-line
582 Benz[a]anthracene 56-55-3 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
583 Benz[a]anthracene 56-55-3 4 19930901 Sep 1,1993 II. Carcinogenicity assessment noted as pending change
584 Benz[a]anthracene 56-55-3 5 19930901 Sep 1,1993 II.D.2. Work group review date added
585 Benz[a]anthracene 56-55-3 6 19931101 Nov 1,1993 II.D.2. Work group reveiw date added
586 Benz[a]anthracene 56-55-3 7 19940301 Mar 1,1994 II. Pending change note removed; no change
587 Benz[a]anthracene 56-55-3 8 19940301 Mar 1,1994 II.D.2. Work group review date added
588 Benz[a]anthracene 56-55-3 9 19940901 Sep 1,1994 I.B. Inhalation RfC now under review
589 Benz[a]anthracene 56-55-3 10 19950801 Aug 1,1995 I.B., II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
590 Benz[a]anthracene 56-55-3 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
591 Benz[a]anthracene 56-55-3 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
592 Benzaldehyde 100-52-7 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
593 Benzaldehyde 100-52-7 2 19891201 Dec 1,1989 VI. Bibliography on-line
594 Benzaldehyde 100-52-7 3 19920101 Jan 1,1992 I.A.7. Secondary contact changed
595 Benzaldehyde 100-52-7 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
596 Benzaldehyde 100-52-7 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
597 Benzaldehyde 100-52-7 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
598 Benzene 71-43-2 1 19881201 Dec 1,1988 II.A.4. Anderson and Richardson citation year corrected
599 Benzene 71-43-2 2 19881201 Dec 1,1988 II.A.4. Kissling and Speck citation year corrected
600 Benzene 71-43-2 3 19890701 Jul 1,1989 I.B. Inhalation RfD now under review
601 Benzene 71-43-2 4 19900201 Feb 1,1990 II. Clarified citations
602 Benzene 71-43-2 5 19900201 Feb 1,1990 II.A.3. Corrected Maltoni, 1979 to Maltoni and Scarnato, 1979
603 Benzene 71-43-2 6 19900201 Feb 1,1990 II.A.3. Corrected Maltoni, 1983 to Maltoni et al., 1983
604 Benzene 71-43-2 7 19900201 Feb 1,1990 II.A.3. Corrected Synder et al., 1980 to 1981
605 Benzene 71-43-2 8 19900201 Feb 1,1990 VI. Bibliography on-line
606 Benzene 71-43-2 9 19900301 Mar 1,1990 VI.C. Clarify Maltoni et al., 1983 and NTP, 1986 references
607 Benzene 71-43-2 10 19900801 Aug 1,1990 III.A.10. Primary contact changed
608 Benzene 71-43-2 11 19900801 Aug 1,1990 IV.F.1. EPA contact changed
609 Benzene 71-43-2 12 19910101 Jan 1,1991 II. Text edited
610 Benzene 71-43-2 13 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
611 Benzene 71-43-2 14 19920101 Jan 1,1992 IV. Regulatory actions updated
612 Benzene 71-43-2 15 19920401 Apr 1,1992 II.B.2. Text revised
613 Benzene 71-43-2 16 19940201 Feb 1,1994 II.D.3. Secondary contact's phone number changed
614 Benzene 71-43-2 17 19981016 Oct 16,1998 II., VI. Revised inhalation carcinogenicity section and references
615 Benzene 71-43-2 18 20000119 Jan 19,2000 II., VI. Revised oral carcinogenicity section and references
616 Benzene 71-43-2 19 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
617 Benzidine 92-87-5 1 19880301 Mar 1,1988 II.B.4. Confidence statement revised
618 Benzidine 92-87-5 2 19880301 Mar 1,1988 II.C.4. Confidence statement revised
619 Benzidine 92-87-5 3 19880301 Mar 1,1988 II.D.3. Contacts switched
620 Benzidine 92-87-5 4 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
621 Benzidine 92-87-5 5 19890101 Jan 1,1989 I.A.1. LOAEL and RfD corrected
622 Benzidine 92-87-5 6 19890101 Jan 1,1989 I.A.2. Dose levels corrected
623 Benzidine 92-87-5 7 19900101 Jan 1,1990 I.A.2. Clarify text
624 Benzidine 92-87-5 8 19900101 Jan 1,1990 II.A.2. Corrected Zavon et al. (1973) to Zavon (1973)
625 Benzidine 92-87-5 9 19900101 Jan 1,1990 II.A.4. Corrected Parodi, 1983 to Parodi et al., 1983
626 Benzidine 92-87-5 10 19900101 Jan 1,1990 VI. Bibliography on-line
627 Benzidine 92-87-5 11 19910501 May 1,1991 I.B. Inhalation RfC now under review
628 Benzidine 92-87-5 12 19910701 Jul 1,1991 I.B. Inhalation RfC message on-line
629 Benzidine 92-87-5 13 19910701 Jul 1,1991 VI.B. Inhalation RfC references added
630 Benzidine 92-87-5 14 19920101 Jan 1,1992 I.A.7. Secondary contact changed
631 Benzidine 92-87-5 15 19920101 Jan 1,1992 IV. Regulatory actions updated
632 Benzidine 92-87-5 16 19930701 Jul 1,1993 II.D.1. Zavon, 1973 reference removed from EPA Documentation
633 Benzidine 92-87-5 17 19950201 Feb 1,1995 I.A.7. Secondary contact's name changed
634 Benzidine 92-87-5 18 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
635 Benzidine 92-87-5 19 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
636 Benzo[a]pyrene (BaP) 50-32-8 1 19890801 Aug 1,1989 VI. Bibliography on-line
637 Benzo[a]pyrene (BaP) 50-32-8 2 19920101 Jan 1,1992 II. Carcinogen assessment noted as pending change
638 Benzo[a]pyrene (BaP) 50-32-8 3 19920101 Jan 1,1992 IV. Regulatory actions updated
639 Benzo[a]pyrene (BaP) 50-32-8 4 19920401 Apr 1,1992 II. Summary revised oral quantitative section added
640 Benzo[a]pyrene (BaP) 50-32-8 5 19920401 Apr 1,1992 VI.C. Carcinogen assessment references revised
641 Benzo[a]pyrene (BaP) 50-32-8 6 19920501 May 1,1992 II.D.2. Work group review and verification date corrected
642 Benzo[a]pyrene (BaP) 50-32-8 7 19920701 Jul 1,1992 II. Text revised in Note
643 Benzo[a]pyrene (BaP) 50-32-8 8 19920701 Jul 1,1992 II.B. Range of slope factors corrected
644 Benzo[a]pyrene (BaP) 50-32-8 9 19920701 Jul 1,1992 II.B.1. Slope factor and risks corrected
645 Benzo[a]pyrene (BaP) 50-32-8 10 19920701 Jul 1,1992 II.B.2. Data table heading corrected
646 Benzo[a]pyrene (BaP) 50-32-8 11 19920701 Jul 1,1992 II.B.3. Slope factor corrected last paragraph
647 Benzo[a]pyrene (BaP) 50-32-8 12 19920701 Jul 1,1992 II.D.3. Secondary contact changed
648 Benzo[a]pyrene (BaP) 50-32-8 13 19930901 Sep 1,1993 II. Carcinogenicity assessment noted as pending change
649 Benzo[a]pyrene (BaP) 50-32-8 14 19930901 Sep 1,1993 II.D.2. Work group review date added
650 Benzo[a]pyrene (BaP) 50-32-8 15 19931201 Dec 1,1993 VI.C. Reference revised - U.S. EPA, 1991b
651 Benzo[a]pyrene (BaP) 50-32-8 16 19940201 Feb 1,1994 II.D.3. Primary contact's phone number changed
652 Benzo[a]pyrene (BaP) 50-32-8 17 19940301 Mar 1,1994 II.D.2. Work group review date added
653 Benzo[a]pyrene (BaP) 50-32-8 18 19940701 Jul 1,1994 II.D.2. Work group review date added
654 Benzo[a]pyrene (BaP) 50-32-8 19 19941101 Nov 1,1994 II.B.1. Slope factor clarified changed O to %220%22
655 Benzo[a]pyrene (BaP) 50-32-8 20 19950801 Aug 1,1995 II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
656 Benzo[a]pyrene (BaP) 50-32-8 21 19940301 Mar 1,1994 II. Pending change note removed no change
657 Benzo[a]pyrene (BaP) 50-32-8 22 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
658 Benzo[a]pyrene (BaP) 50-32-8 23 20170119 Jan 19,2017 All EPA completed a reassessment, updating all values.
659 Benzo[a]pyrene (BaP) 50-32-8 24 20180511 May 11,2018 TR Supplemental Info An error was corrected in Table E-1 of the supplemental information document based on a comment from the IRIS hotline. See errata sheet for additional details.
660 Benzo[a]pyrene (BaP) 50-32-8 25 20180802 Aug 2,2018 Key Values WOE Note Added a note regarding ADAF to both the OSF and IUR entries to further explain what is in the tox review.
661 Benzo[a]pyrene (BaP) 50-32-8 26 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
662 Benzo[b]fluoranthene 205-99-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
663 Benzo[g,h,i]perylene 191-24-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
664 Benzo[k]fluoranthene 207-08-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
665 Benzoic acid 65-85-0 1 20180927 Sep 27,2018 Noncancer Critical Updated the system from none to other so it would show up in the advanced search.
666 Benzoic acid 65-85-0 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
667 Benzotrichloride 98-07-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
668 Benzyl chloride 100-44-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
669 Beryllium and compounds 7440-41-7 1 19880301 Mar 1,1988 I.A.1. Reference dose table clarified
670 Beryllium and compounds 7440-41-7 2 19880301 Mar 1,1988 I.A.2. Text added
671 Beryllium and compounds 7440-41-7 3 19880907 Sep 7,1988 II. Carcinogen summary on-line
672 Beryllium and compounds 7440-41-7 4 19900101 Jan 1,1990 II.A.2. References clarified
673 Beryllium and compounds 7440-41-7 5 19900101 Jan 1,1990 II.A.3. Text revised
674 Beryllium and compounds 7440-41-7 6 19900101 Jan 1,1990 II.B. Quanititative estimate for oral exposure section added
675 Beryllium and compounds 7440-41-7 7 19900101 Jan 1,1990 II.C.3. Text revised
676 Beryllium and compounds 7440-41-7 8 19900101 Jan 1,1990 II.D.2. Work group review dates and verification date added
677 Beryllium and compounds 7440-41-7 9 19900101 Jan 1,1990 VI. Bibliography on-line
678 Beryllium and compounds 7440-41-7 10 19900201 Feb 1,1990 VI.A. Puzanova et al. 1978 citation corrected
679 Beryllium and compounds 7440-41-7 11 19900201 Feb 1,1990 VI.C. Wagner et al. 1969 citation corrected
680 Beryllium and compounds 7440-41-7 12 19900901 Sep 1,1990 I.A. Morgareidge ref. now Cox (same study-authors reversed)
681 Beryllium and compounds 7440-41-7 13 19900901 Sep 1,1990 IV.F.1. EPA contact changed
682 Beryllium and compounds 7440-41-7 14 19900901 Sep 1,1990 VI.A. Morgareidge ref. now Cox (same study-authors reversed)
683 Beryllium and compounds 7440-41-7 15 19910101 Jan 1,1991 II. Text edited
684 Beryllium and compounds 7440-41-7 16 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
685 Beryllium and compounds 7440-41-7 17 19920101 Jan 1,1992 IV. Regulatory actions updated
686 Beryllium and compounds 7440-41-7 18 19920901 Sep 1,1992 II.A.3. U.S. EPA citation year corrected, paragraph 3
687 Beryllium and compounds 7440-41-7 19 19920901 Sep 1,1992 II.D.1. Source document year corrected
688 Beryllium and compounds 7440-41-7 20 19920901 Sep 1,1992 II.D.1. Review statement revised
689 Beryllium and compounds 7440-41-7 21 19920901 Sep 1,1992 VI.C. U.S. EPA reference year corrected
690 Beryllium and compounds 7440-41-7 22 19930201 Feb 1,1993 I.A.7. Primary contact changed
691 Beryllium and compounds 7440-41-7 23 19980403 Apr 3,1998 I.A. Oral RfD Assessment
692 Beryllium and compounds 7440-41-7 24 19980403 Apr 3,1998 I.B. Inhalation RfC Assessment
693 Beryllium and compounds 7440-41-7 25 19980403 Apr 3,1998 II. Carcinogenicity Assessment
694 Beryllium and compounds 7440-41-7 26 19950801 Aug 1,1995 II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. the IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
695 Beryllium and compounds 7440-41-7 27 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were remvoed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
696 Beryllium and compounds 7440-41-7 28 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
697 Bidrin 141-66-2 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
698 Bidrin 141-66-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
699 Biphenthrin 82657-04-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
700 Biphenyl 92-52-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
701 Bis(2-chloro-1-methylethyl) ether 108-60-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
702 Bis(2-chloroethoxy)methane 111-91-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
703 Bis(chloroethyl)ether (BCEE) 111-44-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
704 Bis(chloromethyl)ether (BCME) 542-88-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
705 Bisphenol A 80-05-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
706 Boron and Compounds 7440-42-8 1 None None
707 Boron and Compounds 7440-42-8 2 I.A., I.B., II Revised RfD, added RfC discussion and added carcinogenicity assessment.
708 Boron and Compounds 7440-42-8 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
709 Bromate 15541-45-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
710 Brominated dibenzofurans None 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
711 Bromobenzene 108-86-1 1 20090930 Sep 30,2009 I., II. File first on-line.
712 Bromobenzene 108-86-1 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
713 Bromochloromethane 74-97-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
714 Bromodichloromethane 75-27-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
715 p-Bromodiphenyl ether 101-55-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
716 Bromoform 75-25-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
717 Bromomethane 74-83-9 1 19870930 Sep 30,1987 I.A.1. MF changed to UF -- no change in RfD
718 Bromomethane 74-83-9 2 19870930 Sep 30,1987 I.A.2. Text changes
719 Bromomethane 74-83-9 3 19870930 Sep 30,1987 I.A.3. Text changes
720 Bromomethane 74-83-9 4 19870930 Sep 30,1987 I.A.4. Study descriptions added
721 Bromomethane 74-83-9 5 19870930 Sep 30,1987 I.A.5. Text change
722 Bromomethane 74-83-9 6 19870930 Sep 30,1987 I.A.6. Secondary contact changed
723 Bromomethane 74-83-9 7 19880301 Mar 1,1988 I.A.1. Critical effect added
724 Bromomethane 74-83-9 8 19880630 Jun 30,1988 I.A. Withdrawn; new RfD verified (in preparation)
725 Bromomethane 74-83-9 9 19880926 Sep 26,1988 I.A. Oral RfD summary replaced
726 Bromomethane 74-83-9 10 19890501 May 1,1989 II. Carcinogen assessment now under review
727 Bromomethane 74-83-9 11 19890601 Jun 1,1989 II. Carcinogen summary on-line
728 Bromomethane 74-83-9 12 19890601 Jun 1,1989 VI. Bibliography on-line
729 Bromomethane 74-83-9 13 19890801 Aug 1,1989 VI.A. Oral RfD references added
730 Bromomethane 74-83-9 14 19891001 Oct 1,1989 I.B. Inhalation RfC now under review
731 Bromomethane 74-83-9 15 19900601 Jun 1,1990 I.A.2. Dosing clarified
732 Bromomethane 74-83-9 16 19900601 Jun 1,1990 IV.F.1. EPA contact changed
733 Bromomethane 74-83-9 17 19900801 Aug 1,1990 I.A. Text edited
734 Bromomethane 74-83-9 18 19900801 Aug 1,1990 II. Text edited
735 Bromomethane 74-83-9 19 19900801 Aug 1,1990 III.A. Health Advisory on-line
736 Bromomethane 74-83-9 20 19900801 Aug 1,1990 VI.D. Health Advisory references added
737 Bromomethane 74-83-9 21 19910701 Jul 1,1991 I.A.7. Secondary contact changed
738 Bromomethane 74-83-9 22 19920101 Jan 1,1992 IV. Regulatory actions updated
739 Bromomethane 74-83-9 23 19920401 Apr 1,1992 I.B. Inhalation RfC summary on-line
740 Bromomethane 74-83-9 24 19920401 Apr 1,1992 VI.B. Inhalation RfC references added
741 Bromomethane 74-83-9 25 19920501 May 1,1992 I.B.6. Deleted incorrect work group review date
742 Bromomethane 74-83-9 26 19921001 Oct 1,1992 I.B.1. "NOAEL" corrected to LOAEL
743 Bromomethane 74-83-9 27 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
744 Bromomethane 74-83-9 28 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
745 Bromotrichloromethane 75-62-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
746 Bromoxynil 1689-84-5 1 20180927 Sep 27,2018 Noncancer Critical Updated the system from none to other so it would show up in the advanced search.
747 Bromoxynil 1689-84-5 2 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
748 Bromoxynil 1689-84-5 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
749 Bromoxynil octanoate 1689-99-2 1 20180927 Sep 27,2018 Noncancer Critical Updated the system from none to other so it would show up in the advanced search.
750 Bromoxynil octanoate 1689-99-2 2 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
751 Bromoxynil octanoate 1689-99-2 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
752 1,3-Butadiene 106-99-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
753 Butyl benzyl phthalate (BBP) 85-68-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
754 Butylate 2008-41-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
755 t-Butylchloride 507-20-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
756 Butylphthalyl butylglycolate (BPBG) 85-70-1 1 20180927 Sep 27,2018 Noncancer Critical Updated the system from none to other so it would show up in the advanced search.
757 Butylphthalyl butylglycolate (BPBG) 85-70-1 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
758 Cacodylic acid 75-60-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
759 Cadmium 7440-43-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
760 Calcium cyanide 592-01-8 1 20100928 Sep 28,2010 I.A. Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment
761 Calcium cyanide 592-01-8 2 20180927 Sep 27,2018 n Updated the system value to other so it would show up in the advanced search.
762 Calcium cyanide 592-01-8 3 20181003 Oct 3,2018 I.A. Updated the system value to reproductive.
763 Calcium cyanide 592-01-8 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
764 Caprolactam 105-60-2 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
765 Caprolactam 105-60-2 2 19891101 Nov 1,1989 VI. Bibliography on-line
766 Caprolactam 105-60-2 3 19940901 Sep 1,1994 I.B. Inhalation RfC under review and message on-line
767 Caprolactam 105-60-2 4 19940901 Sep 1,1994 VI.B. Inhalation RfC references on-line
768 Caprolactam 105-60-2 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
769 Caprolactam 105-60-2 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
770 Captafol 2425-06-1 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
771 Captafol 2425-06-1 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
772 Captan 133-06-2 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
773 Captan 133-06-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
774 Carbaryl 63-25-2 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
775 Carbaryl 63-25-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
776 Carbofuran 1563-66-2 1 None None
777 Carbofuran 1563-66-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
778 Carbon disulfide 75-15-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
779 Carbon tetrachloride 56-23-5 30 20100331 Mar 31,2010 I., II., VI. RfD and cancer assessment sections updated RfC assessment added.
780 Carbon tetrachloride 56-23-5 31 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
781 Carbonyl sulfide 463-58-1 1 20181219 Dec 19,2018 Archived Chemical IRIS Program requested that we archive assessments with no values.
782 Carbonyl sulfide 463-58-1 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
783 Carbosulfan 55285-14-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
784 Carboxin 5234-68-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
785 Cerium Oxide and Cerium Compounds 1306-38-3 1 20090929 Sep 29,2009 I., II. RfD, RfC, and cancer assessment first on-line
786 Cerium Oxide and Cerium Compounds 1306-38-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
787 Chloral hydrate 302-17-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
788 Chloramben 133-90-4 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
789 Chloramben 133-90-4 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
790 Chlordane (Technical) 12789-03-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
791 Chlordecone (Kepone) 143-50-0 1 20090922 Sep 22,2009 I., II. RfD, RfC, and cancer assessment first on line
792 Chlordecone (Kepone) 143-50-0 2 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
793 Chlordecone (Kepone) 143-50-0 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
794 Chlorimuron-ethyl 90982-32-4 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
795 Chlorimuron-ethyl 90982-32-4 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
796 Chlorine 7782-50-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
797 Chlorine cyanide 506-77-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
798 Chlorine dioxide 10049-04-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
799 Chlorite (sodium salt) 7758-19-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
800 1-Chloro-1,1-difluoroethane 75-68-3 1 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
801 1-Chloro-1,1-difluoroethane 75-68-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
802 2-Chloroacetophenone 532-27-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
803 p-Chloroaniline 106-47-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
804 Chlorobenzene 108-90-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
805 Chlorobenzilate 510-15-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
806 1-Chlorobutane 109-69-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
807 2-Chlorobutane 78-86-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
808 Chlorocyclopentadiene 41851-50-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
809 Chlorodifluoromethane 75-45-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
810 Chloroform 67-66-3 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
811 Chloromethyl methyl ether (CMME) 107-30-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
812 beta-Chloronaphthalene 91-58-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
813 2-Chlorophenol 95-57-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
814 p-Chlorophenyl methyl sulfide 123-09-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
815 p-Chlorophenyl methyl sulfone 98-57-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
816 p-Chlorophenyl methyl sulfoxide 934-73-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
817 Chloroprene 126-99-8 1 20100930 Sep 30,2010 I, II, VI, VII, VIII RfC, and cancer assessment added
818 Chloroprene 126-99-8 2 20180710 Jul 10,2018 Key Values Table A footnote was added for ADAF.
819 Chloroprene 126-99-8 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
820 Chlorothalonil 1897-45-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
821 o-Chlorotoluene 95-49-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
822 Chlorpropham 101-21-3 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
823 Chlorpropham 101-21-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
824 Chlorpyrifos 2921-88-2 1 19880301 Mar 1,1988 I.A.5. Core grades added
825 Chlorpyrifos 2921-88-2 2 19891101 Nov 1,1989 VI. Bibliography on-line
826 Chlorpyrifos 2921-88-2 3 19920101 Jan 1,1992 IV. Regulatory actions updated
827 Chlorpyrifos 2921-88-2 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
828 Chlorpyrifos 2921-88-2 5 20180314 Mar 14,2018 Archived Assessment IRIS working with OPP agreed to mark this pesticide chemical archived.
829 Chlorpyrifos 2921-88-2 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
830 Chlorsulfuron 64902-72-3 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
831 Chlorsulfuron 64902-72-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
832 Chromium(III), insoluble salts 16065-83-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
833 Chromium(VI) 18540-29-9 1 19870930 Sep 30,1987 II.A.1. Citation corrected
834 Chromium(VI) 18540-29-9 2 19880301 Mar 1,1988 II.C.4. Confidence statement revised
835 Chromium(VI) 18540-29-9 3 19880301 Mar 1,1988 II.D.3. Contacts switched
836 Chromium(VI) 18540-29-9 4 19880301 Mar 1,1988 III.A. Health Advisory added
837 Chromium(VI) 18540-29-9 5 19891201 Dec 1,1989 I.B. Inhalation RfD now under review
838 Chromium(VI) 18540-29-9 6 19900601 Jun 1,1990 II.A.1. Basis - text revised
839 Chromium(VI) 18540-29-9 7 19900601 Jun 1,1990 II.B. Text revised
840 Chromium(VI) 18540-29-9 8 19900601 Jun 1,1990 IV.A.1. Area code for EPA contact corrected
841 Chromium(VI) 18540-29-9 9 19900601 Jun 1,1990 IV.F.1 EPA contact changed
842 Chromium(VI) 18540-29-9 10 19900601 Jun 1,1990 VI. Bibliography on-line
843 Chromium(VI) 18540-29-9 11 19910101 Jan 1,1991 II. Text edited
844 Chromium(VI) 18540-29-9 12 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
845 Chromium(VI) 18540-29-9 13 19910301 Mar 1,1991 II.A.1. Text Revised
846 Chromium(VI) 18540-29-9 14 19910301 Mar 1,1991 II.A.4. Text revised
847 Chromium(VI) 18540-29-9 15 19910301 Mar 1,1991 II.B. Text revised
848 Chromium(VI) 18540-29-9 16 19920101 Jan 1,1992 I.A.7. Secondary contact changed
849 Chromium(VI) 18540-29-9 17 19920101 Jan 1,1992 IV. Regulatory actions updated
850 Chromium(VI) 18540-29-9 18 19920401 Apr 1,1992 IV.A.1. CAA regulatory action withdrawn
851 Chromium(VI) 18540-29-9 19 19920601 Jun 1,1992 All CASRN corrected from 7440-47-3 to 18540-29-9
852 Chromium(VI) 18540-29-9 20 19940901 Sep 1,1994 I.A.6. Work group review date added
853 Chromium(VI) 18540-29-9 21 19950201 Feb 1,1995 I.A. RfD noted as pending change: Work Grp Mtg on 8/3/1994
854 Chromium(VI) 18540-29-9 22 19950801 Aug 1,1995 I.A., I.A.6., I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in 1995. Chemical substance reviews that were not completed by September May 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
855 Chromium(VI) 18540-29-9 23 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
856 Chromium(VI) 18540-29-9 24 19961201 Dec 1,1996 I.A.7. Secondary contact removed
857 Chromium(VI) 18540-29-9 25 19980903 Sep 3,1998 I., II., VI. Revised RfD, RfC, carcinogenicity assessment, and refs.
858 Chromium(VI) 18540-29-9 26 20190718 Jul 18,2019 RFC Particulates Made a correction to the labels in the table for the POD to match the IRIS Summary.
859 Chromium(VI) 18540-29-9 27 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
860 Chrysene 218-01-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
861 Cobalt and Cobalt Compounds 1307-96-6 1 20220624 Jun 24,2022 None EPA announced the cobalt assessment in the program Outlook (Jun 2022).
862 Cobalt and Cobalt Compounds 1307-96-6 2 20221114 Nov 14,2022 None IRIS released the IAP
863 Cobalt and Cobalt Compounds 1307-96-6 3 20221213 Dec 13,2022 None IRIS announced the public science meeting registration was open for the Jan 11, 2023 meeting.
864 Coke oven emissions None 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
865 Copper 7440-50-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
866 Copper cyanide 544-92-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
867 Creosote 8001-58-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
868 Crotonaldehyde 123-73-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
869 Cumene 98-82-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
870 Cyanazine 21725-46-2 1 20181210 Dec 10,2018 Archived Values Requested by the IRIS Program to archive the chemicals with null values.
871 Cyanazine 21725-46-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
872 Cyanide, free 57-12-5 1 20100928 Sep 28,2010 I.A. Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment
873 Cyanide, free 57-12-5 2 19870331 Mar 31,1987 IV.B. RQ - new rationale text
874 Cyanide, free 57-12-5 3 19880301 Mar 1,1988 I.A.5. Confidence levels revised
875 Cyanide, free 57-12-5 4 19880301 Mar 1,1988 III.A. Health Advisory added
876 Cyanide, free 57-12-5 5 19880907 Sep 7,1988 II. Carcinogen summary on-line
877 Cyanide, free 57-12-5 6 19900101 Jan 1,1990 VI. Bibliography on-line
878 Cyanide, free 57-12-5 7 19900801 Aug 1,1990 III.A.10 Primary contact changed
879 Cyanide, free 57-12-5 8 20180927 Sep 27,2018 Noncancer Critical Updated the system value to other so it would show up in the advanced search.
880 Cyanide, free 57-12-5 10 20181003 Oct 3,2018 I.A. Updated the RfD system value to reproductive.
881 Cyanide, free 57-12-5 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
882 Cyanogen 460-19-5 1 None None
883 Cyanogen 460-19-5 2 20100928 Sep 28,2010 I.A. Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment
884 Cyanogen 460-19-5 3 20180927 Sep 27,2018 Noncancer Critical Updated the system value to other so it would show up in the advanced search.
885 Cyanogen 460-19-5 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
886 Cyanogen bromide 506-68-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
887 Cyclohexane 110-82-7 1 all IRIS summary first posted.
888 Cyclohexane 110-82-7 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
889 Cyclohexanone 108-94-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
890 Cyclohexylamine 108-91-8 1 None None
891 Cyclohexylamine 108-91-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
892 Cyhalothrin/Karate 68085-85-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
893 Cypermethrin 52315-07-8 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
894 Cypermethrin 52315-07-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
895 Cyromazine 66215-27-8 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
896 Cyromazine 66215-27-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
897 Dacthal 1861-32-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
898 Dalapon, sodium salt 75-99-0 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
899 Dalapon, sodium salt 75-99-0 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
900 Danitol 39515-41-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
901 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 1 20080630 Jun 30,2008 I., II., VI. RfD, RfC, and cancer assessment sections updated.
902 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
903 Demeton 8065-48-3 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
904 Demeton 8065-48-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
905 Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
906 Di(2-ethylhexyl)adipate 103-23-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
907 2,4-Diaminotoluene 95-80-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
908 Diazomethane 334-88-3 1 20181219 Dec 19,2018 Archive Chemical IRIS Program requested that we archive assessments with no values.
909 Diazomethane 334-88-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
910 Dibenz[a,h]anthracene 53-70-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
911 Dibenzofuran 132-64-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
912 1,2-Dibromo-3-chloropropane (DBCP) 96-12-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
913 1,4-Dibromobenzene 106-37-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
914 Dibromochloromethane 124-48-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
915 Dibromodichloromethane 594-18-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
916 p,p'-Dibromodiphenyl ether 2050-47-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
917 1,2-Dibromoethane 106-93-4 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
918 Dibutyl phthalate (DBP) 84-74-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
919 Dicamba 1918-00-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
920 Dichloroacetic acid 79-43-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
921 1,4-Dichlorobenzene 106-46-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
922 1,3-Dichlorobenzene 541-73-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
923 1,2-Dichlorobenzene 95-50-1 1 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
924 1,2-Dichlorobenzene 95-50-1 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
925 3,3'-Dichlorobenzidine 91-94-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
926 Dichlorodifluoromethane 75-71-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
927 p,p'-Dichlorodiphenyl dichloroethane (DDD) 72-54-8 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
928 p,p'-Dichlorodiphenyl dichloroethane (DDD) 72-54-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
929 p,p'-Dichlorodiphenyldichloroethylene (DDE) 72-55-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
930 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 1 19870930 Sep 30,1987 I.A.6. Documentation changed
931 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 2 19880822 Aug 22,1988 II. Carcinogen summary on-line
932 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 3 19910101 Jan 1,1991 II. Text edited
933 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 4 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
934 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 5 19910501 May 1,1991 II.A.3. Change Lehman, 1952 to '1951'
935 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 6 19910501 May 1,1991 VI. Bibliography on-line
936 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 7 19920101 Jan 1,1992 I.A.7. Secondary contact changed
937 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 8 19920101 Jan 1,1992 IV. Regulatory actions updated
938 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 9 19960201 Feb 1,1996 I.A.7. Contact changed
939 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Office.
940 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 11 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
941 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
942 1,2-Dichloroethane 107-06-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
943 1,1-Dichloroethane 75-34-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
944 cis-1,2-Dichloroethylene 156-59-2 1 19901201 Dec 1,1990 II. Carcinogen assessment on-line
945 cis-1,2-Dichloroethylene 156-59-2 2 19901201 Dec 1,1990 VI. Bibliography on-line
946 cis-1,2-Dichloroethylene 156-59-2 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
947 cis-1,2-Dichloroethylene 156-59-2 4 19950201 Feb 1,1995 II.D.3. Primary contact changed
948 cis-1,2-Dichloroethylene 156-59-2 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
949 cis-1,2-Dichloroethylene 156-59-2 6 20021203 Dec 3,2002 II.D.2. Screening-Level Literature Review Findings message has been added.
950 cis-1,2-Dichloroethylene 156-59-2 7 20100930 Sep 30,2010 I., II., VI. RfD assessment added; RfC and cancer assessment sections revised.
951 cis-1,2-Dichloroethylene 156-59-2 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
952 trans-1,2-Dichloroethylene 156-60-5 1 19880926 Sep 26,1988 I.A. Oral RfD summary on-line
953 trans-1,2-Dichloroethylene 156-60-5 2 19890101 Jan 1,1989 I.A.7. Contact phone number corrected
954 trans-1,2-Dichloroethylene 156-60-5 3 19910301 Mar 1,1991 VI. Bibliography on-line
955 trans-1,2-Dichloroethylene 156-60-5 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
956 trans-1,2-Dichloroethylene 156-60-5 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
957 trans-1,2-Dichloroethylene 156-60-5 6 20021203 Dec 3,2002 I.A.6. Screening-Level Literature Review Findings message has been added
958 trans-1,2-Dichloroethylene 156-60-5 7 20100930 Sep 30,2010 I., II., VI. RfD assessment added; RfC and cancer assessment sections revised.
959 trans-1,2-Dichloroethylene 156-60-5 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
960 1,1-Dichloroethylene (1,1-DCE) 75-35-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
961 Dichloromethane 75-09-2 1 20111118 Nov 18,2011 I., II, VI. RfD and cancer assessment updated. RfC added.
962 Dichloromethane 75-09-2 2 19870420 Apr 20,1987 II.C.1. Unit Risk corrected from 4.1E-4 to 4.1E-6
963 Dichloromethane 75-09-2 3 19870521 May 21,1987 II.A.2. Missing text replaced in 3rd paragraph
964 Dichloromethane 75-09-2 4 19880301 Mar 1,1988 I.A.1. Dose conversion clarified
965 Dichloromethane 75-09-2 5 19880301 Mar 1,1988 I.A.2. Text revised
966 Dichloromethane 75-09-2 6 19880301 Mar 1,1988 II.B.3. Text revised
967 Dichloromethane 75-09-2 7 19880301 Mar 1,1988 II.B.4. Confidence statement revised
968 Dichloromethane 75-09-2 8 19880301 Mar 1,1988 II.C.3. Text revised
969 Dichloromethane 75-09-2 9 19880301 Mar 1,1988 II.C.4. Confidence statement revised
970 Dichloromethane 75-09-2 10 19880301 Mar 1,1988 II.D.3. Primary contact changed
971 Dichloromethane 75-09-2 11 19880301 Mar 1,1988 III.A. Health Advisory added
972 Dichloromethane 75-09-2 12 19890101 Jan 1,1989 II. Carcinogen summary noted as pending change
973 Dichloromethane 75-09-2 13 19891001 Oct 1,1989 II.B.3. Inhalation rate corrected in paragraph 1
974 Dichloromethane 75-09-2 14 19891001 Oct 1,1989 II.C.2. Dose corrections in mg/kg/day
975 Dichloromethane 75-09-2 15 19891001 Oct 1,1989 II.C.3. Inhalation rate corrected in paragraph 1
976 Dichloromethane 75-09-2 16 19891001 Oct 1,1989 II.D.3. Contacts phone number changed
977 Dichloromethane 75-09-2 17 19900801 Aug 1,1990 IV.F.1. EPA contact changed
978 Dichloromethane 75-09-2 18 19900901 Sep 1,1990 II. Carcinogen assessment revised following re-evaluation
979 Dichloromethane 75-09-2 19 19900901 Sep 1,1990 II.C.1. Inhalation unit risk changed
980 Dichloromethane 75-09-2 20 19900901 Sep 1,1990 VI. Bibliography on-line
981 Dichloromethane 75-09-2 21 19910101 Jan 1,1991 II.C.1. Paragraph moved to II.C.3.
982 Dichloromethane 75-09-2 22 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
983 Dichloromethane 75-09-2 23 19910801 Aug 1,1991 VI.C. Citations clarified
984 Dichloromethane 75-09-2 24 19910901 Sep 1,1991 I.B. Inhalation RfC now under review
985 Dichloromethane 75-09-2 25 19920101 Jan 1,1992 IV. Regulatory actions updated
986 Dichloromethane 75-09-2 26 19950201 Feb 1,1995 II.D.3. Primary contact changed
987 Dichloromethane 75-09-2 27 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
988 Dichloromethane 75-09-2 28 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
989 Dichloromethane 75-09-2 29 20021203 Dec 3,2002 I.A.6., II.D.2. Screening-Level Literature Review Findings message has been added.
990 Dichloromethane 75-09-2 30 20030429 Apr 29,2003 II.D.2. Screening Level Literature Review findings revised.
991 Dichloromethane 75-09-2 31 20030730 Jul 30,2003 I., II. This chemical is being reassessed under the IRIS Program.
992 Dichloromethane 75-09-2 32 20180710 Jul 10,2018 Key Values Table A footnote was added for ADAF.
993 Dichloromethane 75-09-2 33 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
994 2,4-Dichlorophenol 120-83-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
995 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) 94-82-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
996 2,4-Dichlorophenoxyacetic acid (2,4-D) 94-75-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
997 1,2-Dichloropropane 78-87-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
998 2,3-Dichloropropanol 616-23-9 1 None None
999 2,3-Dichloropropanol 616-23-9 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1000 1,3-Dichloropropene 542-75-6 1 19880926 Sep 26,1988 II. Carcinogen summary on-line
1001 1,3-Dichloropropene 542-75-6 2 19881201 Dec 1,1988 II.B.3. Text added
1002 1,3-Dichloropropene 542-75-6 3 19890301 Mar 1,1989 II.A.1. Text added
1003 1,3-Dichloropropene 542-75-6 4 19890301 Mar 1,1989 II.A.3. Text added
1004 1,3-Dichloropropene 542-75-6 5 19891001 Oct 1,1989 II.B. Oral quantitative risk estimate has been withdrawn
1005 1,3-Dichloropropene 542-75-6 6 19891001 Oct 1,1989 VI. Bibliography on-line
1006 1,3-Dichloropropene 542-75-6 7 19900901 Sep 1,1990 I.B. Inhalation RfC assessment now under review
1007 1,3-Dichloropropene 542-75-6 8 19901001 Oct 1,1990 I.A. Text edited
1008 1,3-Dichloropropene 542-75-6 9 19901001 Oct 1,1990 II. Text edited
1009 1,3-Dichloropropene 542-75-6 10 19910101 Jan 1,1991 I.B. Inhalation RfC summary on-line
1010 1,3-Dichloropropene 542-75-6 11 19910101 Jan 1,1991 VI.B. Inhalation RfC references added
1011 1,3-Dichloropropene 542-75-6 12 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1012 1,3-Dichloropropene 542-75-6 13 19930201 Feb 1,1993 III.A. Health Advisory on-line
1013 1,3-Dichloropropene 542-75-6 14 19930201 Feb 1,1993 VI.D. Health Advisory references on-line
1014 1,3-Dichloropropene 542-75-6 15 19930901 Sep 1,1993 II. Carcinogenicity assessment noted as pending change
1015 1,3-Dichloropropene 542-75-6 16 19930901 Sep 1,1993 II.D.2. Work group review date added
1016 1,3-Dichloropropene 542-75-6 17 19931001 Oct 1,1993 II.D.3. Primary contact changed; secondary's phone number changed
1017 1,3-Dichloropropene 542-75-6 18 19950801 Aug 1,1995 II., II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1018 1,3-Dichloropropene 542-75-6 19 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Office for this information.
1019 1,3-Dichloropropene 542-75-6 20 20000525 May 25,2000 I.A. Revised RfD
1020 1,3-Dichloropropene 542-75-6 21 20000525 May 25,2000 I.B. Revised RfC
1021 1,3-Dichloropropene 542-75-6 22 20000525 May 25,2000 II. Revised carcinogen summary
1022 1,3-Dichloropropene 542-75-6 23 20000525 May 25,2000 II.A. Added oral cancer potency
1023 1,3-Dichloropropene 542-75-6 24 20000525 May 25,2000 II.B. Added inhalation cancer potency
1024 1,3-Dichloropropene 542-75-6 25 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1025 Dichlorvos 62-73-7 1 19880301 Mar 1,1988 I.A. NOAEL reevaluated-RfD changed
1026 Dichlorvos 62-73-7 2 19880301 Mar 1,1988 I.A.5. Confidence levels revised
1027 Dichlorvos 62-73-7 3 19881201 Dec 1,1988 I.A.1. Converted dose for NOEL added
1028 Dichlorvos 62-73-7 4 19881201 Dec 1,1988 I.A.4. Study 2) NOEL clarified
1029 Dichlorvos 62-73-7 5 19891001 Oct 1,1989 II. Carcinogen summary on-line
1030 Dichlorvos 62-73-7 6 19891201 Dec 1,1989 II.A.3. Correct Kettering Lab (1974) to Shell Chemical (1967)
1031 Dichlorvos 62-73-7 7 19891201 Dec 1,1989 II.A.4. Correct spelling: Setervaick to 'Segerbaeck'
1032 Dichlorvos 62-73-7 8 19891201 Dec 1,1989 II.B.2. Correct reference citations
1033 Dichlorvos 62-73-7 9 19891201 Dec 1,1989 VI. Bibliography on-line
1034 Dichlorvos 62-73-7 10 19920101 Jan 1,1992 II. Carcinogen assessment noted as pending change
1035 Dichlorvos 62-73-7 11 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1036 Dichlorvos 62-73-7 12 19920701 Jul 1,1992 I.A. Withdrawn; new RfD verified (in preparation)
1037 Dichlorvos 62-73-7 13 19920701 Jul 1,1992 VI.A. Oral RfD references withdrawn
1038 Dichlorvos 62-73-7 14 19921201 Dec 1,1992 I.B. Inhalation RfC now under review
1039 Dichlorvos 62-73-7 15 19931001 Oct 1,1993 II.D.3. Primary contact changed; secondary's phone number changed
1040 Dichlorvos 62-73-7 16 19931101 Nov 1,1993 I.A. Oral RfD summary replaced; RfD changed
1041 Dichlorvos 62-73-7 17 19931101 Nov 1,1993 VI.A. Oral RfD references replaced
1042 Dichlorvos 62-73-7 18 19940601 Jun 1,1994 I.B. Inhalation RfC on-line
1043 Dichlorvos 62-73-7 19 19940601 Jun 1,1994 VI.B. Inhalation RfC references on-line
1044 Dichlorvos 62-73-7 20 19941201 Dec 1,1994 II.A.3. Animal strain clarified in NCI, 1977 study
1045 Dichlorvos 62-73-7 21 19950601 Jun 1,1995 VI.C. NTP, 1986a,b reference year corrected
1046 Dichlorvos 62-73-7 22 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1047 Dichlorvos 62-73-7 23 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1048 Dichlorvos 62-73-7 24 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1049 Dicofol 115-32-2 1 19880822 Aug 22,1988 II. Carcinogen summary on-line
1050 Dicofol 115-32-2 2 19900101 Jan 1,1990 VI. Bibliography on-line
1051 Dicofol 115-32-2 3 19920101 Jan 1,1992 II. Carcinogen assessment noted as pending change
1052 Dicofol 115-32-2 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1053 Dicofol 115-32-2 5 19920401 Apr 1,1992 II. Carcinogen assessment withdrawn pending further review
1054 Dicofol 115-32-2 6 19920401 Apr 1,1992 IV. Withdrawn; no assessments on-line
1055 Dicofol 115-32-2 7 19920401 Apr 1,1992 VI. Bibliography withdrawn; no assessments on-line
1056 Dicofol 115-32-2 8 19920701 Jul 1,1992 II. Work gropu review dates added
1057 Dicofol 115-32-2 9 19930701 Jul 1,1993 II. EPA contact changed
1058 Dicofol 115-32-2 10 19950801 Aug 1,1995 II., IV., VI. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1059 Dicofol 115-32-2 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1060 Dicofol 115-32-2 12 20181210 Dec 10,2018 Archived Values Requested by the IRIS Program to archive the chemicals with null values.
1061 Dicofol 115-32-2 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1062 Dieldrin 60-57-1 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
1063 Dieldrin 60-57-1 2 19880907 Sep 7,1988 II. Carcinogen summary on-line
1064 Dieldrin 60-57-1 3 19900301 Mar 1,1990 II.A.2. Ditraglia citation clarified
1065 Dieldrin 60-57-1 4 19900301 Mar 1,1990 II.A.3. Reuber citation year and Deichman spelling corrected
1066 Dieldrin 60-57-1 5 19900301 Mar 1,1990 II.A.4. Shirasu citation year corrected
1067 Dieldrin 60-57-1 6 19900301 Mar 1,1990 II.B.2. Reuber citation year corrected
1068 Dieldrin 60-57-1 7 19900301 Mar 1,1990 VI. Bibliography on-line
1069 Dieldrin 60-57-1 8 19900401 Apr 1,1990 VI.C. Treon and Cleveland, 1955 citation corrected
1070 Dieldrin 60-57-1 9 19900901 Sep 1,1990 I.A. Text edited
1071 Dieldrin 60-57-1 10 19900901 Sep 1,1990 II. Text edited
1072 Dieldrin 60-57-1 11 19900901 Sep 1,1990 III.A. Health Advisory on-line
1073 Dieldrin 60-57-1 12 19900901 Sep 1,1990 VI. Health Advisory references on-line
1074 Dieldrin 60-57-1 13 19910101 Jan 1,1991 II. Text edited
1075 Dieldrin 60-57-1 14 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
1076 Dieldrin 60-57-1 15 19910101 Jan 1,1991 IV. Regulatory Action section on-line
1077 Dieldrin 60-57-1 16 19930701 Jul 1,1993 II.D.3. Secondary contact's phone number changed
1078 Dieldrin 60-57-1 17 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1079 Dieldrin 60-57-1 18 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
1080 Dieldrin 60-57-1 19 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
1081 Diesel engine exhaust None 1 19920701 Jul 1,1992 I.B. Inhalation RfC now under review
1082 Diesel engine exhaust None 2 19920801 Aug 1,1992 I.B.6. Work group review date added
1083 Diesel engine exhaust None 3 19930601 Jun 1,1993 I.B. Inhalation RfC on-line
1084 Diesel engine exhaust None 4 19930601 Jun 1,1993 VI.B. Inhalation RfC references on-line
1085 Diesel engine exhaust None 5 19930701 Jul 1,1993 VI.B. Minor correction made
1086 Diesel engine exhaust None 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1087 Diesel engine exhaust None 7 20030228 Feb 28,2003 All Complete revision based on new health assessment document
1088 Diesel engine exhaust None 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1089 Diethyl phthalate (DEP) 84-66-2 1 19880907 Sep 7,1988 II. Carcinogen summary on-line
1090 Diethyl phthalate (DEP) 84-66-2 2 19890801 Aug 1,1989 VI. Bibliography on-line
1091 Diethyl phthalate (DEP) 84-66-2 3 19910801 Aug 1,1991 I.A.7. Primary and secondary contects changed
1092 Diethyl phthalate (DEP) 84-66-2 4 19910801 Aug 1,1991 II.D.3. Primary and secondary contacts changed
1093 Diethyl phthalate (DEP) 84-66-2 5 19910801 Aug 1,1991 IV.F.1. EPA contact changed
1094 Diethyl phthalate (DEP) 84-66-2 6 19920101 Jan 1,1992 IV. Regulatory actions updated
1095 Diethyl phthalate (DEP) 84-66-2 7 19930201 Feb 1,1993 I.A.7. Primary contact changed
1096 Diethyl phthalate (DEP) 84-66-2 8 19930201 Feb 1,1993 II.D.3. Primary contact changed
1097 Diethyl phthalate (DEP) 84-66-2 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1098 Diethyl phthalate (DEP) 84-66-2 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1099 Diethyl sulfate 64-67-5 1 19911001 Oct 1,1991 I.B. Inhalation RfC now under review
1100 Diethyl sulfate 64-67-5 2 19911101 Nov 1,1991 I.B. Inhalation RfC message on-line
1101 Diethyl sulfate 64-67-5 3 19911101 Nov 1,1991 VI.B. Inhalation RfC references added
1102 Diethyl sulfate 64-67-5 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1103 Diethyl sulfate 64-67-5 5 20181219 Dec 19,2018 Archive Chemical IRIS Program requested that we archive assessments with no values.
1104 Diethyl sulfate 64-67-5 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1105 Diethyl-p-nitrophenylphosphate 311-45-5 1 19911001 Oct 1,1991 II. Carcinogenicy assessment now under review
1106 Diethyl-p-nitrophenylphosphate 311-45-5 2 19921001 Oct 1,1992 II. Carcinogenicity assessment on-line
1107 Diethyl-p-nitrophenylphosphate 311-45-5 3 19921001 Oct 1,1992 VI.C. Carcinogenicity references on-line
1108 Diethyl-p-nitrophenylphosphate 311-45-5 4 19921101 Nov 1,1992 VI.C. Spelling correction
1109 Diethyl-p-nitrophenylphosphate 311-45-5 5 19930701 Jul 1,1993 II.D.1. Other EPA Documentation heading removed
1110 Diethyl-p-nitrophenylphosphate 311-45-5 6 19961201 Dec 1,1996 II.D.3. Secondary contact removed
1111 Diethyl-p-nitrophenylphosphate 311-45-5 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1112 Diethyl-p-nitrophenylphosphate 311-45-5 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1113 Diethylene glycol dinitrate (DEGDN) 693-21-0 1 19920701 Jul 1,1992 II. Carcinogenicity assessment summary now under review
1114 Diethylene glycol dinitrate (DEGDN) 693-21-0 2 19930201 Feb 1,1993 II. Carcinogenicity assessment on-line
1115 Diethylene glycol dinitrate (DEGDN) 693-21-0 3 19930201 Feb 1,1993 VI.C. Carcinogenicity assessment references on-line
1116 Diethylene glycol dinitrate (DEGDN) 693-21-0 4 19930301 Mar 1,1993 VI.C. Minor correction
1117 Diethylene glycol dinitrate (DEGDN) 693-21-0 5 19930701 Jul 1,1993 II.D.1. Other EPA Documentation heading removed
1118 Diethylene glycol dinitrate (DEGDN) 693-21-0 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1119 Diethylene glycol dinitrate (DEGDN) 693-21-0 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1120 Difenzoquat 43222-48-6 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
1121 Difenzoquat 43222-48-6 2 19891201 Dec 1,1989 VI. Bibliography on-line
1122 Difenzoquat 43222-48-6 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1123 Difenzoquat 43222-48-6 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1124 Difenzoquat 43222-48-6 5 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
1125 Difenzoquat 43222-48-6 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1126 Diflubenzuron 35367-38-5 1 19900901 Sep 1,1990 I.A. Principal study clarified
1127 Diflubenzuron 35367-38-5 2 19900901 Sep 1,1990 I.A.4. Citations added
1128 Diflubenzuron 35367-38-5 3 19900901 Sep 1,1990 VI. Bibliography on-line
1129 Diflubenzuron 35367-38-5 4 19920101 Jan 1,1992 IV. Regulatory actions updated
1130 Diflubenzuron 35367-38-5 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1131 Diflubenzuron 35367-38-5 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1132 1,1-Difluoroethane 75-37-6 1 19921001 Oct 1,1992 I.B. Inhalation RfC now under review
1133 1,1-Difluoroethane 75-37-6 2 19940901 Sep 1,1994 I.B. Inhalation RfC on-line
1134 1,1-Difluoroethane 75-37-6 3 19940901 Sep 1,1994 VI.B. Inhalation RfD references on-line
1135 1,1-Difluoroethane 75-37-6 4 19941001 Oct 1,1994 VI.B. Aviado and Belej, 1974 page number corrected
1136 1,1-Difluoroethane 75-37-6 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1137 1,1-Difluoroethane 75-37-6 6 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
1138 1,1-Difluoroethane 75-37-6 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1139 Diisobutyl phthalate (DIBP) 84-69-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1140 Diisononyl phthalate (DINP) 28553-12-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1141 Diisopropyl methylphosphonate (DIMP) 1445-75-6 1 19890301 Mar 1,1989 II. Carcinogen summary on-line
1142 Diisopropyl methylphosphonate (DIMP) 1445-75-6 2 19890401 Apr 1,1989 I.A. Oral RfD summary on-line
1143 Diisopropyl methylphosphonate (DIMP) 1445-75-6 3 19890401 Apr 1,1989 II.A.4. Citation year added
1144 Diisopropyl methylphosphonate (DIMP) 1445-75-6 4 19890401 Apr 1,1989 II.D.1. Corrected EPA citation year
1145 Diisopropyl methylphosphonate (DIMP) 1445-75-6 5 19890401 Apr 1,1989 II.D.1. Citation added
1146 Diisopropyl methylphosphonate (DIMP) 1445-75-6 6 19890701 Jul 1,1989 VI. Bibliography on-line
1147 Diisopropyl methylphosphonate (DIMP) 1445-75-6 7 19900601 Jun 1,1990 I.A. Text edited
1148 Diisopropyl methylphosphonate (DIMP) 1445-75-6 8 19900601 Jun 1,1990 I.A.7. Primary contact changed
1149 Diisopropyl methylphosphonate (DIMP) 1445-75-6 9 19900601 Jun 1,1990 II.A.2. Text added
1150 Diisopropyl methylphosphonate (DIMP) 1445-75-6 10 19901201 Dec 1,1990 III.A. Health Advisory on-line
1151 Diisopropyl methylphosphonate (DIMP) 1445-75-6 11 19901201 Dec 1,1990 VI.D. Health Advisory references added
1152 Diisopropyl methylphosphonate (DIMP) 1445-75-6 12 19920901 Sep 1,1992 II.D.3. Primary contact changed
1153 Diisopropyl methylphosphonate (DIMP) 1445-75-6 13 19930201 Feb 1,1993 I.A.7. Primary contact changed
1154 Diisopropyl methylphosphonate (DIMP) 1445-75-6 14 19930201 Feb 1,1993 II.D.3. Primary contact changed
1155 Diisopropyl methylphosphonate (DIMP) 1445-75-6 15 19930201 Feb 1,1993 II.A.10. Primary contact changed
1156 Diisopropyl methylphosphonate (DIMP) 1445-75-6 16 19930701 Jul 1,1993 II.D.1. EPA Documentation clarified
1157 Diisopropyl methylphosphonate (DIMP) 1445-75-6 17 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1158 Diisopropyl methylphosphonate (DIMP) 1445-75-6 18 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
1159 Diisopropyl methylphosphonate (DIMP) 1445-75-6 19 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1160 Dimethipin 55290-64-7 1 19880822 Aug 22,1988 II. Carcinogen summary on-line
1161 Dimethipin 55290-64-7 2 19900301 Mar 1,1990 I.A. NOTE added; assessment reevaluated - no RfD change
1162 Dimethipin 55290-64-7 3 19900501 May 1,1990 I.A. Reevaluated Oral RfD on-line - no RfD change
1163 Dimethipin 55290-64-7 4 19900501 May 1,1990 VI. Bibliography on-line
1164 Dimethipin 55290-64-7 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1165 Dimethipin 55290-64-7 6 19931001 Oct 1,1993 II.D.3. Primary contact changed; secondary's phone number changed
1166 Dimethipin 55290-64-7 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the approrpriate EPA Program Offices for this information.
1167 Dimethipin 55290-64-7 8 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
1168 Dimethipin 55290-64-7 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1169 Dimethoate 60-51-5 1 19880301 Mar 1,1988 I.A.4. New data entered
1170 Dimethoate 60-51-5 2 19880301 Mar 1,1988 I.A.5. Confidence levels revised
1171 Dimethoate 60-51-5 3 19880301 Mar 1,1988 I.A.6. Review dates added
1172 Dimethoate 60-51-5 4 19880301 Mar 1,1988 I.A.6. Documentation added
1173 Dimethoate 60-51-5 5 19880630 Jun 30,1988 I.A. RfD withdrawn
1174 Dimethoate 60-51-5 6 19880822 Aug 22,1988 I.A. Revised oral RfD summary added
1175 Dimethoate 60-51-5 7 19900901 Sep 1,1990 I.A.4. Citations added
1176 Dimethoate 60-51-5 8 19900901 Sep 1,1990 IV.F.1. EPA contact changed
1177 Dimethoate 60-51-5 9 19900901 Sep 1,1990 VI. Bibliography on-line
1178 Dimethoate 60-51-5 10 19920101 Jan 1,1992 IV. Regulatory actions updated
1179 Dimethoate 60-51-5 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1180 Dimethoate 60-51-5 12 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
1181 Dimethoate 60-51-5 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1182 Dimethyl phthalate 131-11-3 1 19880907 Sep 7,1988 II. Carcinogen summary on-line
1183 Dimethyl phthalate 131-11-3 2 19890401 Apr 1,1989 V. Supplementary data on-line
1184 Dimethyl phthalate 131-11-3 3 19900301 Mar 1,1990 VI. Bibliography on-line
1185 Dimethyl phthalate 131-11-3 4 19900901 Sep 1,1990 I.B. Not verified; data inadequate
1186 Dimethyl phthalate 131-11-3 5 19901001 Oct 1,1990 I.B. Inhalation RfC text modified
1187 Dimethyl phthalate 131-11-3 6 19901001 Oct 1,1990 VI.B. Bibliography on-line
1188 Dimethyl phthalate 131-11-3 7 19910801 Aug 1,1991 II.D.3. Primary and secondary contacts changed
1189 Dimethyl phthalate 131-11-3 8 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1190 Dimethyl phthalate 131-11-3 9 19930201 Feb 1,1993 II.D.3. Primary contact changed
1191 Dimethyl phthalate 131-11-3 10 19940301 Mar 1,1994 I.A. Work group review date added
1192 Dimethyl phthalate 131-11-3 11 19950801 Aug 1,1995 I.A. EPA's RfD/RfC and CRAVE workgroups were discontinured in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1193 Dimethyl phthalate 131-11-3 12 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1194 Dimethyl phthalate 131-11-3 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1195 Dimethyl sulfate 77-78-1 1 19880907 Sep 7,1988 II. Carcinogen summary on-line
1196 Dimethyl sulfate 77-78-1 2 19890401 Apr 1,1989 V. Supplementary data on-line
1197 Dimethyl sulfate 77-78-1 3 19900301 Mar 1,1990 VI. Bibliography on-line
1198 Dimethyl sulfate 77-78-1 4 19911001 Oct 1,1991 I.B. Inhalation RfD now under review
1199 Dimethyl sulfate 77-78-1 5 19920101 Jan 1,1992 I.B. Inhalation RfC on-line
1200 Dimethyl sulfate 77-78-1 6 19920101 Jan 1,1992 VI.B. Inhalation RfC reference added
1201 Dimethyl sulfate 77-78-1 7 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1202 Dimethyl sulfate 77-78-1 8 19940201 Feb 1,1994 II.D.3. Secondary contact's phone number changed
1203 Dimethyl sulfate 77-78-1 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1204 Dimethyl sulfate 77-78-1 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1205 Dimethyl terephthalate (DMT) 120-61-6 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
1206 Dimethyl terephthalate (DMT) 120-61-6 2 19890801 Aug 1,1989 VI. Biliography on-line
1207 Dimethyl terephthalate (DMT) 120-61-6 3 19920101 Jan 1,1992 I.A.7. Secondary contact changed
1208 Dimethyl terephthalate (DMT) 120-61-6 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1209 Dimethyl terephthalate (DMT) 120-61-6 5 19950201 Feb 1,1995 I.A.7. Secondary contact's name changed
1210 Dimethyl terephthalate (DMT) 120-61-6 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1211 Dimethyl terephthalate (DMT) 120-61-6 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1212 Dimethylamine 124-40-3 1 19900701 Jul 1,1990 I.B. Inhalation RfC summary on-line
1213 Dimethylamine 124-40-3 2 19900701 Jul 1,1990 VI. Bibliography on-line
1214 Dimethylamine 124-40-3 3 19910101 Jan 1,1991 I.B. Wtihdrawn; new inhalation RfC verified (in preparation)
1215 Dimethylamine 124-40-3 4 19910101 Jan 1,1991 VI. Bibliography withdrawn
1216 Dimethylamine 124-40-3 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1217 Dimethylamine 124-40-3 6 19950801 Aug 1,1995 I.B., VI. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in Septermber, 1995.
1218 Dimethylamine 124-40-3 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1219 Dimethylamine 124-40-3 8 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
1220 Dimethylamine 124-40-3 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1221 N-N-Dimethylaniline 121-69-7 1 19890801 Aug 1,1989 VI. Bibliography on-line
1222 N-N-Dimethylaniline 121-69-7 2 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1223 N-N-Dimethylaniline 121-69-7 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1224 3,3-Dimethylbenzidine 119-93-7 1 19910701 Jul 1,1991 I.B. Inhalation RfC message on-line
1225 3,3-Dimethylbenzidine 119-93-7 2 19910701 Jul 1,1991 VI. Bibliography on-line
1226 3,3-Dimethylbenzidine 119-93-7 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1227 3,3-Dimethylbenzidine 119-93-7 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1228 3,3-Dimethylbenzidine 119-93-7 5 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
1229 3,3-Dimethylbenzidine 119-93-7 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1230 N,N-Dimethylformamide 68-12-2 1 19901001 Oct 1,1990 I.B. Inhalation RfC summary on-line
1231 N,N-Dimethylformamide 68-12-2 2 19901001 Oct 1,1990 VI. Bibliography on-line
1232 N,N-Dimethylformamide 68-12-2 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1233 N,N-Dimethylformamide 68-12-2 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1234 2,4-Dimethylphenol 105-67-9 1 19901101 Nov 1,1990 I.A. Oral RfD summary on-line
1235 2,4-Dimethylphenol 105-67-9 2 19901101 Nov 1,1990 VI. Bibliography on-line
1236 2,4-Dimethylphenol 105-67-9 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1237 2,4-Dimethylphenol 105-67-9 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appriopriate EPA Program Offices for this information.
1238 2,4-Dimethylphenol 105-67-9 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1239 2,6-Dimethylphenol 576-26-1 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
1240 2,6-Dimethylphenol 576-26-1 2 19910301 Mar 1,1991 VI. Bibliography on-line
1241 2,6-Dimethylphenol 576-26-1 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1242 2,6-Dimethylphenol 576-26-1 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1243 3,4-Dimethylphenol 95-65-8 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
1244 3,4-Dimethylphenol 95-65-8 2 19890101 Jan 1,1989 I.A.7. Contacts phone numbers corrected
1245 3,4-Dimethylphenol 95-65-8 3 19910601 Jun 1,1991 VI. Bibliography on-line
1246 3,4-Dimethylphenol 95-65-8 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1247 3,4-Dimethylphenol 95-65-8 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1248 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
1249 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 2 19890101 Jan 1,1989 I.A.7. Contacts phone numbers corrected
1250 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 3 19910301 Mar 1,1991 VI. Bibliography on-line
1251 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 4 19920101 Jan 1,1992 I.A.7. Secondary contact changed
1252 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1253 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1254 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1255 o-Dinitrobenzene 528-29-0 1 19920501 May 1,1992 II. Carcinogenicity assessment now under review
1256 o-Dinitrobenzene 528-29-0 2 19920601 Jun 1,1992 Synonyms Synonyms added
1257 o-Dinitrobenzene 528-29-0 3 19920901 Sep 1,1992 II. Carcinogenicity assessment on-line
1258 o-Dinitrobenzene 528-29-0 4 19920901 Sep 1,1992 VI. Bibliography on-line
1259 o-Dinitrobenzene 528-29-0 5 19930701 Jul 1,1993 II.D.1. Other EPA Documentation heading removed
1260 o-Dinitrobenzene 528-29-0 6 19961201 Dec 1,1996 II.D.3. Primary contact removed
1261 o-Dinitrobenzene 528-29-0 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1262 o-Dinitrobenzene 528-29-0 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1263 m-Dinitrobenzene 99-65-0 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
1264 m-Dinitrobenzene 99-65-0 2 19900701 Jul 1,1990 II. Carcinogen assessment now under review
1265 m-Dinitrobenzene 99-65-0 3 19910301 Mar 1,1991 II. Carcinogenicity assessment on-line
1266 m-Dinitrobenzene 99-65-0 4 19910301 Mar 1,1991 VI. Bibliography on-line
1267 m-Dinitrobenzene 99-65-0 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1268 m-Dinitrobenzene 99-65-0 6 19930201 Feb 1,1993 II.D.3. Primary contact changed
1269 m-Dinitrobenzene 99-65-0 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1270 m-Dinitrobenzene 99-65-0 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1271 2,4-Dinitrophenol 51-28-5 1 19880301 Mar 1,1988 I.A.3. Text corrected
1272 2,4-Dinitrophenol 51-28-5 2 19900301 Mar 1,1990 I.A.2. U.S. EPA, 1980 citation added
1273 2,4-Dinitrophenol 51-28-5 3 19900301 Mar 1,1990 VI. Bibliography on-line
1274 2,4-Dinitrophenol 51-28-5 4 19910701 Jul 1,1991 I.A. Oral RfD summary noted as pending change
1275 2,4-Dinitrophenol 51-28-5 5 19910701 Jul 1,1991 I.B. Inhalation RfC now under review
1276 2,4-Dinitrophenol 51-28-5 6 19911001 Oct 1,1991 I.B. Inhalation RfC message on-line
1277 2,4-Dinitrophenol 51-28-5 7 19911001 Oct 1,1991 VI.B. Inhalation RfC references added
1278 2,4-Dinitrophenol 51-28-5 8 19920101 Jan 1,1992 I.A.7. Secondary contact changed
1279 2,4-Dinitrophenol 51-28-5 9 19920101 Jan 1,1992 IV. Regulatory actions updated
1280 2,4-Dinitrophenol 51-28-5 10 19950801 Aug 1,1995 I.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1281 2,4-Dinitrophenol 51-28-5 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1282 2,4-Dinitrophenol 51-28-5 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1283 2,4-Dinitrotoluene 121-14-2 1 19910301 Mar 1,1991 I.B. Inhalation RfC message on-line
1284 2,4-Dinitrotoluene 121-14-2 2 19910301 Mar 1,1991 VI. Bibliography on-line
1285 2,4-Dinitrotoluene 121-14-2 3 19910901 Sep 1,1991 I.A. Oral RfD now under review
1286 2,4-Dinitrotoluene 121-14-2 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1287 2,4-Dinitrotoluene 121-14-2 5 19920601 Jun 1,1992 I.A. Oral RfD summary on-line
1288 2,4-Dinitrotoluene 121-14-2 6 19920601 Jun 1,1992 VI.A. Oral RfD references added
1289 2,4-Dinitrotoluene 121-14-2 7 19930201 Feb 1,1993 I.A.7. Primary contact changed
1290 2,4-Dinitrotoluene 121-14-2 8 19930301 Mar 1,1993 VI.D. Health Advisory on-line
1291 2,4-Dinitrotoluene 121-14-2 9 19930301 Mar 1,1993 III.A. Heatlh Advisory references on-line
1292 2,4-Dinitrotoluene 121-14-2 10 19930401 Apr 1,1993 VI.A. Oral RfD references corrected
1293 2,4-Dinitrotoluene 121-14-2 11 19900901 Sep 1,1990 II. Carcinogen assessment on-line
1294 2,4-Dinitrotoluene 121-14-2 12 19900901 Sep 1,1990 VI. Bibliography on-line
1295 2,4-Dinitrotoluene 121-14-2 13 19910801 Aug 1,1991 VI.C. Citations clarified
1296 2,4-Dinitrotoluene 121-14-2 14 19910801 Aug 1,1991 I.A. Oral RfD now under reivew
1297 2,4-Dinitrotoluene 121-14-2 15 19910901 Sep 1,1991 I.A. Oral RfD will be isomer-specific
1298 2,4-Dinitrotoluene 121-14-2 16 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1299 2,4-Dinitrotoluene 121-14-2 17 19950801 Aug 1,1995 I.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1300 2,4-Dinitrotoluene 121-14-2 18 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1301 2,4-Dinitrotoluene 121-14-2 19 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1302 2,4-/2,6-Dinitrotoluene mixture Various 1 19900901 Sep 1,1990 II. Carcinogen assessment on-line
1303 2,4-/2,6-Dinitrotoluene mixture Various 2 19900901 Sep 1,1990 VI. Bibliography on-line
1304 2,4-/2,6-Dinitrotoluene mixture Various 3 19910801 Aug 1,1991 VI.C. Citations clarified
1305 2,4-/2,6-Dinitrotoluene mixture Various 4 19910801 Aug 1,1991 I.A. Oral RfD now under reivew
1306 2,4-/2,6-Dinitrotoluene mixture Various 5 19910901 Sep 1,1991 I.A. Oral RfD will be isomer-specific
1307 2,4-/2,6-Dinitrotoluene mixture Various 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1308 2,4-/2,6-Dinitrotoluene mixture Various 7 19950801 Aug 1,1995 I.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1309 2,4-/2,6-Dinitrotoluene mixture Various 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1310 2,4-/2,6-Dinitrotoluene mixture Various 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1311 Dinoseb 88-85-7 1 19890601 Jun 1,1989 I.A.6. Work group review dates added
1312 Dinoseb 88-85-7 2 19890601 Jun 1,1989 II. Carcinogen assessment now under review
1313 Dinoseb 88-85-7 3 19890801 Aug 1,1989 I.A. Principal study citation corrected
1314 Dinoseb 88-85-7 4 19890801 Aug 1,1989 I.A.4. Citations added
1315 Dinoseb 88-85-7 5 19890801 Aug 1,1989 II. Carcinogen summary on-line
1316 Dinoseb 88-85-7 6 19890801 Aug 1,1989 VI. Bibliography on-line
1317 Dinoseb 88-85-7 7 19900601 Jun 1,1990 I.A. Text edited
1318 Dinoseb 88-85-7 8 19900601 Jun 1,1990 II. Text edited
1319 Dinoseb 88-85-7 9 19910301 Mar 1,1991 II.D.3. Secondary contact changed
1320 Dinoseb 88-85-7 10 19910301 Mar 1,1991 IV.F.1. EPA contact changed
1321 Dinoseb 88-85-7 11 19920101 Jan 1,1992 IV. Regulatory actions updated
1322 Dinoseb 88-85-7 12 19930701 Jul 1,1993 II.D.2. Missing work group review date added
1323 Dinoseb 88-85-7 13 19950801 Aug 1,1995 I.A.6., II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by Septmber 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1324 Dinoseb 88-85-7 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1325 Dinoseb 88-85-7 15 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
1326 Dinoseb 88-85-7 16 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1327 1,4-Dioxane 123-91-1 1 19880822 Aug 22,1988 II. Carcinogen summary on-line
1328 1,4-Dioxane 123-91-1 10 20100811 Aug 11,2010 I., II., VI. RfD and cancer assessment updated RfC discussion added.
1329 1,4-Dioxane 123-91-1 11 20100811 Aug 11,2010 NA %3Ca href=%22http://cfpub.epa.gov/ncea/iris_drafts/archiveDrafts.cfm#D_form%22%3EArchived review drafts and comments from the development of the oral assessment%3C/a%3E are available.
1330 1,4-Dioxane 123-91-1 12 20130920 Sep 20,2013 None Added RfC and inhalation cancer assessment.
1331 1,4-Dioxane 123-91-1 13 20130920 Sep 20,2013 NA Archived review drafts and comments from the development of this assessment are available. Archived version of the 2010 final oral assessment is available (%3Ca href=%22http://hero.epa.gov/index.cfm?action=search.view&reference_id=625580%22%3EU.S. EPA, 2010%3C/a%3E).
1332 1,4-Dioxane 123-91-1 14 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1333 Diphenamid 957-51-7 1 19890401 Apr 1,1989 III. Health Advisory on-line
1334 Diphenamid 957-51-7 2 19910301 Mar 1,1991 I.A. Principal study year corrected
1335 Diphenamid 957-51-7 3 19910301 Mar 1,1991 I.A.4. Citations added
1336 Diphenamid 957-51-7 4 19910301 Mar 1,1991 III.A.5. Principal study year corrected
1337 Diphenamid 957-51-7 5 19910301 Mar 1,1991 VI. Bibliography on-line
1338 Diphenamid 957-51-7 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1339 Diphenamid 957-51-7 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1340 Diphenamid 957-51-7 8 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
1341 Diphenamid 957-51-7 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1342 Diphenylamine 122-39-4 1 19870930 Sep 30,1987 All CASRN corrected
1343 Diphenylamine 122-39-4 2 19900901 Sep 1,1990 I.A.4. Citations added
1344 Diphenylamine 122-39-4 3 19900901 Sep 1,1990 IV.F.1. EPA contact changed
1345 Diphenylamine 122-39-4 4 19900901 Sep 1,1990 VI. Bibliography on-line
1346 Diphenylamine 122-39-4 5 19920101 Jan 1,1992 IV. Regulatory actions updated
1347 Diphenylamine 122-39-4 6 19920701 Jul 1,1992 II. Carcinogen assessment summary now under review
1348 Diphenylamine 122-39-4 7 19930301 Mar 1,1993 III.A. Health Advisory on-line
1349 Diphenylamine 122-39-4 8 19930301 Mar 1,1993 VI.D. Health Advisory references on-line
1350 Diphenylamine 122-39-4 9 19930401 Apr 1,1993 VI.A. Oral RfD reference corrected
1351 Diphenylamine 122-39-4 10 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1352 Diphenylamine 122-39-4 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1353 Diphenylamine 122-39-4 12 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
1354 Diphenylamine 122-39-4 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1355 1,2-Diphenylhydrazine 122-66-7 1 19870331 Mar 31,1987 IV. RQ added
1356 1,2-Diphenylhydrazine 122-66-7 2 19880301 Mar 1,1988 II.B.1. Number rounded off
1357 1,2-Diphenylhydrazine 122-66-7 3 19880301 Mar 1,1988 II.B.3. Text revised
1358 1,2-Diphenylhydrazine 122-66-7 4 19880301 Mar 1,1988 II.B.4. Confidence statement revised
1359 1,2-Diphenylhydrazine 122-66-7 5 19880301 Mar 1,1988 II.C.1. Number rounded off
1360 1,2-Diphenylhydrazine 122-66-7 6 19880301 Mar 1,1988 II.C.4. Text revised
1361 1,2-Diphenylhydrazine 122-66-7 7 19880301 Mar 1,1988 II.D.3. Primary contact changed
1362 1,2-Diphenylhydrazine 122-66-7 8 19890801 Aug 1,1989 VI. Bibliography on-line
1363 1,2-Diphenylhydrazine 122-66-7 9 19910101 Jan 1,1991 II. Text edited
1364 1,2-Diphenylhydrazine 122-66-7 10 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
1365 1,2-Diphenylhydrazine 122-66-7 11 19911001 Oct 1,1991 I.B. Inhalation RfC now under review
1366 1,2-Diphenylhydrazine 122-66-7 12 19911101 Nov 1,1991 I.B. Inhalation RfC message on-line
1367 1,2-Diphenylhydrazine 122-66-7 13 19911101 Nov 1,1991 VI.B. Inhalation references added
1368 1,2-Diphenylhydrazine 122-66-7 14 19920101 Jan 1,1992 IV. Regulatory actions updated
1369 1,2-Diphenylhydrazine 122-66-7 15 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1370 1,2-Diphenylhydrazine 122-66-7 16 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1371 Diquat 2764-72-9 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
1372 Diquat 2764-72-9 2 19890901 Sep 1,1989 II. Carcinogen assessment now under review
1373 Diquat 2764-72-9 3 19900901 Sep 1,1990 I.A. Principal study clarified
1374 Diquat 2764-72-9 4 19900901 Sep 1,1990 I.A.4. Citations added
1375 Diquat 2764-72-9 5 19900901 Sep 1,1990 VI. Bibliography on-line
1376 Diquat 2764-72-9 6 19920101 Jan 1,1992 IV. Regulatory actions updated
1377 Diquat 2764-72-9 7 19940201 Feb 1,1994 I.A.1. Critical dose and NOAEL(ADJ) corrected
1378 Diquat 2764-72-9 8 19950101 Jan 1,1995 I.A. Oral RfD noted as pending change
1379 Diquat 2764-72-9 9 19950101 Jan 1,1995 I.A.6. Work group review date added
1380 Diquat 2764-72-9 10 19950801 Aug 1,1995 I.A., I.A.6., II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1381 Diquat 2764-72-9 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1382 Diquat 2764-72-9 12 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
1383 Diquat 2764-72-9 13 20200929 Sep 29,2020 CASRN Based on a request from CCTE and OLEM, the IRIS program updated the CASRN from 85-00-7 to 2764-72-9, and updated the IRIS Summary to correct an error with the original summary page. Also corrected the Chemicals Dashboard link.
1384 Disulfoton 298-04-4 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
1385 Disulfoton 298-04-4 2 19900201 Feb 1,1990 VI. Bibliography on-line
1386 Disulfoton 298-04-4 3 19920101 Jan 1,1992 IV. Regulatory actions updated
1387 Disulfoton 298-04-4 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1388 Disulfoton 298-04-4 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1389 1,4-Dithiane 505-29-3 1 19910301 Mar 1,1991 II. Carcinogenicity assessment on-line
1390 1,4-Dithiane 505-29-3 2 19910301 Mar 1,1991 VI. Bibliography on-line
1391 1,4-Dithiane 505-29-3 3 19920801 Aug 1,1992 I.A. Oral RfD now under review
1392 1,4-Dithiane 505-29-3 4 19930201 Feb 1,1993 II.D.3. Primary contact changed
1393 1,4-Dithiane 505-29-3 5 19930301 Mar 1,1993 I.A. Oral RfD summary on-line
1394 1,4-Dithiane 505-29-3 6 19930301 Mar 1,1993 III.A. Health Advisory on-line
1395 1,4-Dithiane 505-29-3 7 19930301 Mar 1,1993 VI.A. Oral RfD references on-line
1396 1,4-Dithiane 505-29-3 8 19930301 Mar 1,1993 VI.D. Health Advisory references on-line
1397 1,4-Dithiane 505-29-3 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1398 1,4-Dithiane 505-29-3 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1399 Diuron 330-54-1 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
1400 Diuron 330-54-1 2 19880822 Aug 22,1988 I.A.1. Oral RfD corrected
1401 Diuron 330-54-1 3 19891201 Dec 1,1989 VI. Bibliography on-line
1402 Diuron 330-54-1 4 19901001 Oct 1,1990 III.A. Health Advisory on-line
1403 Diuron 330-54-1 5 19901001 Oct 1,1990 VI.D. Health Advisory references added
1404 Diuron 330-54-1 6 19920101 Jan 1,1992 IV. Regulatory actions updated
1405 Diuron 330-54-1 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1406 Diuron 330-54-1 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1407 Dodine 2439-10-3 1 19900901 Sep 1,1990 I.A.4. Citations added
1408 Dodine 2439-10-3 2 19900901 Sep 1,1990 VI. Bibliography on-line
1409 Dodine 2439-10-3 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1410 Dodine 2439-10-3 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1411 Dodine 2439-10-3 5 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
1412 Dodine 2439-10-3 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1413 Endosulfan 115-29-7 1 19890701 Jul 1,1989 I.A.2. MRID numbers added to principal study
1414 Endosulfan 115-29-7 2 19890701 Jul 1,1989 I.A.4. Citations added
1415 Endosulfan 115-29-7 3 19890701 Jul 1,1989 VI. Bibliography on-line
1416 Endosulfan 115-29-7 4 19920101 Jan 1,1992 IV. Regulatory actions updated
1417 Endosulfan 115-29-7 5 19921201 Dec 1,1992 I.A. Withdrawn; new Oral RfD verified (in preparation)
1418 Endosulfan 115-29-7 6 19921201 Dec 1,1992 VI.A. Oral RfD references withdrawn
1419 Endosulfan 115-29-7 7 19930501 May 1,1993 I.A. Work group review date added
1420 Endosulfan 115-29-7 8 19940701 Jul 1,1994 II. Carcinogenicity assessment now under review
1421 Endosulfan 115-29-7 9 19941001 Oct 1,1994 I.A. Oral RfD summary replaced; new RfD
1422 Endosulfan 115-29-7 10 19941001 Oct 1,1994 VI.A. Oral RfD references replaced
1423 Endosulfan 115-29-7 11 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1424 Endosulfan 115-29-7 12 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1425 Endosulfan 115-29-7 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1426 Endothall 145-73-3 1 19910301 Mar 1,1991 I.A.4. Citations added
1427 Endothall 145-73-3 2 19910301 Mar 1,1991 VI. Bibliography on-line
1428 Endothall 145-73-3 3 19910901 Sep 1,1991 II. Carcinogenicity assessment now under review
1429 Endothall 145-73-3 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1430 Endothall 145-73-3 5 19920701 Jul 1,1992 III.A. Health Advisory on-line
1431 Endothall 145-73-3 6 19920701 Jul 1,1992 VI.D. Health Advisory references on-line
1432 Endothall 145-73-3 7 19920801 Aug 1,1992 III.A.5. Text clarified
1433 Endothall 145-73-3 8 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1434 Endothall 145-73-3 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1435 Endothall 145-73-3 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1436 Endrin 72-20-8 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
1437 Endrin 72-20-8 2 19890401 Apr 1,1989 V. Supplementary data on-line
1438 Endrin 72-20-8 3 19890801 Aug 1,1989 VI. Bibliography on-line
1439 Endrin 72-20-8 4 19891001 Oct 1,1989 II. Carcinogen summary on-line
1440 Endrin 72-20-8 5 19891001 Oct 1,1989 VI.C. Carcinogen references added
1441 Endrin 72-20-8 6 19910401 Apr 1,1991 I.A. Secondary contact changed
1442 Endrin 72-20-8 7 19910401 Apr 1,1991 II. Primary contact changed
1443 Endrin 72-20-8 8 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1444 Endrin 72-20-8 9 19930701 Jul 1,1993 II.D.1. EPA Documentation clarified
1445 Endrin 72-20-8 10 19930701 Jul 1,1993 VI.C. EPA references clarified
1446 Endrin 72-20-8 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1447 Endrin 72-20-8 12 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
1448 Endrin 72-20-8 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1449 Epichlorohydrin 106-89-8 1 19870930 Sep 30,1987 V. Supplementary Data section added
1450 Epichlorohydrin 106-89-8 2 19880301 Mar 1,1988 I.A.1. Dose conversion factor corrected
1451 Epichlorohydrin 106-89-8 3 19880301 Mar 1,1988 I.A.2. Text clarified
1452 Epichlorohydrin 106-89-8 4 19880301 Mar 1,1988 II.B.1. Number rounded off
1453 Epichlorohydrin 106-89-8 5 19880301 Mar 1,1988 II.B.3. Text revised
1454 Epichlorohydrin 106-89-8 6 19880301 Mar 1,1988 II.B.4. Confidence statement revised
1455 Epichlorohydrin 106-89-8 7 19880301 Mar 1,1988 II.C. Slope factor changed
1456 Epichlorohydrin 106-89-8 8 19880301 Mar 1,1988 II.C.1. Number rounded off
1457 Epichlorohydrin 106-89-8 9 19880301 Mar 1,1988 II.C.3. Text revised
1458 Epichlorohydrin 106-89-8 10 19880301 Mar 1,1988 II.C.4. Confidence statement revised
1459 Epichlorohydrin 106-89-8 11 19880301 Mar 1,1988 III.A. Health Advisory added
1460 Epichlorohydrin 106-89-8 12 19880630 Jun 30,1988 II.D.1. Documentation corrected
1461 Epichlorohydrin 106-89-8 13 19890601 Jun 1,1989 I.A.6. Work group review date added
1462 Epichlorohydrin 106-89-8 14 19891001 Oct 1,1989 I.B. Inhalation RfC now under review
1463 Epichlorohydrin 106-89-8 15 19900201 Feb 1,1990 II.A.2. Shellenberger et al., 1979 spelling corrected
1464 Epichlorohydrin 106-89-8 16 19900201 Feb 1,1990 VI. Bibliography on-line
1465 Epichlorohydrin 106-89-8 17 19900601 Jun 1,1990 IV.A.1. Area code for EPA contact corrected
1466 Epichlorohydrin 106-89-8 18 19900801 Aug 1,1990 III.A.10. Primary contact changed
1467 Epichlorohydrin 106-89-8 19 19910101 Jan 1,1991 II. Text edited
1468 Epichlorohydrin 106-89-8 20 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
1469 Epichlorohydrin 106-89-8 21 19910901 Sep 1,1991 I.A. Oral RfD summary noted as pending change
1470 Epichlorohydrin 106-89-8 22 19920101 Jan 1,1992 I.A.7. Secondary contact changed
1471 Epichlorohydrin 106-89-8 23 19920101 Jan 1,1992 IV. Regulatory actions updated
1472 Epichlorohydrin 106-89-8 24 19920401 Apr 1,1992 I.A. Oral RfD summary withdrawn pending further review
1473 Epichlorohydrin 106-89-8 25 19920401 Apr 1,1992 I.B. Inhalation RfC summary on-line
1474 Epichlorohydrin 106-89-8 26 19920401 Apr 1,1992 IV.A.1. CAA regulatory action withdrawn
1475 Epichlorohydrin 106-89-8 27 19920401 Apr 1,1992 VI.A. Oral RfD references withdrawn
1476 Epichlorohydrin 106-89-8 28 19920401 Apr 1,1992 VI.B. Inhalation RfC references added
1477 Epichlorohydrin 106-89-8 29 19920601 Jun 1,1992 III.A.5. DWEL withdrawn
1478 Epichlorohydrin 106-89-8 30 19940201 Feb 1,1994 II.D.3. Secondary contact's phone number changed
1479 Epichlorohydrin 106-89-8 31 19950801 Aug 1,1995 I.A., I.A.6., VI.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1480 Epichlorohydrin 106-89-8 32 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1481 Epichlorohydrin 106-89-8 33 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1482 1,2-Epoxybutane (EBU) 106-88-7 1 19920101 Jan 1,1992 I.B. Inhalation RfC now under review
1483 1,2-Epoxybutane (EBU) 106-88-7 2 19920501 May 1,1992 I.B. Inhalation RfC on-line
1484 1,2-Epoxybutane (EBU) 106-88-7 3 19920501 May 1,1992 VI.B. Bibliography on-line
1485 1,2-Epoxybutane (EBU) 106-88-7 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1486 1,2-Epoxybutane (EBU) 106-88-7 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1487 Ethephon 16672-87-0 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
1488 Ethephon 16672-87-0 2 19910301 Mar 1,1991 I.A.4. Citations added
1489 Ethephon 16672-87-0 3 19910301 Mar 1,1991 VI. Bibliography on-line
1490 Ethephon 16672-87-0 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1491 Ethephon 16672-87-0 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1492 Ethephon 16672-87-0 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1493 Ethion 563-12-2 1 19890201 Feb 1,1989 I.A. Critical study citation year added
1494 Ethion 563-12-2 2 19890601 Jun 1,1989 I.A. Withdrawn; new Oral RfD verified (in preparation)
1495 Ethion 563-12-2 3 19890901 Sep 1,1989 I.A. Oral RfD summary on-line; RfD changed
1496 Ethion 563-12-2 4 19890901 Sep 1,1989 VI. Bibliography on-line
1497 Ethion 563-12-2 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1498 Ethion 563-12-2 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1499 Ethion 563-12-2 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1500 2-Ethoxyethanol 110-80-5 1 19910501 May 1,1991 I.B. Inhalation RfC summary on-line
1501 2-Ethoxyethanol 110-80-5 2 19910501 May 1,1991 VI. Bibliography on-line
1502 2-Ethoxyethanol 110-80-5 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1503 2-Ethoxyethanol 110-80-5 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1504 2-Ethoxyethanol 110-80-5 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1505 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
1506 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 2 20210813 Aug 13,2021 All EPA completed a reassessment, updating all values. There is no value for cancer oral as there was inadequate evidence to derive a value.
1507 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 3 20210816 Aug 16,2021 All Correction edits to the values after release.
1508 Ethyl acetate 141-78-6 1 19890801 Aug 1,1989 VI. Bibliography on-line
1509 Ethyl acetate 141-78-6 2 19920101 Jan 1,1992 I.A.7. Primary contact changed
1510 Ethyl acetate 141-78-6 3 19920101 Jan 1,1992 IV. Regulatory actions updated
1511 Ethyl acetate 141-78-6 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1512 Ethyl acetate 141-78-6 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1513 Ethyl carbamate 51-79-6 1 19920101 Jan 1,1992 I.B. Inhalation RfC now under review
1514 Ethyl carbamate 51-79-6 2 19920401 Apr 1,1992 I.B. Inhalation RfC message on-line
1515 Ethyl carbamate 51-79-6 3 19920401 Apr 1,1992 VI. Bibliography on-line
1516 Ethyl carbamate 51-79-6 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1517 Ethyl carbamate 51-79-6 5 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
1518 Ethyl carbamate 51-79-6 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1519 Ethyl chloride 75-00-3 1 19910401 Apr 1,1991 I.B. Inhalation RfC summary on-line
1520 Ethyl chloride 75-00-3 2 19910401 Apr 1,1991 VI. Bibliography on-line
1521 Ethyl chloride 75-00-3 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1522 Ethyl chloride 75-00-3 4 19950101 Jan 1,1995 II. Carcinogenicity assessment now under review
1523 Ethyl chloride 75-00-3 5 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken our os IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in Septermber, 1995.
1524 Ethyl chloride 75-00-3 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1525 Ethyl chloride 75-00-3 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1526 S-Ethyl dipropylthiocarbamate (EPTC) 759-94-4 1 19900901 Sep 1,1990 I.A.4. Citations added
1527 S-Ethyl dipropylthiocarbamate (EPTC) 759-94-4 2 19900901 Sep 1,1990 VI. Bibliography on-line
1528 S-Ethyl dipropylthiocarbamate (EPTC) 759-94-4 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1529 S-Ethyl dipropylthiocarbamate (EPTC) 759-94-4 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1530 Ethyl ether 60-29-7 1 19900901 Sep 1,1990 I.A. Oral RfD summary on-line
1531 Ethyl ether 60-29-7 2 19900901 Sep 1,1990 VI. Bibliography on-line
1532 Ethyl ether 60-29-7 3 19910701 Jul 1,1991 I.A.7. Primary and secondary contacts changed
1533 Ethyl ether 60-29-7 4 19930701 Jul 1,1993 I.A.6. Source Document and Other EPA Documentation clarified
1534 Ethyl ether 60-29-7 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1535 Ethyl ether 60-29-7 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1536 Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 1 19910301 Mar 1,1991 I.A.4. Citations added
1537 Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 2 19910301 Mar 1,1991 VI. Bibliography on-line
1538 Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 3 19910401 Apr 1,1991 VI.A. MRID numbers added to citations
1539 Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 4 19920101 Jan 1,1992 IV. Regulatory actions updated
1540 Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1541 Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1542 Ethylbenzene 100-41-4 1 19880301 Mar 1,1988 I.A.1. Dose conversion clarified
1543 Ethylbenzene 100-41-4 2 19880301 Mar 1,1988 I.A.6. Documentation revised
1544 Ethylbenzene 100-41-4 3 19880301 Mar 1,1988 III.A. Health Advisory added
1545 Ethylbenzene 100-41-4 4 19880907 Sep 7,1988 II. Carcinogen summary on-line
1546 Ethylbenzene 100-41-4 5 19890801 Aug 1,1989 VI. Bibliography on-line
1547 Ethylbenzene 100-41-4 6 19900801 Aug 1,1990 IV.F.1. EPA contact changed
1548 Ethylbenzene 100-41-4 7 19901001 Oct 1,1990 I.B. Inhalation RfC now under review
1549 Ethylbenzene 100-41-4 8 19910301 Mar 1,1991 I.B. Inhalation RfC summary on-line
1550 Ethylbenzene 100-41-4 9 19910301 Mar 1,1991 VI.B. Inhalation RfC references added
1551 Ethylbenzene 100-41-4 10 19910601 Jun 1,1991 I.A.7. Primary contact changed
1552 Ethylbenzene 100-41-4 11 19910801 Aug 1,1991 II.D.3. Secondary contact changed
1553 Ethylbenzene 100-41-4 12 19920101 Jan 1,1992 I.A.7. Secondary contact changed
1554 Ethylbenzene 100-41-4 13 19920101 Jan 1,1992 IV. Regulatory actions updated
1555 Ethylbenzene 100-41-4 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1556 Ethylbenzene 100-41-4 15 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
1557 Ethylbenzene 100-41-4 16 20181220 Dec 20,2018 All EPA suspended the development of this assessment.
1558 Ethylbenzene 100-41-4 17 20210628 Jun 28,2021 All EPA removed the suspension and restarted the development of an update of this assessment.
1559 Ethylene diamine 107-15-3 1 19910501 May 1,1991 I.B. Inhalation RfC message on-line
1560 Ethylene diamine 107-15-3 2 19910501 May 1,1991 VI. Bibliography on-line
1561 Ethylene diamine 107-15-3 3 19910901 Sep 1,1991 II. Carcinogenicity assessment now under review
1562 Ethylene diamine 107-15-3 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1563 Ethylene diamine 107-15-3 5 19921101 Nov 1,1992 II. Carcinogenicity assessment on-line
1564 Ethylene diamine 107-15-3 6 19921101 Nov 1,1992 VI.C. Carcinogenicity references on-line
1565 Ethylene diamine 107-15-3 7 19921201 Dec 1,1992 VI.C. Slesinski reference clarified
1566 Ethylene diamine 107-15-3 8 19930701 Jul 1,1993 II.D.1. Other EPA Documentation heading removed
1567 Ethylene diamine 107-15-3 9 19961201 Dec 1,1996 II.D.3. Secondary contact removed
1568 Ethylene diamine 107-15-3 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1569 Ethylene diamine 107-15-3 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1570 Ethylene glycol 107-21-1 1 19890901 Sep 1,1989 I.A. Clarified DePass (1986) & DePass et al. (1986) refs
1571 Ethylene glycol 107-21-1 2 19890901 Sep 1,1989 VI. Bibliography on-line
1572 Ethylene glycol 107-21-1 3 19920101 Jan 1,1992 I.A.7. Secondary contact changed
1573 Ethylene glycol 107-21-1 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1574 Ethylene glycol 107-21-1 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1575 Ethylene glycol 107-21-1 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1576 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 1 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1577 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 2 19991230 Dec 30,1999 I...VI RfD, RfC, and carcinogenicity assessment first on line
1578 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 5 20100331 Mar 31,2010 I., II., VI. RfD, RfC, and cancer assessment sections updated.
1579 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1580 Ethylene oxide 75-21-8 1 20180516 May 16,2018 WOE Footnote Added the ADAF footnote to the WOE basis decription.
1581 Ethylene oxide 75-21-8 2 20180628 Jun 28,2018 IRIS Summary Renamed the IRIS Summary to Executive summary to match the attachment.
1582 Ethylene oxide 75-21-8 3 20180710 Jul 10,2018 Key Values Table A footnote was added for ADAF.
1583 Ethylene oxide 75-21-8 4 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
1584 Ethylene thiourea (ETU) 96-45-7 1 19910501 May 1,1991 I.A. Oral RfD summary now on-line
1585 Ethylene thiourea (ETU) 96-45-7 2 19910501 May 1,1991 VI. Bibliography on-line
1586 Ethylene thiourea (ETU) 96-45-7 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1587 Ethylene thiourea (ETU) 96-45-7 4 19920701 Jul 1,1992 I.A.6. Oral RfD source references corrected
1588 Ethylene thiourea (ETU) 96-45-7 5 19920701 Jul 1,1992 VI.A. Oral RfD references corrected
1589 Ethylene thiourea (ETU) 96-45-7 6 19920901 Sep 1,1992 I.B. Inhalation RfC now under review
1590 Ethylene thiourea (ETU) 96-45-7 7 19930901 Sep 1,1993 II. Carcinogenicity assessment now under review
1591 Ethylene thiourea (ETU) 96-45-7 8 19940201 Feb 1,1994 I.A.1. NOAEL and LOAEL were reversed; corrected
1592 Ethylene thiourea (ETU) 96-45-7 9 19950801 Aug 1,1995 I.B., II. EPA's RfD/RFC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS reivew. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1593 Ethylene thiourea (ETU) 96-45-7 10 19961101 Nov 1,1996 I.A.7. Primary contact's office changed
1594 Ethylene thiourea (ETU) 96-45-7 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1595 Ethylene thiourea (ETU) 96-45-7 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1596 Ethyleneimine 151-56-4 1 19920101 Jan 1,1992 I.B. Inhalation RfC now under review
1597 Ethyleneimine 151-56-4 2 19920401 Apr 1,1992 I.B. Inhalation RfC message on-line
1598 Ethyleneimine 151-56-4 3 19920401 Apr 1,1992 VI. Bibliography on-line
1599 Ethyleneimine 151-56-4 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1600 Ethyleneimine 151-56-4 5 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
1601 Ethyleneimine 151-56-4 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1602 Ethylphthalyl ethylglycolate (EPEG) 84-72-0 1 19890801 Aug 1,1989 VI. Bibliography on-line
1603 Ethylphthalyl ethylglycolate (EPEG) 84-72-0 2 19910501 May 1,1991 I.A.4. Text edited
1604 Ethylphthalyl ethylglycolate (EPEG) 84-72-0 3 19950201 Feb 1,1995 I.A.7. Secondary contact's name changed
1605 Ethylphthalyl ethylglycolate (EPEG) 84-72-0 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1606 Ethylphthalyl ethylglycolate (EPEG) 84-72-0 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1607 Express 101200-48-0 1 19890101 Jan 1,1989 I.A. Oral RfD summary on-line
1608 Express 101200-48-0 2 19891001 Oct 1,1989 VI. Bibliography on-line
1609 Express 101200-48-0 3 19900401 Apr 1,1990 I.A.2. Text edited
1610 Express 101200-48-0 4 19910201 Feb 1,1991 II. Carcinogen assessment now under review
1611 Express 101200-48-0 5 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1612 Express 101200-48-0 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1613 Express 101200-48-0 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1614 Fenamiphos 22224-92-6 1 19900901 Sep 1,1990 I.A. Principal study citation corrected
1615 Fenamiphos 22224-92-6 2 19900901 Sep 1,1990 I.A.4. Citations added
1616 Fenamiphos 22224-92-6 3 19900901 Sep 1,1990 VI. Bibliography on-line
1617 Fenamiphos 22224-92-6 4 19901001 Oct 1,1990 III.A. Health Advisory on-line
1618 Fenamiphos 22224-92-6 5 19901001 Oct 1,1990 VI.D. Health Advisory references added
1619 Fenamiphos 22224-92-6 6 19920101 Jan 1,1992 IV. Regulatory actions updated
1620 Fenamiphos 22224-92-6 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1621 Fenamiphos 22224-92-6 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1622 Fluometuron 2164-17-2 1 19880301 Mar 1,1988 I.A.1. Dose conversion clarified
1623 Fluometuron 2164-17-2 2 19900901 Sep 1,1990 I.A.2. Text edited
1624 Fluometuron 2164-17-2 3 19900901 Sep 1,1990 I.A.4. Citations added
1625 Fluometuron 2164-17-2 4 19900901 Sep 1,1990 III.A. Health Advisory on-line
1626 Fluometuron 2164-17-2 5 19900901 Sep 1,1990 VI. Bibliography on-line
1627 Fluometuron 2164-17-2 6 19920101 Jan 1,1992 IV. Regulatory action updated
1628 Fluometuron 2164-17-2 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1629 Fluometuron 2164-17-2 8 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
1630 Fluometuron 2164-17-2 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1631 Fluoranthene 206-44-0 1 19900901 Sep 1,1990 I.A. Oral RfD summary on-line
1632 Fluoranthene 206-44-0 2 19900901 Sep 1,1990 VI. Bibliography on-line
1633 Fluoranthene 206-44-0 3 19901201 Dec 1,1990 II. Carcinogen assessment on-line
1634 Fluoranthene 206-44-0 4 19901201 Dec 1,1990 VI.C. Carcinogen assessment references added
1635 Fluoranthene 206-44-0 5 19910701 Jul 1,1991 I.A.7. Primary and secondary contacts changed
1636 Fluoranthene 206-44-0 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1637 Fluoranthene 206-44-0 7 19930701 Jul 1,1993 I.A.6. Other EPA Documentation added
1638 Fluoranthene 206-44-0 8 19940901 Sep 1,1994 I.B. Inhalation RfC now under review
1639 Fluoranthene 206-44-0 9 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replace the workgroup functions beginning in September, 1995.
1640 Fluoranthene 206-44-0 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1641 Fluoranthene 206-44-0 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1642 Fluorene 86-73-7 1 19901101 Nov 1,1990 I.A. Oral RfD summary on-line
1643 Fluorene 86-73-7 2 19901101 Nov 1,1990 VI. Bibliography on-line
1644 Fluorene 86-73-7 3 19901201 Dec 1,1990 II. Carcinogen assessment on-line
1645 Fluorene 86-73-7 4 19901201 Dec 1,1990 VI.C. Carcinogen assessment references added
1646 Fluorene 86-73-7 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1647 Fluorene 86-73-7 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1648 Fluorene 86-73-7 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1649 Fluorine (soluble fluoride) 7782-41-4 1 19870331 Mar 31,1987 I.A.6. Documentation corrected
1650 Fluorine (soluble fluoride) 7782-41-4 2 19880630 Jun 30,1988 I.A.7. Contacts switched
1651 Fluorine (soluble fluoride) 7782-41-4 3 19890401 Apr 1,1989 V. Supplementary data on-line
1652 Fluorine (soluble fluoride) 7782-41-4 4 19890601 Jun 1,1989 I.A.6. Work group review dates corrected
1653 Fluorine (soluble fluoride) 7782-41-4 5 19890801 Aug 1,1989 VI. Bibliography on-line
1654 Fluorine (soluble fluoride) 7782-41-4 6 19920101 Jan 1,1992 I.A.7. Seconday contact changed
1655 Fluorine (soluble fluoride) 7782-41-4 7 19920101 Jan 1,1992 IV. Regulatory actions updated
1656 Fluorine (soluble fluoride) 7782-41-4 8 19950801 Aug 1,1995 I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1657 Fluorine (soluble fluoride) 7782-41-4 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1658 Fluorine (soluble fluoride) 7782-41-4 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1659 Fluridone 59756-60-4 1 19880822 Aug 22,1988 I.A. Oral RfD summary replaced; RfD not changed
1660 Fluridone 59756-60-4 2 19900901 Sep 1,1990 I.A.4. Citations added
1661 Fluridone 59756-60-4 3 19900901 Sep 1,1990 VI. Bibliography on-line
1662 Fluridone 59756-60-4 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1663 Fluridone 59756-60-4 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1664 Flurprimidol 56425-91-3 1 19890701 Jul 1,1989 I.A. Oral RfD summary on-line
1665 Flurprimidol 56425-91-3 2 19890701 Jul 1,1989 VI. Bibliography on-line
1666 Flurprimidol 56425-91-3 3 19900401 Apr 1,1990 All CASRN corrected
1667 Flurprimidol 56425-91-3 4 19900401 Apr 1,1990 I.A. Text edited
1668 Flurprimidol 56425-91-3 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1669 Flurprimidol 56425-91-3 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1670 Flutolanil 66332-96-5 1 19890501 May 1,1989 I.A. Oral RfD summary on-line
1671 Flutolanil 66332-96-5 2 19890701 Jul 1,1989 VI. Bibliography on-line
1672 Flutolanil 66332-96-5 3 19900501 May 1,1990 I.A.2. Text edited
1673 Flutolanil 66332-96-5 4 19900501 May 1,1990 I.A.4. Text edited
1674 Flutolanil 66332-96-5 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1675 Flutolanil 66332-96-5 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1676 Fluvalinate 69409-94-5 1 19910301 Mar 1,1991 I.A.4. Citations added
1677 Fluvalinate 69409-94-5 2 19910301 Mar 1,1991 VI. Bibliography on-line
1678 Fluvalinate 69409-94-5 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1679 Fluvalinate 69409-94-5 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1680 Fluvalinate 69409-94-5 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1681 Folpet 133-07-3 1 19880822 Aug 22,1988 II. Carcinogen summary on-line
1682 Folpet 133-07-3 2 19910301 Mar 1,1991 I.A.4. Citations added
1683 Folpet 133-07-3 3 19910301 Mar 1,1991 VI. Bibliography on-line
1684 Folpet 133-07-3 4 19910401 Apr 1,1991 VI.C. Carcinogen references added
1685 Folpet 133-07-3 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1686 Folpet 133-07-3 6 19931001 Oct 1,1993 II.D.3. Primary contact changed; secondary's phone no. changed
1687 Folpet 133-07-3 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1688 Folpet 133-07-3 8 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
1689 Folpet 133-07-3 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1690 Fomesafen 72178-02-0 1 19880822 Aug 22,1988 II. Carcinogen summary on-line
1691 Fomesafen 72178-02-0 2 19890101 Jan 1,1989 All CASRN corrected
1692 Fomesafen 72178-02-0 3 19920601 Jun 1,1992 II.A.3. Citation years corrected
1693 Fomesafen 72178-02-0 4 19920601 Jun 1,1992 II.B.2. Citation year corrected
1694 Fomesafen 72178-02-0 5 19920601 Jun 1,1992 VI. Bibliography on-line
1695 Fomesafen 72178-02-0 6 19931001 Oct 1,1993 II.D.3. Primary contact changed
1696 Fomesafen 72178-02-0 7 19970401 Apr 1,1997 III., IV. V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1697 Fomesafen 72178-02-0 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1698 Fonofos 944-22-9 1 19910301 Mar 1,1991 I.A.1. MRID No. corrected
1699 Fonofos 944-22-9 2 19910301 Mar 1,1991 I.A.4. Citations added
1700 Fonofos 944-22-9 3 19910301 Mar 1,1991 VI. Bibliography on-line
1701 Fonofos 944-22-9 4 19910401 Apr 1,1991 V.B. Missing field added (Haz. Decomp. or Byproducts)
1702 Fonofos 944-22-9 5 19920101 Jan 1,1992 IV. Regulatory actions updated
1703 Fonofos 944-22-9 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1704 Fonofos 944-22-9 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1705 Formaldehyde 50-00-0 1 19891001 Oct 1,1989 II. Carcinogen summary on-line
1706 Formaldehyde 50-00-0 2 19891001 Oct 1,1989 VI. Bibliography on-line
1707 Formaldehyde 50-00-0 3 19891201 Dec 1,1989 I.A. Oral RfD now under review
1708 Formaldehyde 50-00-0 4 19900201 Feb 1,1990 VI. Supplementary data on-line
1709 Formaldehyde 50-00-0 5 19900901 Sep 1,1990 I.A. Oral RfD summary on-line
1710 Formaldehyde 50-00-0 6 19900901 Sep 1,1990 II. Text edited
1711 Formaldehyde 50-00-0 7 19900901 Sep 1,1990 VI.A. Oral RfD references added
1712 Formaldehyde 50-00-0 8 19910101 Jan 1,1991 II. Text edited
1713 Formaldehyde 50-00-0 9 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
1714 Formaldehyde 50-00-0 10 19910501 May 1,1991 II.C.1. Corrected units in risk level concentrations
1715 Formaldehyde 50-00-0 11 19910801 Aug 1,1991 VI.A.&C. Citations clarified
1716 Formaldehyde 50-00-0 12 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1717 Formaldehyde 50-00-0 13 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1718 Formaldehyde 50-00-0 14 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
1719 Formic acid 64-18-6 1 19870331 Mar 31,1987 I.A.6. Documentation corrected
1720 Formic acid 64-18-6 2 19880301 Mar 1,1988 I.A.1. Critical effect revised
1721 Formic acid 64-18-6 3 19880301 Mar 1,1988 I.A.2. Text added paragraph 1
1722 Formic acid 64-18-6 4 19901201 Dec 1,1990 I.A. Oral RfD withdrawn pending further review
1723 Formic acid 64-18-6 5 19911001 Oct 1,1991 II. Carcinogenicity assessment now under review
1724 Formic acid 64-18-6 6 19920101 Jan 1,1992 IV. Regulatory action updated
1725 Formic acid 64-18-6 7 19950801 Aug 1,1995 I.A., II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1726 Formic acid 64-18-6 8 19960201 Feb 1,1996 I.A. Contact changed
1727 Formic acid 64-18-6 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1728 Formic acid 64-18-6 10 20181210 Dec 10,2018 Archived Values Requested by the IRIS Program to archive the chemicals with null values.
1729 Formic acid 64-18-6 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1730 Fosetyl-al 39148-24-8 1 19880822 Aug 22,1988 II. Carcinogen summary on-line
1731 Fosetyl-al 39148-24-8 2 19910301 Mar 1,1991 I.A.1. MRID No. added
1732 Fosetyl-al 39148-24-8 3 19910301 Mar 1,1991 I.A.4. Citations added
1733 Fosetyl-al 39148-24-8 4 19910301 Mar 1,1991 VI. Bibliography on-line
1734 Fosetyl-al 39148-24-8 5 19910401 Apr 1,1991 VI.C. Citations clarified
1735 Fosetyl-al 39148-24-8 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1736 Fosetyl-al 39148-24-8 7 19931001 Oct 1,1993 II.D.3. Primary contact changed; secondary's phone no. changed
1737 Fosetyl-al 39148-24-8 8 19940701 Jul 1,1994 II. Carcinogenicity assessment noted as pending change
1738 Fosetyl-al 39148-24-8 9 19950801 Aug 1,1995 II., II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
1739 Fosetyl-al 39148-24-8 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1740 Fosetyl-al 39148-24-8 11 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
1741 Fosetyl-al 39148-24-8 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1742 Furan 110-00-9 1 None None
1743 Furan 110-00-9 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1744 Furfural 98-01-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1745 Furmecyclox 60568-05-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1746 Glufosinate-ammonium 77182-82-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1747 Glycidaldehyde 765-34-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1748 Glyphosate 1071-83-6 1 20190416 Apr 16,2019 Related Links Removed the archived REDs link from top list because they can get to the documents from the new tab.
1749 Glyphosate 1071-83-6 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1750 Haloxyfop-methyl 69806-40-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1751 Harmony 79277-27-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1752 Heptachlor 76-44-8 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
1753 Heptachlor 76-44-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1754 Heptachlor epoxide 1024-57-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1755 n-Heptane 142-82-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1756 Hexabromobenzene 87-82-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1757 Hexabromocyclododecane (HBCD) 3194-55-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1758 Hexabromodiphenyl ether 36483-60-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1759 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 68631-49-2 1 20080630 Jun 30,2008 I., II. RfD, RfC, and cancer assessment first on line.
1760 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 68631-49-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1761 Hexachlorobenzene 118-74-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1762 Hexachlorobutadiene 87-68-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1763 alpha-Hexachlorocyclohexane (alpha-HCH) 319-84-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1764 beta-Hexachlorocyclohexane (beta-HCH) 319-85-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1765 delta-Hexachlorocyclohexane (delta-HCH) 319-86-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1766 epsilon-Hexachlorocyclohexane (epsilon-HC) 6108-10-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1767 gamma-Hexachlorocyclohexane (gamma-HCH) 58-89-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1768 technical Hexachlorocyclohexane (t-HCH) 608-73-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1769 Hexachlorocyclopentadiene (HCCPD) 77-47-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1770 Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 57653-85-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1771 Hexachloroethane 67-72-1 1 19870930 Sep 30,1987 I.A. Oral RfD assessment on-line
1772 Hexachloroethane 67-72-1 2 19880301 Mar 1,1988 I.A.5. Confidence levels revised
1773 Hexachloroethane 67-72-1 3 19880301 Mar 1,1988 II.B.3. Text clarified
1774 Hexachloroethane 67-72-1 4 19880301 Mar 1,1988 II.B.4. Confidence statement revised
1775 Hexachloroethane 67-72-1 5 19880301 Mar 1,1988 II.C.4. Confidence statement revised
1776 Hexachloroethane 67-72-1 6 19910101 Jan 1,1991 II. Text edited
1777 Hexachloroethane 67-72-1 7 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
1778 Hexachloroethane 67-72-1 8 19910401 Apr 1,1991 I.A. Text edited
1779 Hexachloroethane 67-72-1 9 19910401 Apr 1,1991 I.A.7. Secondary contact changed
1780 Hexachloroethane 67-72-1 10 19910401 Apr 1,1991 II. Text edited
1781 Hexachloroethane 67-72-1 11 19910401 Apr 1,1991 VI. Bibliography on-line
1782 Hexachloroethane 67-72-1 12 19911201 Dec 1,1991 I.B. Inhalation RfC now under review
1783 Hexachloroethane 67-72-1 13 19911201 Dec 1,1991 IV.F.1. EPA contact changed
1784 Hexachloroethane 67-72-1 14 19920101 Jan 1,1992 IV. Regulatory actions updated
1785 Hexachloroethane 67-72-1 15 19921201 Dec 1,1992 I.B. Work group review date added
1786 Hexachloroethane 67-72-1 16 19940201 Feb 1,1994 II.D.3. Secondary contact's phone number changed
1787 Hexachloroethane 67-72-1 17 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemicalsubstance reviews that were not completed by September 1995 were taken out of IRISreview. The IRIS Pilot Program replaced the workgroup functions beginning inSeptember, 1995.
1788 Hexachloroethane 67-72-1 18 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Datawere removed from IRIS on or before April 1997. IRIS users were directed to theappropriate EPA Program Offices for this information.
1789 Hexachloroethane 67-72-1 19 20110923 Sep 23,2011 I, II, VI, VIII RfD and cancer assessments updated. RfC added.
1790 Hexachloroethane 67-72-1 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1791 Hexachlorophene 70-30-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1792 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 1 20180830 Aug 30,2018 Updates to Key Value After a rigorous peer review, the IRIS Program update the noncancer RfD value (not enough data was available to update the RfC), and the weight of evidence (woe) oral unit risk value (not enough data was available to update the inhalation unit risk value.
1793 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 2 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
1794 1,6-Hexamethylene diisocyanate 822-06-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1795 n-Hexane 110-54-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1796 2-Hexanone 591-78-6 1 20090925 Sep 25,2009 I., II. RfD, RfC, and cancer assessment first on-line
1797 2-Hexanone 591-78-6 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1798 Hexazinone 51235-04-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1799 Hydrazine/Hydrazine sulfate 302-01-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1800 Hydrogen Cyanide and Cyanide Salts Various 1 19870331 Mar 31,1987 I.A.6. Documentation corrected
1801 Hydrogen Cyanide and Cyanide Salts Various 2 19880301 Mar 1,1988 I.A.2. Text revised
1802 Hydrogen Cyanide and Cyanide Salts Various 3 19880301 Mar 1,1988 III.A. Health Advisory added
1803 Hydrogen Cyanide and Cyanide Salts Various 4 19900801 Aug 1,1990 IV.F.1. EPA contact changed
1804 Hydrogen Cyanide and Cyanide Salts Various 5 19910601 Jun 1,1991 VI. Bibliography on-line
1805 Hydrogen Cyanide and Cyanide Salts Various 6 19920101 Jan 1,1992 I.A.7. Primary contact changed
1806 Hydrogen Cyanide and Cyanide Salts Various 7 19920101 Jan 1,1992 IV. Regulatory actions updated
1807 Hydrogen Cyanide and Cyanide Salts Various 8 19930201 Feb 1,1993 I.A.7. Minor text change
1808 Hydrogen Cyanide and Cyanide Salts Various 9 19930301 Mar 1,1993 I.B. Inhalation RfC now under review
1809 Hydrogen Cyanide and Cyanide Salts Various 10 19940901 Sep 1,1994 I.B. Inhalation RfC on-line
1810 Hydrogen Cyanide and Cyanide Salts Various 11 19940901 Sep 1,1994 VI.B. Inhalation RfC references on-line
1811 Hydrogen Cyanide and Cyanide Salts Various 12 19941101 Nov 1,1994 VI.B. Osuntokun, 1981 reference clarified
1812 Hydrogen Cyanide and Cyanide Salts Various 13 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1813 Hydrogen Cyanide and Cyanide Salts Various 14 20020109 Jan 9,2002 I., II. This chemical is being reassessed under the IRIS Program
1814 Hydrogen Cyanide and Cyanide Salts Various 15 20100928 Sep 28,2010 I., II., VI. RfD and RfC assessment updated cancer assessment added.
1815 Hydrogen Cyanide and Cyanide Salts Various 16 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1816 Hydrogen chloride 7647-01-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1817 Hydrogen sulfide 7783-06-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1818 Hydroquinone 123-31-9 1 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
1819 Hydroquinone 123-31-9 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1820 Imazalil 35554-44-0 1 20160715 Jul 15,2016 Archived Key Values IRIS working with OPP agreed to mark this pesticide chemical archived.
1821 Imazalil 35554-44-0 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1822 Imazaquin 81335-37-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1823 Indeno[1,2,3-cd]pyrene 193-39-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1824 Iprodione 36734-19-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1825 Isobutyl alcohol 78-83-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1826 Isophorone 78-59-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1827 Isopropalin 33820-53-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1828 Isopropyl methyl phosphonic acid (IMPA) 1832-54-8 1 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
1829 Isopropyl methyl phosphonic acid (IMPA) 1832-54-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1830 Isoxaben 82558-50-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1831 Lactofen 77501-63-4 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
1832 Lactofen 77501-63-4 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1833 Lead and compounds (inorganic) 7439-92-1 1 19880926 Sep 26,1988 II. Carcinogen summary on-line
1834 Lead and compounds (inorganic) 7439-92-1 2 19890201 Feb 1,1989 IV.B.1. Effect level corrected in discussion
1835 Lead and compounds (inorganic) 7439-92-1 3 19890601 Jun 1,1989 II.D.3. Primary contact changed
1836 Lead and compounds (inorganic) 7439-92-1 4 19890601 Jun 1,1989 IV.A.1. Reference corrected - changed number for part in CFR
1837 Lead and compounds (inorganic) 7439-92-1 5 19891201 Dec 1,1989 II.A.3. Last paragraph - correct Van Esch 1969 citation
1838 Lead and compounds (inorganic) 7439-92-1 6 19891201 Dec 1,1989 VI. Bibliography on-line
1839 Lead and compounds (inorganic) 7439-92-1 7 19900701 Jul 1,1990 I.A. Changed contact J. Cohen's office and telephone number
1840 Lead and compounds (inorganic) 7439-92-1 8 19900701 Jul 1,1990 IV.F.1. EPA contact chenged
1841 Lead and compounds (inorganic) 7439-92-1 9 19910201 Feb 1,1991 I.A. Message revised to include new EPA document
1842 Lead and compounds (inorganic) 7439-92-1 10 19910201 Feb 1,1991 I.A. EPA contacts changed
1843 Lead and compounds (inorganic) 7439-92-1 11 19910501 May 1,1991 II.A. Text edited
1844 Lead and compounds (inorganic) 7439-92-1 12 19920101 Jan 1,1992 IV. Regulatory actions updated
1845 Lead and compounds (inorganic) 7439-92-1 13 19920601 Jun 1,1992 IV.B.2. MCL monitoring reqs. and BAT corrected
1846 Lead and compounds (inorganic) 7439-92-1 14 19930701 Jul 1,1993 II.D.3. Secondary contact's phone number changed
1847 Lead and compounds (inorganic) 7439-92-1 15 19930701 Jul 1,1993 VI.C. References alphabetized correctly
1848 Lead and compounds (inorganic) 7439-92-1 16 19931101 Nov 1,1993 II.D.1. U.S.EPA 1987 replaced with 1989; rev. state. revised
1849 Lead and compounds (inorganic) 7439-92-1 17 19931101 Nov 1,1993 VI.C. U.S.EPA 1987 deleted; U.S.EPA 1989 added
1850 Lead and compounds (inorganic) 7439-92-1 18 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1851 Lead and compounds (inorganic) 7439-92-1 19 I.A., I.Bl, II. Previous reference value discussions replaced with links to EPA websites containing regulatory information and other websites with risk assessment information; cancer discussion retained, added links to agencies conducting reviews of lead carcinogenicity.
1852 Lead and compounds (inorganic) 7439-92-1 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1853 Libby Amphibole Asbestos 1318-09-8 1 20141117 Nov 17,2014 IB, II, VI. RfC and cancer assessment added
1854 Libby Amphibole Asbestos 1318-09-8 2 20200619 Jun 19,2020 CASRN Added CASRN, DTXSID number (as alternate CASRN) and related link from/to the Chemistry Dashboard.
1855 Libby Amphibole Asbestos 1318-09-8 3 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
1856 d-Limonene 5989-27-5 1 19931101 Nov 1,1993 I.B. Inhalation RfC now under review
1857 d-Limonene 5989-27-5 2 19931201 Dec 1,1993 I.B. Inhalation RfC message on-line
1858 d-Limonene 5989-27-5 3 19911201 Dec 1,1991 VI.B. Inhalation RfC references on-line
1859 d-Limonene 5989-27-5 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1860 d-Limonene 5989-27-5 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1861 Linuron 330-55-2 1 19890501 May 1,1989 II. Carcinogen assessment now under review
1862 Linuron 330-55-2 2 19890801 Aug 1,1989 II. Carcinogen summary on-line
1863 Linuron 330-55-2 3 19890801 Aug 1,1989 VI. Bibliography on-line
1864 Linuron 330-55-2 4 19900801 Aug 1,1990 I.A. Text edited
1865 Linuron 330-55-2 5 19900801 Aug 1,1990 II. Text edited
1866 Linuron 330-55-2 6 19900801 Aug 1,1990 VI.A. RfD references added
1867 Linuron 330-55-2 7 19920101 Jan 1,1992 IV. Regulatory actions updated
1868 Linuron 330-55-2 8 19931001 Oct 1,1993 II.D.3. Secondary actions updated
1869 Linuron 330-55-2 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1870 Linuron 330-55-2 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1871 Londax 83055-99-6 1 19870930 Sep 30,1987 All CASRN added to file
1872 Londax 83055-99-6 2 19880301 Mar 1,1988 I.A.2. LEL text clarified
1873 Londax 83055-99-6 3 19880630 Jun 30,1988 I.A. Withdrawn; new RfD verified (in preparation)
1874 Londax 83055-99-6 4 19880907 Sep 7,1988 I.A. Revised oral RfD summary added
1875 Londax 83055-99-6 5 19900901 Sep 1,1990 I.A.4. Citations added
1876 Londax 83055-99-6 6 19900901 Sep 1,1990 VI. Bibliography on-line
1877 Londax 83055-99-6 7 19910401 Apr 1,1991 I.A. Text edited
1878 Londax 83055-99-6 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1879 Londax 83055-99-6 9 20180801 Aug 1,2018 POD Value Update Made a correction on the POD on the Oral RfD from 1.99 to 19.9 to match the tox review.
1880 Londax 83055-99-6 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1881 Malathion 121-75-5 1 19880301 Mar 1,1988 All CASRN corrected
1882 Malathion 121-75-5 2 19910801 Aug 1,1991 I.B. Inhalation RfC now under review
1883 Malathion 121-75-5 3 19920101 Jan 1,1992 I.A.4. Citations added
1884 Malathion 121-75-5 4 19920101 Jan 1,1992 IV. Regulatory actions updated
1885 Malathion 121-75-5 5 19920101 Jan 1,1992 VI. Bibliography on-line
1886 Malathion 121-75-5 6 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workshops were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken oout of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
1887 Malathion 121-75-5 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1888 Malathion 121-75-5 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1889 Maleic anhydride 108-31-6 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
1890 Maleic anhydride 108-31-6 2 19880926 Sep 26,1988 All CASRN corrected
1891 Maleic anhydride 108-31-6 3 19910401 Apr 1,1991 I.A. Text edited
1892 Maleic anhydride 108-31-6 4 19910401 Apr 1,1991 I.A.7. Secondary contact changed
1893 Maleic anhydride 108-31-6 5 19910801 Aug 1,1991 I.A. All citations clarified - changed to U.S. EPA
1894 Maleic anhydride 108-31-6 6 19910801 Aug 1,1991 VI. Bibliography on-ine
1895 Maleic anhydride 108-31-6 7 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1896 Maleic anhydride 108-31-6 8 19930701 Jul 1,1993 I.A.6. Other EPA Documentation clarified
1897 Maleic anhydride 108-31-6 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1898 Maleic anhydride 108-31-6 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1899 Maleic hydrazide 123-33-1 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
1900 Maleic hydrazide 123-33-1 2 19920101 Jan 1,1992 IV. Regulatory actions updated
1901 Maleic hydrazide 123-33-1 3 19920501 May 1,1992 I.A.7. Primary contact changed
1902 Maleic hydrazide 123-33-1 4 19920501 May 1,1992 VI.A. Bibliography on-line
1903 Maleic hydrazide 123-33-1 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information
1904 Maleic hydrazide 123-33-1 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1905 Maneb 12427-38-2 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
1906 Maneb 12427-38-2 2 19910401 Apr 1,1991 I.A. Text edited
1907 Maneb 12427-38-2 3 19920101 Jan 1,1992 I.A.4. Citations added
1908 Maneb 12427-38-2 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1909 Maneb 12427-38-2 5 19920101 Jan 1,1992 VI. Bibliography on-line
1910 Maneb 12427-38-2 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1911 Maneb 12427-38-2 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1912 Manganese 7439-96-5 1 19880926 Sep 26,1988 II. Carcinogen summary on-line
1913 Manganese 7439-96-5 2 19890901 Sep 1,1989 VI. Bibliography on-line
1914 Manganese 7439-96-5 3 19900601 Jun 1,1990 I.A. Oral RfD now under review
1915 Manganese 7439-96-5 4 19900801 Aug 1,1990 I.A. Oral RfD summary on-line
1916 Manganese 7439-96-5 5 19900801 Aug 1,1990 II. Text edited
1917 Manganese 7439-96-5 6 19900801 Aug 1,1990 VI. Oral RfD references added
1918 Manganese 7439-96-5 7 19900901 Sep 1,1990 I.B. Inhalation RfC now under review
1919 Manganese 7439-96-5 8 19901206 Dec 6,1990 I.B. Inhalation RfC on-line
1920 Manganese 7439-96-5 9 19901206 Dec 6,1990 VI.B. Inhalation RfC references added
1921 Manganese 7439-96-5 10 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1922 Manganese 7439-96-5 11 19920601 Jun 1,1992 VI.B. Iregren, 1990 and Nishiyama et al., 1975 pages corrected
1923 Manganese 7439-96-5 12 19920801 Aug 1,1992 I.A. Oral RfD noted as pending change
1924 Manganese 7439-96-5 13 19920801 Aug 1,1992 I.A.6. Work group review date added
1925 Manganese 7439-96-5 14 19921001 Oct 1,1992 I.A. Oral RfD withdrawn; new summary in preparation
1926 Manganese 7439-96-5 15 19921001 Oct 1,1992 I.A.6. Work group review date added
1927 Manganese 7439-96-5 16 19921001 Oct 1,1992 VI.A. Oral RfD references withdrawn
1928 Manganese 7439-96-5 17 19930101 Jan 1,1993 I.A. Oral RfD replaced (RfD changed)
1929 Manganese 7439-96-5 18 19930101 Jan 1,1993 VI.A. Oral RfD references replaced
1930 Manganese 7439-96-5 19 19930501 May 1,1993 I.A. Work group review date added
1931 Manganese 7439-96-5 20 19930701 Jul 1,1993 II.A.3. 'Inadequate' added to first paragraph
1932 Manganese 7439-96-5 21 19930701 Jul 1,1993 II.D.1. EPA Documentation clarified
1933 Manganese 7439-96-5 22 19931101 Nov 1,1993 I.B. Inhalation RfC noted as pending changed
1934 Manganese 7439-96-5 23 19931101 Nov 1,1993 I.B.6. Work group review date added
1935 Manganese 7439-96-5 24 19931201 Dec 1,1993 I.B. Inhalation RfC replaced; RfC changed
1936 Manganese 7439-96-5 25 19931201 Dec 1,1993 VI.B. Inhalation RfC references replaced
1937 Manganese 7439-96-5 26 19940101 Jan 1,1994 I.A. Oral RfD noted as pending change
1938 Manganese 7439-96-5 27 19940101 Jan 1,1994 I.A.6. Work group review date added
1939 Manganese 7439-96-5 28 19940301 Mar 1,1994 II.D.3. Primary contact changed
1940 Manganese 7439-96-5 29 19940401 Apr 1,1994 I.A.2. Text revised
1941 Manganese 7439-96-5 30 19940401 Apr 1,1994 I.A.3. Test revised
1942 Manganese 7439-96-5 31 19940401 Apr 1,1994 I.A.4. Text revised
1943 Manganese 7439-96-5 32 19940401 Apr 1,1994 I.A.5. Text revised
1944 Manganese 7439-96-5 33 19940401 Apr 1,1994 VI.A. Oral RfD references revised
1945 Manganese 7439-96-5 34 19950601 Jun 1,1995 I.A. Oral RfD noted as pending change
1946 Manganese 7439-96-5 35 19950601 Jun 1,1995 I.A.6. Work group review date added
1947 Manganese 7439-96-5 36 19950801 Aug 1,1995 I.A., I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot PRogram replaced the workgroup functions beginning in September 1995.
1948 Manganese 7439-96-5 37 19951101 Nov 1,1995 I.A. Oral RfD assessment replaced
1949 Manganese 7439-96-5 38 19951101 Nov 1,1995 VI.A. Oral RfD references replaced
1950 Manganese 7439-96-5 39 19960501 May 1,1996 I.A.7. Secondary contact's phone number changed
1951 Manganese 7439-96-5 40 19961201 Dec 1,1996 II.D.3. Primary contact removed
1952 Manganese 7439-96-5 41 19970401 Apr 1,1997 III., IV., V. Drinking Wate Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1953 Manganese 7439-96-5 42 20181220 Dec 20,2018 Reassessment EPA had been working on a reassessment of manganese but this document developmebt was suspended because of other priorities.
1954 Manganese 7439-96-5 43 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
1955 Mepiquat chloride 24307-26-4 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
1956 Mepiquat chloride 24307-26-4 2 19891001 Oct 1,1989 VI. Bibliography on-line
1957 Mepiquat chloride 24307-26-4 3 19910401 Apr 1,1991 I.A. text edited
1958 Mepiquat chloride 24307-26-4 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1959 Mepiquat chloride 24307-26-4 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1960 Mepiquat chloride 24307-26-4 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1961 Mercuric chloride (HgCl2) 7487-94-7 1 19940401 Apr 1,1994 I.B. Inhalation RfC noted as under review on 3/22/1990
1962 Mercuric chloride (HgCl2) 7487-94-7 2 19940401 Apr 1,1994 II. Carcinogenicity assessment now under review
1963 Mercuric chloride (HgCl2) 7487-94-7 3 19950501 May 1,1995 I.A. Oral RfD summary on-line
1964 Mercuric chloride (HgCl2) 7487-94-7 4 19950501 May 1,1995 II. Carcinogenicity assessment summary on-line
1965 Mercuric chloride (HgCl2) 7487-94-7 5 19950501 May 1,1995 VI. Bibliography on-line
1966 Mercuric chloride (HgCl2) 7487-94-7 6 19950601 Jun 1,1995 II.B. Text revised; first paragraph
1967 Mercuric chloride (HgCl2) 7487-94-7 7 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by Setember 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
1968 Mercuric chloride (HgCl2) 7487-94-7 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were direced to the appropriate EPA Program Offices for this information.
1969 Mercuric chloride (HgCl2) 7487-94-7 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1970 Mercury, elemental 7439-97-6 1 19880907 Sep 7,1988 II. Carcinogen summary on-line
1971 Mercury, elemental 7439-97-6 2 19890901 Sep 1,1989 VI. Bibliography on-line
1972 Mercury, elemental 7439-97-6 3 19891201 Dec 1,1989 I.B. Inhalation RfD now under review
1973 Mercury, elemental 7439-97-6 4 19910501 May 1,1991 II.A.3. Text edited
1974 Mercury, elemental 7439-97-6 5 19920101 Jan 1,1992 IV. Regulatory Action Section on-line
1975 Mercury, elemental 7439-97-6 6 19940401 Apr 1,1994 II. Carcinogenicity assessment noted as pending change
1976 Mercury, elemental 7439-97-6 7 19940401 Apr 1,1994 II.D.2. Work group review date added
1977 Mercury, elemental 7439-97-6 8 19950501 May 1,1995 All Name changed from mercury (inorganic)
1978 Mercury, elemental 7439-97-6 9 19950501 May 1,1995 II. Carcinogen assessment replaced
1979 Mercury, elemental 7439-97-6 10 19950501 May 1,1995 VI.C. Carcinogen assessment references replaced
1980 Mercury, elemental 7439-97-6 11 19950601 Jun 1,1995 I.B. Inhalation RfC summary on-line
1981 Mercury, elemental 7439-97-6 12 19950601 Jun 1,1995 VI.B. Inhalation RfC references on-line
1982 Mercury, elemental 7439-97-6 13 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
1983 Mercury, elemental 7439-97-6 14 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1984 Merphos 150-50-5 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
1985 Merphos 150-50-5 2 19890101 Jan 1,1989 All CASRN corrected
1986 Merphos 150-50-5 3 19910401 Apr 1,1991 I.A. Text edited
1987 Merphos 150-50-5 4 19920401 Apr 1,1992 I.A.4. Citations added
1988 Merphos 150-50-5 5 19920401 Apr 1,1992 VI. Bibliography on-line
1989 Merphos 150-50-5 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
1990 Merphos 150-50-5 7 19920801 Aug 1,1992 I.B. Inhalation RfC now under review
1991 Merphos 150-50-5 8 19921101 Nov 1,1992 I.B. Not verified; data inadequate
1992 Merphos 150-50-5 9 19921101 Nov 1,1992 VI.B. No references available
1993 Merphos 150-50-5 10 19970401 Apr 1,1997 III., IV.,V. Dring Water Health Advisories, EPA Regulatory Actions, and Supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program offices for this information.
1994 Merphos 150-50-5 11 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
1995 Merphos 150-50-5 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
1996 Merphos oxide 78-48-8 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
1997 Merphos oxide 78-48-8 2 19910401 Apr 1,1991 I.A. Text edited
1998 Merphos oxide 78-48-8 3 19910401 Apr 1,1991 I.A.4. Citations added
1999 Merphos oxide 78-48-8 4 19910401 Apr 1,1991 VI. Bibliography on-line
2000 Merphos oxide 78-48-8 5 19920801 Aug 1,1992 I.B. Inhalation RfC now under review
2001 Merphos oxide 78-48-8 6 19921101 Nov 1,1992 I.B. Not verified; data inadequate
2002 Merphos oxide 78-48-8 7 19921101 Nov 1,1992 VI.B. No references available
2003 Merphos oxide 78-48-8 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Halth Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2004 Merphos oxide 78-48-8 9 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2005 Merphos oxide 78-48-8 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2006 Metalaxyl 57837-19-1 1 19870301 Mar 1,1987 IV. Regulatory Action section on-line
2007 Metalaxyl 57837-19-1 2 19910301 Mar 1,1991 I.A.4. Citations added
2008 Metalaxyl 57837-19-1 3 19910301 Mar 1,1991 VI. Bibliography on-line
2009 Metalaxyl 57837-19-1 4 19920101 Jan 1,1992 IV. Regulatory action updated
2010 Metalaxyl 57837-19-1 5 19950101 Jan 1,1995 I.A. Oral RfD noted as pending
2011 Metalaxyl 57837-19-1 6 19950101 Jan 1,1995 I.A.6. Work group review date added
2012 Metalaxyl 57837-19-1 7 19950801 Aug 1,1995 I.A., I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2013 Metalaxyl 57837-19-1 8 19970401 Apr 1,1997 III., IV., V. Drinking Water HEalth Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2014 Metalaxyl 57837-19-1 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2015 Methacrylonitrile 126-98-7 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
2016 Methacrylonitrile 126-98-7 2 19890401 Apr 1,1989 V. Supplementary data on-line
2017 Methacrylonitrile 126-98-7 3 19890901 Sep 1,1989 VI. Bibliography on-line
2018 Methacrylonitrile 126-98-7 4 19910101 Jan 1,1991 I.A. Text edited
2019 Methacrylonitrile 126-98-7 5 19920101 Jan 1,1992 I.A.7. Secondary contact changed
2020 Methacrylonitrile 126-98-7 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2021 Methacrylonitrile 126-98-7 7 19960201 Feb 1,1996 I.A.7. Secondary contact deleted
2022 Methacrylonitrile 126-98-7 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplemetary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2023 Methacrylonitrile 126-98-7 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2024 Methamidophos 10265-92-6 1 19880301 Mar 1,1988 I.A.4. Text deleted
2025 Methamidophos 10265-92-6 2 19910301 Mar 1,1991 I.A.4. Citations added
2026 Methamidophos 10265-92-6 3 19910301 Mar 1,1991 VI. Bibliography on-line
2027 Methamidophos 10265-92-6 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2028 Methamidophos 10265-92-6 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2029 Methamidophos 10265-92-6 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2030 Methanol 67-56-1 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
2031 Methanol 67-56-1 2 19891001 Oct 1,1989 I.B. Inhalation RfD now under review
2032 Methanol 67-56-1 3 19891101 Nov 1,1989 VI. Bibliography on-line
2033 Methanol 67-56-1 4 19910101 Jan 1,1991 I.A. Text edited
2034 Methanol 67-56-1 5 19920101 Jan 1,1992 I.A.7. Secondary contact changed
2035 Methanol 67-56-1 6 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2036 Methanol 67-56-1 7 19930701 Jul 1,1993 I.A.6. Other EPA Documnetation added
2037 Methanol 67-56-1 8 19950801 Aug 1,1995 .B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2038 Methanol 67-56-1 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA PRogram Offices for this information.
2039 Methanol 67-56-1 10 20130930 Sep 30,2013 I., VI., VIII. RfD assessment updated. RfC added.
2040 Methanol 67-56-1 11 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2041 Methidathion 950-37-8 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
2042 Methidathion 950-37-8 2 19890401 Apr 1,1989 V. Supplementary data on-line
2043 Methidathion 950-37-8 3 19890501 May 1,1989 II. Carcinogen summary on-line
2044 Methidathion 950-37-8 4 19891201 Dec 1,1989 II.A.3. Paragraph 1: Citation corrected
2045 Methidathion 950-37-8 5 19891201 Dec 1,1989 II.A.3. Paragraph 2: Citation corrected
2046 Methidathion 950-37-8 6 19891201 Dec 1,1989 VI. Bibliography on-line
2047 Methidathion 950-37-8 7 19900801 Aug 1,1990 I.A. Text edited
2048 Methidathion 950-37-8 8 19900801 Aug 1,1990 II. Text edited
2049 Methidathion 950-37-8 9 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2050 Methidathion 950-37-8 10 19930701 Jul 1,1993 II.D.1. EPA Documentation clarified
2051 Methidathion 950-37-8 11 19930701 Jul 1,1993 VI.C. EPA reference year clarified
2052 Methidathion 950-37-8 12 19931001 Oct 1,1993 II.D.3. Secondary contact changed
2053 Methidathion 950-37-8 13 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices.
2054 Methidathion 950-37-8 14 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2055 Methidathion 950-37-8 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2056 Methomyl 16752-77-5 1 19870331 Mar 31,1987 IV. Regulatory Action section on-line
2057 Methomyl 16752-77-5 2 19881201 Dec 1,1988 I.A.4. Core grades added to studies 1, 3 and 4
2058 Methomyl 16752-77-5 3 19910301 Mar 1,1991 I.A.4. Citations added
2059 Methomyl 16752-77-5 4 19910301 Mar 1,1991 III.A. Health Advisory on-line
2060 Methomyl 16752-77-5 5 19910301 Mar 1,1991 VI. Bibliography on-line
2061 Methomyl 16752-77-5 6 19911001 Oct 1,1991 II. Carcinogenicity assessment now under review
2062 Methomyl 16752-77-5 7 19920101 Jan 1,1992 IV. Regulatory actions updated
2063 Methomyl 16752-77-5 8 19920801 Aug 1,1992 II. EPA's RfD/RfC and Crave workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of the IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2064 Methomyl 16752-77-5 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplemntary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2065 Methomyl 16752-77-5 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2066 Methoxychlor 72-43-5 1 19880907 Sep 7,1988 II. Carcinogen summary on-line
2067 Methoxychlor 72-43-5 2 19890201 Feb 1,1989 II.D.3. Primary contact's phone number corrected
2068 Methoxychlor 72-43-5 3 19890601 Jun 1,1989 II.D.3. Secondary contact deleted
2069 Methoxychlor 72-43-5 4 19891201 Dec 1,1989 VI. Bibliography on-line
2070 Methoxychlor 72-43-5 5 19900501 May 1,1990 I.A. Oral RfD now under review
2071 Methoxychlor 72-43-5 6 19900901 Sep 1,1990 I.A. Oral RfD summary on-line
2072 Methoxychlor 72-43-5 7 19900901 Sep 1,1990 III.A. Health Advisory on-line
2073 Methoxychlor 72-43-5 8 19900901 Sep 1,1990 VI.A. Oral RfD references added
2074 Methoxychlor 72-43-5 9 19900901 Sep 1,1990 VI.D. Health Advisory references added
2075 Methoxychlor 72-43-5 10 19901001 Oct 1,1990 II. Text edited
2076 Methoxychlor 72-43-5 11 19910801 Aug 1,1991 I.A.4. Khera citation year corrected
2077 Methoxychlor 72-43-5 12 19910801 Aug 1,1991 VI.A. Khera reference year corrected
2078 Methoxychlor 72-43-5 13 19911201 Dec 1,1991 I.B. Inhalation RfC now under review
2079 Methoxychlor 72-43-5 14 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2080 Methoxychlor 72-43-5 15 19920401 Apr 1,1992 I.B. Inhalation RfC message on-line
2081 Methoxychlor 72-43-5 16 19920401 Apr 1,1992 VI.B. Inhalation RfC references added
2082 Methoxychlor 72-43-5 17 19931201 Dec 1,1993 I.B. Replaced with expanded assessment
2083 Methoxychlor 72-43-5 18 19931201 Dec 1,1993 III.A. Health Advisory withdrawn
2084 Methoxychlor 72-43-5 19 19931201 Dec 1,1993 VI.B. References revised
2085 Methoxychlor 72-43-5 20 19931201 Dec 1,1993 VI.D. Health Advisory references withdrawn
2086 Methoxychlor 72-43-5 21 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2087 Methoxychlor 72-43-5 22 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
2088 Methoxychlor 72-43-5 23 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2089 2-Methoxyethanol 109-86-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2090 Methyl acrylate 96-33-3 1 19901201 Dec 1,1990 II. Carcinogen assessment on-line
2091 Methyl acrylate 96-33-3 2 19901201 Dec 1,1990 VI.C. Bibliography on-line
2092 Methyl acrylate 96-33-3 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2093 Methyl acrylate 96-33-3 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2094 Methyl chloride 74-87-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2095 Methyl chlorocarbonate 79-22-1 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
2096 Methyl chlorocarbonate 79-22-1 2 19890401 Apr 1,1989 V. Supplementary data on-line
2097 Methyl chlorocarbonate 79-22-1 3 19890501 May 1,1989 I.A. Withdrawn pending further review
2098 Methyl chlorocarbonate 79-22-1 4 19911001 Oct 1,1991 II. Carcinogenicity assessment now under review
2099 Methyl chlorocarbonate 79-22-1 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2100 Methyl chlorocarbonate 79-22-1 6 19950801 Aug 1,1995 I.A., II. EPAs RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2101 Methyl chlorocarbonate 79-22-1 7 19960201 Feb 1,1996 I.A. Contact changed
2102 Methyl chlorocarbonate 79-22-1 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA PROgram Offices for this information.
2103 Methyl chlorocarbonate 79-22-1 9 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
2104 Methyl chlorocarbonate 79-22-1 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2105 Methyl ethyl ketone (MEK) 78-93-3 1 19870331 Mar 31,1987 I.A.6. Documentation corrected
2106 Methyl ethyl ketone (MEK) 78-93-3 2 19880301 Mar 1,1988 I.A.2. Paragraph 2 clarified
2107 Methyl ethyl ketone (MEK) 78-93-3 3 19890701 Jul 1,1989 II. Carcinogen assessment now under review
2108 Methyl ethyl ketone (MEK) 78-93-3 4 19890701 Jul 1,1989 VI. Bibliography on-line
2109 Methyl ethyl ketone (MEK) 78-93-3 5 19891201 Dec 1,1989 II. Carcinogen assessment on-line
2110 Methyl ethyl ketone (MEK) 78-93-3 6 19891201 Dec 1,1989 VI.C. Carcinogen references added
2111 Methyl ethyl ketone (MEK) 78-93-3 7 19900401 Apr 1,1990 I.B. Inhalation RfC now under review
2112 Methyl ethyl ketone (MEK) 78-93-3 8 19900601 Jun 1,1990 I.A. Oral RfD summary noted as pending change
2113 Methyl ethyl ketone (MEK) 78-93-3 9 19900601 Jun 1,1990 IV.F.1. EPA contact changed
2114 Methyl ethyl ketone (MEK) 78-93-3 10 19910801 Aug 1,1991 I.A. Withdrawn pending further review
2115 Methyl ethyl ketone (MEK) 78-93-3 11 19910801 Aug 1,1991 VI.A. Oral RfD references withdrawn
2116 Methyl ethyl ketone (MEK) 78-93-3 12 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2117 Methyl ethyl ketone (MEK) 78-93-3 13 19920701 Jul 1,1992 I.B. Inhalation RfC on-line
2118 Methyl ethyl ketone (MEK) 78-93-3 14 19920701 Jul 1,1992 VI.B. Inhalation RfC references on-line
2119 Methyl ethyl ketone (MEK) 78-93-3 15 19920801 Aug 1,1992 VI.B. Inhalation RfC references clarified
2120 Methyl ethyl ketone (MEK) 78-93-3 16 19921001 Oct 1,1992 I.A. Work group review date added
2121 Methyl ethyl ketone (MEK) 78-93-3 17 19921201 Dec 1,1992 I.A. Work group review date added
2122 Methyl ethyl ketone (MEK) 78-93-3 18 19930501 May 1,1993 I.A. Oral RfD summary replaced; RfD changed
2123 Methyl ethyl ketone (MEK) 78-93-3 19 19930501 May 1,1993 VI.A. Oral RfD references replaced
2124 Methyl ethyl ketone (MEK) 78-93-3 20 19930601 Jun 1,1993 VI.C. Minor correction
2125 Methyl ethyl ketone (MEK) 78-93-3 21 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS user were directed to the appropriate EPA Program Offices for this information.
2126 Methyl ethyl ketone (MEK) 78-93-3 22 20020109 Jan 9,2002 I., II. This chemical is being reassessed under the IRIS Program.
2127 Methyl ethyl ketone (MEK) 78-93-3 23 I., II., VI. RfD, RfC, and cancer sections updated
2128 Methyl ethyl ketone (MEK) 78-93-3 24 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2129 Methyl iodide 74-88-4 1 19920901 Sep 1,1992 I.B. inhalation RfC now under review
2130 Methyl iodide 74-88-4 2 19940301 Mar 1,1994 II. Carcinogenicity assessment now under review
2131 Methyl iodide 74-88-4 3 19941001 Oct 1,1994 All CASRN corrected
2132 Methyl iodide 74-88-4 4 19950801 Aug 1,1995 I.B., II. EPA's RfD/RfC and Crave workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2133 Methyl iodide 74-88-4 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisries, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2134 Methyl iodide 74-88-4 6 20181210 Dec 10,2018 Archived Values Requested by the IRIS Program to archive the chemicals with null values.
2135 Methyl iodide 74-88-4 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2136 Methyl isobutyl ketone (MIBK) 108-10-1 1 19880301 Mar 1,1988 I.A.2. Text revised
2137 Methyl isobutyl ketone (MIBK) 108-10-1 2 19890701 Jul 1,1989 VI. Bibliography on-line
2138 Methyl isobutyl ketone (MIBK) 108-10-1 3 19900401 Apr 1,1990 I.B. Inhalation RfD now under review
2139 Methyl isobutyl ketone (MIBK) 108-10-1 4 19910301 Mar 1,1991 I.A. Oral RfD withdrawn pending additional review
2140 Methyl isobutyl ketone (MIBK) 108-10-1 5 19910301 Mar 1,1991 VI. Bibliography on-line
2141 Methyl isobutyl ketone (MIBK) 108-10-1 6 19920101 Jan 1,1992 IV. Regulatory actions updated
2142 Methyl isobutyl ketone (MIBK) 108-10-1 7 19930801 Aug 1,1993 I.A. Work group review date added
2143 Methyl isobutyl ketone (MIBK) 108-10-1 8 19930801 Aug 1,1993 I.A. EPA contact changed
2144 Methyl isobutyl ketone (MIBK) 108-10-1 9 19950801 Aug 1,1995 I.A., I.B., VI. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2145 Methyl isobutyl ketone (MIBK) 108-10-1 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2146 Methyl isobutyl ketone (MIBK) 108-10-1 11 19981210 Dec 10,1998 I., II. This chemical is being reassessed under the IRIS Program.
2147 Methyl isobutyl ketone (MIBK) 108-10-1 12 I., II., VI. RfD, RfC and cancer sections updated
2148 Methyl isobutyl ketone (MIBK) 108-10-1 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2149 Methyl isocyanate 624-83-9 1 19910301 Mar 1,1991 I.B. Inhalation RfC message on-line
2150 Methyl isocyanate 624-83-9 2 19910301 Mar 1,1991 VI. Bibliography on-line
2151 Methyl isocyanate 624-83-9 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2152 Methyl isocyanate 624-83-9 4 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
2153 Methyl isocyanate 624-83-9 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2154 Methyl methacrylate 80-62-6 1 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementart Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2155 Methyl methacrylate 80-62-6 2 19980302 Mar 2,1998 I.A., I.B., II., VI. New RfD, RfC, cancer assessments
2156 Methyl methacrylate 80-62-6 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2157 Methyl parathion 298-00-0 1 19910301 Mar 1,1991 I.A.4. Citations added
2158 Methyl parathion 298-00-0 2 19910301 Mar 1,1991 III.A. Health Advisory on-line
2159 Methyl parathion 298-00-0 3 19910301 Mar 1,1991 VI. Bibliography on-line
2160 Methyl parathion 298-00-0 4 19920101 Jan 1,1992 IV. Regulatory actions updated
2161 Methyl parathion 298-00-0 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1995. IRIS users were directed to the appropriate EPA Program Offices for this information
2162 Methyl parathion 298-00-0 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2163 Methyl tert-butyl ether (MTBE) 1634-04-4 1 19910801 Aug 1,1991 I.B. Inhalation RfC now under review
2164 Methyl tert-butyl ether (MTBE) 1634-04-4 2 19911201 Dec 1,1991 I.B. Inhalation RfC on-line
2165 Methyl tert-butyl ether (MTBE) 1634-04-4 3 19911201 Dec 1,1991 VI. Bibliography on-line
2166 Methyl tert-butyl ether (MTBE) 1634-04-4 4 19930301 Mar 1,1993 I.A. Oral RfD now under review
2167 Methyl tert-butyl ether (MTBE) 1634-04-4 5 19930501 May 1,1993 I.B. Inhalation RfC noted as pending change
2168 Methyl tert-butyl ether (MTBE) 1634-04-4 6 19930501 May 1,1993 I.B.6. Work group review date added
2169 Methyl tert-butyl ether (MTBE) 1634-04-4 7 19930801 Aug 1,1993 I.B. Withdrawn; new RfC verified (in preparation)
2170 Methyl tert-butyl ether (MTBE) 1634-04-4 8 19930801 Aug 1,1993 I.B.6. Work group review date added
2171 Methyl tert-butyl ether (MTBE) 1634-04-4 9 19930801 Aug 1,1993 I.B.7. EPA contact changed
2172 Methyl tert-butyl ether (MTBE) 1634-04-4 10 19930801 Aug 1,1993 VI. Bibliography withdrawn
2173 Methyl tert-butyl ether (MTBE) 1634-04-4 11 19930901 Sep 1,1993 I.B. Inhalation RfC replaced; RfC changed
2174 Methyl tert-butyl ether (MTBE) 1634-04-4 12 19930901 Sep 1,1993 VI.B. Inhalation RfC refereences on-line
2175 Methyl tert-butyl ether (MTBE) 1634-04-4 13 19950801 Aug 1,1995 I.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2176 Methyl tert-butyl ether (MTBE) 1634-04-4 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2177 Methyl tert-butyl ether (MTBE) 1634-04-4 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2178 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 1 19880929 Sep 29,1988 I.A. Oral RfD summary on-line
2179 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 2 19901201 Dec 1,1990 I.A.2. Text edited
2180 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2181 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 4 19920701 Jul 1,1992 VI.A. Oral RfD references on-line
2182 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2183 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2184 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 1 19880301 Mar 1,1988 I.A.1. Dose conversion clarified
2185 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 2 19881201 Dec 1,1988 I.A. Withdrawn; new RfD verified (in preparation)
2186 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 3 19890101 Jan 1,1989 I.A. Oral RfD summary replaced; RfD changed
2187 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 4 19891201 Dec 1,1989 VI. Bibliography on-line
2188 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 5 19900801 Aug 1,1990 I.A. Text edited
2189 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2190 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2191 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 1 19870828 Aug 28,1987 I.A. New Study - RfD changed
2192 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 2 19880301 Mar 1,1988 I.A.6. Verification date changed
2193 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 3 19880926 Sep 26,1988 I.A.1. Citation corrected
2194 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 4 19880926 Sep 26,1988 I.A.2. Text revised
2195 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 5 19880926 Sep 26,1988 I.A.3. UF text revised
2196 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 6 19880926 Sep 26,1988 I.A.4. Study descriptions revised
2197 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 7 19880926 Sep 26,1988 I.A.5. Confidence levels revised
2198 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 8 19910101 Jan 1,1991 I.A. Text edited
2199 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 9 19910301 Mar 1,1991 VI. Bibliography on-line
2200 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 10 19920101 Jan 1,1992 IV. Regulatory action updated
2201 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2202 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2203 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 1 19910801 Aug 1,1991 I.B. Inhalation RfC now under review
2204 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 2 19930301 Mar 1,1993 I.B. Work group review date added
2205 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 3 19940501 May 1,1994 I.B. Inhalation RfC now on-line
2206 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 4 19940501 May 1,1994 VI.B. Inhalation RfC references on-line
2207 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2208 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 6 19980207 Feb 7,1998 I.B., II., VI. Revised RfC, new carcinogenicity assessment
2209 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2210 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 1 19890801 Aug 1,1989 II. Carcinogen summary on-line
2211 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 2 19890801 Aug 1,1989 VI. Bibliography on-line
2212 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 3 19900801 Aug 1,1990 II. Text edited
2213 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 4 19930701 Jul 1,1993 VI.C. References alphabetized correctly
2214 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2215 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2216 Methylmercury (MeHg) 22967-92-6 1 19881201 Dec 1,1988 I.A. Principal study citations added
2217 Methylmercury (MeHg) 22967-92-6 2 19890201 Feb 1,1989 I.A. Oral RfD summary is being reevaluated
2218 Methylmercury (MeHg) 22967-92-6 3 19910801 Aug 1,1991 VI. Bibliography on-line
2219 Methylmercury (MeHg) 22967-92-6 4 19920101 Jan 1,1992 I.A.7. Secondary contact changed
2220 Methylmercury (MeHg) 22967-92-6 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2221 Methylmercury (MeHg) 22967-92-6 6 19940301 Mar 1,1994 I.A.6. Work group review date added
2222 Methylmercury (MeHg) 22967-92-6 7 19940401 Apr 1,1994 II. Carcinogenicity assessment now under review
2223 Methylmercury (MeHg) 22967-92-6 8 19940901 Sep 1,1994 I.A.6. Work group review date added
2224 Methylmercury (MeHg) 22967-92-6 9 19941001 Oct 1,1994 I.A.6. Work group review dates added
2225 Methylmercury (MeHg) 22967-92-6 10 19941101 Nov 1,1994 I.A.6. Work group review date added
2226 Methylmercury (MeHg) 22967-92-6 11 19941201 Dec 1,1994 I.A.6. Work group review date added
2227 Methylmercury (MeHg) 22967-92-6 12 19950501 May 1,1995 I.A. Oral RfD summary replaced; new RfD
2228 Methylmercury (MeHg) 22967-92-6 13 19950501 May 1,1995 VI.A. Oral RfD references replaced
2229 Methylmercury (MeHg) 22967-92-6 14 19950501 May 1,1995 II. Carcinogenicity assessment on-line
2230 Methylmercury (MeHg) 22967-92-6 15 19950501 May 1,1995 VI.C. Carcinogenicity assessment references on-line
2231 Methylmercury (MeHg) 22967-92-6 16 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2232 Methylmercury (MeHg) 22967-92-6 17 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2233 2-Methylnaphthalene 91-57-6 1 All First IRIS RfD, cancer assessment
2234 2-Methylnaphthalene 91-57-6 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2235 4-Methylphenol 106-44-5 1 19880822 Aug 22,1988 I.A. Oral RfD summary on-line
2236 4-Methylphenol 106-44-5 2 19890101 Jan 1,1989 I.A.6. Review statement deleted
2237 4-Methylphenol 106-44-5 3 19891101 Nov 1,1989 II. Carcinogen assessment now under review
2238 4-Methylphenol 106-44-5 4 19891101 Nov 1,1989 VI. Bibliography on-line
2239 4-Methylphenol 106-44-5 5 19900901 Sep 1,1990 I.A. Text edited
2240 4-Methylphenol 106-44-5 6 19900901 Sep 1,1990 II. Carcinogen assessment on-line
2241 4-Methylphenol 106-44-5 7 19900901 Sep 1,1990 VI.C. Carcinogen references added
2242 4-Methylphenol 106-44-5 8 19910801 Aug 1,1991 I.A. Withdrawn pending further review
2243 4-Methylphenol 106-44-5 9 19910801 Aug 1,1991 II.A.3. Kaiser reference year corrected
2244 4-Methylphenol 106-44-5 10 19910801 Aug 1,1991 All Name changed from p-Cresol
2245 4-Methylphenol 106-44-5 11 19910801 Aug 1,1991 VI.A. Oral RfD references withdrawn
2246 4-Methylphenol 106-44-5 12 19910801 Aug 1,1991 VI.C. Kaiser reference year corrected
2247 4-Methylphenol 106-44-5 13 19910801 Aug 1,1991 VI.C. Citations corrected
2248 4-Methylphenol 106-44-5 14 19920101 Jan 1,1992 I.B. Inhalation RfC now under review
2249 4-Methylphenol 106-44-5 15 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2250 4-Methylphenol 106-44-5 16 19920401 Apr 1,1992 I.B. Inhalation RfC now under review
2251 4-Methylphenol 106-44-5 17 19920401 Apr 1,1992 VI.B. Inhalation RfC references added
2252 4-Methylphenol 106-44-5 18 19930801 Aug 1,1993 I.A. Work group review date added
2253 4-Methylphenol 106-44-5 19 19930801 Aug 1,1993 I.A. EPA contact changed
2254 4-Methylphenol 106-44-5 20 19950801 Aug 1,1995 I.A., VI.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2255 4-Methylphenol 106-44-5 21 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2256 4-Methylphenol 106-44-5 22 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2257 3-Methylphenol 108-39-4 1 19880822 Aug 22,1988 I.A. ORal RfD summary on-line
2258 3-Methylphenol 108-39-4 2 19890101 Jan 1,1989 I.A.6. Review statement deleted
2259 3-Methylphenol 108-39-4 3 19891101 Nov 1,1989 II. Carcinogen assessment now under review
2260 3-Methylphenol 108-39-4 4 19891101 Nov 1,1989 VI. Bibliography on-line
2261 3-Methylphenol 108-39-4 5 19900901 Sep 1,1990 I.A. Text edited
2262 3-Methylphenol 108-39-4 6 19900901 Sep 1,1990 II. Carcinogen assessment on-line
2263 3-Methylphenol 108-39-4 7 19900901 Sep 1,1990 VI.C. Carcinogen references added
2264 3-Methylphenol 108-39-4 8 19910801 Aug 1,1991 II.A.3. Kaiser reference year corrected
2265 3-Methylphenol 108-39-4 9 19910801 Aug 1,1991 VI.C. Kaiser reference year corrected
2266 3-Methylphenol 108-39-4 10 19910801 Aug 1,1991 VI.C. Citations corrected
2267 3-Methylphenol 108-39-4 11 19910801 Aug 1,1991 All Name changed from m-Cresol
2268 3-Methylphenol 108-39-4 12 19920101 Jan 1,1992 I.A.7. Secondary contact changed
2269 3-Methylphenol 108-39-4 13 19920101 Jan 1,1992 I.B. Inhalation RfC now under review
2270 3-Methylphenol 108-39-4 14 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2271 3-Methylphenol 108-39-4 15 19920401 Apr 1,1992 I.B. Inhalation RfD message on-line
2272 3-Methylphenol 108-39-4 16 19920401 Apr 1,1992 VI.B. Inhalation RfC references added
2273 3-Methylphenol 108-39-4 17 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2274 3-Methylphenol 108-39-4 18 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2275 2-Methylphenol 95-48-7 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
2276 2-Methylphenol 95-48-7 2 19890101 Jan 1,1989 I.A.7. Contacts phone numbers corrected
2277 2-Methylphenol 95-48-7 3 19890401 Apr 1,1989 V. Supplementary data on-line
2278 2-Methylphenol 95-48-7 4 19890101 Jan 1,1989 II. Carcinogen assessment now under review
2279 2-Methylphenol 95-48-7 5 19891101 Nov 1,1989 VI. Bibliography on-line
2280 2-Methylphenol 95-48-7 6 19900901 Sep 1,1990 I.A. Text edited
2281 2-Methylphenol 95-48-7 7 19900901 Sep 1,1990 II. Carcinogen assessment on-line
2282 2-Methylphenol 95-48-7 8 19900901 Sep 1,1990 VI.C. Carcinogen references added
2283 2-Methylphenol 95-48-7 9 19910801 Aug 1,1991 II.A.3. Kaiser reference year corrected
2284 2-Methylphenol 95-48-7 10 19910801 Aug 1,1991 VI.C. Kaiser reference year corrected
2285 2-Methylphenol 95-48-7 11 19910801 Aug 1,1991 VI.C. Citations corrected
2286 2-Methylphenol 95-48-7 12 19910801 Aug 1,1991 All Name changed from o-Cresol
2287 2-Methylphenol 95-48-7 13 19920101 Jan 1,1992 I.A.7. Secondary contact changed
2288 2-Methylphenol 95-48-7 14 19920101 Jan 1,1992 I.B. Inhalation RfC now under review
2289 2-Methylphenol 95-48-7 15 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2290 2-Methylphenol 95-48-7 16 19920401 Apr 1,1992 I.B. Inhalation RfC message on-line
2291 2-Methylphenol 95-48-7 17 19920401 Apr 1,1992 VI.B. Inhalation references added
2292 2-Methylphenol 95-48-7 18 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Date were removed from IRIS on or before April 1997. IRIS users were directed to the appropirate EPA Program Offices for this information.
2293 2-Methylphenol 95-48-7 19 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2294 Metolachlor 51218-45-2 1 19870331 Mar 31,1987 IV. regulatory Action section on-line
2295 Metolachlor 51218-45-2 2 19880301 Mar 1,1988 I.A.5. Confidence levels revised
2296 Metolachlor 51218-45-2 3 19880630 Jun 30,1988 I.A. Withdrawn pending further review
2297 Metolachlor 51218-45-2 4 19880822 Aug 22,1988 II. Carcinogen summary on-line
2298 Metolachlor 51218-45-2 5 19880907 Sep 7,1988 I.A. Revised oral RfD summary added
2299 Metolachlor 51218-45-2 6 19881201 Dec 1,1988 I.A.1. Clarified effect
2300 Metolachlor 51218-45-2 7 19890201 Feb 1,1989 II.D.3. Secondary contact's area code corrected
2301 Metolachlor 51218-45-2 8 19901001 Oct 1,1990 I.A.1 Oral RfD corrected
2302 Metolachlor 51218-45-2 9 19910201 Feb 1,1991 I.A. Text edited
2303 Metolachlor 51218-45-2 10 19910201 Feb 1,1991 II. Text edited
2304 Metolachlor 51218-45-2 11 19910201 Feb 1,1991 VI. bibliography on-line
2305 Metolachlor 51218-45-2 12 19910301 Mar 1,1991 III.A. Health Advisory on-line
2306 Metolachlor 51218-45-2 13 19910301 Mar 1,1991 VI.D. Health Advisory on-line
2307 Metolachlor 51218-45-2 14 19920101 Jan 1,1992 IV. Regulatory actions updated
2308 Metolachlor 51218-45-2 15 19931001 Oct 1,1993 II.D.3. Primary contact changed; secondary's phone no. changed
2309 Metolachlor 51218-45-2 16 19940101 Jan 1,1994 I.A. Oral RfD noted as pending change
2310 Metolachlor 51218-45-2 17 19940101 Jan 1,1994 I.A.6. Work group review date added
2311 Metolachlor 51218-45-2 18 19950801 Aug 1,1995 .A., I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2312 Metolachlor 51218-45-2 19 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2313 Metolachlor 51218-45-2 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2314 Metribuzin 21087-64-9 1 19870331 Mar 31,1987 IV. Regulatory Action section on-line
2315 Metribuzin 21087-64-9 2 19880301 Mar 1,1988 I.A.5. Confidence levels revised
2316 Metribuzin 21087-64-9 3 19910301 Mar 1,1991 I.A.4. Citations added
2317 Metribuzin 21087-64-9 4 19910301 Mar 1,1991 III.A. Health Advisory on-line
2318 Metribuzin 21087-64-9 5 19910301 Mar 1,1991 VI. Bibliography on-line
2319 Metribuzin 21087-64-9 6 19920101 Jan 1,1992 IV. Regulatory actions updated
2320 Metribuzin 21087-64-9 7 19930301 Mar 1,1993 II. Carcinogenicty assessment now under review
2321 Metribuzin 21087-64-9 8 19931201 Dec 1,1993 II. Carcinogenicity assessment on-line
2322 Metribuzin 21087-64-9 9 19931201 Dec 1,1993 VI.C. Carcinogenicity assessment references on-line
2323 Metribuzin 21087-64-9 10 19940301 Mar 1,1994 I.A. Oral RfD noted as pending change
2324 Metribuzin 21087-64-9 11 19940301 Mar 1,1994 I.A.6. Work group review date added
2325 Metribuzin 21087-64-9 12 19950101 Jan 1,1995 I.A.6. Work group review date added
2326 Metribuzin 21087-64-9 13 19950801 Aug 1,1995 I.A., I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2327 Metribuzin 21087-64-9 14 19961201 Dec 1,1996 II.D.3. Primary contact removed
2328 Metribuzin 21087-64-9 15 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. The IRIS users were directed to the appropriate EPA Program Offices for this information.
2329 Metribuzin 21087-64-9 16 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2330 Mirex 2385-85-5 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
2331 Mirex 2385-85-5 2 19910401 Apr 1,1991 I.A.4. Citations added
2332 Mirex 2385-85-5 3 19910401 Apr 1,1991 VI. Bibliography on-line
2333 Mirex 2385-85-5 4 19920101 Jan 1,1992 IV. Regulatory actions updated
2334 Mirex 2385-85-5 5 19920801 Aug 1,1992 I.A. Withdrawn; new oral RfD verified (in preparation)
2335 Mirex 2385-85-5 6 19920801 Aug 1,1992 IV. Regulatory actions withdrawn
2336 Mirex 2385-85-5 7 19920801 Aug 1,1992 VI.A. Bibliography withdrawn
2337 Mirex 2385-85-5 8 19921001 Oct 1,1992 I.A. Oral RfD summary replaced; RfD changed
2338 Mirex 2385-85-5 9 19921001 Oct 1,1992 IV. Regulatory actions returned in conjunction with RfD
2339 Mirex 2385-85-5 10 19921001 Oct 1,1992 VI.A. Bibliography replaced
2340 Mirex 2385-85-5 11 19930701 Jul 1,1993 II. Carcinogenicity assessment now under review
2341 Mirex 2385-85-5 12 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substances that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2342 Mirex 2385-85-5 13 19970401 Apr 1,1997 III., IV.,V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2343 Mirex 2385-85-5 14 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
2344 Mirex 2385-85-5 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2345 Molinate 2212-67-1 1 19880926 Sep 26,1988 I.A. Oral RfD summary on-line
2346 Molinate 2212-67-1 2 19910201 Feb 1,1991 I.A. Text edited
2347 Molinate 2212-67-1 3 19910201 Feb 1,1991 VI. Biblioraphy on-line
2348 Molinate 2212-67-1 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2349 Molinate 2212-67-1 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2350 Molybdenum 7439-98-7 1 19910801 Aug 1,1991 I.A. Oral RfD now under review
2351 Molybdenum 7439-98-7 2 19921101 Nov 1,1992 I.A. Oral RfD summary on-line
2352 Molybdenum 7439-98-7 3 19921101 Nov 1,1992 VI.A. Oral RfD references on-line
2353 Molybdenum 7439-98-7 4 19930801 Aug 1,1993 I.A.2. Transposed number corrected in para. 1, line 13
2354 Molybdenum 7439-98-7 5 19970401 Apr 1,1997 III., IV.,V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA PRogram Offices for this information.
2355 Molybdenum 7439-98-7 6 20200619 Jun 19,2020 CASRN Added DTXSID and related links from/to Chemistry Dashboard and ATSDR.
2356 Molybdenum 7439-98-7 7 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2357 Monochloramine 10599-90-3 1 19920801 Aug 1,1992 I.A. Oral RfD now under review
2358 Monochloramine 10599-90-3 2 19921101 Nov 1,1992 I.A. Oral RfD summary on-line
2359 Monochloramine 10599-90-3 3 19921101 Nov 1,1992 VI.A. Oral RfD references on-line
2360 Monochloramine 10599-90-3 4 19921101 Nov 1,1992 II. Carcinogenicity assessment now under review
2361 Monochloramine 10599-90-3 5 19930101 Jan 1,1993 II.D.2. Work group review date added
2362 Monochloramine 10599-90-3 6 19931201 Dec 1,1993 I.A.6. Work group review date added
2363 Monochloramine 10599-90-3 7 19931201 Dec 1,1993 II. Carcinogenicity assessment on-line
2364 Monochloramine 10599-90-3 8 19931201 Dec 1,1993 VI.C. Carcinogenicity references on-line
2365 Monochloramine 10599-90-3 9 19940101 Jan 1,1994 I.A. Oral RfD noted as pending change
2366 Monochloramine 10599-90-3 10 19940101 Jan 1,1994 I.A.6. Work group reiew date added
2367 Monochloramine 10599-90-3 11 19940301 Mar 1,1994 I.A. Oral RfD revised; study and number unchanged
2368 Monochloramine 10599-90-3 12 19940301 Mar 1,1994 VI.A. Oral RfD references revised
2369 Monochloramine 10599-90-3 13 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Actions were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2370 Monochloramine 10599-90-3 14 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
2371 Monochloramine 10599-90-3 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2372 Naled 300-76-5 1 19870930 Sep 30,1987 I.A.4. Study description added (number 2.)
2373 Naled 300-76-5 2 19870930 Sep 30,1987 IV. Pesticide Registration Standard added
2374 Naled 300-76-5 3 19890601 Jun 1,1989 I.A.6. Work group review date added
2375 Naled 300-76-5 4 19910301 Mar 1,1991 I.A.4. Citations added
2376 Naled 300-76-5 5 19910301 Mar 1,1991 VI. Bibliography on-line
2377 Naled 300-76-5 6 19920101 Jan 1,1992 IV. Regulatory actions updated
2378 Naled 300-76-5 7 19950101 Jan 1,1995 I.A. Oral RfD noted as pending change
2379 Naled 300-76-5 8 19950101 Jan 1,1995 I.A.6. Work group review date added
2380 Naled 300-76-5 9 19950801 Aug 1,1995 I.A., I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2381 Naled 300-76-5 10 19970401 Apr 1,1997 III., IV.,V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2382 Naled 300-76-5 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2383 Naphthalene 91-20-3 1 19901201 Dec 1,1990 II. Carcinogen assessment on-line
2384 Naphthalene 91-20-3 2 19901201 Dec 1,1990 VI. Bibliography on-line
2385 Naphthalene 91-20-3 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2386 Naphthalene 91-20-3 4 19920901 Sep 1,1992 II. Classification noted as pending change
2387 Naphthalene 91-20-3 5 19920901 Sep 1,1992 II.D.2. Work group review date added
2388 Naphthalene 91-20-3 6 19931101 Nov 1,1993 I.A. Work group review date added
2389 Naphthalene 91-20-3 7 19940901 Sep 1,1994 I.A. Work group review date added
2390 Naphthalene 91-20-3 8 19950501 May 1,1995 II. Pending change note replaced
2391 Naphthalene 91-20-3 9 19950501 May 1,1995 II.D.2. Work group review date added
2392 Naphthalene 91-20-3 10 19950701 Jul 1,1995 II. Pending change note replaced; see new note
2393 Naphthalene 91-20-3 11 19950801 Aug 1,1995 I.A, II., II.D.2. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2394 Naphthalene 91-20-3 12 19950801 Aug 1,1995 II. Note revised
2395 Naphthalene 91-20-3 13 19950801 Aug 1,1995 II.A.3. Paragraph 1 revised
2396 Naphthalene 91-20-3 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2397 Naphthalene 91-20-3 15 19980917 Sep 17,1998 I., II., VI. Revised RfD, RfC, carcinogenicity assessments
2398 Naphthalene 91-20-3 16 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2399 Naphthalene 91-20-3 17 20210628 Jun 28,2021 All EPA removed the suspension and restarted the development of an update of this assessment.
2400 Naphthalene 91-20-3 18 20181220 Dec 20,2018 All EPA suspended the development of this assessment.
2401 Napropamide 15299-99-7 1 19890701 Jul 1,1989 I.A. Oral RfD summary on-line
2402 Napropamide 15299-99-7 2 19890701 Jul 1,1989 VI. Bibliography on-line
2403 Napropamide 15299-99-7 3 19900501 May 1,1990 I.A.2. Text edited
2404 Napropamide 15299-99-7 4 19900501 May 1,1990 I.A.4. Text edited
2405 Napropamide 15299-99-7 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices.
2406 Napropamide 15299-99-7 6 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2407 Napropamide 15299-99-7 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2408 Nickel carbonyl 13463-39-3 1 19891201 Dec 1,1989 VI. Bibliography on-line
2409 Nickel carbonyl 13463-39-3 2 19900601 Jun 1,1990 IV.A.1. Area code for EPA contact corrected
2410 Nickel carbonyl 13463-39-3 3 19910301 Mar 1,1991 II.A.1. Text edited
2411 Nickel carbonyl 13463-39-3 4 19920101 Jan 1,1992 IV. Regulatory actions updated
2412 Nickel carbonyl 13463-39-3 5 19920401 Apr 1,1992 IV.A.1. CAA regulatory action withdrawn
2413 Nickel carbonyl 13463-39-3 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2414 Nickel carbonyl 13463-39-3 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2415 Nickel refinery dust None 1 19900601 Jun 1,1990 II.A.3. Text revised
2416 Nickel refinery dust None 2 19900601 Jun 1,1990 VI. Bibliography on-line
2417 Nickel refinery dust None 3 19910101 Jan 1,1991 II. Text edited
2418 Nickel refinery dust None 4 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
2419 Nickel refinery dust None 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2420 Nickel refinery dust None 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Adivsories, EPA Regulatory Actions, and Supplementary Data were removed on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2421 Nickel refinery dust None 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2422 Nickel subsulfide 12035-72-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2423 Nickel, soluble salts Various 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2424 Nitrapyrin 1929-82-4 1 20181210 Dec 10,2018 Archived Values Requested by the IRIS Program to archive the chemicals with null values.
2425 Nitrapyrin 1929-82-4 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2426 Nitrate 14797-55-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2427 Nitric oxide 10102-43-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2428 Nitrite 14797-65-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2429 Nitrobenzene 98-95-3 1 20090206 Feb 6,2009 I., II. Revised the RfD; added an RfC; revised the cancer assessment.
2430 Nitrobenzene 98-95-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2431 Nitrogen dioxide 10102-44-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2432 Nitroguanidine 556-88-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2433 p-Nitrophenol 100-02-7 1 20181210 Dec 10,2018 Archived Values Requested by the IRIS Program to archive the chemicals with null values.
2434 p-Nitrophenol 100-02-7 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2435 2-Nitropropane 79-46-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2436 N-Nitroso-N-methylethylamine 10595-95-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2437 N-Nitroso-di-n-butylamine 924-16-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2438 N-Nitrosodi-N-propylamine 621-64-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2439 N-Nitrosodiethanolamine 1116-54-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2440 N-Nitrosodiethylamine 55-18-5 1 19870331 Mar 31,1987 IV. RQ added
2441 N-Nitrosodiethylamine 55-18-5 2 19870930 Sep 30,1987 IV. Water Quality Criteria added
2442 N-Nitrosodiethylamine 55-18-5 3 19880301 Mar 1,1988 II.A.1. Text clarified
2443 N-Nitrosodiethylamine 55-18-5 4 19880301 Mar 1,1988 II.B.1. Number rounded off
2444 N-Nitrosodiethylamine 55-18-5 5 19880301 Mar 1,1988 II.B.3. Text revised
2445 N-Nitrosodiethylamine 55-18-5 6 19880301 Mar 1,1988 II.B.4. Confidence statement revised
2446 N-Nitrosodiethylamine 55-18-5 7 19880301 Mar 1,1988 II.C.1. Number rounded off
2447 N-Nitrosodiethylamine 55-18-5 8 19880301 Mar 1,1988 II.C.4. Confidence statement revised
2448 N-Nitrosodiethylamine 55-18-5 9 19880301 Mar 1,1988 II.D.3. Secondary contact changed
2449 N-Nitrosodiethylamine 55-18-5 10 19900201 Feb 1,1990 II.A.3. Rajewsky et al., 1966 spelling corrected
2450 N-Nitrosodiethylamine 55-18-5 11 19900201 Feb 1,1990 VI. Bibliography on-line
2451 N-Nitrosodiethylamine 55-18-5 12 19900301 Mar 1,1990 VI.C. Druckrey, Peto and Mohr reference titles clarified
2452 N-Nitrosodiethylamine 55-18-5 13 19910101 Jan 1,1991 II. Text edited
2453 N-Nitrosodiethylamine 55-18-5 14 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
2454 N-Nitrosodiethylamine 55-18-5 15 19920101 Jan 1,1992 IV. Regulatory actions updated
2455 N-Nitrosodiethylamine 55-18-5 16 19930701 Jul 1,1993 II.D.3. Secondary contact's phone number changed
2456 N-Nitrosodiethylamine 55-18-5 17 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2457 N-Nitrosodiethylamine 55-18-5 18 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2458 N-Nitrosodimethylamine 62-75-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2459 N-Nitrosodiphenylamine 86-30-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2460 N-Nitrosopyrrolidine 930-55-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2461 Nonabromodiphenyl ether 63936-56-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2462 Norflurazon 27314-13-2 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2463 Norflurazon 27314-13-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2464 NuStar 85509-19-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2465 Octabromodiphenyl ether 32536-52-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2466 Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) 2691-41-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2467 Oryzalin 19044-88-3 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2468 Oryzalin 19044-88-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2469 Oxadiazon 19666-30-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2470 Oxamyl 23135-22-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2471 Oxyfluorfen 42874-03-3 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2472 Oxyfluorfen 42874-03-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2473 Paclobutrazol 76738-62-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2474 Paraquat 1910-42-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2475 Parathion 56-38-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2476 Pendimethalin 40487-42-1 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2477 Pendimethalin 40487-42-1 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2478 Pentabromodiphenyl ether 32534-81-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2479 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) 60348-60-9 1 20080630 Jun 30,2008 I., II. RfD, RfC, and cancer assessment first on line.
2480 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) 60348-60-9 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2481 Pentachlorobenzene 608-93-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2482 Pentachlorocyclopentadiene 25329-35-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2483 Pentachloronitrobenzene (PCNB) 82-68-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2484 Pentachlorophenol 87-86-5 1 20100930 Sep 30,2010 I., II., VI. RfD and cancer assessment sections updated. RfC discussion added.
2485 Pentachlorophenol 87-86-5 2 19880301 Mar 1,1988 III.A. Health Advisory added
2486 Pentachlorophenol 87-86-5 3 19880630 Jun 30,1988 I.A.6. Documentation year corrected
2487 Pentachlorophenol 87-86-5 4 19900101 Jan 1,1990 II. Carcinogen assessment now under review
2488 Pentachlorophenol 87-86-5 5 19900101 Jan 1,1990 VI. Bibliography on-line
2489 Pentachlorophenol 87-86-5 6 19900401 Apr 1,1990 I.A.2. NOEL corrected to NOAEL in last sentence, 1st paragraph
2490 Pentachlorophenol 87-86-5 7 19900701 Jul 1,1990 I.B. Inhalation RfC now under Review
2491 Pentachlorophenol 87-86-5 8 19900701 Jul 1,1990 IV.F.1. EPA contact changed
2492 Pentachlorophenol 87-86-5 9 19900801 Aug 1,1990 III.A.10 Primary contact changed
2493 Pentachlorophenol 87-86-5 10 19910301 Mar 1,1991 II. Carcinogenicity assessment on-line
2494 Pentachlorophenol 87-86-5 11 19910301 Mar 1,1991 VI.C. Carcinogenicity references added
2495 Pentachlorophenol 87-86-5 12 19920101 Jan 1,1992 I.A.7. Primary contact changed
2496 Pentachlorophenol 87-86-5 13 19920101 Jan 1,1992 IV. Regulatory actions updated
2497 Pentachlorophenol 87-86-5 14 19930201 Feb 1,1993 I.A.7. Minor text change
2498 Pentachlorophenol 87-86-5 15 19930701 Jul 1,1993 II.D.3. Primary contact's phone number changed
2499 Pentachlorophenol 87-86-5 16 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2500 Pentachlorophenol 87-86-5 17 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2501 Pentachlorophenol 87-86-5 18 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2502 Pentafluoroethane 354-33-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2503 Perchlorate (ClO4) and Perchlorate Salts 7790-98-9 1 20050218 Feb 18,2005 All IRIS assessment for Perchlorate and Perchlorate Salts added to the database.
2504 Perchlorate (ClO4) and Perchlorate Salts 7790-98-9 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2505 Perfluorobutanoic Acid (PFBA) 375-22-4 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2506 Perfluorobutanoic Acid (PFBA) 375-22-4 2 20220210 Feb 10,2022 Supporting document Added a link to the peer review meeting at the request of the public & program (DS).
2507 Perfluorodecanoic Acid (PFDA) 335-76-2 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2508 Perfluorohexanesulfonic Acid (PFHxS) 355-46-4 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2509 Perfluorohexanoic Acid (PFHxA) 307-24-4 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2510 Perfluorohexanoic Acid (PFHxA) 307-24-4 2 20230410 Apr 10,2023 All Released the final report and key values.
2511 Perfluorononanoic Acid (PFNA) 375-95-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2512 Permethrin 52645-53-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2513 Phenanthrene 85-01-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2514 Phenmedipham 13684-63-4 1 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
2515 Phenmedipham 13684-63-4 2 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2516 Phenmedipham 13684-63-4 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2517 Phenol 108-95-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2518 m-Phenylenediamine 108-45-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2519 Phenylmercuric acetate 62-38-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2520 Phosalone 2310-17-0 1 20181210 Dec 10,2018 Archived Values Requested by the IRIS Program to archive the chemicals with null values.
2521 Phosalone 2310-17-0 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2522 Phosgene 75-44-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2523 Phosmet 732-11-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2524 Phosphine 7803-51-2 1 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
2525 Phosphine 7803-51-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2526 Phosphoric acid 7664-38-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2527 Phthalic anhydride 85-44-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2528 Picloram 1918-02-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2529 Pirimiphos-methyl 29232-93-7 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2530 Pirimiphos-methyl 29232-93-7 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2531 Polychlorinated Biphenyls (PCBs) 1336-36-3 1 19890501 May 1,1989 II. Carcinogen summary on-line
2532 Polychlorinated Biphenyls (PCBs) 1336-36-3 2 19900101 Jan 1,1990 II. Text edited
2533 Polychlorinated Biphenyls (PCBs) 1336-36-3 3 19900101 Jan 1,1990 VI. Bibliography on-line
2534 Polychlorinated Biphenyls (PCBs) 1336-36-3 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2535 Polychlorinated Biphenyls (PCBs) 1336-36-3 5 19940601 Jun 1,1994 I.A. Message only
2536 Polychlorinated Biphenyls (PCBs) 1336-36-3 6 19960101 Jan 1,1996 II. Note added to assessment
2537 Polychlorinated Biphenyls (PCBs) 1336-36-3 7 19961001 Oct 1,1996 II. File replaced; cancer potency of mixtures addressed
2538 Polychlorinated Biphenyls (PCBs) 1336-36-3 8 19961101 Nov 1,1996 VI.C. References revised
2539 Polychlorinated Biphenyls (PCBs) 1336-36-3 9 19970601 Jun 1,1997 II.C.3. Units corrected in Upper-bound Unit Risk
2540 Polychlorinated Biphenyls (PCBs) 1336-36-3 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2541 Polychlorinated Biphenyls (PCBs) 1336-36-3 11 20180516 May 16,2018 Footnotes to WOE Notes were added to the WOE-Oral and WOE-inhalation table to further explain these numbers. Additional updates were made to the inhalation unit risk and extrapolation method descriptions.
2542 Polychlorinated Biphenyls (PCBs) 1336-36-3 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2543 Polycyclic aromatic hydrocarbon (PAH) mixtures Various 1 20190927 Sep 27,2019 CASRN Set to various
2544 Polycyclic aromatic hydrocarbon (PAH) mixtures Various 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2545 Potassium cyanide 151-50-8 1 20100928 Sep 28,2010 I.A. Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment
2546 Potassium cyanide 151-50-8 2 20180927 Sep 27,2018 Noncancer Critical Updated the system value to other so it would show up in the advanced search.
2547 Potassium cyanide 151-50-8 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2548 Potassium silver cyanide 506-61-6 1 20100928 Sep 28,2010 I.A. Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment
2549 Potassium silver cyanide 506-61-6 2 20180927 Sep 27,2018 Noncancer Critical Updated the system value to other so it would show up in the advanced search.
2550 Potassium silver cyanide 506-61-6 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2551 Prochloraz 67747-09-5 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
2552 Prochloraz 67747-09-5 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2553 Prometon 1610-18-0 1 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
2554 Prometon 1610-18-0 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2555 Prometryn 7287-19-6 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2556 Prometryn 7287-19-6 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2557 Pronamide 23950-58-5 1 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
2558 Pronamide 23950-58-5 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2559 Propachlor 1918-16-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2560 Propanil 709-98-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2561 Propargite 2312-35-8 1 19900501 May 1,1990 I.A. Oral RfD summary on-line
2562 Propargite 2312-35-8 2 19900501 May 1,1990 VI. Bibliography on-line
2563 Propargite 2312-35-8 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2564 Propargite 2312-35-8 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2565 Propargite 2312-35-8 5 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2566 Propargite 2312-35-8 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2567 Propargyl alcohol 107-19-7 1 19901101 Nov 1,1990 I.A. Oral RfD summary on-line
2568 Propargyl alcohol 107-19-7 2 19901101 Nov 1,1990 VI. Bibliography on-line
2569 Propargyl alcohol 107-19-7 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2570 Propargyl alcohol 107-19-7 4 19930701 Jul 1,1993 I.A.6. Other EPA documentation added
2571 Propargyl alcohol 107-19-7 5 19940101 Jan 1,1994 I.A.1. Citation year changed to 1987
2572 Propargyl alcohol 107-19-7 6 19940101 Jan 1,1994 I.A.2. Citation year changed to 1987
2573 Propargyl alcohol 107-19-7 7 19940101 Jan 1,1994 I.A.6. Citation year changed to 1987
2574 Propargyl alcohol 107-19-7 8 19940101 Jan 1,1994 VI.A. Reference year changed to 1987
2575 Propargyl alcohol 107-19-7 9 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2576 Propargyl alcohol 107-19-7 10 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2577 Propazine 139-40-2 1 19870828 Aug 28,1987 I.A. UF reevaluated - RfD changed
2578 Propazine 139-40-2 2 19901001 Oct 1,1990 I.A.4. Citations added
2579 Propazine 139-40-2 3 19901001 Oct 1,1990 III.A. Health advisory on-line
2580 Propazine 139-40-2 4 19901001 Oct 1,1990 VI. Bibliography on-line
2581 Propazine 139-40-2 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2582 Propazine 139-40-2 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2583 Propazine 139-40-2 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2584 Propham 122-42-9 1 19891201 Dec 1,1989 VI. Bibliography on-line
2585 Propham 122-42-9 2 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2586 Propham 122-42-9 3 19930201 Feb 1,1993 III.A. Health Advisory on-line
2587 Propham 122-42-9 4 19930201 Feb 1,1993 VI.D. Health Advisory references on-line
2588 Propham 122-42-9 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2589 Propham 122-42-9 6 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
2590 Propham 122-42-9 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2591 Propiconazole 60207-90-1 1 19880822 Aug 22,1988 I.A.1. Dose conversion factor changed; RfD changed
2592 Propiconazole 60207-90-1 2 19880822 Aug 22,1988 I.A.2. Dose levels changed; reflects altered conversion factor
2593 Propiconazole 60207-90-1 3 19910201 Feb 1,1991 II. Carcinogen assessment now under review
2594 Propiconazole 60207-90-1 4 19920101 Jan 1,1992 I.A.4. Citations added
2595 Propiconazole 60207-90-1 5 19920101 Jan 1,1992 VI. Bibliography on-line
2596 Propiconazole 60207-90-1 6 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September, 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2597 Propiconazole 60207-90-1 7 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2598 Propiconazole 60207-90-1 8 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2599 Propiconazole 60207-90-1 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2600 beta-Propiolactone 57-57-8 1 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
2601 beta-Propiolactone 57-57-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2602 Propionaldehyde 123-38-6 1 20080930 Sep 30,2008 I., II. RfD, RfC, and cancer assessment first on line.
2603 Propionaldehyde 123-38-6 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2604 Propylene glycol 57-55-6 1 19910601 Jun 1,1991 I.B. Inhalation RfC message on-line
2605 Propylene glycol 57-55-6 2 19910601 Jun 1,1991 VI. Bibliography on-line
2606 Propylene glycol 57-55-6 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2607 Propylene glycol 57-55-6 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2608 Propylene glycol 57-55-6 5 20181210 Dec 10,2018 Archived Values Requested by the IRIS Program to archive the chemicals with null values.
2609 Propylene glycol 57-55-6 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2610 Propylene glycol monoethyl ether 52125-53-8 1 19910601 Jun 1,1991 I.B. Inhalation RfC message on-line
2611 Propylene glycol monoethyl ether 52125-53-8 2 19910601 Jun 1,1991 VI. Bibliography on-line
2612 Propylene glycol monoethyl ether 52125-53-8 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2613 Propylene glycol monoethyl ether 52125-53-8 4 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
2614 Propylene glycol monoethyl ether 52125-53-8 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2615 Propylene glycol monomethyl ether (PGME) 107-98-2 1 19910701 Jul 1,1991 I.B. Inhalation RfC summary on-line
2616 Propylene glycol monomethyl ether (PGME) 107-98-2 2 19910701 Jul 1,1991 VI. Bibliography on-line
2617 Propylene glycol monomethyl ether (PGME) 107-98-2 3 19930701 Jul 1,1993 I.B.1. 'E' notation added
2618 Propylene glycol monomethyl ether (PGME) 107-98-2 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2619 Propylene glycol monomethyl ether (PGME) 107-98-2 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2620 Propylene oxide 75-56-9 1 19901001 Oct 1,1990 II. Carcinogen assessment on-line
2621 Propylene oxide 75-56-9 2 19901001 Oct 1,1990 VI. Bibliography on-line
2622 Propylene oxide 75-56-9 3 19901101 Nov 1,1990 I.B. Inhalation RfC summary on-line
2623 Propylene oxide 75-56-9 4 19901101 Nov 1,1990 VI.B. Inhalation RfC references added
2624 Propylene oxide 75-56-9 5 19910101 Jan 1,1991 II. Text edited
2625 Propylene oxide 75-56-9 6 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
2626 Propylene oxide 75-56-9 7 19910201 Feb 1,1991 II.C.3. Information on extrapolation process included
2627 Propylene oxide 75-56-9 8 19910801 Aug 1,1991 VI.C. References clarified
2628 Propylene oxide 75-56-9 9 19910101 Jan 1,1991 IV. Regulatory Action section on-line
2629 Propylene oxide 75-56-9 10 19940301 Mar 1,1994 II.D.3. Contact's phone number changed
2630 Propylene oxide 75-56-9 11 19940401 Apr 1,1994 II.D.3. Contact changed
2631 Propylene oxide 75-56-9 12 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2632 Propylene oxide 75-56-9 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2633 Propyleneimine 75-55-8 1 19911201 Dec 1,1991 I.B. Inhalation RfC now under review
2634 Propyleneimine 75-55-8 2 19920101 Jan 1,1992 I.B. Inhalation RfC message on-line
2635 Propyleneimine 75-55-8 3 19920101 Jan 1,1992 VI. Bibliography on-line; no inhalation refs available
2636 Propyleneimine 75-55-8 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2637 Propyleneimine 75-55-8 5 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
2638 Propyleneimine 75-55-8 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2639 Pursuit 81335-77-5 1 19900101 Jan 1,1990 I.A. Oral RfD summary on-line
2640 Pursuit 81335-77-5 2 19900101 Jan 1,1990 VI. Bibliography on-line
2641 Pursuit 81335-77-5 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2642 Pursuit 81335-77-5 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2643 Pydrin 51630-58-1 1 19920101 Jan 1,1992 I.A.4. Citations added
2644 Pydrin 51630-58-1 2 19920101 Jan 1,1992 IV. Regulatory Action section added
2645 Pydrin 51630-58-1 3 19920101 Jan 1,1992 VI. Bibliography on-line
2646 Pydrin 51630-58-1 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2647 Pydrin 51630-58-1 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2648 Pyrene 129-00-0 1 19900901 Sep 1,1990 I.A. Oral RfD summary on-line
2649 Pyrene 129-00-0 2 19900901 Sep 1,1990 VI. Bibliography on-line
2650 Pyrene 129-00-0 3 19910101 Jan 1,1991 II. Carcinogen assessment on-line
2651 Pyrene 129-00-0 4 19910101 Jan 1,1991 VI.C. Carcinogen assessment references added
2652 Pyrene 129-00-0 5 19910701 Jul 1,1991 I.A.7. Primary and secondary contacts changed
2653 Pyrene 129-00-0 6 19910801 Aug 1,1991 VI.A. U.S. EPA, 1989 citation clarified
2654 Pyrene 129-00-0 7 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2655 Pyrene 129-00-0 8 19930701 Jul 1,1993 I.A.6. Other EPA Documentation added
2656 Pyrene 129-00-0 9 19940901 Sep 1,1994 I.B. Inhalation RfC now under review
2657 Pyrene 129-00-0 10 19950801 Aug 1,1995 I.B. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2658 Pyrene 129-00-0 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2659 Pyrene 129-00-0 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2660 Pyridine 110-86-1 1 19880301 Mar 1,1988 I.A.4. Text clarified
2661 Pyridine 110-86-1 2 19880630 Jun 30,1988 I.A.2. Clarified principal study
2662 Pyridine 110-86-1 3 19880926 Sep 26,1988 I.A.2. Corrected citation
2663 Pyridine 110-86-1 4 19880926 Sep 26,1988 I.A.4. Corrected citation
2664 Pyridine 110-86-1 5 19890601 Jun 1,1989 I.A.6. Work group review date corrected
2665 Pyridine 110-86-1 6 19900101 Jan 1,1990 VI. Bibliography on-line
2666 Pyridine 110-86-1 7 19920101 Jan 1,1992 I.A.7. Primary contact changed
2667 Pyridine 110-86-1 8 19920101 Jan 1,1992 IV. Regulatory actions updated
2668 Pyridine 110-86-1 9 19950801 Aug 1,1995 I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2669 Pyridine 110-86-1 10 19870401 Apr 1,1987 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this infomation.
2670 Pyridine 110-86-1 11 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2671 Quinalphos 13593-03-8 1 19920101 Jan 1,1992 I.A.4. Citations added
2672 Quinalphos 13593-03-8 2 19920101 Jan 1,1992 VI. Bibiography on-line
2673 Quinalphos 13593-03-8 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2674 Quinalphos 13593-03-8 4 20180927 Sep 27,2018 Noncancer Critical Updated the system value from none to other so it would show up in the advanced search.
2675 Quinalphos 13593-03-8 5 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
2676 Quinalphos 13593-03-8 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2677 Quinoline 91-22-5 1 I.,II.,VI Assessment first on-line
2678 Quinoline 91-22-5 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2679 Quinone 106-51-4 1 19901001 Oct 1,1990 I.B. Inhalation RfC message on-line
2680 Quinone 106-51-4 2 19901001 Oct 1,1990 VI. Bibliography on-line
2681 Quinone 106-51-4 3 19950301 Mar 1,1995 I.B. Agency Work Group Review date corrected
2682 Quinone 106-51-4 4 19970401 Apr 1,1997 III., IV, V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2683 Quinone 106-51-4 5 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
2684 Quinone 106-51-4 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2685 Radium 226,228 Various 1 19890101 Jan 1,1989 II. Withdrawn pending further review
2686 Radium 226,228 Various 2 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2687 Radium 226,228 Various 3 19930301 Mar 1,1993 II. Work Group review date added
2688 Radium 226,228 Various 4 19930501 May 1,1993 II. Work Group review date added
2689 Radium 226,228 Various 5 19930701 Jul 1,1993 II. EPA contact changed
2690 Radium 226,228 Various 6 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2691 Radium 226,228 Various 7 19970401 Apr 1,1997 II., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2692 Radium 226,228 Various 8 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
2693 Radium 226,228 Various 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2694 Radon 222 14859-67-7 1 19880301 Mar 1,1988 II.A.1. Classification clarified
2695 Radon 222 14859-67-7 2 19880301 Mar 1,1988 II.B.1. Number rounded off
2696 Radon 222 14859-67-7 3 19880630 Jun 30,1988 II.D.3. Contacts changed
2697 Radon 222 14859-67-7 4 19890101 Jan 1,1989 II. Withdrawn pending further review
2698 Radon 222 14859-67-7 5 19890701 Jul 1,1989 II. Withdrawn; new assessment verified (in preparation)
2699 Radon 222 14859-67-7 6 19920101 Jan 1,1992 IV. Regulatory actions updated
2700 Radon 222 14859-67-7 7 19921101 Nov 1,1992 II. Work group review date added
2701 Radon 222 14859-67-7 8 19930301 Mar 1,1993 II. Work group review date added
2702 Radon 222 14859-67-7 9 19930501 May 1,1993 II. Work group review date added
2703 Radon 222 14859-67-7 10 19930701 Jul 1,1993 II. EPA contact changed
2704 Radon 222 14859-67-7 11 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2705 Radon 222 14859-67-7 12 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2706 Radon 222 14859-67-7 13 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
2707 Radon 222 14859-67-7 14 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2708 Refractory ceramic fibers None 1 19920901 Sep 1,1992 II. Carcinogenicity assessment under review on 03/31/1992
2709 Refractory ceramic fibers None 2 19920901 Sep 1,1992 II. Carcinogenicity assessment on-line
2710 Refractory ceramic fibers None 3 19920901 Sep 1,1992 VI. Bibliography on-line
2711 Refractory ceramic fibers None 4 19921001 Oct 1,1992 VI.C. Minor corrections to references
2712 Refractory ceramic fibers None 5 19930701 Jul 1,1993 II.D.1. Other EPA Documentation heading removed
2713 Refractory ceramic fibers None 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2714 Refractory ceramic fibers None 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2715 Resmethrin 10453-86-8 1 19880926 Sep 26,1988 I.A. Oral RfD summary on-line
2716 Resmethrin 10453-86-8 2 19891001 Oct 1,1989 VI. Bibliography on-line
2717 Resmethrin 10453-86-8 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2718 Resmethrin 10453-86-8 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2719 Resmethrin 10453-86-8 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2720 Rotenone 83-79-4 1 19880907 Sep 7,1988 I.A. Oral RfD summary on-line
2721 Rotenone 83-79-4 2 19891001 Oct 1,1989 VI. Bibliography on-line
2722 Rotenone 83-79-4 3 19910601 Jun 1,1991 II. Carcinogen assessment now under review
2723 Rotenone 83-79-4 4 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2724 Rotenone 83-79-4 5 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2725 Rotenone 83-79-4 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2726 Rotenone 83-79-4 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2727 Savey 78587-05-0 1 19880926 Sep 26,1988 I.A. Oral RfD summary on-line
2728 Savey 78587-05-0 2 19890501 May 1,1989 II. Carcinogen assessment now under review
2729 Savey 78587-05-0 3 19891001 Oct 1,1989 VI. Bibliography on-line
2730 Savey 78587-05-0 4 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2731 Savey 78587-05-0 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2732 Savey 78587-05-0 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2733 Selenious acid 7783-00-8 1 19890501 May 1,1989 I.A. Oral RfD summary noted as pending change
2734 Selenious acid 7783-00-8 2 19900101 Jan 1,1990 I.A.5. Corrected citation year
2735 Selenious acid 7783-00-8 3 19900101 Jan 1,1990 VI. Bibliography on-line
2736 Selenious acid 7783-00-8 4 19910301 Mar 1,1991 II. Carcinogenicity assessment on-line
2737 Selenious acid 7783-00-8 5 19910301 Mar 1,1991 VI.C. Carcinogenicity references added
2738 Selenious acid 7783-00-8 6 19910501 May 1,1991 I.A. Withdrawn; new Oral RfD verfied (in preparation)
2739 Selenious acid 7783-00-8 7 19910501 May 1,1991 VI.A. Oral RfD references withdrawn
2740 Selenious acid 7783-00-8 8 19910601 Jun 1,1991 I.A. Oral RfD summary replaced; RfD changed
2741 Selenious acid 7783-00-8 9 19910601 Jun 1,1991 VI.A. Oral RfD references replaced
2742 Selenious acid 7783-00-8 10 19910701 Jul 1,1991 I.A.6. Work group review date added
2743 Selenious acid 7783-00-8 11 19910701 Jul 1,1991 I.A.7. Primary contact's phone number corrected
2744 Selenious acid 7783-00-8 12 19910901 Sep 1,1991 I.A.3. Text revised
2745 Selenious acid 7783-00-8 13 19910901 Sep 1,1991 I.A.5. Text revised
2746 Selenious acid 7783-00-8 14 19920101 Jan 1,1992 IV. Regulatory actions added
2747 Selenious acid 7783-00-8 15 19930701 Jul 1,1993 II.D.3. Primary contact's phone number changed
2748 Selenious acid 7783-00-8 16 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2749 Selenious acid 7783-00-8 17 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2750 Selenium and Compounds 7782-49-2 1 19910301 Mar 1,1991 II. Carcinogenicity assessment on-line
2751 Selenium and Compounds 7782-49-2 2 19910301 Mar 1,1991 VI. Bibliography on-line
2752 Selenium and Compounds 7782-49-2 3 19910601 Jun 1,1991 II.A.2. Para 4: Correct Shamber&Willis to Shamberger&Willis
2753 Selenium and Compounds 7782-49-2 4 19910601 Jun 1,1991 I.A. Oral RfD summary on-line
2754 Selenium and Compounds 7782-49-2 5 19910601 Jun 1,1991 VI.A. Oral RfD references added
2755 Selenium and Compounds 7782-49-2 6 19910901 Sep 1,1991 I.A.2. Paragraph 2, line 2: number corrected to 5/349
2756 Selenium and Compounds 7782-49-2 7 19910901 Sep 1,1991 I.A.3. Text revised
2757 Selenium and Compounds 7782-49-2 8 19910901 Sep 1,1991 I.A.5. Confidence in RfD changed; text revised
2758 Selenium and Compounds 7782-49-2 9 19920101 Jan 1,1992 IV. Regulatory section on-line
2759 Selenium and Compounds 7782-49-2 10 19930701 Jul 1,1993 II.D.3. Primary contact's phone number changed
2760 Selenium and Compounds 7782-49-2 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2761 Selenium and Compounds 7782-49-2 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2762 Selenium sulfide 7446-34-6 1 19910301 Mar 1,1991 II. Carcinogenicity assessment on-line
2763 Selenium sulfide 7446-34-6 2 19910301 Mar 1,1991 VI. Bibliography on-line
2764 Selenium sulfide 7446-34-6 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2765 Selenium sulfide 7446-34-6 4 19930701 Jul 1,1993 II.D.3. Primary contact's phone number changed
2766 Selenium sulfide 7446-34-6 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2767 Selenium sulfide 7446-34-6 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2768 Selenourea 630-10-4 1 19870331 Mar 31,1987 I.A.6. Documentation corrected
2769 Selenourea 630-10-4 2 19890501 May 1,1989 I.A. Oral RfDsummary noted as pending change
2770 Selenourea 630-10-4 3 19891201 Dec 1,1989 VI. Bibliography on-line
2771 Selenourea 630-10-4 4 19910501 May 1,1991 I.A. Oral RfD withdrawn pending additional review
2772 Selenourea 630-10-4 5 19910501 May 1,1991 VI. Bibliography withdrawn
2773 Selenourea 630-10-4 6 19920101 Jan 1,1992 IV. Regulatory actions withdrawn
2774 Selenourea 630-10-4 7 19920601 Jun 1,1992 I.A. Work group review dates added
2775 Selenourea 630-10-4 8 19950801 Aug 1,1995 I.A., VI. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed before September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2776 Selenourea 630-10-4 9 19960201 Feb 1,1996 I.A. Contact changed
2777 Selenourea 630-10-4 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2778 Selenourea 630-10-4 11 20181219 Dec 19,2018 Archived Key Values Archived this assessment because there were null key values.
2779 Selenourea 630-10-4 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2780 Sethoxydim 74051-80-2 1 19880301 Mar 1,1988 I.A.5. Confidence levels revised
2781 Sethoxydim 74051-80-2 2 19890701 Jul 1,1989 I.A. Withdrawn; new Oral RfD verified (in preparation)
2782 Sethoxydim 74051-80-2 3 19891101 Nov 1,1989 I.A. Oral RfD summary replaced; RfD changed
2783 Sethoxydim 74051-80-2 4 19891101 Nov 1,1989 VI. Bibliography on-line
2784 Sethoxydim 74051-80-2 5 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2785 Sethoxydim 74051-80-2 6 19970401 Apr 1,1997 II., IV., V. Drinking Water Health Advisoies, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2786 Sethoxydim 74051-80-2 7 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
2787 Sethoxydim 74051-80-2 8 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2788 Silver 7440-22-4 1 19880301 Mar 1,1988 I.A.4. Text revised
2789 Silver 7440-22-4 2 19880301 Mar 1,1988 I.A.7. Seconary contact changed
2790 Silver 7440-22-4 3 19880630 Jun 30,1988 I.A.7. Primary contact changed
2791 Silver 7440-22-4 4 19890601 Jun 1,1989 II. Carcinogen summary on-line
2792 Silver 7440-22-4 5 19890601 Jun 1,1989 VI. Bibliography on-line
2793 Silver 7440-22-4 6 19890801 Aug 1,1989 VI.A. Oral RfD references added
2794 Silver 7440-22-4 7 19910301 Mar 1,1991 I.A. Oral RfD summary noted as pending change
2795 Silver 7440-22-4 8 19910801 Aug 1,1991 I.A. Withdrawn; new oral RfD verified (in preparation)
2796 Silver 7440-22-4 9 19910801 Aug 1,1991 VI.A. Oral RfD references withdrawn
2797 Silver 7440-22-4 10 19911201 Dec 1,1991 I.A. Oral RfD summary replaced; RfD changed
2798 Silver 7440-22-4 11 19911201 Dec 1,1991 VI.A. Oral RfD references replaced
2799 Silver 7440-22-4 12 19920101 Jan 1,1992 IV. Regulatory actions updated
2800 Silver 7440-22-4 13 19961201 Dec 1,1996 I.A.7. Secondary contact removed
2801 Silver 7440-22-4 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2802 Silver 7440-22-4 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2803 Silver cyanide 506-64-9 1 19870331 Mar 31,1987 I.A.6. Documentation corrected
2804 Silver cyanide 506-64-9 2 19880301 Mar 1,1988 I.A.5. Confidence levels raised
2805 Silver cyanide 506-64-9 3 19900101 Jan 1,1990 I.A.2. Add Philbrick et al. 1979 citation
2806 Silver cyanide 506-64-9 4 19900101 Jan 1,1990 VI. Bibliography on- line
2807 Silver cyanide 506-64-9 5 19920101 Jan 1,1992 I.A.7. Primary contact changed
2808 Silver cyanide 506-64-9 6 19920101 Jan 1,1992 IV. Regulatory actions updated
2809 Silver cyanide 506-64-9 7 19960201 Feb 1,1996 I.A.7. Contact changed
2810 Silver cyanide 506-64-9 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2811 Silver cyanide 506-64-9 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2812 Simazine 122-34-9 1 19880301 Mar 1,1988 I.A.4. Data gaps revised
2813 Simazine 122-34-9 2 19890701 Jul 1,1989 I.A. Withdrawn; new Oral RfD verified (in preparation)
2814 Simazine 122-34-9 3 19890901 Sep 1,1989 II. Carcinogen assessment now under review
2815 Simazine 122-34-9 4 19891101 Nov 1,1989 I.A. Oral RfD summary replaced; RfD changed
2816 Simazine 122-34-9 5 19891101 Nov 1,1989 VI. Bibliography on-line
2817 Simazine 122-34-9 6 19910901 Sep 1,1991 I.A. Withdrawn; new Oral RfD verified (in preparation)
2818 Simazine 122-34-9 7 19910901 Sep 1,1991 VI.A. Bibliography withdrawn
2819 Simazine 122-34-9 8 19920101 Jan 1,1992 IV. Regulatory actions updated
2820 Simazine 122-34-9 9 19930901 Sep 1,1993 I.A. Oral RfD summary replaced; RfD changed
2821 Simazine 122-34-9 10 19940401 Apr 1,1994 I.A.1. Study type corrected to 2-year
2822 Simazine 122-34-9 11 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995.
2823 Simazine 122-34-9 12 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2824 Simazine 122-34-9 13 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2825 Sodium azide 26628-22-8 1 19900101 Jan 1,1990 VI. Bibliography on-line
2826 Sodium azide 26628-22-8 2 19920101 Jan 1,1992 I.A.7. Primary contact changed
2827 Sodium azide 26628-22-8 3 19920101 Jan 1,1992 IV. Regulatory actions updated
2828 Sodium azide 26628-22-8 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2829 Sodium azide 26628-22-8 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2830 Sodium cyanide 143-33-9 1 19870331 Mar 31,1987 I.A.6. Documentation corrected
2831 Sodium cyanide 143-33-9 2 19880301 Mar 1,1988 III.A. Health Advisory
2832 Sodium cyanide 143-33-9 3 19900801 Aug 1,1990 IV.F.1. EPA contact changed
2833 Sodium cyanide 143-33-9 4 19910601 Jun 1,1991 VI. Bibliography on-line
2834 Sodium cyanide 143-33-9 5 19920101 Jan 1,1992 I.A.7. Primary contact changed
2835 Sodium cyanide 143-33-9 6 19920101 Jan 1,1992 IV. Regulatory actions updated
2836 Sodium cyanide 143-33-9 7 19960201 Feb 1,1996 I.A.7. Contact changed
2837 Sodium cyanide 143-33-9 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2838 Sodium cyanide 143-33-9 10 20180927 Sep 27,2018 Noncancer Critical Updated the system value to other so it would show up in the advanced search.
2839 Sodium cyanide 143-33-9 12 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2840 Sodium diethyldithiocarbamate 148-18-5 1 19880301 Mar 1,1988 I.A.1. Dose conversion clarified
2841 Sodium diethyldithiocarbamate 148-18-5 2 19900101 Jan 1,1990 VI. Bibliography on-line
2842 Sodium diethyldithiocarbamate 148-18-5 3 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2843 Sodium diethyldithiocarbamate 148-18-5 4 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2844 Sodium fluoroacetate 62-74-8 1 19910501 May 1,1991 I.A. Oral RfD summary on-line
2845 Sodium fluoroacetate 62-74-8 2 19910501 May 1,1991 VI. Bibliography on-line
2846 Sodium fluoroacetate 62-74-8 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2847 Sodium fluoroacetate 62-74-8 4 19930701 Jul 1,1993 I.A.6. Other EPA Documentation added
2848 Sodium fluoroacetate 62-74-8 5 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2849 Sodium fluoroacetate 62-74-8 6 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2850 Strontium 7440-24-6 1 19910801 Aug 1,1991 I.A. Oral RfD now uder review
2851 Strontium 7440-24-6 2 19920801 Aug 1,1992 I.A.6. Work group review dates added
2852 Strontium 7440-24-6 3 19921001 Oct 1,1992 I.A. Oral RfD summary on-line
2853 Strontium 7440-24-6 4 19921001 Oct 1,1992 VI.A. Oral RfD references on-line
2854 Strontium 7440-24-6 5 19961201 Dec 1,1996 I.A.7. Primary contact removed
2855 Strontium 7440-24-6 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2856 Strontium 7440-24-6 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2857 Strychnine 57-24-9 1 19870331 Mar 31,1987 I.A.6. Documentation corrected
2858 Strychnine 57-24-9 2 19880301 Mar 1,1988 I.A.4. Text deleted
2859 Strychnine 57-24-9 3 19900101 Jan 1,1990 VI. Bibliography on-line
2860 Strychnine 57-24-9 4 19920101 Jan 1,1992 I.A.7. Primary contact changed
2861 Strychnine 57-24-9 5 19920101 Jan 1,1992 IV. Regulatory actions updated
2862 Strychnine 57-24-9 6 19870401 Apr 1,1987 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2863 Strychnine 57-24-9 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2864 Styrene 100-42-5 1 19880630 Jun 30,1988 I.A.7. cONTACTS CHANGED
2865 Styrene 100-42-5 2 19891001 Oct 1,1989 I.B. Inhalation RfD now under review
2866 Styrene 100-42-5 3 19900201 Feb 1,1990 VI. Bibliography on-line
2867 Styrene 100-42-5 4 19900501 May 1,1990 I.A. Oral RfD summary noted as pending change
2868 Styrene 100-42-5 5 19900501 May 1,1990 II. Carcinogen assessment now under review
2869 Styrene 100-42-5 6 19900901 Sep 1,1990 I.A. Text edited
2870 Styrene 100-42-5 7 19900901 Sep 1,1990 III.A. Health Advisory on-line
2871 Styrene 100-42-5 8 19900901 Sep 1,1990 VI.D. Health Advisory references added
2872 Styrene 100-42-5 9 19920101 Jan 1,1992 IV. Regulatory actions updated
2873 Styrene 100-42-5 10 19921101 Nov 1,1992 I.B. Inhalation RfC summary on-line
2874 Styrene 100-42-5 11 19921101 Nov 1,1992 VI.B. Inhalation RfC references on-line
2875 Styrene 100-42-5 12 19930701 Jul 1,1993 I.B.1. 'E' notation added
2876 Styrene 100-42-5 13 19950801 Aug 1,1995 I.A., II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2877 Styrene 100-42-5 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2878 Styrene 100-42-5 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2879 Systhane 88671-89-0 1 19880926 Sep 26,1988 I.A. Oral RfD summary on-line
2880 Systhane 88671-89-0 2 19891001 Oct 1,1989 VI. Bibliography on-line
2881 Systhane 88671-89-0 3 19950101 Jan 1,1995 I.A. Oral RfD noted as pending change
2882 Systhane 88671-89-0 4 19950101 Jan 1,1995 I.A.6. Work group review date added
2883 Systhane 88671-89-0 5 19950801 Aug 1,1995 I.A., I.A.6. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2884 Systhane 88671-89-0 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2885 Systhane 88671-89-0 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2886 Tebuthiuron 34014-18-1 1 19880822 Aug 22,1988 I.A.1. NOEL corrected; RfD changed
2887 Tebuthiuron 34014-18-1 2 19880822 Aug 22,1988 I.A.2. Text changed to reflect corrected dose levels
2888 Tebuthiuron 34014-18-1 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2889 Tebuthiuron 34014-18-1 4 19920701 Jul 1,1992 I.A.1. Short citation clarified
2890 Tebuthiuron 34014-18-1 5 19920701 Jul 1,1992 I.A.2. Principal study clarified
2891 Tebuthiuron 34014-18-1 6 19920701 Jul 1,1992 I.A.4. Citations added
2892 Tebuthiuron 34014-18-1 7 19920701 Jul 1,1992 VI.A. Oral RfD references on-line
2893 Tebuthiuron 34014-18-1 8 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2894 Tebuthiuron 34014-18-1 9 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2895 Terbacil 5902-51-2 1 19870331 Mar 31,1987 IV. Regulatory Action section on-line
2896 Terbacil 5902-51-2 2 19890901 Sep 1,1989 I.A. Oral RfD summary sheet revised
2897 Terbacil 5902-51-2 3 19890901 Sep 1,1989 I.A.5. Confidence levels changed
2898 Terbacil 5902-51-2 4 19890901 Sep 1,1989 VI. Bibliography on-line
2899 Terbacil 5902-51-2 5 19920101 Jan 1,1992 IV. Regulatory action updated
2900 Terbacil 5902-51-2 6 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2901 Terbacil 5902-51-2 7 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2902 Terbutryn 886-50-0 1 19880926 Sep 26,1988 I.A. Oral RfD summary on-line
2903 Terbutryn 886-50-0 2 19891201 Dec 1,1989 VI. Bibliography on-line
2904 Terbutryn 886-50-0 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2905 Terbutryn 886-50-0 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2906 Terbutryn 886-50-0 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2907 Tetrabromodiphenyl ether 40088-47-9 1 19900801 Aug 1,1990 II. Carcinogen assessment on-line
2908 Tetrabromodiphenyl ether 40088-47-9 2 19900801 Aug 1,1990 VI. Bibliography on-line
2909 Tetrabromodiphenyl ether 40088-47-9 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
2910 Tetrabromodiphenyl ether 40088-47-9 4 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2911 Tetrabromodiphenyl ether 40088-47-9 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2912 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 5436-43-1 1 20080630 Jun 30,2008 I., II. RfD, RfC, and cancer assessment first on line.
2913 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 5436-43-1 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2914 1,2,4,5-Tetrachlorobenzene 95-94-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2915 Tetrachlorocyclopentadiene 695-77-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2916 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6 1 20120217 Feb 17,2012 I.A. RfD added
2917 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6 2 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2918 1,1,1,2-Tetrachloroethane 630-20-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2919 1,1,2,2-Tetrachloroethane 79-34-5 1 19880301 Mar 1,1988 II.B.4. Confidence statement revised
2920 1,1,2,2-Tetrachloroethane 79-34-5 2 19880301 Mar 1,1988 II.C.4. Confidence statement revised
2921 1,1,2,2-Tetrachloroethane 79-34-5 3 19880301 Mar 1,1988 II.D.3. Secondary contact changed
2922 1,1,2,2-Tetrachloroethane 79-34-5 4 19890801 Aug 1,1989 I.A. Oral RfD under review
2923 1,1,2,2-Tetrachloroethane 79-34-5 5 19890801 Aug 1,1989 VI. Bibliography on-line
2924 1,1,2,2-Tetrachloroethane 79-34-5 6 19910101 Jan 1,1991 II. Text edited
2925 1,1,2,2-Tetrachloroethane 79-34-5 7 19910101 Jan 1,1991 II.C.1. Inhalation slope factor removed (global change)
2926 1,1,2,2-Tetrachloroethane 79-34-5 8 19920101 Jan 1,1992 IV. Regulatory Actions updated
2927 1,1,2,2-Tetrachloroethane 79-34-5 9 19940201 Feb 1,1994 II.D.3. Primary contact's phone number changed
2928 1,1,2,2-Tetrachloroethane 79-34-5 10 19950801 Aug 1,1995 I.A. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2929 1,1,2,2-Tetrachloroethane 79-34-5 11 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2930 1,1,2,2-Tetrachloroethane 79-34-5 12 20021203 Dec 3,2002 II.D.2. Screening-Level Literature Review Findings message has been added.
2931 1,1,2,2-Tetrachloroethane 79-34-5 13 20050307 Mar 7,2005 II.B.1. Text edited
2932 1,1,2,2-Tetrachloroethane 79-34-5 14 20100930 Sep 30,2010 I., II., VI. RfD and cancer assessment updated RfC discussion added.
2933 1,1,2,2-Tetrachloroethane 79-34-5 15 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2934 Tetrachloroethylene (Perchloroethylene) 127-18-4 1 19871223 Dec 23,1987 I.A. RfD withdrawn pending further review
2935 Tetrachloroethylene (Perchloroethylene) 127-18-4 2 19880301 Mar 1,1988 I.A. Revised Oral RfD summary added - RfD changed
2936 Tetrachloroethylene (Perchloroethylene) 127-18-4 3 19880301 Mar 1,1988 III.A. Health Advisory added
2937 Tetrachloroethylene (Perchloroethylene) 127-18-4 4 19890701 Jul 1,1989 VI. Bibliography on-line
2938 Tetrachloroethylene (Perchloroethylene) 127-18-4 5 19900601 Jun 1,1990 IV.A.1. Area code for EPA contact corrected
2939 Tetrachloroethylene (Perchloroethylene) 127-18-4 6 19900601 Jun 1,1990 IV.F.1. EPA contact changed
2940 Tetrachloroethylene (Perchloroethylene) 127-18-4 7 19920101 Jan 1,1992 IV. Regulatory actions updated
2941 Tetrachloroethylene (Perchloroethylene) 127-18-4 8 19920401 Apr 1,1992 IV. Regulatory action section withdrawn
2942 Tetrachloroethylene (Perchloroethylene) 127-18-4 9 19950801 Aug 1,1995 II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
2943 Tetrachloroethylene (Perchloroethylene) 127-18-4 10 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
2944 Tetrachloroethylene (Perchloroethylene) 127-18-4 11 20120210 Feb 10,2012 I., II., VI. RfD updated. RfC and cancer assessment added.
2945 Tetrachloroethylene (Perchloroethylene) 127-18-4 12 20171025 Oct 25,2017 Updates Key Values Removed the basis, POD and UF and added (see note) for users to refer to the IRIS Summary. On the RfD, a table of 4 rows was consolidated to 1 row with the same (see note) update.
2946 Tetrachloroethylene (Perchloroethylene) 127-18-4 13 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2947 2,3,4,6-Tetrachlorophenol 58-90-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2948 Tetrachlorovinphos 961-11-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2949 Tetraethyl lead 78-00-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2950 Tetraethyldithiopyrophosphate 3689-24-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2951 1,1,1,2-Tetrafluoroethane 811-97-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2952 Tetrahydrofuran 109-99-9 1 20111209 Dec 9,2011 I., II, and VI. RfD and RfC added, cancer assessment added.
2953 Tetrahydrofuran 109-99-9 2 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
2954 Tetrahydrofuran 109-99-9 3 20230925 Sep 25,2023 RFC Value The IRIS program requested a correction for the THF POD BMCL10 being represented incorrectly in the key values table on the chemical landing page. Request included removing the %E2%80%9C-12%E2%80%9D from the RFC value.
2955 Thallium (I), soluble salts Various 1 19870331 Mar 31,1987 I.A.6 Documentation corrected.
2956 Thallium (I), soluble salts Various 2 19880301 Mar 1,1988 I.A. RfD changed -- new study (thallium sulfate).
2957 Thallium (I), soluble salts Various 3 19880301 Mar 1,1988 I.A.6. Verification date changed (thallium sulfate).
2958 Thallium (I), soluble salts Various 4 19880630 Jun 30,1988 I.A. RfD withdrawn.
2959 Thallium (I), soluble salts Various 5 19880907 Sep 7,1988 I.A. Revised oral RfD summary added.
2960 Thallium (I), soluble salts Various 6 19890601 Jun 1,1989 I.A.6. Work group review dates revised (thallium acetate, carbonate, chloride, nitrate).
2961 Thallium (I), soluble salts Various 7 19900901 Sep 1,1990 I.A. Text edited.
2962 Thallium (I), soluble salts Various 8 19900901 Sep 1,1990 I.A.7. Secondary contact changed.
2963 Thallium (I), soluble salts Various 9 19900901 Sep 1,1990 II. Carcinogen assessment online.
2964 Thallium (I), soluble salts Various 10 19900901 Sep 1,1990 IV.F.1. EPA contact changed.
2965 Thallium (I), soluble salts Various 11 19900901 Sep 1,1990 VI. Bibliography online.
2966 Thallium (I), soluble salts Various 12 19910801 Aug 1,1991 VI.C. Kada et al. (1980) citation corrected.
2967 Thallium (I), soluble salts Various 13 19920101 Jan 1,1992 IV. Regulatory actions updated.
2968 Thallium (I), soluble salts Various 14 19920601 Jun 1,1992 V.B. Chemical formula corrected (thallium carbonate).
2969 Thallium (I), soluble salts Various 15 19970401 Apr 1,1997 III., IV., V. Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information.
2970 Thallium (I), soluble salts Various 16 20021203 Dec 3,2002 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate).
2971 Thallium (I), soluble salts Various 17 20031028 Oct 28,2003 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium acetate).
2972 Thallium (I), soluble salts Various 18 20090930 Sep 30,2009 I.A.6., II.D.2. Screening-level literature review findings message removed.
2973 Thallium (I), soluble salts Various 19 20090930 Sep 30,2009 All IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed.
2974 Thallium (I), soluble salts Various 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2975 Thallium acetate 563-68-8 1 19870331 Mar 31,1987 I.A.6 Documentation corrected.
2976 Thallium acetate 563-68-8 2 19880301 Mar 1,1988 I.A. RfD changed -- new study (thallium sulfate).
2977 Thallium acetate 563-68-8 3 19880301 Mar 1,1988 I.A.6. Verification date changed (thallium sulfate).
2978 Thallium acetate 563-68-8 4 19880630 Jun 30,1988 I.A. RfD withdrawn.
2979 Thallium acetate 563-68-8 5 19880907 Sep 7,1988 I.A. Revised oral RfD summary added.
2980 Thallium acetate 563-68-8 6 19890601 Jun 1,1989 I.A.6. Work group review dates revised (thallium acetate, carbonate, chloride, nitrate).
2981 Thallium acetate 563-68-8 7 19900901 Sep 1,1990 I.A. Text edited.
2982 Thallium acetate 563-68-8 8 19900901 Sep 1,1990 I.A.7. Secondary contact changed.
2983 Thallium acetate 563-68-8 9 19900901 Sep 1,1990 II. Carcinogen assessment online.
2984 Thallium acetate 563-68-8 10 19900901 Sep 1,1990 IV.F.1. EPA contact changed.
2985 Thallium acetate 563-68-8 11 19900901 Sep 1,1990 VI. Bibliography online.
2986 Thallium acetate 563-68-8 12 19910801 Aug 1,1991 VI.C. Kada et al. (1980) citation corrected.
2987 Thallium acetate 563-68-8 13 19920101 Jan 1,1992 IV. Regulatory actions updated.
2988 Thallium acetate 563-68-8 14 19920601 Jun 1,1992 V.B. Chemical formula corrected (thallium carbonate).
2989 Thallium acetate 563-68-8 15 19970401 Apr 1,1997 III., IV., V. Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information.
2990 Thallium acetate 563-68-8 16 20021203 Dec 3,2002 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate).
2991 Thallium acetate 563-68-8 17 20031028 Oct 28,2003 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium acetate).
2992 Thallium acetate 563-68-8 18 20090930 Sep 30,2009 I.A.6., II.D.2. Screening-level literature review findings message removed.
2993 Thallium acetate 563-68-8 19 20090930 Sep 30,2009 All IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed.
2994 Thallium acetate 563-68-8 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
2995 Thallium carbonate 6533-73-9 1 19870331 Mar 31,1987 I.A.6 Documentation corrected.
2996 Thallium carbonate 6533-73-9 2 19880301 Mar 1,1988 I.A. RfD changed -- new study (thallium sulfate).
2997 Thallium carbonate 6533-73-9 3 19880301 Mar 1,1988 I.A.6. Verification date changed (thallium sulfate).
2998 Thallium carbonate 6533-73-9 4 19880630 Jun 30,1988 I.A. RfD withdrawn.
2999 Thallium carbonate 6533-73-9 5 19880907 Sep 7,1988 I.A. Revised oral RfD summary added.
3000 Thallium carbonate 6533-73-9 6 19890601 Jun 1,1989 I.A.6. Work group review dates revised (thallium acetate, carbonate, chloride, nitrate).
3001 Thallium carbonate 6533-73-9 7 19900901 Sep 1,1990 I.A. Text edited.
3002 Thallium carbonate 6533-73-9 8 19900901 Sep 1,1990 I.A.7. Secondary contact changed.
3003 Thallium carbonate 6533-73-9 9 19900901 Sep 1,1990 II. Carcinogen assessment online.
3004 Thallium carbonate 6533-73-9 10 19900901 Sep 1,1990 IV.F.1. EPA contact changed.
3005 Thallium carbonate 6533-73-9 11 19900901 Sep 1,1990 VI. Bibliography online.
3006 Thallium carbonate 6533-73-9 12 19910801 Aug 1,1991 VI.C. Kada et al. (1980) citation corrected.
3007 Thallium carbonate 6533-73-9 13 19920101 Jan 1,1992 IV. Regulatory actions updated.
3008 Thallium carbonate 6533-73-9 14 19920601 Jun 1,1992 V.B. Chemical formula corrected (thallium carbonate).
3009 Thallium carbonate 6533-73-9 15 19970401 Apr 1,1997 III., IV., V. Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information.
3010 Thallium carbonate 6533-73-9 16 20021203 Dec 3,2002 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate).
3011 Thallium carbonate 6533-73-9 17 20031028 Oct 28,2003 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium acetate).
3012 Thallium carbonate 6533-73-9 18 20090930 Sep 30,2009 I.A.6., II.D.2. Screening-level literature review findings message removed.
3013 Thallium carbonate 6533-73-9 19 20090930 Sep 30,2009 All IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed.
3014 Thallium carbonate 6533-73-9 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3015 Thallium chloride 7791-12-0 1 19870331 Mar 31,1987 I.A.6 Documentation corrected.
3016 Thallium chloride 7791-12-0 2 19880301 Mar 1,1988 I.A. RfD changed -- new study (thallium sulfate).
3017 Thallium chloride 7791-12-0 3 19880301 Mar 1,1988 I.A.6. Verification date changed (thallium sulfate).
3018 Thallium chloride 7791-12-0 4 19880630 Jun 30,1988 I.A. RfD withdrawn.
3019 Thallium chloride 7791-12-0 5 19880907 Sep 7,1988 I.A. Revised oral RfD summary added.
3020 Thallium chloride 7791-12-0 6 19890601 Jun 1,1989 I.A.6. Work group review dates revised (thallium acetate, carbonate, chloride, nitrate).
3021 Thallium chloride 7791-12-0 7 19900901 Sep 1,1990 I.A. Text edited.
3022 Thallium chloride 7791-12-0 8 19900901 Sep 1,1990 I.A.7. Secondary contact changed.
3023 Thallium chloride 7791-12-0 9 19900901 Sep 1,1990 II. Carcinogen assessment online.
3024 Thallium chloride 7791-12-0 10 19900901 Sep 1,1990 IV.F.1. EPA contact changed.
3025 Thallium chloride 7791-12-0 11 19900901 Sep 1,1990 VI. Bibliography online.
3026 Thallium chloride 7791-12-0 12 19910801 Aug 1,1991 VI.C. Kada et al. (1980) citation corrected.
3027 Thallium chloride 7791-12-0 13 19920101 Jan 1,1992 IV. Regulatory actions updated.
3028 Thallium chloride 7791-12-0 14 19920601 Jun 1,1992 V.B. Chemical formula corrected (thallium carbonate).
3029 Thallium chloride 7791-12-0 15 19970401 Apr 1,1997 III., IV., V. Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information.
3030 Thallium chloride 7791-12-0 16 20021203 Dec 3,2002 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate).
3031 Thallium chloride 7791-12-0 17 20031028 Oct 28,2003 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium acetate).
3032 Thallium chloride 7791-12-0 18 20090930 Sep 30,2009 I.A.6., II.D.2. Screening-level literature review findings message removed.
3033 Thallium chloride 7791-12-0 19 20090930 Sep 30,2009 All IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed.
3034 Thallium chloride 7791-12-0 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3035 Thallium nitrate 10102-45-1 1 19870331 Mar 31,1987 I.A.6 Documentation corrected.
3036 Thallium nitrate 10102-45-1 2 19880301 Mar 1,1988 I.A. RfD changed -- new study (thallium sulfate).
3037 Thallium nitrate 10102-45-1 3 19880301 Mar 1,1988 I.A.6. Verification date changed (thallium sulfate).
3038 Thallium nitrate 10102-45-1 4 19880630 Jun 30,1988 I.A. RfD withdrawn.
3039 Thallium nitrate 10102-45-1 5 19880907 Sep 7,1988 I.A. Revised oral RfD summary added.
3040 Thallium nitrate 10102-45-1 6 19890601 Jun 1,1989 I.A.6. Work group review dates revised (thallium acetate, carbonate, chloride, nitrate).
3041 Thallium nitrate 10102-45-1 7 19900901 Sep 1,1990 I.A. Text edited.
3042 Thallium nitrate 10102-45-1 8 19900901 Sep 1,1990 I.A.7. Secondary contact changed.
3043 Thallium nitrate 10102-45-1 9 19900901 Sep 1,1990 II. Carcinogen assessment online.
3044 Thallium nitrate 10102-45-1 10 19900901 Sep 1,1990 IV.F.1. EPA contact changed.
3045 Thallium nitrate 10102-45-1 11 19900901 Sep 1,1990 VI. Bibliography online.
3046 Thallium nitrate 10102-45-1 12 19910801 Aug 1,1991 VI.C. Kada et al. (1980) citation corrected.
3047 Thallium nitrate 10102-45-1 13 19920101 Jan 1,1992 IV. Regulatory actions updated.
3048 Thallium nitrate 10102-45-1 14 19920601 Jun 1,1992 V.B. Chemical formula corrected (thallium carbonate).
3049 Thallium nitrate 10102-45-1 15 19970401 Apr 1,1997 III., IV., V. Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information.
3050 Thallium nitrate 10102-45-1 16 20021203 Dec 3,2002 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate).
3051 Thallium nitrate 10102-45-1 17 20031028 Oct 28,2003 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium acetate).
3052 Thallium nitrate 10102-45-1 18 20090930 Sep 30,2009 I.A.6., II.D.2. Screening-level literature review findings message removed.
3053 Thallium nitrate 10102-45-1 19 20090930 Sep 30,2009 All IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed.
3054 Thallium nitrate 10102-45-1 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3055 Thallium oxide 1314-32-5 1 19870331 Mar 31,1987 I.A.6. Documentation corrected.
3056 Thallium oxide 1314-32-5 2 19880630 Jun 30,1988 I.A. RfD withdrawn.
3057 Thallium oxide 1314-32-5 3 19880907 Sep 7,1988 I.A. Revised oral RfD summary added.
3058 Thallium oxide 1314-32-5 4 19890501 May 1,1989 I.A. Oral RfD withdrawn pending further review.
3059 Thallium oxide 1314-32-5 5 19900901 Sep 1,1990 II. Carcinogen assessment online.
3060 Thallium oxide 1314-32-5 6 19900901 Sep 1,1990 IV.F.1. EPA contact changed.
3061 Thallium oxide 1314-32-5 7 19900901 Sep 1,1990 VI. Bibliography online.
3062 Thallium oxide 1314-32-5 8 19910801 Aug 1,1991 VI.C. Kada et al. (1980) citation corrected.
3063 Thallium oxide 1314-32-5 9 19920101 Jan 1,1992 IV. Regulatory actions updated.
3064 Thallium oxide 1314-32-5 10 19930801 Aug 1,1993 I.A. Work group review date added.
3065 Thallium oxide 1314-32-5 11 19930801 Aug 1,1993 I.A. EPA contact changed.
3066 Thallium oxide 1314-32-5 12 19950801 Aug 1,1995 I.A., I.A.6. EPA's RfD/RfC and CRAVE work groups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS pilot program replaced the work group functions beginning in September 1995.
3067 Thallium oxide 1314-32-5 13 19960701 Jul 1,1996 I.A. WG review date corrected contact changed.
3068 Thallium oxide 1314-32-5 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulated Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
3069 Thallium oxide 1314-32-5 15 20021203 Dec 3,2002 I.A., II.D.2. Screening-Level Literature Review Findings message has been added.
3070 Thallium oxide 1314-32-5 16 20090930 Sep 30,2009 All RfD, RfC, and cancer sections updated.
3071 Thallium oxide 1314-32-5 17 20090930 Sep 30,2009 All Name of file changed from thallic oxide to thallium oxide.
3072 Thallium oxide 1314-32-5 18 20090930 Sep 30,2009 I.A., II.D.2. Screening-Level Literature Review Findings message removed.
3073 Thallium oxide 1314-32-5 19 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3074 Thallium selenite 12039-52-0 1 19870331 Mar 31,1987 I.A.6. Documentation corrected.
3075 Thallium selenite 12039-52-0 2 19880630 Jun 30,1988 I.A. RfD withdrawn.
3076 Thallium selenite 12039-52-0 3 19880907 Sep 7,1988 I.A. Revised oral RfD summary added.
3077 Thallium selenite 12039-52-0 4 19890501 May 1,1989 I.A. Oral RfD noted as pending change.
3078 Thallium selenite 12039-52-0 5 19890601 Jun 1,1989 I.A.6. Work group review dates revised.
3079 Thallium selenite 12039-52-0 6 19890601 Jun 1,1989 I.A.7. Secondary contact changed.
3080 Thallium selenite 12039-52-0 7 19900901 Sep 1,1990 I.A. Text edited.
3081 Thallium selenite 12039-52-0 8 19900901 Sep 1,1990 II. Carcinogen assessment online.
3082 Thallium selenite 12039-52-0 9 19900901 Sep 1,1990 IV.F.1. EPA contact changed.
3083 Thallium selenite 12039-52-0 10 19900901 Sep 1,1990 VI. Bibliography online.
3084 Thallium selenite 12039-52-0 11 19910801 Aug 1,1991 VI.C. Kada et al. (1980) citation corrected.
3085 Thallium selenite 12039-52-0 12 19920101 Jan 1,1992 IV. Regulatory actions updated.
3086 Thallium selenite 12039-52-0 13 19930801 Aug 1,1993 I.A. Withdrawn inadequate data.
3087 Thallium selenite 12039-52-0 14 19930801 Aug 1,1993 I.A. Work group review date added.
3088 Thallium selenite 12039-52-0 15 19930801 Aug 1,1993 I.A. EPA contact changed.
3089 Thallium selenite 12039-52-0 16 19930801 Aug 1,1993 VI.A. Oral RfD references withdrawn.
3090 Thallium selenite 12039-52-0 17 19950801 Aug 1,1995 I.A., I.A.6. EPA's RfD/RfC and CRAVE work groups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS pilot program replaced the work group functions beginning in September 1995.
3091 Thallium selenite 12039-52-0 18 19960701 Jul 1,1996 I.A. Contact changed.
3092 Thallium selenite 12039-52-0 19 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulated Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
3093 Thallium selenite 12039-52-0 20 20031028 Oct 28,2003 I.A., II.D.2. Screening-Level Literature Review Findings message has been added.
3094 Thallium selenite 12039-52-0 21 20090930 Sep 30,2009 All RfD, RfC, and cancer sections updated.
3095 Thallium selenite 12039-52-0 22 20090930 Sep 30,2009 I.A., II.D.2. Screening-Level Literature Review Findings message removed.
3096 Thallium selenite 12039-52-0 23 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3097 Thallium(I) sulfate 7446-18-6 1 19870331 Mar 31,1987 I.A.6 Documentation corrected.
3098 Thallium(I) sulfate 7446-18-6 2 19880301 Mar 1,1988 I.A. RfD changed -- new study (thallium sulfate).
3099 Thallium(I) sulfate 7446-18-6 3 19880301 Mar 1,1988 I.A.6. Verification date changed (thallium sulfate).
3100 Thallium(I) sulfate 7446-18-6 4 19880630 Jun 30,1988 I.A. RfD withdrawn.
3101 Thallium(I) sulfate 7446-18-6 5 19880907 Sep 7,1988 I.A. Revised oral RfD summary added.
3102 Thallium(I) sulfate 7446-18-6 6 19890601 Jun 1,1989 I.A.6. Work group review dates revised (thallium acetate, carbonate, chloride, nitrate).
3103 Thallium(I) sulfate 7446-18-6 7 19900901 Sep 1,1990 I.A. Text edited.
3104 Thallium(I) sulfate 7446-18-6 8 19900901 Sep 1,1990 I.A.7. Secondary contact changed.
3105 Thallium(I) sulfate 7446-18-6 9 19900901 Sep 1,1990 II. Carcinogen assessment online.
3106 Thallium(I) sulfate 7446-18-6 10 19900901 Sep 1,1990 IV.F.1. EPA contact changed.
3107 Thallium(I) sulfate 7446-18-6 11 19900901 Sep 1,1990 VI. Bibliography online.
3108 Thallium(I) sulfate 7446-18-6 12 19910801 Aug 1,1991 VI.C. Kada et al. (1980) citation corrected.
3109 Thallium(I) sulfate 7446-18-6 13 19920101 Jan 1,1992 IV. Regulatory actions updated.
3110 Thallium(I) sulfate 7446-18-6 14 19920601 Jun 1,1992 V.B. Chemical formula corrected (thallium carbonate).
3111 Thallium(I) sulfate 7446-18-6 15 19970401 Apr 1,1997 III., IV., V. Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information.
3112 Thallium(I) sulfate 7446-18-6 16 20021203 Dec 3,2002 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate).
3113 Thallium(I) sulfate 7446-18-6 17 20031028 Oct 28,2003 I.A.6., II.D.2. Screening-level literature review findings message has been added (thallium acetate).
3114 Thallium(I) sulfate 7446-18-6 18 20090930 Sep 30,2009 I.A.6., II.D.2. Screening-level literature review findings message removed.
3115 Thallium(I) sulfate 7446-18-6 19 20090930 Sep 30,2009 All IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed.
3116 Thallium(I) sulfate 7446-18-6 20 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3117 Thiobencarb 28249-77-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3118 Thiophanate-methyl 23564-05-8 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
3119 Thiophanate-methyl 23564-05-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3120 Thiram 137-26-8 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
3121 Thiram 137-26-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3122 Toluene 108-88-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3123 2,4-/2,6-Toluene diisocyanate mixture (TDI) 26471-62-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3124 Toxaphene 8001-35-2 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
3125 Toxaphene 8001-35-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3126 Tralomethrin 66841-25-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3127 Triallate 2303-17-5 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
3128 Triallate 2303-17-5 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3129 Triasulfuron 82097-50-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3130 1,2,4-Tribromobenzene 615-54-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3131 Tribromochloromethane 594-15-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3132 Tribromodiphenyl ether 49690-94-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3133 Tributyltin oxide (TBTO) 56-35-9 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3134 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) 76-13-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3135 Trichloroacetic acid 76-03-9 1 20110930 Sep 30,2011 I., II. RfD and cancer assessment sections updated. RfC discussion added.%0A
3136 Trichloroacetic acid 76-03-9 2 19921001 Oct 1,1992 I.A. Oral RfD now under review
3137 Trichloroacetic acid 76-03-9 3 19930301 Mar 1,1993 II. Carcinogenicity assessment now under review
3138 Trichloroacetic acid 76-03-9 4 19930501 May 1,1993 I.A., II. Work group review date added
3139 Trichloroacetic acid 76-03-9 5 19930701 Jul 1,1993 I.A. Work group review date added
3140 Trichloroacetic acid 76-03-9 6 19930901 Sep 1,1993 II. Work group review date added
3141 Trichloroacetic acid 76-03-9 7 19940101 Jan 1,1994 I.A. Work group review date added
3142 Trichloroacetic acid 76-03-9 8 19950801 Aug 1,1995 I.A., II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
3143 Trichloroacetic acid 76-03-9 9 19960201 Feb 1,1996 II. Carcinogenicity assessment on-line
3144 Trichloroacetic acid 76-03-9 10 19960201 Feb 1,1996 VI.C. Carcinogenicity assessment references on-line
3145 Trichloroacetic acid 76-03-9 11 19960301 Mar 1,1996 II.A.3. Citation revised
3146 Trichloroacetic acid 76-03-9 12 19960301 Mar 1,1996 II.D.3. Primary contact changed
3147 Trichloroacetic acid 76-03-9 13 19960301 Mar 1,1996 VI.C. U.S. EPA, 1993 revised to DeAngelo, 1993
3148 Trichloroacetic acid 76-03-9 14 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
3149 Trichloroacetic acid 76-03-9 15 20021203 Dec 3,2002 II.D.2. Screening-Level Literature Review Findings message has been added.
3150 Trichloroacetic acid 76-03-9 16 20030730 Jul 30,2003 I., II. This chemical is being reassessed under the IRIS Program.
3151 Trichloroacetic acid 76-03-9 17 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3152 1,2,4-Trichlorobenzene 120-82-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3153 Trichlorocyclopentadiene 77323-84-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3154 1,1,1-Trichloroethane 71-55-6 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
3155 1,1,2-Trichloroethane 79-00-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3156 Trichloroethylene 79-01-6 1 19880301 Mar 1,1988 II.B.3. Text revised
3157 Trichloroethylene 79-01-6 2 19880301 Mar 1,1988 II.B.4. Confidence statement revised
3158 Trichloroethylene 79-01-6 3 19880301 Mar 1,1988 II.C.2. Text added
3159 Trichloroethylene 79-01-6 4 19880301 Mar 1,1988 II.C.4. Confidence statement revised
3160 Trichloroethylene 79-01-6 5 19880301 Mar 1,1988 II.D.4. Documentation corrected
3161 Trichloroethylene 79-01-6 6 19890501 May 1,1989 II. Carcinogen assessment summary noted as pending change
3162 Trichloroethylene 79-01-6 7 19890601 Jun 1,1989 II.D.3. Primary contact changed
3163 Trichloroethylene 79-01-6 8 19890701 Jul 1,1989 II. Withdrawn new assessment verified (in preparation)
3164 Trichloroethylene 79-01-6 9 19891201 Dec 1,1989 I.B. Inhalation RfD now under review
3165 Trichloroethylene 79-01-6 10 19900601 Jun 1,1990 IV.A.1. Area code for EPA contact corrected
3166 Trichloroethylene 79-01-6 11 19900601 Jun 1,1990 IV.F.1. EPA contact changed
3167 Trichloroethylene 79-01-6 12 19920101 Jan 1,1992 IV. Regulatory actions updated
3168 Trichloroethylene 79-01-6 13 19920401 Apr 1,1992 IV.A.1. CAA regulatory action withdrawn
3169 Trichloroethylene 79-01-6 14 19920701 Jul 1,1992 II. EPA contact changed work group review dates added
3170 Trichloroethylene 79-01-6 15 19920801 Aug 1,1992 I.A. Oral RfD now under review
3171 Trichloroethylene 79-01-6 16 19931101 Nov 1,1993 II. Work group review date added
3172 Trichloroethylene 79-01-6 17 19940701 Jul 1,1994 II. Work group review date added
3173 Trichloroethylene 79-01-6 18 19950801 Aug 1,1995 I.A., I.B., II. EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
3174 Trichloroethylene 79-01-6 19 19970401 Apr 1,1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
3175 Trichloroethylene 79-01-6 20 19980102 Jan 2,1998 I., II. This chemical is being reassessed under the IRIS Program.
3176 Trichloroethylene 79-01-6 21 20030605 Jun 5,2003 Status of Data Correction of administrative error concerning the date the carcinogenicity assessment (II.) was withdrawn from IRIS.
3177 Trichloroethylene 79-01-6 22 20040607 Jun 7,2004 VIII Text revised.
3178 Trichloroethylene 79-01-6 23 20110928 Sep 28,2011 I., II., VI. RfD, RfC, and Cancer assessment added.
3179 Trichloroethylene 79-01-6 24 20180710 Jul 10,2018 Key Values Table A footnote was added for ADAF.
3180 Trichloroethylene 79-01-6 25 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
3181 Trichlorofluoromethane 75-69-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3182 2,4,6-Trichlorophenol 88-06-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3183 2,4,5-Trichlorophenol 95-95-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3184 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) 93-72-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3185 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) 93-76-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3186 1,1,2-Trichloropropane 598-77-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3187 1,2,3-Trichloropropane 96-18-4 1 20090930 Sep 30,2009 I.A., I.B., II. Revised RfD, added RfC and carcinogenicity assessments.
3188 1,2,3-Trichloropropane 96-18-4 2 20180710 Jul 10,2018 Key Values Table A footnote was added for ADAF.
3189 1,2,3-Trichloropropane 96-18-4 3 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3190 Tricresol 1319-77-3 1 20181024 Oct 24,2018 Archived Archived nulls at the request of the NCEA Center Director (T. Bahadori).
3191 Tricresol 1319-77-3 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3192 Tridiphane 58138-08-2 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
3193 Tridiphane 58138-08-2 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3194 Triethylamine 121-44-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3195 Triethylene glycol monobutyl ether 143-22-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3196 Triethylene glycol monoethyl ether 112-50-5 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3197 Trifluralin 1582-09-8 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3198 1,3,5-Trimethylbenzene 108-67-8 1 20160909 Sep 9,2016 All RfD, RfC and carcinogenic assessment added.
3199 1,3,5-Trimethylbenzene 108-67-8 2 20180802 Aug 2,2018 Updates to Key Value Added chronic/subchronic values into the key table to correspond with the Toxicological Review (TR). Made additional corrections to the system specific values based on input from the CM from the TR.
3200 1,3,5-Trimethylbenzene 108-67-8 3 20180813 Aug 13,2018 IRIS Summary Renamed label to Executive Summary to match the linked document.
3201 1,3,5-Trimethylbenzene 108-67-8 4 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
3202 1,2,3-Trimethylbenzene 526-73-8 1 20160909 Sep 9,2016 All RfD, RfC, and cancer assessment added.
3203 1,2,3-Trimethylbenzene 526-73-8 2 20180802 Aug 2,2018 Updates to Key Value Added chronic/subchronic values into the key table to correspond with the Toxicological Review (TR). Made additional corrections to the system specific values based on input from the CM from the TR.
3204 1,2,3-Trimethylbenzene 526-73-8 3 20180813 Aug 13,2018 IRIS Summary Renamed label to Executive Summary to match the linked document.
3205 1,2,3-Trimethylbenzene 526-73-8 4 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
3206 1,2,4-Trimethylbenzene 95-63-6 1 20160909 Sep 9,2016 All RfD, RfC and cancer assessment added.
3207 1,2,4-Trimethylbenzene 95-63-6 4 20180802 Aug 2,2018 Updates to Key Value Added chronic/subchronic values into the key table to correspond with the Toxicological Review (TR). Made additional corrections to the system specific values based on input from the CM from the TR.
3208 1,2,4-Trimethylbenzene 95-63-6 5 20180813 Aug 13,2018 IRIS Summary Renamed label to Executive Summary to match the linked document.
3209 1,2,4-Trimethylbenzene 95-63-6 6 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
3210 2,2,4-Trimethylpentane 540-84-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3211 1,3,5-Trinitrobenzene 99-35-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3212 2,4,6-Trinitrotoluene (TNT) 118-96-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3213 Uranium, natural 7440-61-1 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
3214 Uranium, natural 7440-61-1 2 20181220 Dec 20,2018 All EPA suspended the development of this assessment.
3215 Uranium, natural 7440-61-1 3 20210628 Jun 28,2021 All EPA removed the suspension and re-started this assessment.
3216 Uranium, soluble salts Various 1 19891001 Oct 1,1989 I.A. Oral RfD summary on-line
3217 Uranium, soluble salts Various 2 19891001 Oct 1,1989 VI. Bibliography on-line
3218 Uranium, soluble salts Various 3 19920101 Jan 1,1992 IV. Regulatory Action section on-line
3219 Uranium, soluble salts Various 5 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3220 Urea 57-13-6 1 20110713 Jul 13,2011 I., II., VI. RfD and RfC discussion added cancer assessment added.
3221 Urea 57-13-6 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3222 Vanadium and Compounds (Inhalation) Various 1 20210528 May 28,2021 Step 1 EPA released the draft document, IRIS Assessment Plan (IAP) for Inhalation Exposure to Vanadium and Compounds, for a 30-day public review and comment period.
3223 Vanadium and Compounds (Oral) Various 1 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link and DTX SID number
3224 Vanadium pentoxide 1314-62-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3225 Vernam 1929-77-7 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
3226 Vernam 1929-77-7 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3227 Vinclozolin 50471-44-8 1 20160715 Jul 15,2016 Archived Chemical IRIS working with OPP agreed to mark this pesticide chemical archived.
3228 Vinclozolin 50471-44-8 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3229 Vinyl acetate 108-05-4 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3230 Vinyl bromide 593-60-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3231 Vinyl chloride 75-01-4 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3232 Warfarin 81-81-2 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3233 White phosphorus 7723-14-0 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3234 Xylenes 1330-20-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3235 Zinc and Compounds 7440-66-6 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3236 Zinc cyanide 557-21-1 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3237 Zinc phosphide 1314-84-7 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3238 Zineb 12122-67-7 1 20190515 May 15,2019 Pesticide Marked this chemical as a pesticide. %5BSR%5D
3239 Zineb 12122-67-7 2 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3240 n-Butanol 71-36-3 1 20200715 Jul 15,2020 Related Topics Added Chemicals Dashboard link
3241 tert-Butyl Alcohol (tBA) 75-65-0 1 20160719 Jul 19,2016 Draft Document EPA released the draft document (step 1) for public review and comment. This is a new assessment so a new chemical landing page (draft) was also launched.
3242 tert-Butyl Alcohol (tBA) 75-65-0 2 20200714 Jul 14,2020 Related Topics Added Chemicals Dashboard link
3243 tert-Butyl Alcohol (tBA) 75-65-0 3 20210813 Aug 13,2021 All EPA completed a reassessment, updating all values.